Document dnqd8YOaEXyqyyOqr0D668yB6

DownloadViewSend us a messageRandom document
S A N IT IZ E D AR jU -co3 $ i REPORT EXPLORATORY 28-DAY ORAL TOXICITY STUDY WITH TELOMER ALCOHOL, TELOMER ACRYLATE PFHS AND PFOS (positive control) BY DAILY GAVAGE IN THE RAT FOLLOWED BY A 14/28-DAY RECOVERY PERIOD NOTOX Project 242933 NOTOX Substances 83484, 83493, 83502, 84456 and 84141 3M Test No. T-7023, T-7024, T-7022, T-7032, T-6295 - page 1 of 451 - 000002 TELOMER ALCOHOL/TELOMER ACRYLATE/ REPORT APPROVAL PFHS/PFOS NOTOX Project 242933 Study Director Ir. S.C.M. de Hoog Date: 1^99 Management Drs. W.J.A.M. Frieling Date : l CjC^Cj - Page 2 000003 TELOMER ALCOHOL/TELOMER ACRYLATE/ CONTENTS PFHS/PFOS ' REPORT APPROVAL SUMMARY PREFACE STUDY PLAN MATERIALS AND METHODS Test Substances Test Substance Formulation Purpose and Rationale Guidelines Archiving Test System Allocation Animal Husbandry Treatment Recovery Observations Mortality / Viability Clinical Signs Body Weights Food Consumption Water Consumption Clinical Laboratory Investigations Haematology Clinical Biochemistry Urinalysis Pathology Necropsy Organ Weights Liver Sampling Histotechnology Histopathology Statistical Analysis RESULTS Observations Mortality Clinical Signs NOTOX Project 242933 2 5 7 8 9 9 10 11 11 11 12 12 13 13 13 14 14 14 14 14 14 14 15 16 17 17 17 18 18 18 19 19 20 20 20 20 - Page 3 - 000004 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS NOTOX Project 242933 RESULTS (continued) 21 Body Weight Food Consumption Clinical Laboratory Investigations Haematology Ciinical Biochemistry Pathology Macroscopic Examination Organ Weights Microscopic Examination Discussion and Conclusion 21 21 22 22 23 24 24 24 25 25. FIGURES Body Weights Body Weight Gain Food Consumption Relative Food Consumption 27 28-29 30-31 32-33 34-35 TABLES - SUMMARY DATA Clinical Signs Body Weights Body Weight Gain Food Consumption Relative Food Consumption Haematology Clinical Biochemistry Organ Weights-Organ/Body Weight Ratios Historical data Haematology / Clinical Biochemistry 36 37-60 61-64 65-68 69-72 73-76 77-88 89-100 101-112 113-118 TABLES - INDIVIDUAL DATA 119 Mortality 120-125 Clinical Signs, Dally 126-152 Body Weights 153-160 Body Weights Gain 161-168 Food Consumption 169-172 Relative Food Consumption 173-184 Key to Missing Values and Remarks Haematology / Clinical Biochemistry 185 Haematology 186-221 Clinical Biochemistry 222-257 Macroscopic Findings 258-281 Organ Weights-Organ/Body Weight Ratios 282-305 APPENDIX 1 Pathology Report LAST PAGE OF REPORT 1-146 451 - Page 4 - n n n n n tr TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS NOTOX Project 242933 SUMMARY Exploratory 28-day oral toxicity study with Telomer Alcohol, Telomer Acrylate, PFHS and PFOS (positive control) by daily gavage 1n the rat followed by a 14/28-day recovery period. Dose levels for this study, provided by the sponsor, were selected to be 0 (Vehicle Control), 3 (PFOS), 10 (PFHS) and 30 mg/kg body weight/day (Telomer Alcohol, Telomer Acrylate ). The study was based on the following guidelines: - EEC Directive 96/54/EEC, B.7 Repeated Dose (28 days) Toxicity (oral), 1996. - OECD 407, Repeated Dose 28-day Oral Toxicity Study in Rodents, 1995 The test substance, formulated in 1% aqueous carboxymethyl cellulose, was administered dally for at least 28 days by oral gavage to SPF-bred Sprague Dawley rats. One vehicle control group and five treated groups were tested, each consisting of 8 males and 8 females. An extra 3 animals per sex per group were allowed 14 days of recovery and another 3 animals per sex per group were allowed 28 days of recovery. The following parameters were evaluated: clinical signs twice daily (treatment) or once daily (recovery); body weight twice weekly; food consumption weekly; clinical pathology after 4 weeks and at the end of both recovery periods; macroscopy at termination; organ weights and histopathology on a selection of tissues. RESULTS Telomer Alcohol: (30 mg/kg/day) 1. Total protein, globulin and total cholesterol were decreased (d1) after treatment. Total protein was still decreased after 2 and 4 weeks recovery (cf). 2. Midzonal/centrllobular hypertrophy was observed in the Uver, and exocrine apoptosis/single cell necrosis in the pancreas (d1) after treatment and had partially or completely resolved after 4 weeks recovery. Telomer Acrylate: (30 mg/kg/day) 1. Body weights were decreased at the end of treatment (?) 2. Total protein, globulin and total cholesterol were decreased (<?) and albumln/globulin ratios were increased (d1) after treatment. (30 mg/kg/day) 1. Total protein, globulin, aspartate aminotransferase activity (d1) and prothrombin time (?) were decreased and albumin/globulin ratios were increased (ef) after treatment. Prothrombin time was still decreased after 2 weeks recovery (?). - Page 5 - oooooo TELOMER ALCOHOL/TELOMER ACRYLATE/- PFHS/PFOS NOTOX Project 242933 PFHS: (10 mg/kg/day) PFOS: (3 mg/kg/day) 1. Total cholesterol (d1 and ?), total protein, globulin, triglycerides, aspartate aminotransferase activity (d1) and prothrombin time (f and ?) were decreased; albumln/globulin ratios and alkaline phosphatase activity were increased (tf) after treatment. Prothrombin time was still decreased after 2 weeks recovery (?). 2. Liver weights were increased after treatment (<?). 3. Midzonal/centrilobular hypertrophy was observed in the liver (d1) after treatment and had completely resolved after 4 weeks recovery. 1. Body weights and food consumption were decreased during treatment and recovery {?). 2. Total protein, globulin, total cholesterol, . triglycerides, aspartate aminotransferase activity (<?) and prothrombin time (?) were decreased; albumin/globulin ratios were increased (cf) after treatment. 3. Autopsy body weights were decreased (?). Liver weights were Increased after treatment and recovery (cf and ?). 4. Midzonal/centrllobular hypertrophy was observed in the Uv e r (d1 and ?) after treatment and remained in evidence among males after recovery. From the results presented in this report it can be concluded that the positive control compound PFOS dosed at 3 mg/kg/day was Indeed the compound with the most striking and persistent effects, mainly in the liver. Compounds with comparable but less severe effects as PFOS Included PFHS (10 mg/kg/day) and TELOMER ALCOHOL (30 mg/kg/day). Despite slightly reduced body weights in females (TELOMER ACRYLATE only) and some slight changes in the blood after treatment, 30 mg/kg TELOMER ACRYLATE or per day did not result 1n clear systemic toxicity and organ dysfunction at macroscopic or microscopic level. - Page 6 - 000007 TELOMER ALCOHOL/TELOMER ACRYLATE/" PFHS/PFOS PREFACE Sponsor Study Monitor Invoice Contact Testing Facility Study Director Histopathology 3M Toxicology Services 3M Center, Bldg 220-2E-02 St. Paul, MN 55144-1000 USA . Marvin T. Case, DVM, PhD 3M Toxicology Services 3M Center, Bldg 220-2E-02 St. Paul MN 55144-1000 Telephone (651)- 733-5180 Fax (651)- 733-1773 Barbara Nelson 3M Procurement Operations 3M Center, Bldg 224-1N-04 St. Paul, MN 55144-1000 Telephone (651)- 733-0766 Fax (651)- 733-1799 NOTOX B.V. Hambakenwetering 3 5231 DD 's-Hertogenbosch The Netherlands Ir. S.C.M. de Hoog Dr. J. Th. Wilson NOTOX Project 242933 Page 7 - T 000008 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS NOTOX Project 242933 STUDY PLAN Start of Treatment 06 October 1998 (males) 08 October 1998 (females) Start Recovery 04 November 1998 (males) 06 November 1998 (females) Blood sampling 03 November 1998 (Main groups, males) 04 November 1998 (Main and Recovery groups 1 and 2, males) 05 November 1998 (Main groups, females) 06 November 1998 (Main and Recovery groups 1 and 2, females) 18 November 1998 (Recovery groups 1, males) 20 November 1998 (Recovery groups 1, females) 02 December 1998 (Recovery groups 2, males) 04 December 1998 (Recovery groups 2, females) Urine collection predose day 7 day 7 day 14 day 14 end of treatment end of treatment end of recovery end of recovery end of recovery end of recovery 29-30 September 1998 (Recovery groups 1 and 2) 11-12 October .1998 (Recovery groups 1 and 2, males) 13-14 October 1998 (Recovery groups 1 and 2, females) 18-19 October 1998 (Recovery groups 1 and 2, males) 20-21 October 1998 (Recovery groups 1 and 2, females) 03-04 November 1998 (Recovery groups 1 and 2, males) 05-06 November 1998 (Recovery groups 1 and 2, females) 17-18 November 1998 (Recovery groups 1, males) 19-20 November 1998 (Recovery groups 1, females) 01-02 December 1998 (Recovery groups 2, males) 03-04 December 1998 (Recovery groups 2, females) Necropsy 03 November 1998 (Main groups, males) 04 November 1998 (Main groups, males) 05 November 1998 (Main groups, females) 06 November 1998 (Main groups, females) 18 November 1998 (Recovery groups 1, males) 20 November 1998 (Recovery groups 1, females) 02 December 1998 (Recovery groups 2, males) 04 December 1998 (Recovery groups 2, females) - Page 8 000009 TELOMER ALCOHOL/TELOMER ACRYLATE/ ~ PFHS/PFOS MATERIALS AND METHODS NOTOX Project 242933 TEST SUBSTANCES The sponsor 1s responsible for the completeness of all test substance data. All available Information on characteristics of the test substance were taken Into account before the start of the study in order to determine if they conflict with/might affect the proceeding of the study. NOTOX SUBSTANCE 83484 Identification Description Batch Purity Test substance storage . Stability under storage conditions Expiry date Specific Gravity Stability in vehicle TELOMER ALCOHOL Pale to medium tan waxy solid T -7023 Not indicated by sponsor; treated as 100% pure At room temperature in the dark Stable 07 September 2000 1.7 1% aqueous carboxymethyl cellulose: not indicated NOTOX SUBSTANCE 83493 Identification Description Batch Purity Test substance storage Stability under storage conditions Expiry date Density Stability in vehicle TELOMER ACRYLATE Yellow liquid T-7024 Not indicated by sponsor; treated as 100% pure At room temperature protected from light Stable 07 September 2000 Approx. 1.6 g/cm3 at 50 C 1% aqueous carboxymethyl cellulose: not indicated NOTOX SUBSTANCE 83502 Identification Description Batch Purity Test substance storage Stability under storage conditions Expiry date Stability in vehicle White powder T-7022 Not indicated by sponsor; treated as 100% pure At room temperature in the dark Stable 07 September 2000 1% aqueous carboxymethyl cellulose: not indicated - Page 9 - 000010 TELOMER ALCOHOL/TELOMER ACRYLATE/ " PFHS/PFOS NOTOX Project 242933 NOTOX SUBSTANCE 84456/B Identification Description Batch Purity Test substance storage Stability under storage conditions Expiry date Stability in vehicle NOTOX SUBSTANCE 84141 Identification Description Batch Purity Test substance storage Stability under storage conditions Expiry date ' Stability 1n vehicle PFHS Off-white crystalline solid T-7042 Not indicated by sponsor; treated as 100% pure At room temperature in the dark Stable 25 September 2000 1% aqueous carboxymethyl cellulose: not indicated PFOS White solid T-6295 Not Indicated by sponsor; treated as 100% pure At room temperature in the dark Stable 07 September 2000 1% aqueous carboxymethyl cellulose: not indicated Vehicle Rationale for vehicle Stability in vehicle 1% aqueous carboxymethyl cellulose Based on trial formulations performed at NOTOX Stability over 4 hours will be determined by the sponsor TEST SUBSTANCE FORMULATION Method Formulations (w/w) were prepared daily within 4 hours prior to dosing. No adjustment was made for specific gravity of the test substance. Storage conditions At ambient temperature No chemical analysis of dose preparations was performed. Page 10 - OOOOli TELOMER ALCOHOL/TELOMER ACRYLATE/" PFHS/PFOS NOTOX Project 242933 PURPOSE AND RATIONALE The nature and purpose of this exploratory study was to determine and compare the relative oral toxicity in rats following oral (gastric gavage) doses administered dally over 28 days and identify developmental compounds of lesser toxicity for commercial development. This study should provide part of a rational, basis for toxicological risk assessment in man. The oral route was selected as it 1s a possible route of human exposure during manufacture, handling or use of the test substance. GUIDELINES The protocol was reviewed and agreed by the Article 14-functionary and the Ethical Committee of NOTOX as required by the Dutch Act on Animal Experimentation. The study procedures described in this report were based on the following guidelines: 1) EC Directive 96/54/EEC, Annex IV.D, replacing EEC Directive 67/548/EEC, Part B : Methods for the Determination of Toxicity and other Health Effects; B.7: Repeated Dose (28 days) Toxicity (oral)*. Official Journal of the European Communities No. L248, September 1996. 2) OECD Guideline for Testing of Chemicals, Guideline 407: 'Repeated Dose 28-day Oral Toxicity Study in Rodents', Paris Cedex, 27 July 1995 The protocol, study procedures and the report were not Inspected by the NOTOX Quality Assurance Unit. ARCHIVING NOTOX B.V., will archive the following data for at least 10 years: protocol, raw data, report and all specimens. No data will be withdrawn without the sponsor's written consent. ooooifc TELOMER ALCOHOL/TELOMER ACRYLATE/ ' PFHS/PFOS NOTOX Project 242933 TEST SYSTEM Test System Age at Start of Treatment Number of animals Randomisation Identification Sprague Dawley rat Crl:CD BR (outbred, SPF-Quality) Recognised by International guidelines as the recommended test system (e.g. EPA, FDA, OECD, EEC). Females were nulUparous and non-pregnant. Source : Charles River, Sulzfeld, Germany Approximately 6 weeks. 84 males, 84 females At least 5 days before study start, by computer generated random algorithm according to body weight, with all animals within 20% of the sex mean. A health inspection was performed prior to commencement of treatment to ensure that the animals were in a good state of health. Earmark and tattoo ALLOCATION Group Identification Test Substance Number of animals Animal numbers males females males females 1 Main group 1 Recovery group 1 1 Recovery group 2 2 Main group 2 Recovery group 1 2 Recovery group 2 3 Main group 3 Recovery group 1 3 Recovery 'group 2 4 Main group 4 Recovery group 1 4 Recovery group 2 5 Main group 5 Recovery group 1 5 Recovery group 2 6 Main group 6 Recovery group 1 6 Recovery group 2 Vehicle control 8 Vehicle control 3 Vehicle control 3 Telomer Alcohol 8 Telomer Alcohol 3 Telomer Alcohol 3 Telomer Acrylate 8 Telomer Acrylate 3 Telomer Acrylate 3 8 3 .3 PFHS 8 PFHS 3 PFHS 3 PFOS (positive control) 8 PFOS (positive control) 3 PFOS (positive control) 3 8 3 3 8 3 3 8 3 3 8 3 3 8 3 3 8 3 3 1- 8 9-11 13-15 17-24 25-27 29-31 33-40 41-43 45-47 49-56 57-59 61-63 65-72 73-75 77-79 81-88 89-91 93-95 97-104 105-107 109-111 113-120 121-123 125-127 129-136 137-139 141-143 145-152 153-155 157-159 161-168 169-171 173-175 177-184 185-187 189-191 Test substances Telomer Alcohol (substance 83484), Telomer Acrylate (substance 83493) and (substance 83502) were tested at a dose level of 30 mg/kg body weight/day. PFHS (substance 84456) was tested at a dose level of 10 mg/kg body weight/day. PFOS (substance 84141) was tested at a dose level of 3 mg/kg body weight/day. - Page 12 - 000013 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS NOTOX Project 242933 ANIMAL HUSBANDRY Conditions Air-conditioned room with approximately 15 air changes per hour and the environment controlled with optimal conditions considered as being a temperature of 21"C and a relative humidity of 50%. Lighting was 12 hours artificial fluorescent light and 12 hours dark per day. Deviations from these optimal conditions occurred, but were considered not to have affected study Integrity. Accommodation Group housing of 3-4 animals per sex per cage in stainless steel suspended cages with wire mesh floors. Acclimatisation period was at least 5 days before start of treatment under laboratory conditions. Diet Free access to standard pelleted laboratory animal diet (from Carfll Quality BVBA, Oud-Turnhout, Belgium). Each batch 1s analysed for nutrients and contaminants are analysed on a regular basis. Results are examined and archived. Water Free access to tap-water. Certificates of analysis (performed quarterly) were examined and archived. TREATMENT Method Frequency Dose volume Dose level Oral gavage, using a stainless steel stomach tube. Formulations were placed on a magnetic stirrer during dosing. Once daily for at least 28 days, approximately the same time each day, 7 days per week. Main group animals were dosed up to the day prior to necropsy 5 ml/kg body weight. Actual dose volumes were calculated weekly according to the latest body weight. Group 1: 0 mg/kg b.w./day (Vehicle Control) Group 2: 30 mg/kg...b .w./day (Telomer Alcohol) Group 3: 30 mg/kg b.w./day (Telomer Acrylate) Group 4: 30 mg/kg b.w./day ( ) Group 5: 10 mg/kg b.w./day (PFHS) Group 6: 3 mg/kg b.w./day (PFOS, positive control) RECOVERY Duration Recovery group 1: at least 14 days Recovery group 2: at least 28 days - Page 13 - 000014 TELOMER ALCOHCL/TELOMER ACRYLATE/- PFHS/PFOS NOTOX Project 242933 OBSERVATIONS Mortality / Viability Clinical signs Body weights Food consumption Water consumption Twice.daily. During the treatment period detailed clinical observations were made twice daily in all animals: once immediately after dosing and once approximately 4 hours after dosing. During the recovery period only one observation per day was performed. The time of onset, degree and duration were recorded. All symptoms were recorded and graded according to fixed scales: Maximum grade 4: grading slight (1) to very severe (4). Maximum grade 3: grading slight (1) to severe (3). Maximum grade 1: presence is scored (1). Treatment period : on days 1, 5, 8, 12, 15, 19, 22, 25 and 28. Recovery period : on days 1, 5, 8, 12, 14, 19, 22, 25 and 28. Weekly. Subjective appraisal was maintained during the study, but no quantitative investigation introduced as no effect was suspected. CLINICAL LABORATORY INVESTIGATIONS Blood samples were collected under light ether anaesthesia, between 7.30 and 9.30 a.m. immediately prior to post mortem examination for Main and Recovery group animals, and for Recovery group animals also at the end of the treatment period. The animals were fasted overnight (with a maximum of 20 hours) before blood sampling, but water was provided. Blood samples were drawn from the retroorbital sinus of all Main and Recovery rats/sex/group and collected into tubes prepared with EDTA for haematological parameters (0.5 ml), with citrate for clotting tests (1.0 ml) and untreated tubes for clinical biochemistry parameters (>2.0 ml). From animal numbers 17-20, 33-36, 49-52, 65-68, 81-83, 113, 115, 131 and 132 a second EDTA-sample was collected after 4 weeks, due to inexplicable clotting of the first sample. - Page 14 -. oooois TELOMER ALCOHOL/TELOMER ACRYLATE/ ' PFHS/PFOS NOTOX Project 242933 HAEMATOLOGY The following haematology parameters were determined from blood prepared with EDTA as an anti-coagulant, using the Instruments listed: Parameter/Abbreviation Unit Instrumentation Erythrocyte count/RBC T/l Haemoglobin/HB mmol/1 Haematocr1t/HCT 1/1 Mean corpuscular volume/MCV fl Mean corpuscular haemoglobin/MCH fmol Mean corpuscular haemoglobin mmol/1 concentrtion/MCHC Platelet count G/l Red cell distribution width/RDW % Total leucocyte count/WBC G/l Differential leucocyte count/SEG (Neutrophils) EO (Eosinophils), BASO (Basophils), LYMPH (Lymphocytes), MONO (Monocytes) l(rel) Sysmex K-1000 Sysmex K-1000 Sysmex K-1000 Sysmex K-1000 Sysmex K-1000 Sysmex K-1000 Sysmex K-1000 Sysmex K-1000 Sysmex K-1000 Manual (Microscope) The following haematology parameters were determined from blood prepared with citrate as an anti-coagulant, using the instruments listed: Parameter/Abbreviation Unit Instrumentation/Method Prothrombin time/PT Partial thromboplastin time/PTT sec sec Sysmex CA-5000 Sysmex CA-5000 - Page 15 - 000016 TELOMER ALCOHOL/TELOMER ACRYLATE/ - PFHS/PFOS NOTOX Project 242933 CLINICAL BIOCHEMISTRY The following clinical biochemistry parameters were determined from serum samples using the instruments listed: Parameter/Abbreviation Unit Instrumentation Alanine aminotransferase/ (ALAT/GPT) pkat/1 Aspartate aminotransferase/ pkat/1 (ASAT/GOT) Bilirubin, total/ BILI T. pmol/1 Cholesterol, total/ CHOLEST. T. mmol/1 Triglycerides/ TRIGL. mmol/1 Creatinine pmol/1 Glucose mmol/1 Urea mmol/1 Protein, total/ PROTEIN T. Protein, albumin/ ALBUMIN Protein, globulin/ GLOBULIN Albumin Globulin ratio A/G RATIO Alkaline phosphatase/ ALP Sodium Potassium Chloride Calcium Phosphorus/ INORG. PHOSPH g/1 g/1 g/1 1 pkat/1 mmol/1 mmol/1 mmol/1 mmol/1 mmol/1 Epos selective analyser 5060 (Eppendorf) Epos selective analyser 5060 (Eppendorf) Epos selective analyser 5060 (Eppendorf) Epos selective analyser 5060 (Eppendorf) Epos selective analyser 5060 (Eppendorf) Epos selective analyser 5060 (Eppendorf) Epos selective analyser 5060 (Eppendorf) Epos selective analyser 5060 (Eppendorf) Epos selective analyser 5060 (Eppendorf) Epos selective analyser 5060 (Eppendorf) Calculation [PROTEIN T.-ALBUMIN] Calculation [ALBUMIN/GLOBULIN] Epos selective analyser 5060 (Eppendorf) EFIX 5055 Flame Photometer Eppendorf EFIX 5055 Flame Photometer Eppendorf Jenway PCLM3 EFIX 5055 Flame Photometer Eppendorf Epos selective analyser 5060 (Eppendorf) 16 - 000017 TELOMER ALCOHOL/TELOMER ACRYLATE/ " PFHS/PFOS NOTOX Project 242933 URINALYSIS (Recovery group animals only) Urine samples were collected overnight (approximately 16 hrs) from all animals assigned to the Recovery groups according to the following schedule: - predose - during the treatment period on days 7, 14 and at the end of treatment - at the end of the recovery period, prior to scheduled necropsy. During the sampling period animals were deprived of food but water was provided. Urine was collected into a specimen vial, using a metabolism cage. After collection the samples were frozen and stored at -20C at NOTOX until further analysis. PATHOLOGY NECROPSY All animals surviving to the end of the observation period were deeply anaesthetised using ether vapour and subsequently exsanguinated. All animals assigned to the study were necropsied and descriptions of all macroscopic abnormalities recorded. Prior to exsangulnation a blood sample (1-2 ml) for serum collection was taken from the aorta. Serum samples were stored at -20BC at NOTOX until further analysis. Inadvertently, no serum sample was collected from all Main males and females from groups 1, 2, 3 and 6 (animal numbers 97-100, 113-116, 129-132 and 177-180). Instead, reserve samples intended for clinical biochemistry might be used for possible further analysis. Samples of the following tissues and organs were collected from all animals at necropsy and fixed in neutral phosphate buffered 4% formaldehyde solution: Identification marks Adrenal glands Aorta Brain Caecum Colon Duodenum Epididymides Eyes with optic nerve and Harderian gland Female mammary gland area Heart Ileum Jejunum Kidneys Liver Lung, infused with formalin Lymph nodes - mandibular, mesenteric Oesophagus Ovaries Pancreas - Page 17 - 000018 TELOMER ALCOHOL/TELOMER ACRYLATE/ ' PFHS/PFOS NOTOX Project 242933 Peyer's patches (jejunum, ileum) if detectable Pituitary gland Prostate gland Rectum Salivary glands - mandibular Sciatic nerve Seminal vesicles Spinal cord -cervical, midthoracic, lumbar Spleen Sternum with bone marrow Stomach Testes Thymus Thyroid including parathyroid Trachea Urinary bladder Uterus All gross lesions ORGAN WEIGHTS The following organ weights (and terminal body weight) were recorded from the surviving animals on the scheduled day of necropsy: Adrenal glands Brain Heart Kidneys Liver Ovaries Spleen Testes Both absolute and relative (% body weight) organ weight data are included 1n the study report. LIVER SAMPLING From all animals surviving until the scheduled necropsy at least 1 gram of the left lateral liver lobe was frozen in Isopentane^. Liver samples were stored at -20C at NOTOX and on 01 February 1999 dispatched on dry 1ce to the sponsor. Analysis is performed under the responsibility of the sponsor. Results may be reported by the sponsor in a separate document. HISTOTECHNOLOGY All underlined organ and tissue samples (see under Necropsy) from all Main and Recovery group animals were processed, embedded and cut at a thickness of 2-4 micrometers and stained with haematoxylin and eosin. - Page 18 - 000019 TELOMER ALCOHOL/TELOMER ACRYLATE/ - PFHS/PFOS NOTOX Project 242933 HISTOPATHOLOGY Slides of all underlined organs and tissues (see under Necropsy) collected at the scheduled sacrifice from all Main group animals of all dose groups as well as from all animals of all dose groups which died spontaneously, and all gross lesions of all animals (all dose groups) were examined by a pathologist. Based on treatment related morphologic changes, the following organs were also examined from all rats of Recovery groups 1 and 2 : - U v e r from males of the Vehicle control, Telomer Alcohol, PFHS and PFOS groups; - liver from females of the Vehicle Control and PFOS groups; - pancreas from males of the Vehicle Control and Telomer Alcohol groups. All abnormalities were described and included in the report. STATISTICAL ANALYSIS The following statistical methods were used to analyse the data: Univariate one-way analysis of variance was used to assess the significance of intergroup differences. If the variables could be assumed to follow a normal distribution, the Dunnetttest (many-to-one t-test) based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex. The Steel-test (many-to-one rank test) was applied instead of the Dunnett-test when the data could not be assumed to follow a normal distribution. All tests were two-sided and in all cases p < 0.05 was accepted as the lowest level of significance. Group means were calculated for continuous data and medians were calculated for discrete data (scores) in the summary tables. Test statistics were calculated on the basis of exact values for means and pooled variances. Individual values, means and standard deviations may have been rounded off before printing. Therefore, two groups may display the same printed means for a given parameter, yet display different test statistics values. References: - C.W. Dunnett A Multiple Comparison Procedure for Comparing Several Treatments with a Control, J. Amer. Stat. Assoc. 50, 1096-1121 (1955). - R.G. Miller Simultaneous Statistical Inference, Springer Verlag, New York (1981). - Page 19 - 000020 TELOMER ALCOHOL/TELOMER ACRYLATE/ ~ PFHS/PFOS RESULTS NOTOX Project 242933 OBSERVATIONS MORTALITY No treatment-related mortality occurred during the study period. One female receiving TELOMER ACRYLATE died following blood sampling, prior to necropsy. This was considered to be an accidental death. CLINICAL SIGNS TELOMER ALCOHOL Rales were noted in one male Immediately and 4 hours after dosing. This was observed at the end of the treatment period until the third week of recovery. TELOMER ACRYLATE A hunched posture was observed in two Main group females in weeks 2 and 3 of the treatment period and in two Recovery group females at the end of treatment and during the first week(s) of recovery. Piloerection was also observed in the one female during the first week of recovery. In general the findings were observed immediately and 4 hours after dosing. A hunched posture was observed immediately and 4 hours after dosing in one Main group female from week 3 until the end of the treatment period. PFHS A hunched posture was observed immediately and 4 hours after dosing in one male at the end of treatment until the second day of recovery. A similar finding was seen 4 hours after dosing in one Main group female on one occasion at the end of treatment. PFOS A hunched posture was observed in two Main group females in weeks 3 and 4 of treatment. A swelling on the abdominal skin was observed in one Main group male at the end of the treatment period. Other findings such as alopecia, salivation, a missing tall apex, red discolouration of the skin, wounds, scabs, scales, fissures with bleeding on the paws, swelling of the ear and eye abnormalities were noted among the treated and/or control animals. These findings were considered to be of no toxicological significance as Incidences remained within the range of biological variation for rats of this age and strain or could be attributed to the blood sampling procedure. - Page 20 - 000021 TELOMER ALCOHOL/TELOMER ACRYLATE/ ~ PFHS/PFOS NOTOX Project 242933 BODY WEIGHT TELOMER ALCOHOL Body weight gain of males was decreased at the end of the recovery period when compared to the corresponding control values. Absolute body weights of these animals remained however within the range of control values. TELOMER ACRYLATE Body weights of females were slightly decreased when compared to control values at the end of the treatment period. PFHS Body weight gain of males was decreased at the end of the recovery period. Absolute body weights of these males were also below control values, but did not differ with statistical significance. PFOS Body weights and body weight gain of females were decreased with statistical significance from week 2 of treatment until the end of the recovery period. Statistical significance was achieved in the majority of cases, mainly for absolute body weights. Among males, body weight gain was reduced with statistical significance in weeks 3 and 4 of the recovery period. Absolute body weights of these males were also below control values, but did not differ with statistical significance. Body weights and body weight gain of animals receiving remained in the same range as controls over the treatment and recovery period. FOOD CONSUMPTION PFHS Absolute food consumption among males was slightly reduced at the end of the 4week recovery period. However, after correction for body weight this effect was not observed anymore. PFOS Absolute food consumption of females was reduced from week 3 of treatment until the end of recovery. This effect was less apparent after allowance for body weight. Among males, absolute food consumption was slightly reduced at the end of the 4week recovery period, but relative food consumption was within control values. There were no differences in food consumption before or after allowance for body weight between animals receiving TELOMER ALCOHOL, TELOMER ACRYLATE or and control animals. - Page 21 - 000022 TELOMER ALCOHOL/TELOMER ACRYLATE/ ~ PFHS/PFOS NOTOX Project 242933 CLINICAL LABORATORY INVESTIGATIONS HAEMATOLOGY TELOMER ALCOHOL After 4 weeks, red blood cell count, haemoglobin and haematocrit values were decreased in females. After 2 weeks recovery, prothrombin time was decreased in females. After 4 weeks recovery, red cell distribution width was decreased in males. TELOMER ACRYLATE After 4 weeks, total red blood cell count was slightly decreased in males. This decrease was no apparent anymore after the 2- and 4-week drug-free recovery periods. After 4 weeks, differential leucocyte count revealed decreased relative values of neutrophilic granulocytes and Increased relative lymphocytes values in males. Partial thromboplastin time was increased in males of this dose group. Prothrombin time was decreased in females. After 2 weeks recovery, prothrombin time was still decreased in females. After 4 weeks recovery, red cell distribution width was decreased in males. PFHS After 4 weeks, total red blood cell count, haemoglobin, haematocrit, total number of platelets and prothrombin time were decreased in males. Total red blood cell count, haematocrit and prothrombin time were decreased in females. After 2 weeks recovery, prothrombin time and total platelet numbers were decreased in females. After 4 weeks recovery, no statistically significant differences when compared to controls were observed. PFOS After 4 weeks, mean corpuscular haemoglobin was increased in males and haematocrit and prothrombin time were decreased in females. After the 2- and 4-week drug-free recovery periods no statistically significant differences were observed. - Page 22 - 000023 TELOMER ALCOHOL/TELOMER ACRYLATE/ - PFHS/PFOS NOTOX Project 242933 CLINICAL BIOCHEMISTRY TELOMER ALCOHOL After 4 weeks, total cholesterol, total protein and globulin values were decreased in males. After 2 weeks recovery, total protein was still decreased in males. After 4 weeks recovery, total cholesterol, total protein, potassium and calcium values were decreased in males. TELOMER ACRYLATE After 4 weeks, total cholesterol, total protein and globulin were decreased and albumin/globulin ratios were Increased in males. After 2 weeks recovery these differences were not apparent anymore. After 4 weeks recovery, total protein, potassium and calcium values were decreased in males. After 4 weeks, aspartate aminotransferase activity, total protein, globulin and potassium values were decreased and albumin/globulin ratios were increased in males. After 2 weeks recovery, glucose values were increased and sodium values were decreased in males. Urea was Increased in females. After 4 weeks recovery, total protein, inorganic phosphate, potassium and calcium values were decreased in males. PFHS After 4 weeks, aspartate aminotransferase activity, total cholesterol, triglycerides, total protein and globulin values were decreased and albumin/globulin ratios, alkaline phosphatase activity and chloride were increased in males. Total cholesterol was decreased and chloride values were increased in females. After 2 weeks recovery, no statistically significant differences were observed anymore. After 4 weeks recovery, total cholesterol, glucose and potassium values in males were below control values with statistical significance. PFOS After 4 weeks, aspartate aminotransferase activity, total cholesterol, triglycerides, total protein and globulin values were decreased and albumin/globulin ratios and chloride were Increased in males. Urea and chloride values were increased in females. After 2 weeks recovery no such findings were observed. After 4 weeks recovery, aspartate aminotransferase activity, total bilirubin, total-protein, potassium and' calcium values were decreased and chloride was increased in males. - Page 23 00024 TELOMER ALCOHOL/TELOMER ACRYLATE/ - PFHS/PFOS NOTOX Project 242933 PATHOLOGY MACROSCOPIC EXAMINATION Macroscopic observations at necropsy did not reveal any alterations that were considered to have arisen as a result of treatment. The few macroscopic findings recorded at all sacrifices were unremarkable and did not distinguish treated rats from the vehicle control group. ORGAN WEIGHTS PFHS After 4 weeks, liver weights and HVer:body weight ratios were increased in males. After 2 and 4 weeks recovery, this effect had disappeared. Increased braintbody weight and testes:body weight ratios observed after the 4week recovery period is attributed to the slightly low autopsy body weights of these animals. PFOS After 4 weeks, autopsy body weights were decreased in females. Liver weights and liver:body weight ratios were increased 1n males and females. K1dney:body weight ratios were increased in females. After 2 weeks recovery, liver weights and liver:body weight ratios were still increased in males. After 4 weeks recovery, liver:body weight ratios were increased in males and females and kidney:body weight ratios were increased in females. Other changes noted 1n PFOS treated animals Included decreased absolute heart weights and increased brain:body weight ratios 1n females after 4 weeks of treatment and 2 weeks-recovery. In addition, absolute spleen weights were increased in males after 2 weeks recovery and testes:body weight ratios were increased after 4 weeks recovery. All these changes were likely to reflect slightly low or high body weights at autopsy. Organ weights and organ:body weight ratios of animals treated with TELOMER ALCOHOL, TELOMER ACRYLATE or were considered to be similar to those of control animals. - Page 24 - 000025 TELOMER ALCOHOL/TELOMER ACRYLATE/ - PFHS/PFOS NOTOX Project 242933 MICROSCOPIC EXAMINATION (see Appendix 1) TELOMER ALCOHOL After 4 weeks, midzonal/centrilobular hypertrophy was seen at a minimal or slight degree in six males. In the pancreas a slight Increase in the incidence of minimal or slight degrees of exocrine apoptosis/single cell necrosis was recorded in six males. After 2 and 4 weeks recovery, the liver changes had partially or completely resolved and the pancreas findings returned to the level of the vehicle control group. PFHS After 4 weeks, midzonal/centrilobular hypertrophy was seen at slight to moderate degrees in all males. After 2 weeks recovery, this finding had partially resolved. After 4 weeks recovery, this finding had completely resolved. PFOS After 4 weeks, midzonal/centrilobular hypertrophy was seen at minimal to moderate degrees in all males and females. After 2 and 4 weeks recovery, this finding had partially or completely resolved in females, however remained in evidence in males. The remainder of the microscopic findings recorded after treatment and recovery were within the range of background pathology encountered in Sprague Dawley rats of this age ad strain and occurred at similar incidences and severity in both control and treated rats. DISCUSSION AND CONCLUSION Following daily oral administrations of TELOMER ALCOHOL, TELOMER ACRYLATE, PFHS or PFOS to male and female Sprague Dawley rats for at least 28 days, treatment-related changes were most pronounced in the TELOMER ALCOHOL, PFHS and PFOS groups. Hepatocellular hypertrophy 1n the liver together with higher liver weights was seen in animals receiving PFHS and PFOS. In the TELOMER ALCOHOL group the hepatic hypertrophy was not accompanied by increased liver weights. This liver enlargement is most likely related to the higher enzymatic activity in metabolising a xenobiotic compound. Among males receiving PFOS this effect was rather persistent since it was still observed at the end of the 4-week drugfree period. Minimal to slight exocrine apoptosis/single cell necrosis was recorded in the pancreas of males receiving TELOMER ALCOHOL for 4 weeks and had resolved after the recovery period. - Page 25 - 000026 TELOMER ALCOHOL/TELOMER ACRYLATE/- PFHS/PFOS NOTOX Project 242933 Investigations of the blood showed that various parameters were slightly reduced in one or both sexes after treatment. The most characteristic decreases were: - total protein and globulin in all dose groups; - total cholesterol in all dose groups except for the group; - triglycerides in the PFHS and PFOS groups; - aspartate aminotransferase activity and prothrombin time in the , PFHS and PFOS groups. In the majority of cases these changes were not observed anymore after a 2-week drug-free period. A possible explanation for these changes could be liver damage as the liver is involved in the synthesis and metabolism of these compounds. However, the only microscopic change noted in the liver was hepatocellular hypertrophy in the TELOMER ALCOHOL, PFHS and PFOS groups only. Moreover, it should be noted that the majority of values remained within the range of values that can be expected for animals of this age and strain. Changes in clinical biochemistry parameters noted after 4 weeks of recovery but not after 2 weeks were considered to have occurred by chance. At this time point in the study it seems very unlikely that they represent an effect of treatment. Fluctuations in electrolyte levels were seen at all time points in all dose groups. Moreover, urea levels and kidney weights were Increased after treatment in females receiving PFOS. However, in the absence of evidence of renal dysfunction at microscopic level these changes are considered to be of little toxicological relevance. Haematological examination revealed slightly decreased red blood cell counts, haemoglobin and/or haematocrit values in animals treated with TELOMER ALCOHOL, TELOMER ACRYLATE, PFHS and PFOS. However, since the effects were slight in nature and no further evidence of an anaemic response was obtained at macroscopic or microscopic level, the toxicological relevance of these findings is doubted. Other haematological changes noted were not supported by corresponding signs of toxicity and again the toxicological impact is considered to be of little relevance also because the values were within the range of historical data. An effect on body weight and food consumption was most pronounced among females receiving PFOS. This effect lasted until the end of the recovery period. Body weights of females receiving TELOMER ACRYLATE were slightly reduced at the end of treatment. Other effects on body weight gain and food consumption were mainly seen at the end of the recovery period and therefore no toxicological relevance is attached to these findings. Clinical signs such as a hunched posture, piloerection and/or rales were observed incidentally in all five dose groups 1n a few animals only. At this low incidence and the severity observed these symptoms are considered not to represent a clear indication of toxicity. From the results presented in this report it can be concluded that the positive control compound PFOS dosed at 3 mg/kg/day was indeed the compound with the most striking and persistent effects, mainly in the liver. Compounds with comparable but less severe effects as PFOS included PFHS (10 mg/kg/day) and TELOMER ALCOHOL (30 mg/kg/day). Despite slightly reduced body weights in females (TELOMER ACRYLATE only) and some slight changes in the blood after treatment, 30 mg/kg TELOMER ACRYLATE or per day did not result in clear systemic toxicity and organ dysfunction at macroscopic or microscopic level. - Page 26 - 000027 TELOMER ALCOHOL/TELOMER ACRYLATE/ - PFHS/PFOS NOTOX Project 242933 FIGURES 27 000028 NOTOX Project 242933 BODY WEIGHTS MALES GRAM BW-SPLT - 1 08-DEC-98 -------------- GROUP 1 (VEHICLE CONTROL) .............. GROUP 2 (TELOMER ALCOHOL) ----------------GROUP 3 (TELOMER ACRYLATE) -------------- GROUP 4 ------------- GROUP 5 (PFHS) -------------- GROUP 6 (PFOS) 28 000029 NOTOX Project 242933 BODY WEIGHTS FEMALES GRAM BW-SPLT - 2 08-DEC-98 -------------- GROUP 1 (VEHICLE CONTROL) .............. GROUP 2 CTELOMER ALCOHOL) ----------------GROUP 3 (TELOMER ACRYLATE) -------------- GROUP 4 ------------- GROUP 5 (PFHS) -------------- GROUP 6 (PFOS) 29 000030 NOTOX Project 242933 BODY WEIGHT GAIN MALES X BWG-SPLT - 1 08-DEC-98 -------------- GROUP 1 (VEHICLE CONTROL) .............. GROUP 2 (TELOMER ALCOHOL) ----------------GROUP 3 (TELOMER ACRYLATE) -------------- GROUP 4 -------------- GROUP 5 (PFHS) -------------- GROUP 6 (PFOS) 30 000031 NOTOX Project 242933 BODY WEIGHT GAIN FEMALES x BWG-SPLT - 2 08-DEC-98 -------------- GROUP 1 (VEHICLE CONTROL) .............. GROUP 2 (TELOMER ALCOHOL) ----------------GROUP 3 (TELOMER ACRYLATE) -------------- GROUP 4 ------------- GROUP 5 (PFHS) -------------- GROUP 6 (PFOS) 31 000032 NOTOX Project 242933 FOOD CONSUMPTION MALES G/ANIMAL/DAY FC-SPLT - 1 01-MAR-99 -------------- GROUP 1 (VEHICLE CONTROL) .............. GROUP 2 (TELOMER ALCOHOL) ----------------GROUP 3 (TELOMER ACRYLATE) -------------- GROUP 4 ------------- GROUP 5 (PFHS) -------------- GROUP 6 (PFOS) 32 000033 NOTOX Project 242933 FOOD CONSUMPTION FEMALES G/ANIMAL/DAY FC-SPLT - 2 01-MAR-99 -------------- GROUP 1 (VEHICLE CONTROL) .............. GROUP 2 (TELOMER ALCOHOL) ----------------GROUP 3 (TELOMER ACRYLATE) -------------- GROUP 4 ------------- GROUP 5 (PFHS) -------------- GROUP 6 (PFOS) 33 000034 NOTOX Project 242933 RELA TIVE FOOD CONSUMPTION MALES G/KG BODY VEIGHT/DAY RFC-SPLT - 1 01-MAR-99 -------------- GROUP 1 (VEHICLE CONTROL) .............. GROUP 2 (TELOMER ALCOHOL) ----------------GROUP 3 (TELOMER ACRYLATE) -------------- GROUP A ------------- GROUP 5 (PFHS) -------------- GROUP 6 (PFOS) 34 WEEKS 000035 NOTOX Project 242933 RELA TIVE FOOD CONSUMPTION FEMALES G/KG BODY VEIGHT/DAY RFC-SPLT - 2 01-MAR-99 -------------- GROUP 1 (VEHICLE CONTROL) .............. GROUP 2 (TELOMER ALCOHOL) ----------------GROUP 3 (TELOMER ACRYLATE) --------------- GROUP 4 -------- g r o u p 5 (PFHS -------------- GROUP & (PFOS) 35 000036 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS NOTOX 242933 TABLES SUMMARY DATA 000037 36 NOTOX Project 242933 - SYM-SUM - 1 1 7 - M A R - 99 CLINICAL SIGNS (SUMMARY) MALES GROUP 1 (VEHICLE CONTROL) SIGN (MAX.GRADE) TREATMENT WEEKS: 1.......... 2.......... 3.......... 4.......... 5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABASABABABAB SKIN / FOR / PLOMAGE ALOPECIA (3) (BACK) ALOPECIA (3) (NECK) ALOPECIA (3) (ABDOMEN) ALOPECIA (3) (CHEST) ALOPECIA (3) (FORELEG LEFT) ALOPECIA (3) (HINDLEG LEFT) ALOPECIA (3) (HINDLEG RIGHT) SCABS (3) (NECK) VARIOUS BULGING EXE (1) (EYE RIGHT) DARK (3) (EYE RIGHT) G: ........................... 1111111111........... %: ........................... 1111111111........... ....................... . .1111111111111111111........ %: ...................... 1111111111111111111........ G: ...... ......... 111111111111111111111111111111111111.. %: ................111111111111111111111111111111111111.. G: ..11....................................... .... %: ..11........................................... G: ...1222222222221111111111111111111111111.............. %: ...1111111111111111111111111111111111111.............. G: .... 11111111111113311111111111111........ .......... %: .... 11111111111111111111111111111.................. ....... 1111111111111111111111111111111111.............. %: .... lllllllimillllllllllllllllllllll.............. G: ............ 111111111111111111111111111............ %: ............ 111111111111111111111111111............ .................................................. %: ............................................... G: ............................................... %................................................ G: Median value oC the highest individual grades %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%,..., A = more than 95%) Time after treatment (H.Mi) A: 0.00 B: 4.00 37 00003S NOTOX Project 242933 CLINICAL SIGNS, DAILY (SUMMARY) MALES GROUP 1 (VEHICLE CONTROL) SIC2J (MAX.GRADE) LOCATION RECOVERY WEEKS: 1 ..... 2 ..... 3 ..... 4 ..... 5. SKIN / FUR / PLUMAGE ALOPECIA (3) (CHEST) VARIOUS BULGING EYE (1) (EYE RIGHT) DARK (3) (EYE RIGHT) G: ..... 12222222 % ....... 22222222 G: 11 %: 12 G: 11 %: 12 S Y M - S U M - SL 2 5 - M A R - 99 G: Median value of the highest individual daily grades %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%,..., A = more than 95%) 38 000039 NOTOX Project 242933 SYM-SM - 3 17-MAR-99 CLINICAL SIGNS (SUMMARY) MALES GROUP 2 (TELOMER ALCOHOL) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ......................... 2 .......................... 3 .......................... 4 .......................... 5 . DAYS: 1 . 2 . 3 . 4 . 5 . 6 . 7 . 1 . 2 . 3 . 4 . 5 . 6 . 7 . 1 . 2 . 3 . 4 . 5 . 6 . 7 . 1 . 2 . 3 . 4 . 5 . 6 . 7 . 1 . TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB BREATHING RALES (3) SKIN / FOR / PLUMAGE ALOPECIA (3) (CHEEK RIGHT) ALOPECIA (3) (NECK) ALOPECIA (3) (ABDOMEN) ALOPECIA (3) (SHOOLDER LEFT) ALOPECIA (3) (FORELEG LEFT) SCABS (3) (SNOUT) SCABS (3) (BACK) SCABS (3) (NECK) WOUND (3) (GENITAL REGION) RED STAINING (3) (PERIORBITAL REGION LEFT) RED STAINING (3) (PERIORBITAL REGION RIGHT) G: 111 %: 111 G: ............................... 111111111...... %: ............................... 111111111...... G: .......................................... 11111 %: ...........................................11111 G: ........... llllllllllllllllllllimilllllllllllllllllllll - %: ........... llllllllllllllllllllimilllllllllllllllllllll ...... .................................. 11 %: .... ..................................11 G: %: 11111111111111 G: ..... .................................................... 1 %: ........... ,............................................. 1 G: ................. ............................. %....................................... 11 G: ........................................ 11..... 1111 %: ...........................................11..... 1111 G: %: 11 G: %: G: %: G: Median value of the highest individual grades % : Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, Time after treatment (H.Mi) A: 0.00 B: 4.00 39 A = more than 95%) 000040 NOTOX Project 242933 CLINICAL SIGNS, DAILY (SUMMARY) MALES GROUP 2 (TELOMER ALCOHOL) SIGN (MAX.GRADE) LOCATION RECOVERY WEEKS: 1 ..... 2 ..... 3 ..... 4 ..... 5. BREATHING RALES (3) SKIN / FUR / PLUMAGE ALOPECIA (3) (ABDOMEN) SCABS (3) (SNOUT) RED STAINING (3) (PERIORBITAL REGION LEFT) RED STAINING (3) (PERIORBITAL REGION RIGHT) % : 1222222222222223..3333 G: U 1 U %: 12222 G: 11... %: 12... G ........ Ill %: ...... 222 - G: %: .... ... 12______ SYM-SUM - 4 2 5 - M A R - 99 G: Median value of the highest individual daily grades %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%,. .., A = more than 95%) 000041 NOTOX Project 242933 S Y M - S O M - gr 1 7 - M A R - 99 CLINICAL SIGNS (SUMMARY) MALES GROUP 3 (TELOMER ACRYLATE) SIGN (MAX.GRADE) TREATMENT WEEKS: 1............ 2 .............3 .............4 ............. 5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.S.7.1.2.3.4.5.S.7.1.2.3.4.5.S.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABAEABABAB SKIN / FOR / PLUMAGE ALOPECIA (3) (NECK) ALOPECIA (3) (FLANK LEFT) ALOPECIA (3) (CHEST) ALOPECIA (3) (FORELEG RIGHT) SCABS (3) (BACK) SCABS (3) (TAIL) RED STAINING (3) (NECK) G: ........................ m i n %: ..........................:......................................limi G: %: 1111111121212111111111111111111111111111....................... G: %: 111111121212121212121111111111111111111111111111111111111111111111111111 G: 11122222221111111111 %: 11111111111111111111 G: %: ...................................... .............................. 1111......11111111 G: ........................................ ....immillili.. %: ............................................immillili.. G: %: G: Median value of the highest individual grades %: Percent of affected animals <0 = less than 5%, 1 = between 5% and 15%, Time after treatment (H.Mi) A: 0.00 B: 4.00 41 A * more than 95%) 000042 NOTOX Project 242933 CLINICAL SIGNS, DAILY (SUMMARY) MALES GROUP 3 (TELOMER ACRYLATE) SIGN (MAX.GRADE) LOCATION RECOVERY WEEKS: 1 ............2 ......3 .... SKIN / FOR / PLUMAGE RED STAINING (3) (NECK) G: .................... ..mm. % ...................... ..333333. 'SYM-SUM - 6 25-MAR-99 G: Median value of the highest individual daily grades %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%,..., A = more than 95%) 4 2 000043 NOTOX Project 242933 SYM-SUM - 7 17-MAR-9 9 CLINICAL SIGNS (SUMMARY) MALES GROUP 4 SIGH (MAX.GRADE) TREATMENT WEEKS DAYS: 11..2...3...4...5...6...7..21...2...3...4...5...6...7..31...2...3...4...5...6...7..41...2...3...4...5...6...7..51.. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB SKIN / FOR / PLUMAGE ALOPECIA (3) (EYE RIGHT) ALOPECIA (3) (FORELEG RIGHT) ' SCABS (3) (NECK) RED STAINING (3) (PERIORBITAL REGION LEFT) VARIOUS EYE RIGHT, INJURED (1) DEHYDRATED (3) (EYE RIGHT) BULGING EYE (1) (EYE RIGHT) DARK (3) (EYE RIGHT) G: %: G: %: G: %: G: %: G: %: G: %: G: %: G: %: ........ ........ 111111111111111111111111 1111111111............................ 1111...... G: Median value of the highest individual grades %: Percent of affected animals ( O s less than 5%, 1 = between 5% and 15%, Time after treatment (H.Mi) A: 0.00 B: 4.00 43 A = more than 95%) 000044 NOTOX Project 242933 ,. _ CLINICAL SIGNS, DAILY (SUMMARY) MALES GROUP 4 SIGN (MAX.GRADE) LOCATION - RECOVERY WEEKS: 1 ..... 2 ..... 3 ..... 4 ..... S. SKIN / FDR / PLUMAGE ALOPECIA (3) (e y e Rican?) VARIOUS EYE RIGHT, INJURED (1) DEHYDRATED (3) (EYE RIGHT) BULGING EYE (1) (EYE RIGHT) DARK (3) (EYE RIGHT) G: ........... 1111111111111111. %: ........... 2223333333333333. G: 1111111111111111111111111111. %: 1222222222222223333333333333. G: .22222....................... %: .22222....................... G: 111111....................... %: 122222....................... G: 111111....................... 232222....................... SYM-SUM - g 2 5 - M A R - 99 G: Median value of the highest individual daily grades %: Percent of affected animals (0 - less than 5%, 1 = between 5% and 15%,.... 44 A = more than 95%) 000045 NOTOX Project 242933 SYM-SUM - 5 1 7 -MAR-39 CLINICAL SIGNS (SUMMARY) MALES GROUP 5 (PFHS) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 .............3 .............4 ............. 5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.S.6.7.1.2.3.4.5.6.7.1.2.3.4.5.S.7.1. TIME: ABABABABAHABABABABABABABABABABABABABABABABABABABABAEABABAB POSTURE HUNCHED POSTURE (1) SKIN / FUR / PLUMAGE WOUND (3) (BACK) RED STAINING (3) (EAR LEFT) RED STAINING (3) (SNOUT) RED STAINING (3) (NECK) RED STAINING (3) (CERVICAL REGION) VARIOUS DARK (3) (EYE RIGHT) G: ....................................................... 1111 %: ........... ...........................................1111 G: .... %: ___ ___in ........................ G: .... .... 11111111111___ %: .... ..........m in im i____ G: .... %: ___ G: .... %: ___ G: .... %: .... G: %: G: Median value of the highest individual grades %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%,.... A = more than 95%) Time after treatment (H.Mi) A: 0.00 B: 4.00 45 000046 NOTOX Project 242933 CLINICAL SIGNS, DAILY (SUMMARY) MALES GROUP 5 (PFHS) SIGN (MAX.GRADE) LOCATION RECOVERY WEEKS: 1 ..... 2 ..... 3 ..... 4 ..... 5. POSTURE HUNCHED POSTURE (1) SKIN / FUR / PLUMAGE RED STAINING (3) (NECK) RED STAINING (3) (CERVICAL REGION) VARIOUS DARK (3) (EYE RIGHT) G: 11 %: 12 G: ...... 11.................... %: ...... 2 2 ..................... G: ........ 1111111111111111111. % .......... 2222223333333333333. G: 11 %: 12 STO-SUM -to 25-MAR-9 9 G: Median value of the highest individual daily grades %: Percent of affected animals (0 less than 5%, 1 = between 5% and 15%,.... A = more than 95%) 46 000047 NOTOX Proiect 242933 SYM-SUM - n 1 7 - M A R - 99 CLINICAL SIGNS (SUMMARY) MALES GROUP 6 (PFOS) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2............ 3 .............4 .............5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABAEABABABAB SKIN / FUR / PLUMAGE SWELLING (3) (ABDOMEN) ALOPECIA (3) (CHEEK LEFT) SCABS (3) (NECK) RED STAINING (3) (HEAD) G: ........... % ............. ............... %: ........... ............... % ............. G: ........... .%: ........... G: Median value of the highest Individual grades %: Percent of affected animals (0 less than 5%, 1 = between 5% and 15%,.... A = more than 95%) Time after treatment (H.Mi) A: 0.00 B: 4.00 47 000048 NOTOX Project 242933 CLINICAL SIGNS, DAILY (SUMMARY) MAT.TCfi GROUP 6 (PFOS) SXOI (MAX.GRADE) LOCATION RECOVERY WEEKS: 1 ..... 2 ..... 3 --- ...4......5. SKIN / FUR / PLUMAGE RED STAINING (3) (HEAD) G: .................. 111111111. %: .......... ........ 333333333. SYM-SUM -la 2 5 - M A R - 99 G: Median value of the highest individual daily grades %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15% 48 A = more than 95%) 000049 NOTOX Project 242933 S Y M - S U M - 13 1 7 - M A R - 99 CLINICAL SIGNS (SUMMARY) FEMALES GROUP 1 (VEHICLE CONTROL) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 ............. 3 ............ 4 .............5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB SKIN / FOR / PLUMAGE ALOPECIA (3) (GENERAL) ALOPECIA (3) (CHEEK LEFT) ALOPECIA (3) (BACK) ALOPECIA (3) (NECK) ALOPECIA (3) (ABDOMEN) ALOPECIA (3) (FLANK LEFT) ALOPECIA (3) (FLANK RIGHT) ALOPECIA (3) (SHOULDER LEFT) ALOPECIA (3) (THIGH HIND LEFT) ALOPECIA (3) (THIGH HIND RIGHT) Al o p e c i a (3) (HINDLEG LEFT) SCABS (3) (ABDOMEN) WOUND (3) (ABDOMEN) SECRETION / EXCRETION SALIVATION (3) VARIOUS MISSING (1) (TAIL APEX) G: %: G: %: ........................... %: .............. -.......... 111111111111111111.. G: %: G: 1111222211111111111111111111111111111111111111111111111111 % : 1111111111111111111111111111111111111111111111111111111111 G: %: ....................................... ............................... 1l1i1l1l1l1l1l1l1l1l1l1l1l1l1l1l1l1l1l ........... 111111111111111.1111111111111111111111111111111 %: ........ 111111111111111.1111111111111111111111111111111 G: %: ............................. ................ ...... 11111111111111111111111111111111111111111111.. G: ...11111111111...........................111111111. % : ...11111111111...........................111111111. G: 11111111111111................ '...l llllUinilllll.... Ill % : 11111111111111................... 1111111111111111.... Ill G: .111111111111111. %: .111111111111111. G: %: ................................................... ......................................... 11111111111111 G: %: G: %: G: ......................... 1111111111111111111111111111111.. % ........................... 1111111111111111111111111111111.. G: Median value of the highest individual grades %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, Time after treatment (H.Mi) A: 0.00 B: 4.00 49 A = more than 95%) 000050 NOTOX Project 242933 CLINICAL SIGNS, DAILY (SUMMARY) FEMALES GROUP 1 (VEHICLE CONTROL) SIGN {MAX.(GRADE) LOCATION RECOVERY WEEKS: 1 ..... 2 ..... 3 ..... 4..... 5. SKIN / FOR / PLUMAGE ALOPECIA (3) (GENERAL) ALOPECIA (3) (CHEEK LEFT) ALOPECIA (3) (BACK) ALOPECIA (3) (NECK) ALOPECIA (3) (ABDOMEN) ALOPECIA (3) (FLANK LEFT) ALOPECIA (3) (FLANK RIGHT) ALOPECIA (3) (THIGH HIND LEFT) ALOPECIA (3) (THIGH HIND RIGHT) SCABS (3) (ABDOMEN) G: ................ l m i l U l l l %: ................ 33333333333 G: ............. ..11.......... %: .............. 33 ........... G: ..... 11111111111.......... ......... 22222222233.......... G: ......... 1111.............. %: ..........2222............... G: ..... 11111111111.......... %: ..... 22222222233........... - G: 11111111111111111 %: 12222222222222233 G: 11122222222222222 %: 12222222333322233 G: ...111111111111 %: .. .222222222222 G: 111111111111111 %: 122222222222222 G: %: ......21212121212121212121 SYM-SUM - M 25-MAR-99 G: Median value of the highest individual daily grades %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%,..., A = more than 95%) 50 000051 \Q I- NOTOX Project 242933 SYM-SUM 17-MAR- CLINICAL SIGNS (SUMMARY) FEMALES GROUP 2 (TELOMER ALCOHOL) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 .............3 .............4 .............5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB SKIN / FUR / PLUMAGE ALOPECIA (3) (HEAD) ALOPECIA (3) (CHEEK LEFT) ALOPECIA (3) (CHEEK RIGHT) ALOPECIA (3) (BACK) ALOPECIA (3) (NECK) ALOPECIA (3) (FORET.KGS) SCALES (3) (CHEEK LEFT) SCALES (3) (CHEEK RIGHT) SCABS (3) (FLANK LEFT) RED STAINING (3) (EAR RIGHT) G: %: G: ......... '............................ 1111111111......... %: ........... ........................... 1111111111......... G: ......................................................... 11 %: ......................................................... 11 G: ...................................................... 11111 %: ...................................... ................ 11111 G: 11111111111111111....... 1 - %: 11111111111111111....... 1 G: ............................................... 1111111112.. %: ..................... ....................... ..1111111111.. G: %: G: %: G: ...................................11 %: ................................... 11 G ............. 11 %: ........... 11 G: Median value of the highest individual grades %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%,..., A = mare than 95%) Time after treatment (H.Mi) A: 0.00 B: 4.00 51 000052 NOTOX Proiect 242933 CLINICAL SIGNS, DAILY. (SUMMARY) FEMALES GROUP 2 (TELOMER ALCOHOL) SIGN (MAX.GRADE) LOCATION RECOVERY WEEKS: 1 ..... 2 ..... 3 ..... 4 ......5. SKIN / FUR / PLUMAGE ALOPECIA (3) (HEAD) ALOPECIA (3) (CHEEK LEFT) ALOPECIA (3) (CHEEK RIGHT) SCALES (3) (CHEEK LEFT) SCALES (3) (CHEEK RIGHT) G: 2222211 %: 2222222 G: .1112222222222 %: .2222333333333 G: 1222222222 % ..... 3333333333 ......... 1111111 % ........ 2222222 G: 1111111 %.: 2222222 SYM-SUM 25-MAR-99 G: Median value of the highest individual daily grades %: Percent of affected animals (0 less than 5%, 1 = between 5% and 15%,..., 52 A more than 95%) 000053 NOTOX Proiect 242933 S Y M - S U M - 17 1 7 - M A R - 99 CLINICAL SIGNS (SUMMARY) FEMALES GROUP 3 (TELOMER ACRYLATE) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 .............3 .............4 .............5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB POSTURE HUNCHED POSTURE (1) G: %: 11111111111111111111111111........................ 11111111111111 SKIN / FUR / PLUMAGE PILOERECTION (1) ALOPECIA (3) (ABDOMEN) ALOPECIA (3) (CHEST) ALOPECIA (3) (SHOULDER LEFT) G: %: G: 1111222211111111111111111111112122222211111111111111111111 %: 1111111111112222111111111133321111111122222232222222211111 G: . %: .................... .................... 1111111111111111111111.................................. G: %: .................. .................. 11111111111111............................................ FISSURES WITH BLEEDINGS (3) (PAW HIND RIGHT) G: %: 11 11 SCABS (3) (BACK) SCABS (3) (NECK) RED STAINING (3) (HEAD) RED STAINING (3) (BACK) RED STAINING (3) (NECK) RED STAINING (3) (PAW HIND RIGHT) G: %: G: %: G: %: G: %: G: %: G: %: ....11 ___11 111111111111 111111...................................................... 11111111111111 111111111111 11111111111111111111111111................................ 11111111 111111111111111 m inim um G: Median value of the highest individual grades %: Percent of affected animals (0 = less than 5%, 1 =* between 5% and 15%,..., A = more than 95%) Time after treatment (H.Mi) A: 0.00 B: 4.00 53 OO0O54 NOTOX Proiect 242933 CLINICAL SIGNS, DAILY (SUMMARY) FEMALES GROUP 3 (TELOMER ACRYLATE) SIGH (MAX.GRADE) LOCATION RECOVERY WEEKS: 1 ..... 2 ..... 3 ..... 4 ..... 5. POSTURE HUNCHED POSTURE (1) SKIN / FUR / PLUMAGE PILOERECTION (1) ALOPECIA (3) (ABDOMEN) RED STAINING (3) (HEAD) G: 11111111111111............. %: 23333332222222............. G: .1111....................... %: .2222....................... G: 11111111111111............. %: 12222222222222............. G: .......................... 11 %: .......................... 77 S Y M - S U M -18 2 5 - M A R - 99 G: Median value of the highest individual daily grades %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%,..., A = more than 95%) 54 000055 NOTOX Proiect 242933 S Y M - S U M - ig 1 7 - M A R - 99 CLINICAL SIGNS (SUMMARY) FEMALES GROUP 4 SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 ......... ...3............ 4 ............ 5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB POSTURE HUNCHED POSTURE (1) G: %: 11111111111111111111111111111111111111111111111111111111 SKIN / FUR / PLUMAGE SWELLING (3) (EAR RI G I D ALOPECIA (3) (b a c k ) ALOPECIA (3) (NECK) ALOPECIA (3) (THROAT REGION) SCALES (3) (THROAT REGION) G: ............ 1111111111111 %: ............ 1111111111111 .................... 111111111111... 1111111111111.... 1111111.. % : ................ liiiiiiiiiii... immillili.... m in i.. G: ......................lllllllllllllllllimillllllllllllll % : ......................... 111111111111111111111111111122222222 G ....................... %: ................. .111111111111111111111111111111111111 G: ....................... 1111111111111 %: ....................... 1111111111111 SCABS (3) (NECK) G: %: RED STAINING (3) (EYE R I G I D ' G: %: RED STAINING (3) (PERIORBITAL REGION RIGHT) G: %: RED STAINING (3) (EAR LEFT) ......................... 111111111 % ........................ 111111111 RED STAINING (3) (EAR RIGHT) G ............. 1111111111111111111111111111111111111111111111 % ............. . SECRETION ! EXCRETION WATERY DISCHARGE FROM EYE (3) G: (EYE RIGHT) %: G: Median value of the highest Individual grades %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%,..., A = more than 95%) Time after treatment (H.Mi) A: 0.00 B: 4.00 55 000056 NOTOX Proiect 242933 CLINICAL SIGNS, DAILY (SUMMARY) FEMALES GROUP 4 SIGN (MAX.GRADE) LOCATION RECOVERY WEEKS: 1 ..... 2 ..... 3 ..... 4 ..... 5. SKIN / FOR / PLUMAGE SCABS (3) (NECK) * -......................... RED STAINING (3) (EYE RIGHT) G: ...11..... %: ...22..... RED STAINING (3) (PERIORBITAL REGION RIGHT) G: .... 11.... ..... 1111.... %: .... 22 ___ ..... 3333.... SECRETION ! EXCRETION WATERY DISCHARGE FROM EYE (3) G: ........ .....11 (EYE RIGHT) %: ............. 23 S Y M - S U M - 2.0 2 5 -MAP.-9 9 G: Median value o Che highest individual daily grades %: Percent of affected animals (0 less than 5%, 1 = between 5% and 15%,... , A = more than 95%) 56 000057 NOTOX Pro1 ect 242933 S Y M - S U M - 2.1 17-MAR-9 9 CLINICAL SIGNS (SUMMARY) FEMALES GROUP 5 (PFHS) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 .............3 .............4 .............5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB POSTURE HUNCHED POSTURE (1) SKIN / FUR / PLUMAGE ALOPECIA (3) (BACK) ALOPECIA (3) (NECK) ALOPECIA (3) (ABDOMEN) ALOPECIA (3) (SHOULDER RIGHT) ALOPECIA (3) (HINDLEG RIGHT) SCABS (3) (NECK) MOUND (3) (NECK) SECRETICI / EXCRETION SALIVATION (3) G: ........................................................1.. %: ........... :........................................... 1.. G: ......................11111112111111...................... %: ......................11111111111111...................... G: ..111111111222222111111111111111111111111112222222222222.. %.: ..111111111111111111113333333344333322222222211111111111.. G: ........... 1111111111222222222222222222222222111111111111 . %: ........... 1111111111111111111111111111111111111111111111 G: ........................................................1.. %: ........................................................1.. G: ............................ .............................. %: ........................................................... G: 1111112222111111111111222222111111111111111111111111111... %: 1111111111111111111111111111111111111111111111111111111... G: ....... 11.. 111112222211................. ................. %: ....... 11.. 111111111111.................................. ......... 1 ................................................... %: ...... 1 ................................................... G: Median value of the highest individual grades %: Percent of affected animals (0 = less than 5%, 1 * between 5% and 15%,..., A = more than 95%) Time after treatment (H.Mi) A: 0.00 B: 4.00 57 000058 NOTOX Prolect 242933 CLINICAL SIGNS, DAILY (SUMMARY) FEMALES GROUP 5 (PFHS) SIGN (MAX.GRADE) LOCATION RECOVERY WEEKS: 1 ..... 2 ..... 3 ..... 4 ..... 5. SION / FOR / PLUMAGE ALOPECIA (3) (BACK) ALOPECIA (3) (NECK) ALOPECIA (3) (ABDOMEN) ALOPECIA (3) (HINDLEG RIGHT) G: %: G: 111..11111111111111111111111 %: 122..22222333337777777777777 G: 111....111111111111111111111 %: 122___ .222222223333333333333 G: ..... 1111.................. %: ..... 2222.................. SYM-SUM - 12 2 5 - M A R - 99 G: Median value of the highest individual daily grades %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, 58 A = more than 95%) 000059 NOTOX Project 242933 SYM-SUM - 23 17-MAR-99 CLINICAL SIGNS (SUMMARY) FEMALES GROUP 6 (PFOS) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 .............3 ............ 4 .............5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.S.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB POSTURE HUNCHED POSTURE (i) SKIN / FUR / PLUMAGE ALOPECIA (3) (ABDOMEN) ALOPECIA (3) (FORELEG LEFT) ALOPECIA (3) (FORELEG RIGHT) SCABS (3) (NECK) RED STAINING (3) (HEAD) RED STAINING (3) (EAR LEFT) RED STAINING (3) (EAR RIGHT) RED STAINING (3) (SNOUT) RED STAINING (3) (NECK) G: ...... %: ...... G: ...... ....... l i u i i i i u ii ii i ii iiii ii i im ...liiiiiiiiiii %: ...... G: ...... %: ...... G: ...... %: ...... G: ...... %: ...... G: ...... %: ...... G: ...... %: ...... G: ...... %: ...... G: ...... %: ...... G: ...... % ...... G: Median, value of the highest individual grades %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, Time after treatment (H.Mi) A: 0.00 B: 4.00 59 A = more than 95%) 000060 NOTOX Proiect 242933 CLINICAL SIGNS, DAILY (SUMMARY) PENALES GROUP 6 (PFOS) SIGN (MAX.GRADE) LOCATION RECOVERY WEEKS; 1 ..... 2 ..... 3 ..... 4 ..... 5. SKIN / FUR / PLUMAGE ALOPECIA (3) (ABDOMEN) RED STAINING (3) (HEAD) RED STAINING (3) (EAR LEFT) RED STAINING (3) (EAR RIGHT) RED STAINING (3) (NECK) G; %; 1121212121............... G: 11111111111111 %: 12255332222233 G: %; ......212112121212121212.... G: %: ................212121.... G: ........ 11111 %: ........ 22222 SYM-SUM 25-MAR-99 G: Median value of the highest individual daily grades %: Percent of affected animals (0 = less than 5%, 1 = between 5% and 15%, 60 A = more than 95%) 000061 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS BW-SUM - 1 09-DEC-98 BODY W EIGHTS (GRAM) SUMMARY M ALES TREATMENT GROUP 1 VEHICLE CONTROL DAY 1 WEEK 1 DAY 5 WEEK 1 DAY 8 WEEK 2 DAY 12 WEEK 2 DAY 15 WEEK 3 DAY 19 WEEK 3 DAY 22 WEEK 4 DAY 25 WEEK 4 DAY 28 WEEK 4 MEAN ST.DEV. N MEAN ST. DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST. DEV.. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N 203 14.0 14 232 14.9 14 248 19.8 14 272 20.7 14 281 25.2 14 302 26.8 14 312 27.4 14 324 29.8 14 336 29.9 14 GROUP 2 TELOMER ALCOHOL 212 13.5 14 237 14.4 14 252 17.6 14 277 18.6 14 288 22.9 14 308 23.2 14 316 23.6 14 329 25.4 14 340 27.5 14 GROUP 3 TELOMER ACRYLATE GROUP 4 209 210 9.2 9.4 14 14 234 8.9 14 248 11.8 14 273 9.3 14 283 10.9 14 304 10.3 14 315 9.5 14 328 12.6 14 338 13.0 14 238 10.8 14 252 13.2 14 279 17.7 14 288 19.4 14 312 24.1 14 319 26.5 14 333 28.4 14 347 31.6 14 GROUP 5 PFHS 208 13.8 14 231 16.5 14 246 23.4 14 270 24.5 14 275 26.3 14 301 30.4 14 307 31.9 14 321 34.8 14 328 37.1 14 GROUP 6 PFOS 210 10.9 14 237 13.9 14 252 17.8 14 279 21.0 14 288 25.2 14 310 29.0 14 318 31.4 14 333 33.5 14 342 33.7 14 / ** : Dunnett-Test based on pooled variance significant at 5% (*) or 1% (**) level 61 000062 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS BW-SUM - 2 09-DEC-98 BO DY W EIGHTS (GRAM) SUMMARY M ALES RECOVERY GROUP 1 VEHICLE CONTROL DAY 1 WEEK 1 DAY 5 WEEK 1 DAY 8 WEEK 2 DAY 12 WEEK 2 DAY 14 WEEK 2 DAY 19 WEEK 3 DAY 22 WEEK 4 DAY 25 WEEK 4 DAY 28 WEEK 4 MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N 304 27.9 6 338 31.2 6 346 32.8 6 358 32.8 6' 362 32.4 6 391 24.6 3 399 24.2 3 412 25.2 3 415 26.7 3 GROUP 2 TELOMER ALCOHOL 298 20.2 6 331 28.8 6 338 28.1 6 350 28.5 6 351 28.6 6 375 35.7 3 382 33.5 3 391 38.5 3 391 37.1 3 GROUP 3 TELOMER ACRYLATE GROUP 4 GROUP 5 PFHS 314 12.4 6 351 23.5 6 356 20.9 6 372 21.0 6 374 20.8 6 389 7.2 3 399 5.5 3 407 7.8 3 412 2.6 3 330 28.2 6 372 31.8 6 383 35.2 6 400 36.9 6 398 38.0 6 419 35.0 3 426 37.6 3 437 38.7 3 435 37.6 3 291 40.4 6 327 45.4 6 338 46.9 6 344 48.5 -6 345 47.6 6 347 19.1 3 351 19.1 3 368 20.8 3 362 20.8 3 GROUP 6 PFOS 313 40.4 6 352 46.8 6 360 46.0 6 374 46.8 6 376 47.6 6 351 39.7 3 359 38.6 3 371 34.8 3 370 39.3 3 * / ** : Ounnett-Test based on pooled variance significant at 5% (*) or 1% (**) level 62 000063 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS BW-SUM - 3 09-DEC-98 BO DY W EIGHTS (GRAM) SUMMARY FEM ALES TREATMENT GROUP 1 VEHICLE CONTROL DAY 1 WEEK 1 DAY 5 WEEK 1 DAY 8 WEEK 2 DAY 12 WEEK 2 DAY 15 WEEK 3 DAY 19 WEEK 3 DAY 22 WEEK 4 DAY 25 WEEK 4 DAY 28 WEEK 4 MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N 174 11.9 14 181 . 14.3 14 188 . 15.6 14 202 16.2 14 206 19.8 14 219 20.1 14 221 19.4 14 232 21.4 14 236 21.8 14 GROUP 2 TELOMER ALCOHOL GROUP 3 TELOMER ACRYLATE GROUP 4 169 8.0 14 176 8.5 14 182 11.9 14 194 11.9 14 200 15.0 14 213 15.5 14 216 15.7 14 227 16.5 14 230 16.9 14 ' 166 10.0 14 173 11.2 14 179 13.2 14 191 13.3 14 192 15.0 14 203 15.5 14 207 16.9 14 218 17.3 14 219 * 17.0 14 170 11.9 14 177 14.5 14 182 15.9 14 198 16.8 14 202 18.2 14 214 19.6 14 218 20.4 14 230 18.6 14 231 20.5 14 GROUP 5 PFHS GROUP 6 PFOS 169 8.0 14 174 10.4 14 180 9.8 14 194 10.9 14 196 11.3 14 209 11.3 14 212 12.6 14 222 13.0 14 224 12.6 14 166 8.7 14 171 9.8 14 176 10.1 14 188 * 9.8 14 187 * 11.5 ' 14 198 ** 12.7 14 200 ** 13.2 14 207 ** 14.3 14 207 * 13.3 14 * / ** : Dunnett-Test based on pooled variance significant at 5% {*) or 1% (**) level 63 000064 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS BW-SUM - 4 09-DEC-98 B O D Y W EIGHTS (GRAM) SUMMARY FEM ALES RECOVERY GROUP 1 VEHICLE CONTROL DAY 1 WEEK 1 DAY 5 WEEK 1 DAY 8 WEEK 2 DAY 12 WEEK 2 DAY 14 WEEK 2 DAY 19 WEEK 3 DAY 22 WEEK 4 DAY 25 WEEK 4 DAY 28 WEEK 4 MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST. DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N 213 21.9 6 239 24.1 6 244 25.1 6 251 25.8 6 257 27.3 6 254 27.5 3 258 28.0 3 263 28.6 3 268 27.8 3 GROUP 2 TELOMER ALCOHOL 200 9.9 6 226 11.3 6 229 12.7 6 238 12.3 6 237 16.7 6 246 13.2 3 251 12.9 3 251 10.8 3 251 12.7 3 GROUP 3 TELOMER ACRYLATE GROUP 4 193 16.2 6 219 18.2 6 222 19.9 6 233 20.2 6 231 20.6 6 245 26.6 3 248 25.3 3 249 25.4 3 248 26.0 3 212 23.9 6 236 20.3 6 240 21.1 6 248 23.0 6 248 20.0 6 253 29.1 3 258 30.3 3 265 31.0 3 262 35.5 3 GROUP 5 PFHS GROUP 6 PFOS 206 12.8 6 231 14.4 6 235 14.1 6 243 12.8 6 241 13.6 6 243 12.9 3 246 14.5 3 254 17.3 3 254 13.2 3 185 * 7.0 6 207 * 9.5 6 213 * 8.6 6 219 * ` 8.2 6 220 ** 5.5 6 226 11.3 3 224 9.8 3 226 10.7 3 229 13.0 3 * / ** : Dunnett-Test based on pooled variance significant at 5% (*) or 1% (**) level 6 4 000065 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS BWG-SUM - 1 09-DEC-98 B O D Y W EIGHT GAIN (%) SUM M ARY M ALES TREATMENT GROUP 1 VEHICLE CONTROL DAY 1 WEEK 1 DAY 5 WEEK 1 DAY 8 WEEK 2 DAY 12 WEEK 2 DAY 15 WEEK 3 DAY 19 WEEK 3 DAY 22 WEEK 4 DAY 25 WEEK 4 DAY 28 WEEK 4 MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N 0 0.0 14 12 6.3 14 19 7.4 14 31 7.9 14 35 9.5 14 45 10.1 14 50 10.4 14 56 11.2 14 61 11.4 14 GROUP 2 TELOMER ALCOHOL 0 0.0 14 12 1.9 14 19 3.3 14 30 4.8 14 36 6.5 14 45 7.6 14 49 7.9 14 55 8.8 14 60 9.1 14 GROUP 3 TELOMER ACRYLATE GROUP 4 00 0.0 0.0 14 14 12 13 1.5 2.3 14 14 19 20 3.7 3.5 14 14 31 33 4.7 5.5 14 14 35 37 5.0 6.5 14 14 45 48 5.8 9.0 14 14 51 52 5.7 9.9 14 14 57 58 6.5 11.4 14 14 62 65 7.1 12.9 14 14 GROUP 5 PFHS 0 0.0 14 11 2.2 14 18 4.6 14 30 4.5 14 32 7.2 14 45 6.7 14 48 7.3 14 54 8.5 14 58 9.6 14 GROUP 6 PFOS 0 0.0 14 13 1.5 14 20 4.2 14 33 4.8 14 37 7.4 14 47 8.9 14 51 10.3 14 58 10.8 14 62 11.1 14 * / * Dunnett-Test based on pooled variance significant at 5% (:) Or 1% ( *) level 65 000066 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS BWG-SUM - 2 09-DEC-98 B O D Y W EIGHT GAIN (%) SUM M ARY M ALES RECOVERY DAY 1 WEEK 1 DAY 5 WEEK 1 DAY 8 WEEK 2 DAY 12 WEEK 2 DAY 14 WEEK 2 DAY 19 WEEK 3 DAY 22 WEEK 4 DAY 25 WEEK 4 DAY 28 WEEK 4 MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST. DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 51 7.9 6 68 9.7 6 72 9.8 6 78 9.1 6 80 9.0 6 92 6.4 3 97 5.7 3 103 6.2 3 105 6.5 3 GROUP 2 TELOMER ALCOHOL 45 5.8 6 61 8.7 6 65 8.6 6 71 8.2 6 71 8.9 6 77 13.0 3 80 12.0 3 84 14.2 3 84 * 13.5 3 GROUP 3 TELOMER ACRYLATE GROUP 4 51 57 3.8 10.6 66 69 78 7.4 12.3 66 72 83 6.8 12.8 66 79 91 7.3 14.1 66 80 90 7.0 15.8 66 88 93 7.1 5.8 33 93 97 6.3 6.8 33 97 102 6.9 7.3 33 99 101 6.1 7.6 33 GROUP 5 PFHS 45 12.6 6 63 13.9 6 69 14.4 6 72 15.6 6 72 15.2 6 77 7.1 3 79 * 7.2 3 87 9.9 3 84 * 8.1 3 GROUP 6 PFOS 49 14.5 6 68 16.5 6 71 16.5 6 78 16.6 6 79 17.2 6 70 * 5.6 3 74 * 4.9 3 80 * 2.7 3 80 * 4.5 3 * / ** : Dunnett-Test based on pooled variance significant at 5% (*) or 1% (**) level 66 000067 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS BWG-SUM - 3 09-DEC-98 B O D Y W EIG H T GAIN (%) SUM M ARY FEM ALES TREATMENT DAY 1 WEEK 1 DAY 5 WEEK 1 DAY 8 WEEK 2 DAY 12 WEEK 2 DAY 15 WEEK 3 DAY 19 WEEK 3 DAY 22 WEEK 4 DAY 25 WEEK 4 DAY 28 WEEK 4 MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL GROUP 3 TELOMER ACRYLATE GROUP 4 000 0.0 0.0 0.0 14 14 14 454 2.7 2.5 2.3 14 14 14 8 .8 3.2 ' 3.9 14 14 8 2.6 14 16 15 15 4.3 4.2 2.9 14 14 14 18 18 16 5.5 5.8 4.3 14 14 14 26 26 23 5.6 5.8 5.3 14 14 14 27 28 25 4.5 5.5 6.2 14 14 14 33 34 31 6.7 5.8 5.6 14 14 14 36 36 32 6.7 7.0 4.8 14 14 14 0 0.0 14 4 2.3 14 7 3.2 14 17 3.5 14 19 4.2 14 26 4.2 14 28 4.6 14 35 3.9 14 36 4.5 14 GROUP 5 PFHS 0 0.0 14 3 3.2 14 7 2.9 14 14 3.4 14 16 3.7 14 23 3.9 14 26 4.5 14 31 4.3 14 S3 4.9 14 GROUP 6 PFOS 0 0.0 14 3 3.4 14 6 2.7 14 13 4.0 14 13 * 4.6 14 19 * 6.4 14 21 * 6.9 14 24 ** 7.3 14 25 ** 7.5 14 * / * ' . : Dunnett-Test based on pooled variance significant at 5% {*) or 1% (**) level 6 7 000068 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS BWG-SUM - 4 09-DEC-98 B O D Y W EIGH T GAIN (%) SUM M ARY FEM ALES RECOVERY DAY 1 WEEK 1 DAY 5 WEEK 1 DAY 8 WEEK 2 DAY 12 WEEK 2 DAY 14 WEEK 2 DAY 19 WEEK 3 DAY 22 WEEK 4 DAY 25 WEEK 4 DAY 28 WEEK 4 MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 23 5.7 6 37 6.4 6 41 7.0 6 44 7.2 6 48 8.8 6 47 12.5 3 50 12.1 3 53 12.7 3 56 13.8 3 GROUP 2 TELOMER ALCOHOL GROUP 3 TELOMER ACRYLATE GROUP 4 21 18 3.7 7.7 6 .6 37 35 4.6 9.5 66 39 36 5.4 9.9 66 44 43 4.8 9.8 6 6 43 42 7.8 9.8 66 50 48 7.0 4.8 33 53 50 6.7 6.2 33 53 50 5.4 3.8 33 53 50 6.2 3.0 33 25 4.4 6 39 3.7 6 41 '5.7 6 46 6.1 6 46 4.6 6 45 5.1 3 48 3.7 3 52 2.8 3 50 5.6 3 GROUP 5 PFHS 22 5.0 6 37 6.1 6 39 6.2 6 44 7.2 6 43 8.5 6 45 8.6 3 47 9.5 3 52 7.6 3 52 8.8 3 GROUP 6 PFOS 15 6.1 6 29 7.7 . 6 33 7.3 6 37 7.2 6 37 5.9 6 41 10.3 3 39 9.5 3 40 10.0 3 42 11.5 3 * / * Dunnett-Test based on pooled variance significant at 5% () or 1* (** ) level 68 000069 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS FC-SUM - 1 01-MAR-99 FO O D CONSUMPTION (G/ANIMAL/DAY) SUMMARY M ALES TREATMENT GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL ' GROUP 3 TELOMER ACRYLATE GROUP 4 DAYS 1-8 WEEKS 1/2 DAYS 8-15 WEEKS 2/3 DAYS 15-22 WEEKS 3/4 DAYS 22-28 WEEK 4 MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) 26 2.1 4 28 2.7 4 30 ' 3.3 4 30 2.3 4- 26 1.9 4 28 2.4 4 29 1.3 4 30 1.5 4 27 1.0 4 28 0.9 4 30 1.5 4 31 . 1.1 4 26 1.0 4 29 0.6 4 30 2.3 4 31 2.4 4 GROUP 5 PFHS 26 2.4 4 27 2.1 4 29 1.2 4 30 1.6 4 GROUP 6 PFOS 27 0.9 4 29 1.6 4 30 2.7 4 31 3.0 4 MEAN OF MEANS OVER TREATMENT MEAN GROUP 1 VEHICLE CONTROL 28 GROUP 2 TELOMER ALCOHOL 28 GROUP 3 TELOMER ACRYLATE GROUP 4 29 29 GROUP 5 PFHS 28 GROUP 6 PFOS 29 * / ** : Dunnett-Test based on pooled variance significant at 5% (*) or 1% (**) level 69 000070 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS FC-SUM - 2 01-MAR-99 FO O D CONSUMPTION (G/AN1MAL/DAY) SUMMARY M ALES RECOVERY DAYS 1-8 WEEKS 1/2 DAYS 8-14 WEEK 2 DAYS 14-19 WEEKS 2/3 DAYS 19-22 WEEKS 3/4 DAYS 22-28 WEEK 4 MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) GROUP 1 VEHICLE CONTROL 30 2.5 2 30 1.8 2 30 -- 1 31 1` 31 BOX 1 GROUP 2 TELOMER ALCOHOL 28 2.0 2 28 1.8 2 28 1 29 -- 1 28 1 GROUP 3 TELOMER ACRYLATE GROUP 4 30 1.8 2 31 1.4 2 30 ... 1 32 ... 1 30 ... 1 32 1.4 2 31 2.0 2 30 ... 1 31 ... 1 29 -- 1 GROUP 5 PFHS 30 0.8 2 29 1.2 2 26 ... 1 27 ... 1 27 ... 1 GROUP 6 pros 30 3.7 2 30 4.0 2 27 -- 1 28 ... 1 27 -- 1 MEAN OF MEANS OVER RECOVERY MEAN GROUP 1 VEHICLE CONTROL 30 GROUP 2 TELOMER ALCOHOL 28 GROUP 3 TELOMER ACRYLATE GROUP 4 30 30 GROUP 5 PFHS 28 GROUP 6 PFOS 28 * / ** : Dunnett-Test based on pooled variance significant at 5% (*) or 1% (*) level 70 000071 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS FC-SUM - 3 01-MAR-99 FOO D CONSUMPTION (G/ANIMAL/DAY) SUMMARY FEM ALES TREATMENT DAYS 1-8 WEEKS 1/2 DAYS 8-15 WEEKS 2/3 DAYS 15-22 WEEKS 3/4 DAYS 22-28 WEEK 4 MEAN ST. DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) GROUP 1 VEHICLE CONTROL 19 0.7 4 21 0.5 4 22 1.3 4 24 1.2 4 GROUP 2 TELOMER ALCOHOL 18 1.2 4 20 0.5 4 22 0.8 4 23 0.7 4 GROUP 3 TELOMER ACRYLATE GROUP 4 19 19 1.2 0.6 44 20 21 1.1 0.8 44 22 22 1.2 1.1 44 23 23 1.3 0.5 44 GROUP 5 PFHS 20 1.6 4 21 1.4 4 22 1.3 4 23 0.7 4 GROUP 6 PFOS 19 1.9 4 19 0.8 4 20 * 1.0 4 20 * 0.5 4 MEAN OF MEANS OVER TREATMENT MEAN GROUP 1 VEHICLE CONTROL 22 GROUP 2 TELOMER ALCOHOL 21 GROUP 3 TELOMER ACRYLATE GROUP 4 21 21 GROUP 5 PFHS 22 GROUP 6 PFOS 19 * / ** : Dunnett-Test based on pooled variance significant at 5% () or 1% (**) level 71 000072 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS FC-SUM - 4 0 1 -MAR-99 FO O D CONSUMPTION (G/ANIMAL/DAY) SUMMARY FEM ALES RECOVERY DAYS 1-8 WEEKS 1/2 DAYS 8-14 WEEK 2 DAYS 14-19 WEEKS 2/3 DAYS 19-22 WEEKS 3/4 DAYS 22-28 WEEK 4 MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) GROUP 1 VEHICLE CONTROL 25 0.4 2 24 0.2 2 22 ... 1 24 ... 1 24 ... 1 GROUP 2 TELOMER ALCOHOL 24 1.0 2 23 1.1 2 22 ... 1 23 ... 1 22 ... 1 GROUP 3 TELOMER ACRYLATE GROUP 4 24 24 1.2 1.1 22 23 23 0.8 1.2 22 22 20 ... ... 11 22 21 ... ... 11 22 22 ... ... 1. 1 GROUP 5 PFHS 24 0.6 2 24 0.6 2 20 ... 1 22 ... 1 21 -- 1 GROUP 6 PFOS 21 ** 0.2 2 20 * 0.3 2 19 ... 1 19 ... 1 19 ... 1 MEAN OF MEANS OVER RECOVERY MEAN GROUP 1 VEHICLE CONTROL 24 GROUP 2 TELOMER ALCOHOL 23 GROUP 3 TELOMER ACRYLATE GROUP 4 22 22 GROUP 5 PFHS 22 GROUP 6 PFOS 20 * / ** : Dunnett-Test based on pooled variance significant at 5% (*) or 1% (**) level 72 000073 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS RFC-SUM - 1 01-MAR-99 R ELATIVE FOOD CONSUMPTION SUMMARY (G/KG BODY WEIGHT/DAY) M ALES TREATMENT GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL DAYS 1-8 WEEKS 1/2 DAYS 8-15 WEEKS 2/3 DAYS 15-22 WEEKS 3/4 DAYS 22-28 WEEK 4 MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) 114 8.7 4 103 9.3 4 99 11.1 4 93 6.8 4 112 3.6 4 102 3.3 4 96 4.5 4 91 1.1 4 GROUP 3 TELOMER ACRYLATE GROUP 4 115 111 3.8 2.9 44 103 102 2.0 2.3 44 99 96 5.2 5.9 44 94 92 3.4 5.3 44 GROUP 5 PFHS 112 7.1 4 101 2.6 4 98 5.5 4 93 3.6 4 GROUP 6 PFOS 115 3.7 4 104 1.9 4 98 6.8 4 94 6.1 4 MEAN OF MEANS OVER TREATMENT MEAN GROUP 1 VEHICLE CONTROL 102 GROUP 2 TELOMER ALCOHOL 100 GROUP 3 TELOMER ACRYLATE GROUP 4 103 100 GROUP 5 PFHS 101 GROUP 6 PFOS 103 * / * : Dunnett-Test based on pooled variance significant at 5% (*) or 1% (**) level 73 000074 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS RFC-SUM - 2 01-MAR-99 R ELATIV E FOOD CONSUMPTION SUMMARY (G/KG BODY WE1GHT/DAY) M ALES RECOVERY DAYS 1-8 WEEKS 1/2 DAYS 8-14 WEEK 2 DAYS 14-19 WEEKS 2/3 DAYS 19-22 WEEKS 3/4 DAYS 22-28 WEEK 4 MEAN ST. DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) GROUP 1 VEHICLE CONTROL 90 1.5 2 84 0.1 2 77 -- 1 78 --* 1 75 ... 1 GROUP 2 TELOMER ALCOHOL 85 0.9 2 80 0.7 2 74 ... 1 76 ... 1 72 ... 1 GROUP 3 TELOMER ACRYLATE GROUP 4 87 85 4.9 4.1 22 82 78 2.6 5.8 22 76 71 -- ... 11 80 72 -- ... 11 74 67 ... ... 11 GROUP 5 PFHS 91 0.3 2 83 0.1 2 76 ... 1 77 -- 1 73 ... 1 GROUP 6 PFOS 86 2.1 2 81 0.2 2 76 ... 1 78 ... 1 72 -- i MEAN OF MEANS OVER RECOVERY MEAN GROUP 1 VEHICLE CONTROL 81 GROUP 2 TELOMER ALCOHOL 77 GROUP 3 TELOMER ACRYLATE GROUP 4 80 74 GROUP 5 PFHS 80 GROUP 6 PFOS 79 * / ** : Dunnett-Test based on pooled variance significant at 5% (*) or 1% ('*) level 7 4 000075 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS RFC-SUM - 3 Ol-MAR-99 R ELATIVE FOOD CONSUMPTION SUMMARY (G/KG BODY WEIGHT/DAY) FEM ALES TREATMENT DAYS 1-8 WEEKS 1/2 DAYS 8-15 WEEKS 2/3 DAYS 15-22 WEEKS 3/4 DAYS 22-28 WEEK 4 MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) GROUP 1 VEHICLE CONTROL 106 1.2 4 104 2.4 4 103 6.8 4 102 6.1 4 GROUP 2 TELOMER ALCOHOL 104 6.1 4 105 2.8 4 105 6.7 4 102 4.6 4 GROUP 3 TELOMER ACRYLATE GROUP 4 110 108 5.0 5.4 44 107 107 4.7 4.7 44 108 105 5.7 6.2 44 105 101 2.8 3.4 44 GROUP 5 PFHS 113 11.8 4 109 8.0 4 107 4.9 4 104 1.9 4 GROUP 6 PFOS 111 11.4 4 103 6.4 4 100 7.9 4 95 4.6 4 MEAN OF MEANS OVER TREATMENT MEAN GROUP 1 VEHICLE CONTROL 104 GROUP 2 TELOMER ALCOHOL 104 GROUP 3 TELOMER ACRYLATE GROUP 4 107 105 GROUP 5 PFHS 108 GROUP 6 PFOS 102 * / ** : Dunnett-Test based on pooled variance significant at 5% (*) or 1% (**) level 7 5 000076 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS RFC-SUM - 4 01-MAR-99 R ELATIVE FOOD CONSUMPTION SUMMARY (G/KG BODY WEIGHT/DAY) FEM ALES RECOVERY DAYS 1-8 WEEKS 1/2 DAYS 8-14 WEEK 2 DAYS 14-19 WEEKS 2/3 DAYS 19-22 WEEKS 3/4 DAYS 22-28 WEEK 4 MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) MEAN ST.DEV. N (CAGE) GROUP 1 VEHICLE CONTROL 105 3.5 2 95 0.2 2 86 ... 1 92 ... 1 91 ... 1 GROUP 2 TELOMER ALCOHOL 104 2.7 2 95 3.7 2 88 ... 1 92 ... 1 86 -- 1 GROUP 3 TELOMER ACRYLATE GROUP 4 107 102 2.4 5.3 22 97 94 1.0 4.0 22 88 81 ... ... 11 87 83 ... ... 11 90 81 ... ... 11 GROUP 5 PFHS 106 1.2 2 97 0.2 2 84 -- 1 88 ... 1 84 ... 1 GROUP 6 PFOS 100 4.0 2 93 3.9 2 85 ... 1 86 ... 1 85 ... 1 MEAN OF MEANS OVER RECOVERY MEAN GROUP 1 VEHICLE CONTROL 94 GROUP 2 TELOMER ALCOHOL 93 GROUP 3 TELOMER ACRYLATE GROUP 4 94 88 GROUP 5 PFHS 92 GROUP 6 PFOS 90 * / ** : Dunnett-Test based on pooled variance significant at 5% (*) or 1% (**) level 76 000077 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/-PFOS HEM-SUM - 1 0 9 -NOV-98 HAEM ATOLOGY SUMMARY AFTER 4 W EEKS M ALES TREATMENT HAEMATOLOGY PARAMETERS RBC T/l HB nunol/1 HCT 1/1 MCV fl MCH fmol MCHC mrnol/1 ROW % PLATELETS G/l WBC G/l SEG. X EO. 1 BASO. 1 MONO. 1 LYMPH. 1 MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST :DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL GROUP 3 TELOMER ACRYLATE GROUP 4 GROUP 5 PFHS GROUP 6 PFOS 7.05 0.24 10 9.1 0.4 10 0.407 0.011 1 57.8 1.1 10 1.294 0.036 10 22.4 0.4 10 12.4 0.4 10 1182 110 10 11.3 3.5 10 0.124 0.033 10 0.007 0.005 10 0.000 0.000 10 0.026 0.006 10 0.844 0.030 10 6.72 0.32 14 8.8 0.4 14 0.395 0.016 14 58.8 1.4 14 1.313 0.030 14 22.3 0.4 14 12.0 0.7 14 1025 116 14 10.0 2.0 14 0.125 0.041 14 0.011 0.011 14 0.000 0.000 14 0.022 0.012 14 0.841 0.048 14 6.61 * 0.27 14 8.7 0.4 14 0.388 0.014 14 58.7 1.0 14 1.317 0.027 14 22.4 0.5 14 12.2 0.6 14 1115 158 14 10.2 2.1 14 0.117 0.035 14 0.007 0.005 14 0.000 0.000 14 0.020 0.010 14 0.857 0.040 14 6.79 0.32 13 8.8 0.5 13 0.397 0.021 13 58.5 1.2 13 1.297 0.045 13 22.2 0.4 13 12.0 0.3 13 1050 158 13 11.7 2.4 13 0.087 + 0.025 13 0.007 0.004 13 0.000 0.000 13 0.023 0.009 13 0.883 + 0.031 13 6.57 * 0.52 14 8.5 ** 0.6 14 0.383 * 0.026 14 58.4 1.8 14 1.297 0.035 14 22.2 0.4 14 12.0 0.7 14 870 ** 306 14 9.7 3.0 14 0.148 0.049 14 0.008 0.007 14 0.000 0.000 14 0.026 0.013 14 0.818 0.053 14 6.66 0.39 12 8.9 0.4 12 0.392 0.019 12 59.0 1.9 12 1.338 * 0.047 12 22.7 0.4 12 12.0 0.8 12 1092 75 12 10.7 2.2 12 0.114 0.039 12 0.005 0.005 12 0.000 0.000 12 0.023 0.009 12 0.858 0.041 12 */**: Ounnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test s1g. at 5% level. 77 000078 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/' PFHS/PFOS HEM-SUM - 2 09-NOV-98 HAEM ATOLOGY SUMMARY AFTER 4 WEEKS M ALES TREATMENT HAEMATOLOGY PARAMETERS PT MEAN SEC ST.DEV. N PTT MEAN SEC ST.DEV. N GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL GROUP 3 TELOMER ACRYLATE GROUP 4 GROUP 5 PFHS GROUP 6 PFOS 14.9 0.6 13 16.1 0.8 13 15.0 0.6 14 16.0 0.7 14 14.9 0.6 13 17.1 2.2 13 14.4 0.6 12 18.2 * 3.2 11 14.1 ** 0.4 9 16.8 0.8 9 14.7 0.6 13 17.2 1.8 13 */**: Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test s1g. at 5% level. 000079 78 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS HEM-SUM - 3 09-N0V-98 HAEM ATOLOGY SUMMARY AFTER 4 WEEKS FEM ALES TREATMENT GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL GROUP 3 TELOMER ACRYLATE GROUP 4 GROUP 5 PFHS GROUP 6 PFOS HAEMATOLOGY PARAMETERS R8C MEAN 6.72 6.27 ** 6.61 6.62 6.35 * 6.41 T/l ST.DEV. 0.14 0.39 0.34 0.36 0.28 0.37 N 11 13 13 13 13 11 HB MEAN 9.1 8.5 * 8.8 9.0 8.7 8.6 mmol/I ST.DEV. 0.3 0.5 0.5 0.4 0.4 .5 N 11 13 13 13 13 11 HCT MEAN 0.378 0.355 ** 0.370 0.377 0.358 * 0.359* 1/1 ST.DEV. 0.012 0.018 0.019 0.014 0.017 0.019 N 11 13 13 13 13 11 MCV MEAN 56.2 56.6 56.0 57.1 56.3 56.0 fl ST.DEV. 1.9 1.4 1.7 1.9 2.6 1.9 N 11 13 13 13 13 11 MCH fmol MEAN ST.DEV. N 1.350 0.034 11 1.356 0.035 13 1.329 0.049 13 1.363 0.053 13 1.356 0.050 13 1.348 0.041 11 MCHC mmol/I MEAN ST.DEV. N 24.0 0.5 11 24.0 0.6 13 23.7 0.6 13 23.9 0.5 13 24.3 0.5 13 24.1 0.2 11 RDW MEAN 11.3 11.2 11.4 11.3 11.3 11.2 % ST.DEV. 0.4 0.5 0.6 0.3 0.6 0.5 N 11 13 13 13 13 11 PLATELETS G/1 MEAN ST.DEV. N 1166 127 11 1141 149 13 1149 125 13 1169 74 13 1035 236 13 1134 131 11 WBC MEAN 7.4 7.5 6.8 7.6 6.3 8.4 G/1 ST.DEV. 2.1 1.6 2.3 1.8 1.9 2.4 N 11 13 13 13 13 11 SEG. 1 MEAN ST.DEV. N 0.082 0.027 11 0.103 0.041 13 0.109 0.039 13 0.087 0.024 13 0.080 0.035 13 0.077 0.020 11 EO. MEAN 0.010 0.004 0.009 0.011 0.009 0.005 1 ST. DEV. 0.007 0.005 0.009 0.006 0.006 0.004 N 11 13 13 13 13 11 BASO. 1 MEAN ST.DEV. N 0.000 0.000 11 0.000 0.000 13 0.000 0.000 13 0.000 0.000 13 0.000 0.000 13 0.000 0.000 11 MONO. 1 MEAN ST.DEV. N 0.025 0.011 11 0.020 0.011 13 0.017 0.009 13 0.024 0.008 13 0.024 0.012 13 0.020 0.007 11 LYMPH. MEAN 0.883 0.873 0.865 0.877 0.887 0.898 x ST.DEV. 0.034 0.044 - 0.040 0.030 0.039 0.026 N 11 13 13 13 13 11 /**: Dunnett test based on pooled variance sig. at 5% or 1% level +: Steel test s1g. at 5% level 7 9 000080 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS HEM-SUM - 4 0 9 -NOV-98 HAEMATOLOGY SUMMARY AFTER 4 WEEKS FEMALES TREATMENT GROUP 1 VEHICLE CONTROL HAEMATOLOGY PARAMETERS PT MEAN SEC ST.DEV. N PTT MEAN SEC ST.DEV. N 15.4 1.0 14 15.9 1.4 14 GROUP 2 TELOMER ALCOHOL 15.0 0.6 14 15.0 0.9 14 GROUP 3 TELOMER ACRYLATE GROUP 4 15.0 0.8 13 15.7 0.8 12 14.5 * 0.5 13 17.0 0.9 13 GROUP 5 PFHS 14.5 * 0.7 12 16.8 2.0 11 GROUP 6 PFOS 14.4 0.4 14 16.5 2.2 14 */**: Dunnett-test based on pooled variance s1g. at 5% or 1% level. +: Steel-test s1g,,. at 5% level. 000081 80 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS HEM-SUM - 5 09-DEC-98 HAEM ATOLOGY SUMMARY AFTER 2 WEEKS RECOVERY M ALES TREATMENT HAEMATOLOGY PARAMETERS GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL GROUP 3 TELOMER ACRYLATE GROUP 4 GROUP 5 PFHS GROUP 6 PFOS RBC MEAN 7.23 7.04 6.97 7.00 6.97 7.01 T/l ST.DEV. 0.18 0.25 0.27 0.27 0.21 0.22 N 3 3 333 3 HB MEAN 9.1 8.9 8.7 8.8 8.6 8.9 mmol/I ST.DEV. 0.4 0.1 0.5 0.1 0.1 0.0 N 33 333 3 HCT MEAN 0.417 0.404 0.401 0.402 0.392 0.408 1/1 ST.OEV. 0.011 0.008 0.018 0.014 0.004 0.006 N 3 3 333 3 MCV MEAN 57.7 57.3 57.5 57.4 56.3 58.2 fl ST. DEV. 0.1 1.0 0.6 0.3 1.6 1.0 N 3 3 333 3 MCH fmol MEAN ST.DEV. N 1.259 0.036 3 1.260 0.037 3 1.253 0.028 3 1.259 0.034 3 1.230 0.020 3 1.270 0.041 3 MCHC mmol/1 MEAN ST.DEV. N 21.8 0.6 3 22.0 0.3 3 21.8 0.3 3 21.9 0.5 3 21.8 0.3 3 21.8 0.3 3 RDW MEAN 14.1 13.7 13.4 13.3 14.4 13.1 % ST.DEV. 0.5 0.6 0.8 1.3 0.5 0.8 N 3 3 333 3 PLATELETS G/l MEAN ST.DEV. N 1177 106 3 1081 102 3 1186 170 3 1080 49 3 1053 22 3 1078 58 3 WBC MEAN 8.5 12.0 12.1 12.2 8.5 11.6 G/l ST.DEV. 1.8 3.2 1.9 1.8 2.4 1.9 N 3 3 33 3 3 SEG. 1 MEAN ST.DEV. N 0.112 0.043 3 0.127 0.073 3 0.088 0.048 3 0.058 0.019 3 0,133 0.063 3 0.137 0.016 3 EO. MEAN 0.013 0.005 0.005 0.003 0.012 0.002 1 ST.DEV. 0.003 0.005 0.005 0.003 0.003 0.003 N 3 3 333 3 BASO. 1 MEAN ST.DEV. N 0.000 0.000 3 0.000 0.000 3 0.000 0.000 3 0.000 0.000 3 0.000 0.000 3 0.000 0.000 3 MONO. 1 MEAN ST.DEV. N 0.027 0.003 3 0.022 0.008 3 0.025 0.005 3 0.023 0.006 3 0.018 0.008 3 0.018 0.003 3 LYMPH. MEAN 0.848 0.847 . 0.882 0.915 0.837 0.843 1 ST.DEV. 0.043 0.077 0.055 0.022 0.073 0.020 N 33 333 3 /**: Dunnett -test based on pooled variance sig. at 5% or 1% level. +: Steel -test s1g. at 5% le\i 000082 81 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS HEM-SUM - 6 09-DEC-98 HAEM ATOLOGY SUMMARY AFTER 2 WEEKS RECOVERY M ALES TREATMENT HAEMATOLOGY PARAiCTERS PT MEAN SEC ST.DEV. N PTT MEAN SEC ST.DEV. N GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL GROUP 3 TELOMER ACRYLATE GROUP 4 GROUP 5 PFHS GROUP 6 PFOS 14.6 0.4 3 16.2 1.1 3 15.2 0.5 3 15.3 0.7 3 14.9 0.7 3 16.0 1.0 3 14.6 0.6 3 15.0 1.3 3 15.2 , 0.4 2 15.2 0.2 2 15.5 0.5 3 14.7 1.6 3 '/**: Dunnett-test based on pooled variance s1g. at 5% or 1% level. +: Steel-test s1g. at 5% level. 82 000083 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS HEM-SUM - 7 09-DEC-98 HAEM ATOLOGY SUMMARY AFTER 2 W EEKS RECOVERY FEM ALES TREATMENT GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL GROUP 3 TELOMER ACRYLATE GROUP 4 GROUP 5 PFHS GROUP 6 PFOS HAEMATOLOGY PARAMETERS RBC MEAN 7.02 6.47 6.62 6.71 6.61 6.53 T/1 ST.DEV. 0.09 0.19 0.23 0.51 0.35 0.33 N 3 333 33 HB MEAN 9.0 8.4 8.7 9.0 8.6 8.5 mmol/I ST.DEV. 0.2 0.2 0.3 0.4 0.5 0.4 N 333333 HCT MEAN 0.404 0.378 0.389 0.396 0.383 0.387 1/1 ST.DEV. 0.009 0.005 0.012 0.012 0.030 0.016 N 333333 MCV MEAN 57.5 58.4 58.9 59.2 57.9 59.3 fl ST.DEV. 0.7 1.7 2.8 2.7 2.1 0.6 N 3 333 33 MCH fmol MEAN ST.DEV. N 1.277 0.021 3 1.305 0.060 3 1.310 0.055 3 1.339 0.048 3 1.301 0.041 3 1.307 0.012 3 MCHC mmol/1 MEAN ST.DEV. N 22.2 0.2 3 22.4 0.4 3 22.3 0.2 3 22.6 0.4 3 22.5 0.5 3 22.1 0.2 3 ROW MEAN 14.5 15.2 15.4 15.3 14.6 15.7 % ST.DEV. 1.5 1.1 1.3 1.7 1.1 0.1 N 333333 PLATELETS G/l MEAN ST.DEV. N 1232 165 3 1117 144 3 1066 133 3 1111 56 3 854 ' 145 3 1034 233 3 WBC MEAN 7.3 8.7 7.3 6.7 6.6 6.8 G/l ST.DEV. 1.8 2.8 3.3 1.3 1.0 2.5 N 333333 SEG. 1 MEAN ST.DEV. N 0.075 0.035 3 0.077 0.020 3 0.065 0.018 3 0.080 0.033 3 0.050 0.030 3 0.100 0.015 3 EO. 1 BASO. 1 MEAN ST.OEV. N MEAN ST.DEV. N 0.005 0.005 3 0.000 0.000 3 0.007 0.008 3 0.000 0.000 3 0.003 0.003 3 0.000 0.000 3 0.010 0.005 3 0.000 0 . 000. 3 0.008 0.010 3 0.000 0.000 3 0.002 0.003 3 0.000 0.000 3 MONO. 1 MEAN ST.DEV. N 0.017 0.008 3 0.025 0.010 3 0.017 0.013 3 0.033 0.013 3 0.010 0.009 3 0.027 0.008 3 LYMPH. MEAN 0.903 0.892 0.915 0.877 0.932 0.872 1 ST.OEV. 0.038 0.023 - 0.022 0.023 0.032 0.010 N 3333 33 /**: Dunnett -test based on pooled variance s1g. at 5% or 1% level. +: Steel -test slg; at 5% level 000084 83 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/. 'PFHS/PFOS HEM-SUM - 8 09-DEC-98 HAEM ATOLOGY SUMMARY AFTER 2 WEEKS RECOVERY FEM ALES TREATMENT HAEMATOLOGY PARAMETERS GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL GROUP 3 TELOMER ACRYLATE GROUP 4 GROUP 5 PFHS GROUP 6 PFOS PT MEAN 16.0 14.9 * 15.6 14.8 * 14.8 * 15.5 SEC ST.DEV. 0.4 0.4 0.6 0.3 0.1 0.1 N 333322 PTT MEAN 15.5 14.4 15.1 14.8 15.7 13.7 SEC ST.DEV. 2.0 0.3 1..1 0.9 1.3 0.0 N 333322 */**: Dunnett-test based on pooled variance s1g. at 5% or 1% level. +: Steel-test slg. at 5% level. 84 000085 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS HEM-SUM - 9 09-DEC-98 HAEM ATOLOGY SUMMARY AFTER 4 W EEKS RECOVERY M ALES TREATMENT GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL GROUP 3 TELOMER ACRYLATE GROUP 4 GROUP 5 PFHS GROUP 6 PFOS HAEMATOLOGY PARAMETERS RBC MEAN 7.35 7.01 6.85 7.01 6.89 6.99 T/1 ST.OEV. 0.50 0.14 0.16 0.17 0.08 0.31 N 3 3 333 3 HB MEAN 9.1 9.1 9.1 9.2 9.0 9.0 mmol/I ST.OEV. 0.6 0.2 0.3 0.3 0.4 0.2 N 3 3 333 3 HCT MEAN 0.396 0.391 0.384 0.392 0.390 0.389 1/1 ST.DEV. 0.026 0.005. 0.012 0.015 0.014 0.015 N 3 3333 3 MCV MEAN 53.9 55.8 56.1 55.8 56.7 55.7 fl ST.DEV. 1.6 0.8 1.6 0.8 1.4 1.8 N 3 3333 3 MCH fmol MEAN ST.OEV. N 1.243 0.052 3 1.294 0.037 3 1.323 0.020 3 1.317 0.031 3 1.307 0.042 3 1.284 0.041 3 MCHC mmol/1 MEAN ST.DEV. N 23.1 0.3 3 23.2 0.3 3 23.6 0.4 3 23.6 0.6 3 23.1 0.2 3 23.1 0.3 3 RDW MEAN 14.5 12.9 * 13.7 12^9 * 13.6 13.7 % ST.DEV. 0.4 0.5 0.3 0.4 0.3 0.9 N 3 3 333 3 PLATELETS G/l MEAN ST.OEV. N 1082 113 3 1025 95 3 1076 149 3 1179 70 3 966 71 3 1077 27 3 WBC MEAN 12.2 12.3 10.8 9.4 7.7 11.2 G/l ST.DEV. 0.9 3.0 4.2 1.3 1.6 3.3 N 3 3333 3 SEG. 1 MEAN ST.DEV. N 0.103 0.053 3 0.095 0.028 3 0.090 0.033 3 0.060 0.009 3 0.063 0.003 3 0.078 0.046 3 EO. MEAN 0.007 0.003 0.010 0.005 0.007 0.007 1 ST.OEV. 0.006 0.006 0.005 0.005 0.003 0.003 N 33333 3 BASO. 1 MEAN ST.DEV. N 0.000 0.000 3 0.000 0.000 3 0.000 0.000 3 0.000 0.000 3 0.000 0.000 3 0.000 0.000 3 MONO. 1 MEAN ST.DEV. N 0.052 0.025 3 0.055 0.018 3 0.047 0.033 3 0.020 0.009 3 0.025 0.009 3 0.027 0.020 3 LYMPH. MEAN 0.838 0.847 0.853 0.915 0.905 0.888 1 ST.OEV. 0.056 0.050 0.068 0.005 0.013 0.059 N 3 3333 3 /**: Dunnett test based on pooled variance slg. at 5% or IX level. +: Steel -test sig. at 5% level 85 000086 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHSAPFOS HEM-SUM -10 09-DEC-98 HAEM ATOLOGY SUMMARY AFTER 4 WEEKS RECOVERY M ALES TREATMENT HAEMATOLOGY PARAMETERS PT MEAN SEC ST.DEV. N PTT MEAN SEC ST.DEV. N GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL GROUP 3 TELOMER ACRYLATE GROUP 4 GROUP 5 PFHS GROUP 6 PFOS 13.1 0.6 2 16.0 0.1 2 13.0 0.4 2 15.2 0.8 2 13.4 0.2 3 16.8 0.2 3 13.8 1.1 2 16.5 0.8 2 14.2 0.5 2 15.2 0.4 2 14.0 0.2 3 14.6 2.0 3 */**: Ounnett-test based on pooled variance s1g. at 5% or 1% level. + : Steel-test s1g. at 5% level. 86 000087 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ ' -/PFHSAPFOS HEM-SUM -11 ' 09-DEC-98 HAEM ATOLOGY SUMMARY AFTER 4 W EEKS RECOVERY FEM ALES TREATMENT GROUP 1 VEHICLE CONTROL GROUP 2 GROUP 3 TELOMER . TELOMER ALCOHOL ACRYLATE GROUP 4 GROUP 5 PFHS GROUP 6 PFOS HAEMATOLOGY PARAMETERS RBC MEAN 6.87 6.86 6.79 6.99 6.80 6.56 T/l ST.DEV. 0.19 0.09 0.27 0.22 0.25 0.15 N 3 33333 HB MEAN 9.3 9.4 9.0 9.1 8.9 8.7 mmol/I ST.DEV. 0.1 0.2 0.2 0.2 0.3 0.6 N 3 33333 HCT I O N 0.397 0.402 0.389 0.393 0.389 0.379 1/1 ST.DEV. 0.023 0.002 0.009 0.008 0.022 0.030 N 3 33333 MCV MEAN 57.8 58.7 57.4 56.2 57.2 57.8 fl ST.DEV. 1.8 1.1 2.3 0.9 3.4 3.3 N 3 33333 MCH fmol MEAN ST.DEV. N 1.349 0.020 3 1.366 0.018 3 1.322 0.033 3 1.297 0.030 3 1.314 0.049 3 1.321 0.058 3 MCHC mmol/1 MEAN ST.DEV. N 23.4 1.0 3 23.3 0.4 3 23.1 0.4 3 23.1 0.2 3 23.0 0.5 3 22.9 0.6 3 RDW MEAN 12.8 13.5 13.3 12.6 13.3 12.9 % ST.DEV. 0.8 0.5 0.2 0.3 1.1 0.9 N 3 33333 PLATELETS MEAN 972 980 965 1014 978 994 G/l ST.DEV. 54 103 126 40 127 80 N 3 33333 WBC MEAN 6.0 8.8 7.7 6.2 6.8 8.7 G/l ST.DEV. 0.6 1.1 3.7 0.4 2.3 2.3 N 3 33333 SEG. 1 MEAN ST.DEV. N 0.053 0.031 3 0.070 0.013 3 0.038 0.015 3 0.077 0.045 3 0.075 0.017 3 0.062 0.025 3 EO. MEAN 0.008 0.003 0.010 0.020 0.007 0.005 1 ST.DEV. 0.010 0.003 0.000 0.000 0.003 0.009 N 3 33333 BASO. 1 MEAN ST.DEV. N 0.000 0.000 3 0.000 0.000 3 0.000 0.000 3 0.000 0.000 3 0.000 0.000 3 0.000 0.000 3 MONO. X LYMPH. 1 MEAN ST.DEV. N MEAN ST.DEV. N 0.015 0.005 3 0.923 0.032 3 0.027 0.008 3 0.900 0.005 3 0.018 0.014 3 0.933 . 0.010 3 0.030 0.000 3 0.873 0.045 3 0.035 0.018 3 0.883 0.030 3 0.017 0.008 3 0.917 0.033 3 /**: Dunnett -test based on pooled variance s1g. at 5% or 1% level. +: Steel -test s1g. at 5% level 8 7 000088 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS HEM-SUM -12 09-DEC-98 HAEM ATOLOGY SUMMARY AFTER 4 WEEKS RECOVERY FEM ALES TREATMENT HAEMATOLOGY PARAMETERS PT MEAN SEC ST.DEV. N PTT MEAN SEC ST.DEV. N GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL GROUP 3 TELOMER ACRYLATE GROUP 4 GROUP 5 PFHS GROUP 6 PFOS 12.3 0.6 3 15.7 1.2 3 12.2 0.3 3 14.6 0.5 3 11.9 0.4 3 15.7 1.1 3 12.2 0.6 3 15.0 0.6 3 11.7 0.3 3 15.3 0.2 3 12.2 0.4 3 14.9 1.1 3 */*: Dunnett-test based on pooled variance s1g. at 514 or 1% level. +: Steel-test s1g. at 5% level. 88 000089 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/JPFOS CHE-SUM - 1 09-N0V-98 CLINICAL BIOCHEMISTRY SUMMARY AFTER 4 W EEKS M ALES TREATMENT ALAT(GPT) ukat/1 ASAT(GOT) ukat/1 Bill T. umol/1 CHOLEST.T. mmol/I TRIGL. mmol/I CREATININE umol/1 GLUCOSE mmol/1 UREA mmol/1 PROTEIN T. g/1 ALBUMIN 9/1 GLOBULIN g/1 A/G RATIO ALP ukat/1 MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.OEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL 0.64 0.12 14 2.80 0.38 14 2 1 14 2.00 0.39 14 0.80 0.25 14 33. 4 14 6.32 0.75 14 6.9 1.1 14 56.8 2.9 14 29.3 0.9 14 27.5 2.5 14 1.1 0.1 14 7.76 1.75 14 0.61 0.10 14 2.62 0.41 14 2 0 14 1.28 ** 0.44 14 0.63 0.29 14 30 3 . 14 6.48 0.95 14 7.0 1.0 14 53.2 ** 2.1 14 28.7 1.3 14 24.4 + 1.8 14 1.2 0.1 14 8.08 1.94 14 GROUP 3 TELOMER ACRYLATE GROUP 4 0.61 0.14 13 2.58 0.46 14 2 1 14 1.43 ** 0.47 14 0.73 0.39 14 31 2 14 6.24 0.73 14 6.7 1.1 14 53.9 * 2.9 14 29.3 1.7 14 24.6 + 2.0 14 1.2 + 0.1 14 7.70 1.14 14 0.57 0.11 13 2.31 ** 0.30 14 2 0 14 1.76 0.40 14 0.65 0.21 14 34 4 14 6.59 1.07 14 6.9 1.0 14 53.8 * 2.2 14 29.8 1.3 14 24.0 + 1.5 14 1.2 + 0.1 14 8.00 1.16 14 GROUP 5 PFHS 0.67 0.25 14 2.39 * 0.26 14 2 0 14 0.97 ** 0.20 14 0.43 '* 0.15 14 35 5 14 6.72 1.47 14 7.7 1.5 14 53.7 ** 2.8 14 30.4 1.4 14 23.3 + 2.4 14 1.3 + 0.1 14 9.33 * 1.50 14 GROUP 6 PFOS 0.59 0.06 14 . 2.37 * 0.45 14 2 1 14 1.13 * 0.40 14 0.48 ** 0.17 14 32 3 14 6.38 1.24 14 7.6 1.2 14 54.1 * 2.0 14 29.3 1.2 14 24.8 + 2.1 14 1.2 + 0.1 14 7.26 1.48 14 */V: Ounnett test based on pooled variance s1g. at 5% or 1% level + : Steel test s1g. at 5% level. 000090 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/fFOS CHE-SUM - 2 09-N0V-98 CLINICAL BIOCHEMISTRY SUMMARY AFTER 4 WEEKS M ALES TREATMENT INORG PHOSPH MEAN mmol/1 ST.DEV. N SODIUM mmol/1 MEAN ST.DEV. N POTASSIUM mmol/1 MEAN ST.DEV. N CALCIUM mmol/1 MEAN ST.DEV. N CHLORIDE mmol/1 MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL . GROUP 2 TELOMER ALCOHOL 2.83 0.16 14 142.6 1.3 14 4.85 0.31 14 2.53 0.08 14 100 2 14 2.75 0.13 14 142.9 0.9 14 4.60 0.27 14 2.47 0.06 14 100 2 14 GROUP 3 TELOMER ACRYLATE GROUP 4 2.88 0.19 14 143.2 0.7 14 4.72 0.39 14 2.50 0.06 14 102 1 14 2.71 0.23 14 143.0 0.7 14 4.50 * 0.22 14 2.47 0.07 14 101 2 14 GROUP 5 PFHS 3.02 0.30 14 143.3 0.8 14 4.55 0.46 14 2.51 0.08 14 103 ** 2 14 GROUP PFOS 2.96 0.20 14 142.9 0.9 14 4.66 0.35 14 2.52 0.08 14 103 *' 3 14 */'*: Dunnett-test baaed on pooled variance slg. at 5% or 1% level. +: Steel-test slg. at 5% level. 90 000091 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/fFOS CHE-SUM - 3 09-N0V-98 CLINICAL BIOCHEMISTRY SUMMARY AFTER 4 WEEKS FEM ALES TREATMENT ALAT(GPT) ukat/1 ASAT(GOT) ukat/1 BILI T. umol/1 CHOLEST.T. mmol/I TRIGL. mmol/I CREATININE umol/1 GLUCOSE mmol/1 UREA mmol/1 PROTEIN T. 9/1 ALBUMIN 8/1 GLOBULIN 0/1 a /g r a t i o ALP ukat/1 MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 0.52 0.12 14 2.62 0.34 14 3 1 14 2.21 0.44 14 0.60 0.18 14 40 3 14 6.05 0.52 14 8.3 1.8 . 14 65.9 3.3 14 34.0 1.4 14 31.9 2.2 14 1.1 0.1 14 4.46 0.62 14 GROUP 2 TELOMER ALCOHOL 0.47 0.09 14 2.37 0.53 14 2 1 14 2.26 0.40 14 0.57 0.18 14 38 4 14 5.90 0.58 14 8.4 1.5 14 64.8 2.8 14 33.8 1.4 14 31.0 2.4 14 1.1 0.1 14 4.04 0.95 14 GROUP 3 TELOMER ACRYLATE GROUP 4 0.55 0.14 14 2.24 0.36 14 3 0 14 2.09 0.40 14 0.58 0.14 14 39 4 14 6.14 0.70 14 8.8 1.7 14 65.4 2.5 14 34.1 1.6 14 31.3 1.9 14 1.1 0.1 14 4.52 1.18 14 0.52 0.12 14 2.30 0.35 14 3 1 14 2.32 0.33 14 0.56 0.13 14 41 4 14 6.00 0.50 14 9.0 1.7 14 66.2 2.9 14 33.8 2.2 14 32.4 2.0 14 1.0 0.1 14 4.30 0.87 14 GROUP 5 PFHS 0.57 0.09 14 2.45 0.69 14 2 1 14 1.81 * 0.28 14 0.51 0.16 14 40 3 14 6.02 0.72 14 8.5 0.9 14 65.4 4.1 14 33.7 1.5 14 31.7 3.1 14 1.1 0.1 14 4.06 1.10 14 GROUP 6 PFOS 0.63 0.32 14 2.32 0.38 14 3 1 14 2.04 0.35 14 0.54 0.16 14 41 4 14 5.98 1.02 14 10.2 * 1.9 14 66.8 3.1 14 34.9 1.7 14 31.8 2.4 14 1.1 0.1 14 4.30 1.14 14 */**: Dunnett test based on pooled variance sig. at 5% or 1% level +: Steel -test sig. at 5% level 000092 91 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/-PFOS CHE-SUM - 4 0 9 -NOV-98 CLINICAL BIOCHEMISTRY SUMMARY AFTER 4 WEEKS FEM ALES TREATMENT INORG PHOSPH MEAN mmol/1 ST.DEV. N SODIUM mrnol/1 MEAN ST.DEV. N POTASSIUM mmol/1 MEAN ST.DEV. N CALCIUM mmol/1 MEAN ST.DEV. N CHLORIDE mmol/1 MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 2.5S 0.23 14 142.2 1.6 14 4.13 0.39 14 2.56 0.09 14 97 3 14 GROUP 2 TELOMER ALCOHOL 2.53 0.16 14 142.6 O.S 14 4.14 0.34 14 2.60 0.06 14 99 2 14 GROUP 3 TELOMER ACRYLATE GROUP 4 2.47 0.20 14 142.6 1.1 14 4.11 0.32 14 2.60 0.05 14 98 2 14 2.42 0.19 14 142.0 1.0 14 ' 4.19 0.24 14 2.60 0.05 14 99 2 14 GROUP 5 PFHS 2.43 0.21 14 141.8 0.7 14 4.08 0.28 14 2.56 0.06 14 102 ** 2 14 GROUP 6 PFOS 2.59 0.23 14 142.5 1.1 14 4.06 0.30 14 2.60 0.07 14 101 * 2 4 */**: Dunnett-test based on pooled variance s1g. at 5% or 1% level. +: Steel-test s1g. at 5% level. 000093 92 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS CHE-SUM - 5 09-DEC-98 CLINICAL BIOCHEMISTRY SUMMARY AFTER 2 WEEKS RECOVERY MALES TREATMENT ALAT(GPT) ukat/1 ASAT(GOT) ukat/1 BILI T. umol/1 CHOLEST.T. mmol/I TRIGL. mmol/I CREATININE umol/1 GLUCOSE mmol/I UREA mmol/I PROTEIN T. 0/1 ALBUMIN g/1 GLOBULIN 0/1 A/G RATIO ALP ukat/1 MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 0.86 0.19 3 2.80 0.55 3 3 0 3 1.95 0.50 3 0.53 0.09 3 35 8 3 5.65 0.39 3 6.8 1.3 3 55.9 1.5 3 29.0 1.0 3 26.9 2.1 3 1.1 0.1 3 6.59 2.07 3 GROUP 2 TELOMER ALCOHOL 0.62 0.08 3 2.70 0.40 3 3 1 3 1.67 0.69 3 0.61 0.20 3 34 2 3 6.23 1.66 3 7.3 0.5 3 51.5 * 1.0 3 28.1 0.5 3 23.4 0.8 3 1.2 0.0 3 6.93 1.02 3 GROUP 3 TELOMER ACRYLATE GROUP 4 0.65 0.12 3 2.91 0.03 3 3 1 3 1.57 0.04 3 0.89 0.35 3 33 2 3 6.85 0.93 3 6.9 0.7 3 57.6 0.9 3 29.5 0.3 3 28.1 0.8 3 1.0 0.0 3 5.82 1.22 3 0.85 0.18 3 2.86 0.59 3 3 1 3 1.93 0.43 3 0.70 0.10 3 39 2 3 8.33 * 0.11 3 6.8 0.5 3 53.6 3.2 3 27.8 1.3 3 25.8 2.1 3 1.1 0.1 3 5.94 1.02 3 GROUP 5 PPHS 0.81 0.13 3 2.43 0.42 3 2 0 3 1.38 0.22 3 0.65 0.09 3 39 4 3 7.14 0.16 3 6.7 0.8 3 54.7 0.7 3 28.9 1.0 3 25.8 0.9 3 1.1 0.1 3 6.72 0.80 3 GROUP 6 PFOS 0.64 0.17 3 1.92 0.48 3 3 1 3 1.27 0.19 3 0.50 0.10 3 39 9 3 6.22 1.02 3 7.4 0.7 3 56.5 0.7 3 29.7 0.6 3 26.8 0.5 3 1.1 0.0 3 5.61 1.21 3 */**: Dunnett test based on pooled variance s1g. at 5% or 1% level. +: Steel -test sig. at 5% leve' S3 000094 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS CHE-SUM - 6 0 9 -DEC-98 CLINICAL BIOCHEMISTRY SUMMARY AFTER 2 WEEKS RECOVERY M ALES TREATMENT INORG PHOSPH MEAN mmol/1 ST.DEV. N SODIUM mmol/1 MEAN ST.DEV. N POTASSIUM mmol/1 MEAN ST.DEV. N CALCIUM mmol/1 MEAN ST.DEV. N CHLORIDE mmol/1 MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 2.81 0.06 3 144.3 1.1 3 4.46 0.42 3 2.48 0.04 3 103 1 3 GROUP 2 TELOMER ALCOHOL 2.78 0.16 3 143.4 2.1 3 4.51 0.23 3 2.44 0.06 3 102 3 3 GROUP 3 TELOMER ACRYLATE GROUP 4 2.74 0.23 3 142.0 0.8 3 4.95 0.13 3 2.48 0.03 3 100 2 3 2.64 0.11 3 141.1 * 0.7 3 4.41 0.20 3 2.50 0.11 3 100 1 3 GROUP 5 PFHS 2.51 0.14 3 142.4 0.9 3 4.56 0.15 3 2.45 0.04 3 102 2 3 GROUP 6 PFOS 2.65 0.12 3 142.8 0.1 3 4.56 0.24 3 2.57 0.07 3 103 2 3 */**: Dunnett-test based on pooled variance $1g. at 5% or 1% level. + : Steel-test s1g. at 5% level. 94 000093 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS CHE-SUM - 7 09-DEC-98 CLINICAL BIOCHEMISTRY SUMMARY AFTER 2 WEEKS RECOVERY FEM ALES TREATMENT ALAT(GPT) ukat/1 ASAT(GOT) ukat/1 Bill T. uraol/1 CHOLEST.T. mmol/I TRIGL. mmol/1 CREATININE umol/1 GLUCOSE mmol/1 UREA mmol/1 PROTEIN T. g/1 ALBUMIN g/1 GLOBULIN g/1 A/G RATIO ALP ukat/1 MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 0.47 0.05 3 2.53 0.58 3 3 1 3 2.16 0.38 3 0.69 0.24 3 39. 2 3 7.34 1.68 3 6.8 0.7 3 63.6 2.8 3 32.2 2.7 3 31.5 1.2 3 1.0 0.1 3 3.30 0.12 3 GROUP 2 TELOMER ALCOHOL 0.63 0.34 3 2.61 0.69 3 2 1 3 1.92 0.43 3 0.43 0.03 3 40 2 3 6.52 0.66 3 7.3 1.4 3 61.7 3.8 3 32.7 2.8 3 29.0 2.8 3 1.1 0.2 3 3.60 1.10 3 GROUP 3 TELOMER ACRYLATE GROUP 4 0.49 0.11 3 2.10 0.36 3 2 0 3 1.74 0.40 3 0.61 0.24 3 41 5 3 7.31 0.54 3 8.2 1.1 3 61.1 1.6 3 31.6 1.9 3 29.5 2.3 3 1.1 0.1 3 4.36 1.08 3 0.57 0.08 3 2.53 0.34 3 3 1 3 2.41 0.28 3 0.73 0.26 3 45 7 3 7.41 1.04 3 9.8 * 1.1 3 65.2 3.1 3 33.8 1.7 3 31.4 1.8 .3 1.1 0.0 3 3.85 0.83 3 GROUP 5 PFHS 0.52 0.12 3 1.66 0.15 3 3 0 3 2.11 0.40 3 0.40 0.09 3 44 4 3 7.55 1.70 3 7.6 0.4 3 66.4 4.2 3 31.4 1.0 3 35.1 3.3 3 0.9 0.1 3 3.27 1.20 3 GROUP 6 PFOS 0.45 0.07 3 2.09 0.17 3 2 1 3 2.02 0.37 3 0.31 0.08 3 42 1 3 7.69 0.33 3 8.0 1.2 3 60.6 5.2 3 32.5 1.2 3 28.1 4.0 3 1.2 0.1 3 4.32 1.51 3 */**: Dunnett -test based on pooled variance sig. at 5% or 1% level. +: Steel -test sig. at 5% level 000096 95 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ -" /PFHS/PFOS CHE-SUM - 8 09-DEC-98 CLINICAL BIOCHEMISTRY SUMMARY AFTER 2 WEEKS RECOVERY FEM ALES TREATMENT INORG PHOSPH MEAN mmol/I ST.DEV. N SODIUM mmol/1 MEAN ST.DEV. N POTASSIUM mmol/1 MEAN ST.DEV. N CALCIUM mmol/1 MEAN ST.DEV. N CHLORIDE mmol/1 MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 2.47 0.09 3 142.4 1.0 3 4.08 0.09 3 2.63 0.14 3 99 1 3 GROUP 2 TELOMER ALCOHOL 2.57 0.36 3 142.8 1.3 3 3.96 0.20 3 2.59 0.06 3 99 1 3 GROUP 3 TELOMER ACRYLATE GROUP 4 2.32 0.06 3 142.0 1.0 3 4.05 0.42 3 2.57 0.09 3 99 4 3 2.55 0.27 3 141.3 1.5 3 4.34 0.38 3 2.68 0.03 . 3 98 2 3 GROUP 5 PFHS 2.42 0.26 3 141.6 0.8 3 3.90 0.23 3 2.68 0.14 3 98 3 3 GROUP 6 PFOS 2.29 0.10 3 142.5 0.8 3 4.11 0.15 3 2.63 0.07 3 100 2 3 */**: Dunnett-test based on pooled variance s1g. at 5% or 1% level. +; Steel-test sig. at 5% level. 000097 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ 'PFHS/PFOS CHE-SUM - 9 09-N0V-98 CLINICAL BIOCHEMISTRY SUMMARY AFTER 4 WEEKS RECOVERY M ALES TREATMENT ALAT(GPT) ukat/1 ASAT(GOT^ ukat/1 BILI T. umol/1 CHOLEST.T . mmol/1 TRIGL. mmol/1 CREATININE umol/1 GLUCOSE mmol/1 UREA mmol/1 PROTEIN T. 0/1 ALBUMIN g/i GLOBULIN g/i A/G RATIO ALP ukat/1 MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL 0.59 0.17 3 2.65 0.25 3 3 1 3 1.94 0.18 3 0.76 0.39 3 36 1 3 8.01 0.40 3 6.3 0.3 3 62.2 0.1 3 28.6 0.6 3 33.5 0.6 3 0.9 0.0 3 4.33 0.65 3 0.68 0.07 3 2.44 0.25 3 2 1 3 1.25 * 0.13 3 0.58 0.03 3 33 4 3 7.45 1.37 3 6.3 0.2 3 55.9 * 1.8 3 27.3 0.5 3 28.6 2.3 3 1.0 . 0.1 3 6.20 1.91 3 GROUP 3 TELOMER ACRYLATE GROUP 4 0.60 0.03 3 2.06 0.24 3 3 1 3 1.53 0.39 3 0.53 0.11 3 34 4 3 7.06 1.05 3 6.6 0.9 3 55.4 * 3.5 3 27.0 1.4 3 28.4 2.3 3 1.0 0.0 3 5.28 1.46 3 0.58 0.17 3 2.39 0.50 3 3 1 3 1.66 0.35 3 0.56 0.02 3 38 1 3 6.12 0.55 3 7.5 0.7 3 57.0 * 2.3 3 27.7 1.3 3 29.3 1.8 3 0.9 0.1 3 5.43 1.31 3 GROUP 5 PFHS 0.75 0.17 3 2.40 0.20 3 2 1 3 1.24 * 0.09 3 0.36 0.19 3 43 6 3 5.57 * 0.70 3 8.3 2.0 3 57.3 1.2 3 27.3 0.6 3 30.0 1.0 3 0.9 0.0 3 6.00 1.94 3 GROUP 6 PFOS 0.64 0.12 3 1.87 * 0.13 3 2* 0 3 1.34 0.37 3 0.45 0.12 3 32 4 3 6.70 0.62 3 6.0 0.5 3 54.5 ** 2.5 3 27.5 0.7 3 26.9 2.0 3 1.0 0.1 3 4.73 0.19 3 */**: Dunnett test based on pooled variance sig. at 5% or 1% level. + : Steel -test s1g. at 5% level 97 000098 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ 'PFHS/PFOS CHE-SUM -10 09-NOV-98 CLINICAL BIOCHEMISTRY SUMMARY AFTER 4 WEEKS RECOVERY M ALES TREATMENT INORG PHOSPH MEAN mmol/1 ST.DEV. N SODIUM nmol/I MEAN ST.DEV. N POTASSIUM mmol/1 MEAN ST.DEV. N CALCIUM mmol/1 MEAN ST.DEV. N CHLORIDE mmol/1 MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 3.02 0.13 3 141.6 0.9 3 5.33 0.21 3 2.58 0.02 3 102 2 3 GROUP 2 TELOMER ALCOHOL 2.64 0.28 3 142.9 1.3 3 4.59 * 0.14 3 2.48 * 0.06 3 103 3 3 GROUP 3 TELOMER ACRYLATE GROUP 4 2.64 0.24 3 142.5 1.2 3 4.64 * 0.33 3 2.48 * 0.05 3 104 2 3 2.46 * 0.18 3 142.0 0.6 3 4.55 ** 0.12 3 2.46 * 0.03 3 104 1 3 GROUP 5 PFHS 2.65 0.18 3 143.8 1.0 3 4.57 * 0.42 3 2.49 0.02 3 103 1 3 GROUP 6 PFOS 2.59 0.20 3 142.7 0.2 3 4.65 * 0.11 3 2.48 * 0.05 3 107 * 2 3 */*; Dunnett-test based on pooled variance sig. at 5% or 1% level. +: Steel-test sig. at 5% level. 9 8 000099 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ *~" /PFHS/PFOS CHE-SUM -11 09-NOV-98 CLINICAL BIOCHEMISTRY SUMMARY AFTER 4 WEEKS RECOVERY FEM ALES TREATMENT ALAT(GPT) ukat/1 ASAT(GOT) ukat/1 BILI T. uraol/1 CHOLEST.T. nimol/1 TRIGL. mmol/I CREATININE umol/1 GLUCOSE mmol/1 UREA nunol/1 PROTEIN T. g/1 ALBUMIN g/1 GLOBULIN g/1 A/G RATIO ALP ukat/1 MEAN ST.DEV. . N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 0.38 0.09 3 2.25 0.31 3 2 1 3 2.50 0.38 3 0.63 0.13 3 41 3 3 7.16 1.26 3 7.5 1.6 3 64.9 4.1 3 31.3 1.7 3 33.6 2.5 3 0.9 0.0 3 2.95 0.46 3 GROUP 2 TELOMER ALCOHOL GROUP 3 TELOMER ACRYLATE GROUP 4 0.37 0.04 2 2.31 0.33 3 2 1 3 2.41 0.36 3 0.74 0.27 3 42 5 3 6.43 0.47 3 7.5 1.3 3 64.3 2.5 3 31.6 1.2 3 32.6 1.9 3 1.0 0.1 3 3.03 1.24 3 0.46 . 0.12 3 1.89 0.45 3 3 1 3 2.30 0.11 3 0.47 0.04 3 42 3 3 6.90 0.37 3 8.0 1.0 3 67.7 2.2 3 33.4 3.4 3 34.4 1.5 3 1.0 0.1 3 3.11 0.92 3 0.63 0.31 3 2.45 0.26 3 2 0 3 2.51 0.49 3 0.51 0.18 3 44 4 3 6.34 1.56 3 8.3 1.5 3 65.3 3.4 3 30.6 1.3 3 34.7 2.1 3 0.9 0.0 3 2.93 0.85 3 GROUP 5 PFHS 0.47 0.16 3 2.52 0.49 3 2 0 3 2.06 0.35 3 0.40 0.06 3 39 1 3 6.86 0.41 3 7.0 0.3 3 69.4 0.9 3 34.2 0.7 3 35.2 1.4 3 1.0 0.1 3 2.70 0.85 3 GROUP 6 PFOS 0.50 0.02 3 1.92 0.05 3 2 1 3 2.13 0.22 3 0.50 0.21 3 39 1 3 7.65 1.09 3 10.7 3.7 3 65.3 5.4 3 32.8 2.0 3 32.5 3.3 3 1.0 0.0 3 3.38 0.19 3 */'*: Dunnett -test based on pooled variance s1g. at 5K or 1% level. +: Steel -test s1g. at 5% level OOOIOO 99 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ " PFHS/PFOS CHE-SUM -12 09-N0V-98 CLINICAL BIOCHEMISTRY SUMMARY AFTER 4WEEKS RECOVERY FEM ALES TREATMENT INORG PHOSPH MEAN mmol/I ST.DEV. N SODIUM mmol/I MEAN ST.OEV. N POTASSIUM mmol/1 MEAN ST.DEV. N CALCIUM mmolM MEAN ST.DEV. N CHLORIDE mmol/1 MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 2.33 0.17 3 142.3 1.8 3 4.12 0.34 3 2.'52 0.05 3 100 4 3 GROUP 2 TELOMER ALCOHOL 2.24 0.12 3 141.6 0.5 3 4.14 0.29 3 2.53 0.10 3 101 3 3 GROUP 3 TELOMER ACRYLATE GROUP 4 1.98 0.20 3 140.7 1.7 3 4.48 0.89 3 2.55 0.07 3 100 4 3 2.22 0.30 3 141.3 0.7 3 4.26 0.51 3 2.57 0.04 3 99 3 3 GROUP 5 PFHS GROUP 6 PFOS 2.16 0.08 3 141.0 1.4 3 4.02 0.33 3 2.60 0.01 3 102 3 3 2.27 0.26 3 141.1 1.6 '3 4.16 0.18 3 2.64 0.03 3 103 5 3 */*': Dunnett-test based on pooled variance s1g. at 5% or 1% level. +: Steel-test s1g. at 5% level. 000101 1 00 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ ~ PFHS/PFOS OW-SUM - 1 0 8 -DEC-98 O RG AN WEIGHTS (GRAM) SUMMARY AFTER 4 WEEKS M ALES TREATMENT BODY W. BRAIN HEART LIVER KIDNEYS ADRENALS SPLEEN TESTES MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL GROUP 2 TELOMER ALCOHOL 315 315 30 16 88 2.01 0.07 8 1.96 0.07 8 1.133 1.134 0.108 - 0.144 88 10.05 1.24 8 10.35 0.68 8 2.30 0.38 8 2.34 0.18 8 0.045 0.006 8 0.053 0.008 8 0.580 0.119 8 0.566 0.069 8 2.87 0.23 8 3.05 0.22 8 GROUP 3 TELOMER ACRYLATE GROUP 4 305 13 8 1.95 0.06 a 1.097 0.115 8 9.36 0.60 8 2.20 0.15 8 0.052 0.007 8 0.567 0.065 8 2.78 0.15 8 306 27 8 2.00 0.06 8 1.154 0.106 8 9.04 1.08 8 2.16 0.25 8 0.046 0.008 8 0.578 0.075 8 2.86 0.19 8 GROUP 5 PFHS 308 28 8 1.96 0.09 8 1.107 0.088 8 13.78 " 1.83 8 2.34 0.22 8 0.050 0.009 8 0.570 0.076 8 2.80 0.80 8 GROUP 6 PFOS 318 25 8 2.00 0.05 a 1.131 0.103 8 11.79 * 1.00 8 2.19 0.18 8 0.046 0.013 8 0.558 0.096 8 2.85 0.18 8 */**: Dunnett-test based on pooled variance s1g. at 5% or 1% level. 1 01 000102 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ ' PFHS/PFOS OW-SUM - 2 08-DEC-98 ORGAN/BODY W EIGHT RATIOS SUMMARY AFTER 4 W EEKS M ALES TREATMENT BODY W. (GRAM) BRAIN (%) HEART (%) LIVER (%) KIDNEYS (%} ADRENALS (%) SPLEEN (%) TESTES (%) MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.OEV. N MEAN ST. DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP I VEHICLE CONTROL 315 30 8 0.64 0.05 8 0.362 0.037 8 3.19 0.21 8 0.73 0.09 8 0.014 0.002 8 0.183 0.027 8 0.91 0.05 8 GROUP 2 TELOMER ALCOHOL 315 16 8 0.62 0.03 8 0.361 0.046 8 3.30 0.29 8 0.74 0.06 8 0.017 0.003 8 0.180 0.017 8 0.97 0.09 8 GROUP 3 TELOMER ACRYLATE GROUP 4 305 13 8 0.64 0.03 8 0.360 0.037 8 3.07 0.11 8 0.72 0.05 8 0.017 0.002 8 0.186 0.015 8 0.91 0.06 8 306 27 8. 0.66 0.05 8 0.378 0.026 8 2.95 0.14 8 0.70 0.03 8 0.015 0.003 8 0.189 0.018 8 0.94 0.12 8 GROUP 5 PFHS 308 28 8 0.64 0.05 8 0.36a 0.023 8 4.47 ** 0.40 8 0.76 0.05 8 0.016 0.003 8 0.185 o:oi6 8 0.90 0.24 8 GROUP 6 PFOS 318 25 8 0.63 0.05 8 0.357 0.041 8 3.71 ** 0.30 8 0.69 0.07 8 0.014 0.003 8 0.175 0.026 8 0.90 0.05 8 */**: Dunnett-test based on pooled variance s1g. at 5% or 1% level. 102 000103 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS OW-SUM - 3 08-DEC-98 O R G A N W EIGHTS (GRAM) SUMMARY AFTER 4 W EEKS FEM ALES TREATMENT BODY W. BRAIN HEART LIVER KIDNEYS ADRENALS SPLEEN OVARIES MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 214 22 a 1.88 0.08 8 0.852 0.054 8 6.62 0.50 8 1.50 0.15 8 0.060 0.009 8 0.423 0.051 8 0.124 0.023 8 GROUP 2 TELOMER ALCOHOL 211 16 8 1.93 0.08 8 0.813 0.054 8 7.18 0.55 8 1.63 0.15 8 0.064 0.009 8 0.450 0.037 8 0.133 0.020 8 GROUP 3 TELOMER ACRYLATE GROUP 4 200 16 8 1.85 0.05 7 0.790 0.071 7 6.37 0.47 7 1.51 0.11 7 0.060 0.009 7 0.417 0.086 7 0.135 0.015 7 208 15 8 1.90 0.08 8 0.805 0.073 8 6.53 0.72 8 1.53 0.17 8 0.070 0.037 8 0.608 0.373 8 0.124 0.030 8 GROUP 5 PFHS 201 13 8 1.88 0.09 8 0.806 0.083 8 6.71 0.70 8 1.51 0.12 8 0.058 0.009 8 0.407 0.033 8 0.132 0.018 8 GROUP 6 PFOS 187 * 16 a 1.88 0.05 8 0.748 * 0.073 8 7.80 ** 0.88 8 1.46 0.12 8 0.054 0.006 8 0.412 0.046 8 0.128 0.019 8 */**: Dunnett-tast based on pooled variance sig. at 5% or 1% level. 103 000104 NOTOX Project 242933 - TELOMER ALCOHOL/TELOMER ACRYLATE/ . PFHS/PFOS OW-SUM - 4 08-DEC-98 ORGAN/BODY WEIGHT RATIOS SUMMARY AFTER 4 WEEKS FEM ALES TREATMENT BODY W. (GRAM) BRAIN (%) HEART (%) LIVER (%) KIDNEYS (%) ADRENALS (%) SPLEEN (%) OVARIES (%) MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST. DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 214 22 8 0.89 0.08 8 0.401 0.035 8 3 .'ll 0.19 8 0.70 0.03 8 0.028 0.006 8 0.198 0.024 8 0.058 0.010 8 GROUP 2 TELOMER ALCOHOL 211 16 8 0.92 0.05 8 0.385 0.027 8 3.40 0.13 8 0.77 0.07 8 0.031 0.005 8 0.214 0.020 8 0.063 0.012 8 GROUP 3 TELOMER ACRYLATE GROUP 4 GROUP 5 PFHS 200 16 8 0.93 0.06 7 0.395 0.023 7 3.19 0.13 7 0.76 0.04 7 0.030 0.002 7 0.208 0.037 7 0.068 0.008 7 208 15 8 0.91 0.04 8 0.388 0.030 8 3.14 0.28 8 0.74 0.08 8 0.033 0.016 8 0.298 0.201 8 0.060 0.015 8 201 13 8 0.94 0.05 .8 0.402 0.034 8 3.35 0.35 8 0.75 0.06 8 0.029 0.005 8 0.204 0.016 8 0.066 0.008 8 GROUP 6 PFOS 187 * 16 8 1.01 * 0.07 8 0.399 0.028 8 4.15 * 0.18 8 0.78 * 0.03 8 0.029 0.003 8 0.220 0.013 8 0.069 0.013 8 */**: Dunnett-test based on pooled variance s1g. at 5% or 1% level. OOOIOS NOTOX Project 242933 V" TELOMER ALCOHOL/TELOMER.ACRYLATE/ . /PFHS/PFCS OW-SUM - 5 08-DEC-98 ORGAN WEIGHTS (GRAM) SUMMARY AFTER 2 WEEKS RECOVERY M ALES TREATMENT BODY W. BRAIN HEART LIVER KIDNEYS ADRENALS SPLEEN TESTES MEAN ST. DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 320 37 3 1.95 0.12 3 1.091 0.117 3 8.24 0.78 3 2.04 0.31 3 0.042 0.007 3 0.441 0.084 3 2.81 0.24 3 GROUP 2 TELOMER ALCOHOL 314 17 3 1.98 0.07 3 1.062 0.053 3 8.27 0.63 3 2.08 0.03 3 0.039 0.008 3 0.568 0.012 3 2.13 0.89 3 GROUP 3 TELOMER ACRYLATE GROUP 4 344 31 3 1.95 0.13 3 1.172 0.097 3 9.89 1.91 3 2.41 0.31 3 0.043 0.006 3 0.543 0.037 3 3.09 0.16 3 366 44 3 2.02 0.11 3 1.153 0.027 3 10.30 1.19 3 2.39 0.25 3 0.055 0.012 3 0.623 0.102 3 3.35 0.17 3 GROUP 5 PFHS 324 69 3 1.93 0.18 3 1.149 0.145 3 9.55 2.63 3 2.18 0.51 3 0.041 0.005 3 0.541 0.080 3 2.61 1.09 3 GROUP 6 PFOS 380 12 3 2.03 0.03 3 1.299 0.054 3 14.07 0.63 3 2.65 0.06 3 0.048 0.007 3 0.635 0.121 3 3.03 0.26 3 */**: Dunnett-test based on pooled variance s1g. at 5% or 1% level. 10 5 000106 NOTOX Project 242933 TELOMER ALCOHOL/TEL<OMER ACRYLATE/ /PFHS/PFOS OW-SUM - 6 08-DEC-98 ORGAN/BODY W EIGHT RATIOS SUMMARY AFTER 2 W EEKS RECOVERY M ALES TREATMENT BODY W. (GRAM) BRAIN (%) HEART (%) LIVER (%) KIDNEYS (%) ADRENALS (%) SPLEEN (%) TESTES (%) MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 320 37 3 0.61 0.04 3 0.342 0.007 3 2.58 0.11 3 0.64 0.06 3 0.013 0.002 3 0.138 0.016 3' 0.88 0.04 3 GROUP 2 TELOMER ALCOHOL 314 17 3 0.63 0.04 3 0.339 0.029 3 2.63 0.07 3 0.66 0.05 3 0.013 0.003 3 0.181 0.011 3 0.68 0.30 3 GROUP 3 TELOMER ACRYLATE GROUP 4 344 31 3 0.57 0.06 3 0.344 0.055 3 2.86 0.30 3 0.70 0.03 3 0.013 0.001 3 0.159 0.024 3 0.90 0.09 3 366 44 3 0.55 0.04 3 0.318 0.042 3 2.82 0.12 3 0.65 . 0.05 3 0.016 0.005 3 0.170 0.007 3 0.92 0.06 3 GROUP 5 PFHS 324 69 3 0.61 0.09 3 0.361 0.045 3 2.93 0.20 3 0.67 0.04 3 0.013 0.001 3 0.169 0.019 3 0.78 0.22 3 GROUP 6 PFOS 380 12 3 0.53 0.02 3 0.342 0.009 3 3.70 ** 0.22 3 0.70 0.02 3 0.013 0.002 3 0.167 0.028 3 - 0.80 0.04 3 */**: Dunnatt-test based on pooled variance s1g. at 5% or 1% level. 1 06 000107 NOTOX Project 242933 " TELOMER ALCOHOL/TELOMER ACRYLATE/ ... PFHS/PFOS OW-SUM 7 08-DEC-98 ORGAN WEIGHTS (GRAM) SUMMARY AFTER 2 WEEKS RECOVERY FEM ALES TREATMENT BODY W. BRAIN HEART LIVER KIDNEYS ADRENALS SPLEEN OVARIES MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 239 29 3 1.96 0.10 3 0.898 0.053 3 7.69 1.33 3 1.54 0.16 3 0.055 0.003 3 0.420 0.042 3 0.285 0.250 3 GROUP 2 TELOMER ALCOHOL 211 17 3 1.89 0.07 3 0.858 0.052 3 6.82 0.86 3 1.51 0.17 3 0.063 0.010 3 0.424 0.097 3 0.130 0.005 3 GROUP 3 TELOMER ACRYLATE GROUP 4 . GROUP 5 PFHS 202 14 3 1.91 0.03 3 0.831 0.056 3 6.38 0.91 3 1.52 0.16 3 0.065 0.017 3 0.416 0.094 3 0.126 0.010 3 217 28 3 1.91 0.03 3 0.936 0.052 3 7.07 0.09 3 1.60 0.12 3 0.069 0.005 3 0.414 0.016 3 0.145 0.020 3 224 11 3 1.92 0.02 3 0.840 0.054 3 7.19 0.67 3 1.51 0.06 3 0.058 0.003 3 0.449 0.077 3 0.133 0.015 3 GROUP 6 PFOS 200 3 3 1.99 0.06 3 0.723 * 0.018 3 7.55 0.56 3 1.38 0.11 3 0.056 0.001 3 0.392 0.025 3 0.132 0.006 3 */**: Dunnett-test based on pooled variance slg. at 5% or 1% level. 1 07 000108 NOTOX Project 242933 - TELOMER ALCOHOL/TELOMER ACRYLATE/ .... PFHS/PFOS OW-SUM - 8 08-DEC-98 ORGAN/BODY WEIGHT RATIOS SUMMARY AFTER 2 WEEKS RECOVERY FEM ALES TREATMENT BODY W. (GRAM) BRAIN <%) HEART (%) LIVER (%> KIDNEYS (%) ADRENALS (%) SPLEEN (%) OVARIES (%) MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 239 29 3 0.83 0.08 3 0.378 0.024 3 3.21 0.18 3 0.65 0.04 3 0.023 0.002 3 0.177 0.026 3 0.113 0.085 3 GROUP 2 TELOMER ALCOHOL 211 17 3 0.90 0.04 3 0.408 0.042 3 3.22 0.23 3 0.72 0.08 3 0.030 0.006 3 0.199 0.028 3 0.062 0.005 3 GROUP 3 TELOMER ACRYLATE GROUP 4 202 14 3 0.95 0.07 3 0.412 0.013 3 3.15 0.23 3 0.75 0.03 3 0.032 0.006 3 0.205 0.035 3 0.063 0.007 3 217 28 3 0.89 0.10 3 0.435 0.042 3 3.30 0.45 3 0.74 0.04 3 0.032 0.005 3 0.192 0.018 3 0.067 0.003 3 GROUP 5 PFHS 224 11 3 0.86 0.04 3 0.375 0.008 3 3.21 0.23 3 0.68 0.06 3 0.026 0.001 3 0.202 0.041 3 0.059 0.004 3 GROUP 6 PFOS 200 3 3 1.00 * 0.03 3 0.362 0.007 3 3.78 0.32 3 0.69 0.06 3 0.028 0.001 3 0.197 0.015 3 0.066 0.004 3 */**: Dunnett-test based on pooled variance s1g. at 5% or 1% level. 1 08 000109 NOTOX Project 242933 ~" TELOMER ALCOHOL/TELOMER ACRYLATE/ - 'PFHS/PFOS OW-SUM - 9 0 8 -DEC-98 ORGAN WEIGHTS (GRAM) SUMMARY AFTER 4 WEEKS RECOVERY M ALES TREATMENT BODY W. BRAIN HEART LIVER KIDNEYS ADRENALS SPLEEN . TESTES MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N CAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 389 28 3 1.97 0.15 3 1.196 0.093 3 10.77 1.37 3 2.44 0.23 3 0.046 0.011 3 0.614 0.040 3 2.86 0.14 3 GROUP 2 TELOMER ALCOHOL 363 33 3 2.05 0.04 3 1.207 0.018 3 9.78 0.44 3 2.42 0.06 3 0.050 0.009 3 0.540 0.082 3 3.19 0.43 3 GROUP 3 TELOMER ACRYLATE GROUP 4 378 3 3 2.09 0.03 3 1.217 0.077 3 10.30 0.69 3 2.51 0.04 3 0.054 0.004 3 0.591 0.061 3 3.11 0.06 3 401 36 3 2.11 0.19 3 1.299 0.147 3 10.06 0.35 3 2.59 0.24 3 0.056 0.013 3 0.720 0.037 3 3.10 0.22 3 GROUP 5 PFHS 335 20 3 2.02 0.08 3 1.048 0.153 3 8.84 0.63 3 2.24 0.41 3 0.047 0.003 3 0.552 0.065 3 3.09 0.11 3 GROUP 6 pros 344 38 3 2.00 0.07 3 1.231 0.248 3 11.17 1.94 3 2.48 0.21 3 0.046 0.009 3 0.629 0.136 3 3.27 0.30 3 */**: Dunnett-test based on pooled variance s1g. at 5% or 1% level. 109 000110 NOTOX Project 242933 - TELOMER ALCOHOL/TELOMER ACRYLATE/ ... /PFHS/PFOS OW-SUM - 10 08-DEC-98 ORGAN/BODY WEIGHT RATIOS SUMMARY AFTER 4 WEEKS RECOVERY M ALES TREATMENT BODY W. (GRAM) BRAIN (%) HEART (%) LIVER (%) KIDNEYS (%) ADRENALS (%) SPLEEN (%) TESTES (%) MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 389 28 3 0.51 0.03 3 0.308 0.027 3 2.76 0.17 3 0.63 . 0.05 3 0.012 0.003 3 0.159 0.017 3 0.74 0.04 3 GROUP 2 TELOMER ALCOHOL 363 33 3 0.57 0.04 3 0.335 0.030 3 2.70 0.13 3 0.67 0.04 3 0.014 0.002 3 0.149 0.019 3 0.88 0.14 3 GROUP 3 TELOMER ACRYLATE GROUP 4 378 3 3 0.55 0.01 3 0.322 0.018 3 2.72 0.18 3 0.66 0.01 3 0.014 0.001 3 0.156 0.016 3 0.82 0.02 3 401 36 3 0.53 0.03 3 0.324 0.016 3 2.52 0.21 3 0.65 0.08 3 0.014 0.002 3 0.181 0.026 3 0.78 0.05 3 GROUP 5 PFHS 335 20 3 0.60 * 0.01 3 0.313 0.042 3 2.64 0.03 3 0.67 0.14 3 0.014 0.000 3 0.164 0.010 3 0.92 * 0.02 3 GROUP 6 PFOS 344 38 3 0.59 0.05 3 0.356 0.035 3 3.23 * 0.22 3 0.72 0.02 3 0.014 0.004 3 0.182 0.022 3 0.95 * 0.08 3 */**: Dunnett-test based on pooled variance s1g. at 5% or 1% level. 11 o OOOlll NOTOX Project 242933 -_ - TELOMER ALCOHOL/TELOMER ACRYLATE/ .... I P FHS/PFOS OW-SUM - 11 0 8 -DEC-98 ORG AN WEIGHTS (GRAM) SUMMARY AFTER 4 WEEKS RECOVERY FEM ALES TREATMENT BODY W. BRAIN HEART LIVER KIDNEYS ADRENALS SPLEEN OVARIES MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.OEV. N MEAN ST.OEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 243 27 3 1.91 0.09 3 0.916 0.118 3 7.01 1.14 3 1.60 0.25. 3 0.065 0.012 3 0.445 0.056 3 0.133 0.013 3 GROUP 2 TELOMER ALCOHOL 228 11 3 1.97 0.06 3 0.851 0.109 3 6.87 0.57 3 1.63 0.09 3 0.064 0.013 3 0.443 0.140 3 0.146 0.029 3 GROUP 3 TELOMER ACRYLATE GROUP 4 226 25 3 1.88 0.06 3 0.870 0.046 3 6.85 0.86 3 1.54 0.14 3 0.062 0.008 3 0.426 0.065 3 0.145 0.013 3 235 35 3 1.96 0.05 3 0.918 0.092 3 7.30 1.56 3 1.68 0.25 3 0.061 0.001 3 0.504 0.104 3 0.165 0.040 3 GROUP 5 PFHS 226 13 3 1.88 0.08 3 0.860 0.065 3 6.83 0.20 3 1.62 0.12 3 0.065 0.003 3 0.355 0.024 3 0.153 0.047 3 GROUP 6 PFOS 208 11 3 1.88 0.09 3 0.825 0.028 3 7.49 0.30 3 1.68 0.12 3 0.058 0.010 3 0.427 0.060 3 0.141 0.003 3 */**: Dunnett-test based on pooled variance s1g. at 5% or 1% level. 111 000112 NOTOX Project 242933 ' TELOMER ALCOHOL/TELOMER ACRYLATE/ .... PFHS/PFOS OW-SUM - 12 08-DEC-98 ORGAN/BODY WEIGHT RATIOS SUMMARY AFTER 4 WEEKS RECOVERY FEM ALES TREATMENT BODY W. (GRAM) BRAIN (%) HEART w LIVER (%) KIDNEYS (%) ADRENALS (%) SPLEEN (%) OVARIES (%) MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N MEAN ST.DEV. N GROUP 1 VEHICLE CONTROL 243 27 3 0.79 0.08 3 0.379 0.039 3 2.68 0.20 3 0.66 0.04 3 0.027 0.005 3 0.184 0.023 3 0.055 0.009 3 GROUP 2 TELOMER ALCOHOL 228 11 3 0.86 0.03 3 0.372 0.029 3 3.02 0.21 3 0.72 0.07 3 0.028 0.006 3 0.193 0.052 3 0.064 0.010 3 GROUP 3 TELOMER ACRYLATE GROUP 4 GROUP 5 PFHS GROUP 6 PFOS 226 25 3 0.84 0.06 3 0.387 0.021 3 3.03 0.14 3 0.69 0.07 3 0.028 0.004 3 0.192 0.046 3 0.065 0.011 3 235 35 3 0.85 0.12 3 0.392 0.021 3 3.09 0.29 3 0.71 0.05 3 0.026 0.003 3 0.216 0.048 3 0.070 0.012 3 226 13 3 0.83 0.01 3 0.380 0.017 3 3.02 0.17 3 0.72 0.08 3 0.029 0.001 3 0.157 0.019 3 0.06B 0.023 3 208 11 3 0.90 0.04 3 0.398 .0.032 .3 3.61 ** 0.20 3 0.81 * 0.03 3 0.028 0.006 3 0.206 0.031 3 0.068 0.002 3 */**: Dunnett-test based on pooled variance s1g. at 5% or 1% level. 112 000113 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ HISTORICAL DATA HAEM ATOLOGY ANIM ALS O F 10-12 W EEKS O F A G E MALES AND FEMALES PARAMETER SEX N MEAN RBC M T/l F HB mmol/I M F HCT M 1/1 F MCV M fl F MCH fmol M F MCHC mmol/1 M F PLATELETS M G/l F RDW M %F WBC M G/l F SEG l(rel) M F EO l(rel) M F BASO l(rel) M F LYMPH l(rel) M F MONO l(rel) M F PT M sec F PTT M sec F 50 44 50 44 ' 50 44 50 44 50 44 50 44 50 44 50 44 50 44 50 44 50 44 50 44 50 44 50 44 44 37 44 36 7.08 6.63 9.8 9.5 0.415 0.386 58.6 58.3 1.387 1.441 23.7 24.7 1137 1114 12.2 11.7 11.8 9.2 0.11 0.097 0.006 0.008 0 0 0.855 0.87 0.028 0.025 13.2 13.9 16.5 15.5 PFHS/PFOS ST. DEV. MIN. 0.36 0.32 0.5 0.3 0.019 0.016 1.8 1.4 0.073 0.055 1.1 0.6 148 139 0.7 0.6 2.7 2.6 0.049 0.065 0.007 0.008 0 0 0.061 0.07 0.021 0.020 1 0.9 1.8 1.9 6.42 6 8.8 8.9 0.384 0.353 55 55.4 1.245 1.345 21.1 23.5 760 753 11.1 10.6 4.7 5.3 0.015 0.02 0 0 0 0 0.705 0.705 0 0 11.2 12 11.9 10.3 MAX. 7.95 7.5 10.8 10.4 0.463 0.437 63.6 60.7 1.52 1.584 25.5 26.3 1486 1513 14.4 13.1 17.5 18.7 0.235 0.27 0.02 0.03 0 0 0.985 0.965 0.085 0.075 15.5 15.7 19.7 19.4 HIS-SUM - 1 22-APR-99 1 Data are from Sprague Dawley control rata which received the vehicle (1n general 0.9% NaCI) via continuous Intravenous Infusion. Due to the limited availability of data no confidence Intervals were calculated. 113 000114 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ HISTORICAL DATA HAEM ATOLOGY 1 ANIM ALS O F 13-18 W EEKS O F A G E MALES AND FEMALES PARAMETER SEX N MEAN RBC M T/l F HB mmol/I M F HCT M 1/1 F MCV M fl F MCH fmol M F rnvwrtL mmol/I M F PLATELETS M G/l F ROW M %F WBC M G/l F SEG l(rel) M F EO l(rel) M F BASO l(rel) M F LYMPH l(rel) M F MONO l(rel) M F PT M sec F PTT M sec F 42 7.34 30 6.81 42 9.3 30 6.8 42 0.399 30 0.376 42 54 30 55.2 42 1.251 30 1.3 42 23.1 30 23.6 42 1096 30 1130 42 14.6 30 12.9 42 14.2 30 8.4 42 0.157 30 0.148 42 0.009 30 0.008 42 0 30 0 42 0.803 30 0.823 42 0.031 30 0.020 38 14.2 29 13.8 38 16.4 29 16.3 PFHS/PFOS ST. DEV. MIN. 0.73 0.47 1.3 0.6 0.047 0.027 2.9 2.1 0.087 0.054 0.8 0.5 170 145 1.8 0.8 5.6 2 0.093 0.102 0.009 0.008 0 0 0.108 0.105 0.025 0.016 1.3 1 2.1 1.9 5.59 5.59 5.6 7 0.264 0.313 45.3 51.5 0.961 1.19 21.2 22.4 669 855 12.7 11.6 6.1 4.7 0.04 0.04 0 0 0 0 0.45 0.54 0 0 11.9 11.9 11.6 12.3 MAX. 8.7 7.65 11 9.9 0.472 0.423 59.6 59.8 1.391 1.42 24.4 24.6 1455 1515 20.5 15.2 33.9 12 0.505 0.42 0.035 0.03 0 0 0.935 0.945 0.105 0.065 17.3 15.6 21.2 19.6 HIS-SUM - 2 22-APR-99 1 Data are from Sprague Dawley control rats which received the vehicle (1n general 0.9% NaCl) via continuous Intravenous Infusion. Due to the limited availability of data no confidence Intervals were calculated. 114 000115 N0T0X Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE PFHS/PFOS HISTORICAL DATA CLINICAL BIOCHEMISTRY1 ANIM ALS O F 10-12 W EEKS O F A G E MALES AND FEMALES PARAMETER SEX N MEAN ST. DEV. MIN. ALAT/GPT pkat/1 ASAT/GOT pkat/1 Bill T. pmol/1 CHOLEST. T. mraol/1 TRIGL. mmol/1 CREATININE pmol/1 GLUCOSE mmol/1 UREA mmol/1 PROTEIN T. fl/1 ALBUMIN 9/1 GLOBULIN 0/1 A/G RATIO 1 ALP pkat/1 SODIUM mmol/1 POTASSIUM mmol/1 CHLORIDE mmol/1 M F M F M F M F M F M F M F M F M F M F M F M F M F M F M F M F 51 45 51 45 51 45 51 45 51 45 51 45 51 45 51 45 51 45 51 45 51 45 51 45 51 45 51 45 51 45 51 45 0.66 0.54 2.51 2.46 2 3 1.95 2.05 0.69 0.42 33 40 6.03 5.32 6.1 8.1 64.1 67.4 29.5 32.6 34.6 34.8 0.9 1 7.38 4.3 143.3 141.2 4.83 4.59 100 101 0.11 0.15 0.6 0.43 1 1 0.34 0.4 0.37 0.09 6 6 1.07 0.68 1.6 2.1 2.9 4.2 1.8 2 2.5 4.5 0.1 0.1 1.87 1.19 1.6 1.6 0.43 0.3 3 3 0.45 0.24 1.54 1.69 1 2 1.25 1.08 0.34 0.26 25 31 3.86 3.87 3 4.5 57.7 59.5 24.5 28.4 29.1 25.8 0.6 0.7 2.94 2.63 138.5 137.5 3.35 3.97 95 94 MAX. 0.98 1.06 3.8 3.48 4 5 2.98 3.31 2.11 0.68 54 56 8.45 7.4 8.9 12.8 70.9 75.5 32.8 36.6 40.9 43.7 1 1.3 12.3 7.86 146.3 144.8 5.97 5.32 106 110 HIS-SUM - 3 22-APR-99 1 Data are from Sprague Dawley control rats which received the vehicle (1n general 0.9% NaCl) via continuous Intravenous Infusion. Due to the limited availability of data no confidence Intervals were calculated. 000116 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE PFHS/PFOS HISTORICAL DATA CLINICAL BIOCHEMISTRY1 ANIM ALS O F 10-12 W EEKS O F A G E MALES AND FEMALES PARAMETER SEX N CALCIUM mmol/1 M F INORG. PHOSPH. M mmol/1 F 51 45 51 45 MEAN 2.6 2.67 2.78 2.55 ST. DEV. MIN. 0.09 0.09 .21 0.25 2.41 2.46 2.29 2.09 MAX. 2.8 2.86 3.27 3.38 HIS-SUM - 4 22-APR-99 1 Data are from Sprague Dawley control rats which received the vehicle (1n general 0.9% NaCI) via continuous Intravenous Infusion. Due to the limited availability of data no confidence Intervals were calculated. 116 000117 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS HISTORICAL DATA CLINICAL BIOCHEMISTRY ANIM ALS O F 13-18 W EEKS O F A G E MALES AND FEMALES PARAMETER SEX N ALAT/6PT pkat/1 ASAT/GOT pkat/1 BILI T. pmol/1 CHOLEST. T. mmol/1 TRIGL. mmol/1 CREATININE pmol/1 GLUCOSE mmol/1 UREA mmol/1 PROTEIN T. 9/1 ALBUMIN 9/1 GLOBULIN 9/1 A/G RATIO 1 ALP pkat/1 SODIUM mmol/1 POTASSIUM mmol/1 CHLORIDE mmol/1 M F M F M F M F M F M F M F M F M F M F M F M F M F M F M F M F 42 28 42 28 42 28 42 28 42 28 41 28 42 28 46 32 42 28 42 28 42 28 42 28 42 28 42 28 42 . 28 42 28 MEAN 0.77 0.64 2.64 2.31 2 3 1.93 2.49 0.58 0.47 37 42 6.38 5.93 5.5 5.7 66.4 72.5 28.1 32 38.2 40.5 0.7 0.8 4.21 3.32 142 140 5 4.43 101 103 ST. DEV. MIN. 0.38 0.19 0.55 0.42 1 1 0.43 0.45 0.25 Q.19 4 5 1.22 0.71 1.4 1.5 3.8 3.5 3 3.8 4.2 4.4 0.1 0.2 1.04 2.51 2.4 2.7 0.36 0.29 3 3 0.47 0.33 1.65 1.45 1 2 0.98 1.69 0.23 0.27 27 35 4.21 5.04 3 3.7 56 66.8 21 23.9 31 34.4 0.4 0.5 2.45 1.15 137.1 135.8 4.38 3.87 96 98 MAX. 2.98 1.15 4.05 3.09 4 5 2.8 3.27 1.13 1.24 46 52 10.65 7.43 8.5 9.6 74 81 32.8 38.2 49 50.8 1 1.1 7.55 14.54 148.3 147.1 5.81 5.19 107 110 HIS-SUM - 5 22-APR-99 1 Data are from Sprague Dawley control rats which received the vehicle (in general 0.9% NaCl) via continuous intravenous infusion. Due to the limited availability of data no confidence Intervals were calculated. 117 000118 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE PFHS/PFOS HISTORICAL DATA CLINICAL BIOCHEM ISTRY1 ANIM ALS O F 13-18 W EEKS O F A G E MALES AND FEMALES PARAMETER SEX CALCIUM mmol/1 M F INORG. PHOSPH. M mmol/1 F N 42 28 42 28 MEAN 2.53 2.5 2.6 2.1 ST. DEV. MIN. 0.14 0.17 0.24 0.23 2.23 2.26 2.17 1.65 MAX. 2.78 2.8 3.34 2.56 HIS-SUM - 6 22-APR-99 1 Data are from Sprague Oawley control rats which received the vehicle (1n general 0.9% NaCl) via continuous Intravenous Infusion. Due to the limited availability of data no confidence Intervals were calculated. 118 000119 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS NOTOX 242933 TABLES - INDIVIDUAL DATA 119 000120 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE PFHS/PFOS M ORTALITY DATA M ALES GROUP 1 (VEHICLE CONTROL) SCHEDULED ANIMAL NECROPSY OTHER TREATMENT FROM TO 1 03-N0V-98 2 03-NOV-98 3 03-NOV-98 4 03-N0V-98 5 04-N0V-98 6 04-N0V-98 7 04-NOV-98 8 04-NOV-98 9 18-N0V-98 10 18-N0V-98 11 18-N0V-98 13 02-DEC-98 14 02-DEC-98 15 02-DEC-98 06-OCT-98 06-0CT-98 06-OCT-98 06-0CT-98 06-0CT-98 06-0CT-98 06-OCT-98 06-0CT-98 06-OCT-98 06-OCT-98 06-0CT-98 06-0CT-98 06-0CT-98 06-OCT-98 02-NOV-98 02-NOV-98 02-NV-98 02-NOV-98 03-N0V-98 0 3 -NOV-98 0 3 -NOV-98 0 3 -NOV-98 03-N0V-98 03-N0V-98 03-NOV-98 03-NOV-98 03-NOV-98 03-NOV-98 M ALES GROUP 2 (TELOM ER ALCOHOL) SCHEDULED ANIMAL NECROPSY OTHER TREATMENT FROM TO 17 03-N0V-98 18 03-N0V-98 19 03-N0V-98 20 03-N0V-98 21 04-N0V-98 22 O4-N0V-98 23 04-NOV-98 24 04-N0V-98 25 18-N0V-98 26 18-NOV-98 27 18-NOV-98 29 02-DEC-98 30 02-DEC-98 31 02-DEC-98 06-OCT-98 06-0CT-98 06-0CT-98 06-0CT-98 06-0CT-98 06-0CT-98 06-0CT-98 06-OCT-98 06-OCT-98 06-0CT-98 06-0CT-98 06-0CT-98 06-OCT-98 06-0CT-98 02-N0V-98 02-NOV-98 0 2 -NOV-98 02-N0V-98 03-N0V-98 03-N0V-98 0 3 -NOV-98 03-NOV-98 03-N0V-98 03-N0V-98 03-N0V-98 03 -NOV-98 03 -NOV-98 0 3 -NOV-98 MORT-IND 1 2 4 -FEB-99 120 000121 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS M ORTALITY DATA M ALES GROUP 3 (TELOM ER ACRYLATE) SCHEDULED ANIMAL NECROPSY OTHER TREATMENT FROM TO 33 03-N0V-98 34 03-N0V-98 35 03-NOV-98 36 03-NOV-98 37 04-NOV-98 38 04-NOV-98 39 04-NOV-98 40 04-NOV-98 41 18-N0V-98 42 18-N0V-98 43 18-N0V-98 45 02-DEC-98 46 02-DEC-98 47 02-DEC-98 06-OCT-98 06-0CT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-0CT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-0CT-98 02-NOV-98 0 2 -NOV-98 0 2 -NOV-98 0 2 -NOV-98 03-NOV-98 03-NOV-98 03-N0V-98 03-NOV-98 03-N0V-98 03-NOV-98 03-NOV-98 0 3 -NOV-98 0 3 -NOV-98 0 3 -NOV-98 M ALES GROUP 4 SCHEDULED ANIMAL NECROPSY 49 03-N0V-98 50 03-NOV-98 51 03-NOV-98 52 03-NOV-98 53 04-N0V-98 54 04-N0V-98 55 04-N0V-98 56 04-NOV-98 57 18-NOV-98 58 18-NOV-98 59 18-NOV-98 61 02-DEC-98 62 02-DEC-98 63 02-DEC-98 OTHER TREATMENT FROM TO 06-OCT-98 06-OCT-98 06-OCT-98 06-0CT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 0 2 -NOV-98 02-N0V-98 02-NOV-98 02-NOV-98 0 3 -NOV-98 0 3 -NOV-98 0 3 -NOV-98 03-NOV-98 03-N0V-98. 03-N0V-98 03-NOV-98 03-NOV-98 03-NOV-98 03-N0V-98 MORT-IND 2 2 4 -FEB-99 1 21 000122 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS M ORTALITY DATA M ALES GROUP 5 (PFHS) SCHEDULED ANIMAL NECROPSY 65 03-N0V-98 66 03-NOV-98 67 03-NOV-98 68 03-N0V-98 69 04-NOV-98 70 04-NOV-98 71 04-N0V-98 72 04-N0V-98 73 18-NOV-98 74 18-N0V-98 75 18-NOV-98 77 02-DEC-98 78 02-DEC-98 79 02-DEC-98 OTHER TREATMENT FROM TO O6-0CT-98 06-OCT-98 06-0CT-98 06-0CT-98 06-OCT-98 06-OCT-9806-0CT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 0 2 -NOV-98 02-N0V-98 02-N0V-98 02-N0V-98 03-NOV-98 03-NOV-98 0 3 -NOV-98 0 3 -NOV-98 03-NOV-98 03-NOV-98 03-N0V-98 03-N0V-98 03-NOV-98 03-N0V-98 . M ALES GROUP 6 (PFOS) SCHEDULED ANIMAL NECROPSY 81 03-N0V-98 82 03-NOV-98 83 03-NOV-98 84 03-NOV-98 85 04-N0V-98 86 04-N0V-98 87 04-N0V-98 88 04-NOV-98 89 18-NOV-98 90 18-N0V-98 91 18-N0V-98 93 02-DEC-98 94 02-DEC-98 95 02-DEC-98 OTHER TREATMENT FROM TO 06-0CT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-0CT-98 06-OCT-98 06-OCT-98 06-OCT-98 06-0CT-98 06-OCT-98 06-OCT-98 02-N0V-98 02-NOV-98 02-NOV-98 02-NOV-98 03-NOV-98 03-N0V-98 0 3 -NOV-98 03-N0V-98 03-NOV-98 03-NOV-98 03-NOV-98 03-N0V-98 03-NOV-98 03-NOV-98 MORT-IND - 3 24-FEB-99 1 22 000123 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS M ORTALITY DATA FEM ALES GROUP 1 (VEHICLE CONTROL) SCHEDULED ANIMAL NECROPSY OTHER TREATMENT FROM TO 97 05-N0V-98 98 05-NOV-98 99 05-NOV-98 100 05-NOV-98 101 06-NOV-98 102 06-NOV-98 103 06-NOV-98 104 06-NOV-98 105 20-NOV-98 106 20-N0V-98 107 20-NOV-98 109 04-DEC-98 110 04-DEC-98 111 04-DEC-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-0CT-98 08-OCT-98 08-OCT-98 08-0CT-98 0 4 -NOV-98 0 4 -NOV-98 0 4 -NOV-98 0 4 -NOV-98 0 5 -NOV-98 O5-N0V-98 0 5 -NOV-98 05-N0V-98 0 5 -NOV-98 05 -NOV-98 0 5 -NOV-98 0 5 -NOV-98 05 -NOV-98 05 -NOV-98 ' FEM ALES GROUP 2 (TELOM ER ALCOHOL) SCHEDULED ANIMAL NECROPSY OTHER TREATMENT FROM TO 113 05-NOV-98 114 05-NOV-98 115 05-N0V-98 116 05-NOV-98 117 06-N0V-98 118 06-N0V-98 119 06-NOV-98 120 06-NOV-98 121 20-NOV-98 122 20-N0V-98 123 20-NOV-98 125 04-DEC-98 126 04-DEC-98 127 04-DEC-98 08-0CT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-0CT-98 08-0CT-98 08-OCT-98 08-0CT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-0CT-98 08-OCT-98 0 4 -NOV-98 0 4 -NOV-98 0 4 -NOV-98 0 4 -NOV-98 0 5 -NOV-98 0 5 -NOV-98 0 5 -NOV-98 0 5 -NOV-98 0 5 -NOV-98 0 5 -NOV-98 05-N0V-98 0 5 -NOV-98 0 5 -NOV-98 0 5 -NOV-98 MORT-INO - 4 24-FEB-99 1 2 3 000124 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ ,'PFHS/PFOS M ORTALITY DATA FEM ALES GROUP 3 (TELOM ER ACRYLATE) SCHEDULED ANIMAL NECROPSY OTHER TREATMENT FROM TO 129 130 05-N0V-98 131 05-NOV-98 132 05-NOV-98 133 O6-N0V-98 134 06-NOV-98 135 06-NOV-98 136 06-N0V-98 137 20-NOV-98 138 20-NOV-98 139 20-N0V-98 141 04-DEC-98 142 04-DEC-98 143 04-DEC-98 FEM ALES GROUP 4 SCHEDULED ANIMAL NECROPSY 05-NOV-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-0CT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-0CT-98 08-OCT-98 08-0CT-98 08-0CT-98 04-N0V-98 04-NOV-98 04-NOV-98 0 4 -NOV-98 05-NOV-98 05-N0V-98 0 5 -NOV-98 05-NOV-98 05-N0V-98 05-N0V-98 0 5 -NOV-98 0 5 -NOV-98 0 5 -NOV-98 0 5 -NOV-98 OTHER TREATMENT FROM TO 145 05-NOV-98 146 05-N0V-98 147 05-NOV-98 148 05-NOV-98 149 06-N0V-98 150 06-N0V-98 151 06-N0V-98 152 06-NOV-98 153 20-NOV-98 154 20-N0V-98 155 20-N0V-98 157 04-DEC-98 158 04-DEC-98 159 04-DEC-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-OCT-98 08-0CT-98 04-N0V-98 04-NOV-98 04-NOV-98 04-N0V-98 0 5 -NOV-98 0 5 -NOV-98 05-N0V-98 0 5 -NOV-98 05-NOV-98 05-N0V-98 05-NOV-98 05-NOV-98 05-N0V-98 0 5 -NOV-98 MORT-IND 5 24-FEB-99 000125 1 24 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ PFHS/PFOS M ORTALITY DATA FEM ALES GROUP 5 (PFHS) SCHEDULED ANIMAL NECROPSY OTHER 161 05-NOV-98 162 05-NOV-98 163 05-NOV-98 164 05-NOV-98 165 06-NOV-98 166 06-N0V-98 167 06-N0V-98 168 06-NOV-98 169 20-NOV-98 170 20-N0V-98 171 20-NOV-98 173 04-0EC-98 174 04-DEC-98 175 04-DEC-98 FEM ALES GROUP 6 (PFOS) SCHEDULED ANIMAL NECROPSY OTHER 177 05 -NOV-98 178 05-N0V-98 179 05-NOV-98 180 05-NOV-98 181 06-NOV-98 182 06-NOV-98 183 06-NOV-98 184 06-NOV-98 185 20-NOV-98 186 20-NOV-98 187 20-N0V-98 189 04-DEC-98 190 04-DEC-98 191 04-DEC-98 TREATMENT FROM 0 8 -OCT-98 08 -OCT-98 0 8 -OCT-98 0 8 -OCT-98 0 8 -OCT-98 08-0CT-98 08-0CT-98 08-OCT-98 08-0CT-98 08-0CT-98 08-0CT-98 08-OCT-98 08-OCT-9B 08-0CT-98 04-NOV-98 04-N0V-98 04-NOV-98 04-NOV-98 05-N0V-98 05-NOV-98 05-NOV-98 05-NOV-98 05-N0V-98 0 5 -NOV-98 05-NOV-98 05-NOV-98 0 5 -NOV-98 05-N0V-98 TREATMENT FROM TO 08-OCT-98 08-0CT-98 08-0CT-98 0 8 -OCT-98 08-0CT-98 0 8 -OCT-98 0 8 -OCT-98 0 8 -OCT-98 08-0CT-98 08-OCT-98 08-0CT-98 08-OCT-98 0 8 -OCT-98 08-OCT-98 0 4 -NOV-98 04-N0V-98 04-N0V-98 04-N0V-98 05-NOV-98 05-NOV-98 05-NOV-98 05-NOV-98 05-NOV-98 05-NOV-98 05-NOV-98 05-NOV-98 05-NOV-98 05-NOV-98 MORT-IND - 6 2 4 -FEB-99 1 25 000126 NOTOX Project 242933 SYM-IND - 1 25-FEB-9 9 CLINICAL SIGNS MALES GROUP 1 (VEHICLE CONTROL) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 ............ 3 ............ 4 ............ 5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.S.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB ANIMAL 2 SKIN / FUR / PLUMAGE ALOPECIA (3) (BACK) ALOPECIA (3) (NECK) ALOPECIA (3) (FORELEG LEFT) ALOPECIA (3) (HINDLEG LEFT) ALOPECIA (3) (HINDLEG R i a n 1) G: .................. 111111111___ G: ........................ 1111111111111111111. G: .1222222222221111111111111111111111111..... G: ___ 11111111111113311111111111111............. G: ___ 1111111111111111111111111111111111............... ANIMAL 3 SKIN / FUR / PLUMAGE ALOPECIA (3) (CHEST) SCABS (3) (NECK) G: G: .111111111111111111111111111. ANIMAL 4 SKIN / FUR / PLUMAGE ALOPECIA (3) (BACK) ALOPECIA (3) (NECK) G: G: ANIMAL 9 SKIN / FUR / PLUMAGE ALOPECIA (3) (ABDOMEN) ALOPECIA (3) (CHEST) ANIMAL 15 G: G: .111111111111111111111111111111111111. VARIOUS BULGING EYE (1) (EYE RIGHT) DARK (3) (EYE RIGHT) G: G: NO FURTHER CLINICAL SIGNS NOTED IN G: Highest grades Time after treatment (H.Mi) A: 0.00 B: 4.00 1 26 000127 NOTOX Project 242933 CLINICAL SIGNS, DAILY MALES GROUP 1 (VEHICLE CONTROL) SIGN (MAX.GRADE) (LOCATION) RECOVERY WEEKS: 1 ..... 2 ..... 3 ..... 4 ..... 5. ANIMAL 9 SKIN / FUR / PLUMAGE ALOPECIA (3) (CHEST) G: ..... 12222222. ANIMAL 15 VARIOUS BULGING EYE (1) (EYE RIGHT) DARK (3) (EYE RIGHT) G: 11 ........................... G: 11........................... NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP S Y M - I N D - j, 2 5 - MAR-99 G: Highest daily grades 1 27 000128 NOTOX Project 242933 SYM-IND - 3 25-FEB-9 9 CLINICAL SIGNS HALES GROUP 2 (TELOMER ALCOHOL) SIGN (MAX.GRADE) TREATMENT i ............ 2,. .......... .3 ............. 4............. 5 , d a y s :' TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB ANIMAL 17 SKIN / FUR / PLUMAGE ALOPECIA (3) (NECK) ANIMAL 18 SKIN / FUR / PLUMAGE SCABS (3) (BACK) ANIMAL 19 SKIN / FUR / PLUMAGE ALOPECIA (3) (SMOULDER LEFT) ANIMAL 20 SKIN / FUR / PLUMAGE WOUND (3) (GENITAL REGION) ANIMAL 21 SKIN / FUR / PLUMAGE SCABS (3) (NECK) ANIMAL 23 SKIN / FUR / PLUMAGE ALOPECIA (3) (FORELEG LEFT) ANIMAL 25 SKIN / FUR / PLUMAGE RED STAINING (3) (PERIORBITAL REGION LEFT) ANIMAL 26 SKIN / FUR / PLUMAGE SCABS (3) (SNOUT) ANIMAL 27 SKIN / FUR / PLUMAGE RED STAINING (3) (PERIORBITAL REGION RIGHT) ANIMAL 29 BREATHING RALES (3) SKIN / FUR / PLUMAGE ALOPECIA (3) (ABDOMEN) :::::::::::::::::::::::: G: ........... :................ ............. 11111. G: ............................................... 1 :::::::::::::::::::::::: :::::::::::::::::::::::: G: ...................................... 11....... :::::::::::::::::::::::::: : : : : : : : : : : : : : : : : : : : i ::::: i G: ............................................... 1 .... :::::::::::::::::::::::::: G: ........................................ 11..... 1111, :::::::::::::::::::::::::: : : : : : : : : : : : : : : : : : : : i : ii G: ............................................. 1111111 :::::::::::::::::::::::::: :::::::::::::::::::::::::: G: ..................................................... G: 1 G: ::::::::::::::::::::::::::::: G: ........................................................ Ill G: ............1111111111111111111111111111111111111111111111 G: Highest grades Time after treatment (H.Mi) A: 0.00 B: 4.00 1 28 000129 NOTOX Project 242933 SYM-IND 25-FEB-99 CLINICAL SIGNS MALES GROUP 2 (TELOMER ALCOHOL) SIGH (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 .............3 .............4 .............5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB ANIMAL 30 SKIN / FUR / PLUMAGE ALOPECIA (3) (CHEEK RIGHT) G: NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP 111111111 G: Highest grades Time after treatment (H.Mi) A: 0.00 B: 4.00 1 29 000130 NOTOX Project 242933 CLINICAL SIGNS, DAILY . MALES GROUP 2 (TELOMER ALCOHOL) SIGN (MAX.GRADE) (LOCATION) RECOVERY WEEKS: ANIMAL 25 SKIN / FUR / PLUMAGE RED STAINING (3) (PERIORBITAL REGION LEFT) G: ...... Ill..... ANIMAL 26 SKIN / FUR / PLUMAGE SCABS (3) (SNOUT) G: 11............ ANIMAL 27 SKIN / FUR / PLUMAGE RED STAINING (3) G: .... 1 ......... (PERIORBITAL REGION RIGHT) . ANIMAL 29 BREATHING RALES (3) SKIN / FUR / PLUMAGE ALOPECIA (3) (ABDOMEN) G: 1111111111111111..1111...... G: 11111..... NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP SYM-IND - S 25-MAR-9 9 G: Highest daily grades 13 0 000131 NOTOX Project 242933 SYM-IND - 6 2S - F E B - 9 9 CLINICAL SIGNS MALES GROUP 3 (TELOMER ACRYLATE) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 .............3 .............4 ............. 5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB ANIMAL 33 SKIN / FOR / PLUMAGE ALOPECIA (3) (NECK) ALOPECIA (3) (CHEST) ALOPECIA (3) (FORELEG RIGHT) G: iiiiiil G: 111222222211111111111111111111111111 G: 11122222221111111111............... ANIMAL 35 SKIN / FUR / PLUMAGE ALOPECIA (3) (FLANK LEFT) ALOPECIA (3) (CHEST) ALOPECIA (3) (FORELEG RIGHT) SCABS (3) (TAIL) ANIMAL 45 G: 11112221111111111111...................................... G: ............................111111........................ G : ..111111111111111111....................................... G: ........................................... 1111111111111.. : : : : : ........ : : : : : : : : : : : : : : SKIN / FUR / PLUMAGE SCABS (3) (BACK) RED STAINING (3) (NECK) : :: :: :: : :: : : :: :: :: I :: i i ! G: .....................'................. 11...1111 G ......... ........................................ NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP G: Highest grades Time after treatment (H.Mi) A: 0.00 B: 4.00 1 31 000132 NOTOX Project 242933 CLINICAL SIGNS, DAILY MALES GROUP 3 (TELOMER ACRYLATE) SIGN (MAX.GRADE) (LOCATION) RECOVERY WEEKS: 1 ..... 2 ..... 3 ..... 4 ..... 5. ANIMAL 45 SKIN / FUR / PLUMAGE RED STAINING (3) (NECK) G: ......................111111. NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP SYM-IND - 7 2 5 - M A R -9 9 G; Highest daily grades 1 32 000133 NOTOX Project 242933 SYM-IND - g 25-FEB-9 9 CLINICAL SIGNS MALES GROUP 4 SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 .............3.............4 .............5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB ANIMAL 51 SKIN / FOR / PLOMAGE ALOPECIA (3) (FORELEG RIGHT) G: ANIMAL 56 ::::::::::::: SKIN / FUR / PLOMAGE RED STAINING (3) (PERIORBITAL REGION LEFT) ................. : : : : : : : : G: .....................11111 ANIMAL 61 SKIN / FOR / PLOMAGE ALOPECIA (3) (EYE RIGHT) VARIOUS EYE RIGHT, INJURED (1) DEHYDRATED (3) (EYE RIGHT) BODGING EYE (1) (EYE RIGHT) DARK (3) (EYE RIGHT) G: G: G: G: G: ANIMAL 62 VARIOUS DARK (3) (EYE RIGHT) G: ............................................ ANIMAL 63 :::::::::::::::::::::: SKIN / FOR / PLOMAGE SCABS (3) (NECK) :::::::::::::::::::::: G: ................................ 111111111111 NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP .11.. G: Highest grades Time after treatment (H.Mi) A: 0.00 B: 4.00 1 33 000134 NOTOX Project 242933 CLINICAL SIGNS, DAILY MALES GROUP 4 SIGN (MAX.GRADE) (LOCATION) RECOVERY WEEKS: 1 ..... 2 ......3 ..... 4 ..... 5. ANIMAL 61 SKIN / FOR / PLUMAGE ALOPECIA (3) (EXE RIGHT) VARIOUS - EYE RIGHT, INJURED (1) DEHYDRATED (3) (EXE RIGHT) BULGING EXE (1) (EYE RIGHT) DARK (3) (EXE RIGHT) G: ........... 1 1 1 U 1 1 U 1 1 U U 1 . G: 1111111111111111111111111111. G: .22222 G: 111111 G: 111111 ANIMAL 62 VARIOUS DARK (3) (EXE RIGHT) G: 1 1 ........ NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP SYM-IND - 3 2 5 - M A R - 99 G: Highest daily grades 1 34 000135 NOTOX Project 242933 SYM-IND -lo 25-FEB-99 CLINICAL SIGNS MAT.TCS GROUP 5 (PFHS) SIGN (MAX.GRADE) TREATMENT WEEKS: X ............ 2 .............3 .............4 ............. 5. DAYS: 1 .2 . 3 . 4 .5 . 6. 7 . 1 .2 .3 . 4 . 5 . 6. 7 . 1 .2 . 3 . 4 . 5 .6 . 7 . 1 . 2 . 3 .4 . 5. 6. 7 . 1 . TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB ANIMAL 65 SKIN / FUR / PLUMAGE RED STAINING (3) (EAR LEFT) G: ........ 11111111111. ANIMAL 67 SKIN / FUR / PLUMAGE RED STAINING (3) (SNOUT) G: ANIMAL 72 SKIN / FUR / PLUMAGE WOUND (3) (BACK) G: ANIMAL 74 POSTURE HUNCHED POSTURE (1) . G: ANIMAL 79 SKIN / FUR / PLUMAGE RED STAINING (3) (NECK) RED STAINING (3) (CERVICAL REGION) VARIOUS DARK (3) (EIE RIGHT) G: G: G: NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP .111. .11.. .1111 G: Highest grades Time after treatment (H.Mi) A: 0.00 B: 4.00 1 35 000136 NOTOX Proiect 242933 CLINICAL SIGNS, DAILY MALES GROUP 5 (PFHS) SIGN (MAX.GRADE) (LOCATION) RECOVERY WEEKS: 1 ..... 2 ......3 ..... 4 ..... 5. ANIMAL 74 POSTURE HUNCHED POSTURE (1) G: 11............ ANIMAL 79 SKIN / FUR / PLUMAGE RED STAINING (3) (NECK) RED STAINING (3) (CERVICAL REGION) VARIOUS DARK (3) (EYE RIGHT) G ........ 11.................... G: ........ 1111111111111111111. G: 11........................... NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP SYM-IND -11 25-MAR-99 G: Highest daily grades 1 36 000137 NOTOX Project 242933 S Y M - I N D - L2 2 5 - F E B - 99 CLINICAL SIGNS MALES GROUP 6 (PFOS) SIGH (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 ............ 3 ............ 4 ............ 5. DAYS: 1.2.3.4.5.S.7.1.2.3.4.5.6.7.1.2.3.4.S.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB ANIMAL 81 SKIN / FUR / PLUMAGE SWELLING (3) (ABDOMEN) G: ANIMAL 87 :::::::::::::::::::: SKIN / FUR / PLUMAGE ALOPECIA (3) (CHEEK LEFT) :::::::::::::::::::: G: ......................... 11111111111111 ANIMAL 93 SKIN / FUR / PLUMAGE SCABS (3) (NECK) ::::::: ::::::::: : :: i G: ................................ 1111111 ANIMAL 95 :::::: SKIN / FUR / PLUMAGE RED STAINING (3) (HEAD) :::::: G: ........... NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP m in.. G: Highest grades Time after treatment (H.Mi) A: 0.00 B: 4.00 1 37 000138 NOTOX Project 242933 CLINICAL SIGNS, DAILY MALES GROUP 6 (PFOS) SIGN {MAX.GRADE) (LOCATION) RECOVERY WEEKS: 1 ..... 2 ..... 3 ......4 ..... 5. ANIMAL 95 SKIN / FUR / PLUMAGE RED STAINING (3) (HEAD) ...................... 111111111. NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP SYM-IND -13 25-MAR-99 G: Highest daily grades 1 38 000139 NOTOX Project 242933 S Y M - I N D - 1425-FEB-9 9 CLINICAL SIGNS k k MAT GROUP 1 (VEHICLE CONTROL) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 .............3 .............4 .............5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ARARARARARABARARABABABABARARABABAHARABABARABABABABARARARAB ANIMAL 97 VARIOOS MISSING (1) (TAIL APEX) ANIMAL 98 VARIONS MISSING (1) (TAIL APEX) ANIMAL 104 SKIN / FOR / PLOMAGE ALOPECIA (3) (BACK) ANIMAL 10S SKIN / FOR / PLOMAGE SCABS (3) (ABDOMEN) WOUND (3) (ABDOMEN) ANIMAL 106 SKIN / FOR / PLOMAGE ALOPECIA (3) (NECK) ANIMAL 109 SKIN / FUR / PLOMAGE ALOPECIA (3) (FLANK RIGHT) ALOPECIA (3) (THIGH HIND LEFT) ALOPECIA (3) (THIGH KIND. RIGHT) ANIMAL 110 SKIN / FOR / PLOMAGE ALOPECIA (3) (ABDOMEN) SECRETION / EXCRETION SALIVATION (3) ANIMAL 111 SKIN / FOR / PLOMAGE ALOPECIA (3) (GENERAL) ALOPECIA (3) (CHEEK LEFT) ALOPECIA (3) (BACK) ALOPECIA (3) (ABDOMEN) ALOPECIA (3) (FLANK LEFT) ALOPECIA (3) (FLANK RIGHT) G: .m nuuim iiuiiiuuuiiiii. G: .liiim m iuuiiuiuiim un. G:................................. 111111111. G: G: G: G: G: G: G: .1111111111111111111111111111111111111111111111 G: G: G: G: G: 11112222111111111111111111 G: ....................................... 1111111111111111111 G ............ 111111111111111.1111111111111111111111111111111 G: Highest grades Time after treatment (H.Mi) A: 0.00 B: 4.00 1 39 000140 NOTOX Project 242933 S Y M - I N D - IS 2 5 - F E B - 99 CLINICAL SIGNS FEMALES GROUP 1 (VEHICLE CONTROL) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 .............3 .............4 .............5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: AEABABABABABABABABABABABABABABABABABABABABABABABABABABABAB ALOPECIA (3l (SHOULDER LEFT) ALOPECIA (3) (HINDLEG LEFT) G: ............................. 1111111111111111111111...... G: ....................... ............. 111111111111111...... NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP G: Highest grades Time after treatment (H.Mi) A: 0.00 B: 4.00 1 40 000141 NOTOX Project 242933 CLINICAL SIGNS, DAILY females GROUP 1 (VEHICLE CONTROL) SIGN (MAX.GRADE) (LOCATION) RECOVERY WEEKS: 1 ..... 2 ..... 3 ..... 4 ..... 5. ANIMAL 105 SKIN i FUR / PLUMAGE SCABS (3) (ABDOMEN) g: ...minim.. ANIMAL 106 SKIN / FUR /. PLUMAGE ALOPECIA (3) (NECK) G: .......... 1111. ANIMAL 109 SKIN / FUR / PLUMAGE ALOPECIA (3) (FLANK RIGHT) ALOPECIA (3) (THIGH HIND LEFT) ALOPECIA (3) (THIGH HIND RIGHT) G: ....... 1111................ G: ...111111111111............ G: 111111111111111............ ANIMAL 111 SKIN / FUR / PLUMAGE ALOPECIA (3) (GENERAL) ALOPECIA (3) (CHEEK LEFT) ALOPECIA (3) (BACK) ALOPECIA (3) (ABDOMEN) ALOPECIA (3) (FLANK LEFT) ALOPECIA (3) (FLANK RIGHT) ..................... 11111111111 G: .............. 11........... G: ..... 11111111111........... ......... 11111111111.......... G: 11111111111111111.......... G: 11122222222222222.......... NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP SYM-IND -l6 25-MAR-9 9 G: Highest daily grades 141 000142 NOTOX Project 242933 SYM-IND - 1T 25-FEB-99 CLINICAL SIGNS FEMALES GROUP 2 (TELQMER ALCOHOL) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 .............3 .............4 ...........-..5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB ANIMAL 113 SKIN / FUR / PLUMAGE ALOPECIA (3) (FORELEGS) - G: ANIMAL 117 SKIN / FUR / PLUMAGE RED STAINING (3) (EAR RIGHT) G: .11. ANIMAL 119 SKIN / FUR / PLUMAGE ALOPECIA (3) (BACK) G: ANIMAL 121 SKIN / FUR / PLUMAGE ALOPECIA (3) (HEAD) ALOPECIA (3) (CHEEK LEFT) ALOPECIA (3) (CHEEK RIGHT) ALOPECIA (3) (NECK) SCABS (3) (FLANK LEFT) G: G: G: G: G: ANIMAL 122 SKIN / FUR / PLUMAGE ALOPECIA (3) (CHEEK LEFT) ALOPECIA (3) (CHEEK RIGHT) SCALES (3) (CHEEK LEFT) SCALES (3) (CHEEK RIGHT) G: G: G: G: ANIMAL 123 SKIN / FUR / PLUMAGE ALOPECIA (3) (CHEEK LEFT) G: ANIMAL 126 SKIN / FUR / PLUMAGE ALOPECIA (3) (NECK) G: 11111111111111111. NO FURTHER CLINICAL SIC2JS NOTED IN THIS GROUP .1111111112. .11111 .11 . 11. .1111111111. G: Highest grades Time after treatment (H.Mi) A: 0.00 B: 4.00 1 42 000143 NOTOX Project 242933 CLINICAL SIGNS, DAILY FEMALES GROUP 2 (TELOMER ALCOHOL) SIGN (MAX.GRADE) (LOCATION) RECOVERY WEEKS: 1 ..... 2 ..... 3 ..... 4 ..... 5. ANIMAL 121 SKIN / FUR / PLUMAGE ALOPECIA (3) (HEAD) ALOPECIA (3) (CHEEK LEFT) ALOPECIA' (3) (CHEEK RIGHT) G: ...... 2222211. G: .1112222222222. G ..... 1222222222. ANIMAL 122 SKIN / FOR / PLUMAGE ALOPECIA (3) (CHEEK LEFT) ALOPECIA (3) (CHEEK RIGHT) SCALES (3) (CHEEK LEFT) SCALES (3) (CHEEK RIGHT) G: .... 112222222. G: ___ 1222222222. G .........1111111. G: .......1111111. NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP SYM-IND -18 25-MAR-9 9 G: Highest daily grades 1 43 000144 NOTOX Project 242933 S Y M - I N D - ig 25-FEB-99 CLINICAL SIGNS FEMALES GROUP 3 (TELOMER ACRYLATE) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 .............3 .............4 .............5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB ANIMAL 129 :::::::::::::::::::::: POSTURE HUNCHED POSTURE (1) :::::::::::::::::::::: G: ............ :............. 111111111........ ANIMAL 131 :::::::::::::::::::::: SKIN / FUR / PLUMAGE ALOPECIA (3) G: ......................... 11111111111...................... RED STAINING (3) (HEAD) RED STAINING (3) (NECK) G: ..................................................1111111.. G: ............................ 111111111..................... ANIMAL 132 SKIN / FUR / PLUMAGE ALOPECIA (3) (ABDOMEN) ALOPECIA (3) (SHOULDER LEFT) RED STAINING (3) (HEAD) RED STAINING (3) (BACK) RED STAINING (3) (NECK) G G G G G ...1111...................................................... 1111111.......................... . . . 1 ...................................................1 ............................................m in ............... .liiiiiiiimi.........................mi... ANIMAL 133 POSTURE HUNCHED POSTURE (1) G: ...................... 1111111111111 ANIMAL 134 SKIN / FUR / PLUMAGE SCABS (3) (NECK) ::::::::::::::::::::::::::::: G: .....................................................111111 ANIMAL 136 SKIN / FUR / PLUMAGE SCABS (3) (BACK) RED STAINING (3) (HEAD) ............................................................ 11 G: .................................................. 1 ....... ANIMAL 137 -- -- -- -- ------ -- -- -- -- -- -- SKIN / FUR / PLUMAGE ALOPECIA (3) (ABDOMEN) G: 1111222211111111.. ANIMAL 138 -- -- ------ ---- ---- -- ---- -- ---- POSTURE ; HUNCHED POSTURE (1) G: SKIN / FUR / PLUMAGE PILOERECTIQN (1) G: ALOPECIA (3) G: (ABDOMEN) ; .ill. * liliiil G: Highest grades Time after treatment (H.Ml) A: 0.00 B: 4.00 1 44 000145 NOTOX Project 242933 SYM-IND - 20 25-FEB-99 CLINICAL SIGNS FEMALES GROUP 3 (TELOMER ACRYLATE) SIGN (MAX.GRADE) TREATMEOT WEEKS: 1 ............ 2 ............ 3 .............4 .............5. DAYS: 1.2.3.4.5.S.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABAEABABABABABABABAB ANIMAL 139 POSTURE HUNCHED POSTURE (1) SKIN / FUR / PLUMAGE ALOPECIA (3) (ABDOMEN) G: ........... (.............................................1 G: ........... 1111111111111122222122222222222222222211111111 ANIMAL 141 SKIN / FUR / PLUMAGE RED STAINING (3) (HEAD) G: ANIMAL 142 SKIN / FUR / PLUMAGE RED STAINING (3) (HEAD) : : : : : : ........ .. : : : G: Ill ANIMAL 143 SKIN / FUR / PLUMAGE ALOPECIA (3) G (ABDOMEN) FISSURES WITH BLEEDINGS (3) G ' (PAW HIND RIGHT) RED STAINING (3) G (PAW HIND RIGHT) .1111222211111111 1111111.11111111111111111111111111111111 ............................... 11............ .................................. .......111111111111111. NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP G; Highest grades Time after treatment (H.Mi) A: 0.00 B: 4.00 5 000146 NOTOX Project 242933 CLINICAL SIGNS, DAILY ^ KMTAT GROUP 3 (TELOMER ACRYLATE) SIGN (Max. GRADE) (LOCATION) RECOVERY WEEKS: 1...I..2..... 3 ..... 4 ..... 5. ANIMAL 138 POSTURE HUNCHED POSTURE (1) SKIN / FUR / PLUMAGE PILOERECTIQN (1) G: 11111111111111. G: .1111....... ANIMAL 139 POSTURE HUNCHED POSTURE (1) SKIN / FUR / PLUMAGE ALOPECIA (3) (ABDOMEN) G: 1111111....... G: 11111111111111. ANIMAL 141 SKIN / FUR / PLUMAGE RED STAINING (3) (HEAD) G: ................ . ANIMAL 142 SKIN / FUR / PLUMAGE RED STAINING (3) (HEAD) G: .................... NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP SYM-IND -21 25-MAR-9 9 G: Highest daily grades 1 46 000147 NOTOX Project 242933 S Y M - I N D - 22. 25-FEB-99 CLINICAL SIGNS FEMALES GROUP 4 ( ) STi^| (MAX.GRADE) TREATMENT WEEKS: 1 ..........................2 .......................... 3 ..........................4 .......................... 5 . DAYS: 1 . 2 . 3 . 4 . 5 . 6 . 7 . 1 . 2 . 3 . 4 . 5 . 6 . 7 . 1 . 2 . 3 . 4 . 5 . 6 . 7 . 1 . 2 . 3 . 4 . 5 . 6 . 7 . 1 . TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB ANIMAL 147 8: : : : : : : : : : s S : : : : : : : : : : : : : : : SKIM / FOR / PLUMAGE ALOPECIA (3) (BACK) : : : : : : : : : : : : : ................. : : : : : : : : : : : G: ........................ . ' . . . . 111111111111... 1111111111111___ 1111111.. ANIMAL 148 SKIN / FOR / PLOMAGE SWELLING (3) (EAR RIGHT) RED STAINING (3) (EAR LEFT) RED STAINING (3) (EAR RIGHT) g : .iiiiiiiiiiiii. G: ......................111111111................... G: .................... 11111111111111111111111111111111111111 ANIMAL 151 SKIN / FOR / PLOMAGE ALOPECIA (3) (NECK) G: ........................................................................................................11111111 ANIMAL 152 POSTURE HUNCHED POSTURE (1) SKIN / FUR / PLUMAGE RED STAINING (3) (EAR RIGHT) ..................................................................1111111111111111111111111111 G : ......................................... 111111111111111111111111111111111111 ANIMAL 155 SKIN / FOR / PLOMAGE RED STAINING (3) (EAR RIGHT) G: ................................................................................................... 1111111111 ANIMAL 157 SKIN / FUR / PLOMAGE ALOPECIA (3) (NECK) ALOPECIA (3) (THROAT REGION) SCALES (3) (THROAT REGION) ' G: G: G: iiiiiiiiii 222222222222222222222222222222221111 .1111111111111....................................... ANIMAL 159 SKIN / FOR / PLOMAGE ALOPECIA (3) G: (NECK) SCABS (3) G: (NECK) RED STAINING (3) G: (EYE RIGHT) RED STAINING (3) G: (PERIORBITAL REGION RIGHT) SECRETION / EXCRETION WATERY DISCHARGE FROM EY (3) G: (EYE RIGHT) iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP G: Highest grades Time after treatment (H.Mi) A: 0.00 B: 4.00 1 47 000148 N O T O X Pro-ject 242933 CLINICAL SIGNS, DAILY FEMALES GROUP 4 ( ) SIGN (MAX.GRADE) (LOCATION) RECOVERY WEEKS: 1 ..... 2, 4 ..... S. ANIMAL 159 SKIN / KIR / PLUMAGE SCABS (3) G: (NECK) RED STAINING (3) G: . . . 11. (EYE RIGHT) RED STAINING (3) G: ...11 (PERIORBITAL REGION RIGHT) SECRETION / EXCRETION WATERY DISCHARGE FROM EY (3) G: (EYE RIGHT) ' NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP -.1111 11 1. S Y M - I N D - 2.3 2 5 - M A R - 99 G: Highest daily grades 1 48 000149 NOTOX Project 242933 SYM-IND - 54 25-FEB-9 9 CLINICAL SIGNS FEMALES GROUP 5 (PFHS) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 ............. 3 .............4 ............ 5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB ANIMAL 162 SKIN / FUR / PLUMAGE ALOPECIA (3) (NECK) SCABS (3) (NECK) WOUND (3) (NECK) ANIMAL 163 POSTURE HUNCHED POSTURE (1) ANIMAL 166 G: .111111111222222111111111222222222211112222222222222222 G: 1111112222111111111111222222111111111111111111111111111... G: ....... 11. .111112222211.................................. G: SKIN / FUR / PLUMAGE ALOPECIA (3) (NECK) G: . 1111111111. ANIMAL 167 SKIN / FUR / PLUMAGE ALOPECIA (3) (NECK) G: 111111111111111 ANIMAL 169 SKIN / FUR / PLUMAGE ALOPECIA (3) (BACK) SECRETION / EXCRETION SALIVATION (3) ANIMAL 173 G: G: 1 1 SKIN / FUR / PLUMAGE ALOPECIA (3) (NECK) ALOPECIA (3) (ABDOMEN) ALOPECIA (3) ' (SHOULDER RIGHT) G: G: G: ......... 11111111111111111111132 lim iii.......................illinium .. i ANIMAL 174 .......... : : SKIN / FUR /PLUMAGE . ALOPECIA (3) (BACK) ALOPECIA (3) (ABDOMEN) ::::::::::::::::::::::::::::: G: ...................... 11111112111111...................... G: ........... 1111111111222222222222222222222222111111111111 ANIMAL 175 ::::::::::::::::::::::::::::: SKIN / FUR /PLUMAGE ALOPECIA (3) (NECK) ALOPECIA (3) (HINDLEG RIGHT) ::::::::::::::::::::::::::::: G: ...................... 11111111111111...................... G ............................................................. NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP G: Highest grades Time after treatment (H.Mi) A: 0.00 B: 4.00 149 000150 NOTOX Project 242933 CLINICAL SIGNS, DAILY females GROUP 5 (PFHS) SIGN (MAX.GRADE) (LOCATION) RECOVERY WEEKS: 1 ..... 2 ..... 3 ..... 4 ..... ! ANIMAL 173 SKIN / FUR / PLUMAGE ALOPECIA (3) (NECK) G: .11111111111111111111111 ANIMAL 174 SKIN / FUR / PLUMAGE ALOPECIA (3) (BACK) ALOPECIA (3) (ABDOMEN) G: G: 111. .. .111111111111111111111 ANIMAL 175 SKIN / FUR / PLUMAGE ALOPECIA (3) (NECK) ALOPECIA (3) (HINDLEG RIGHT) G: 111. ..... 111111111111111111 G: ..1111................. NO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP SYM-IND - 2J 2 5 - M A R - 99 G: Highest daily grades 1 50 000151 NOTOX Project 242933 SYM-IND 25-FEB-99 CLINICAL SIGNS FEMALES GROUP 6 (PFOS) SIGN (MAX.GRADE) TREATMENT WEEKS: 1 ............ 2 .............3 ............ 4 .............5. DAYS: 1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1.2.3.4.5.6.7.1. TIME: ABABABABABABABABABABABABABABABABABABABABABABABABABABABABAB ANIMAL 178 POSTURE HUNCHED POSTURE (1) SKIN / FUR / PLUMAGE RED STAINING (3) (SNOUT) G: ........... .................. ........111111.............. ................................................. ........................ 1111... ANIMAL 179 POSTURE HUNCHED POSTURE (1) SKIN / FUR / PLUMAGE ALOPECIA (3) (FORELEG LEFT) ALOPECIA (3) (FORELEG RIGHT) g : I.!.!.!.!.!.!.!..'.!.!...!.!.!.!.!.!.iiiiiiii I. G: .............................. 111111112. .222222222222222.. G: ............... .............. 222222222.. 222222222222222.. ANIMAL 183 SKIN / FUR / PLUMAGE SCABS (3) (NECK) g : I.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.!.iiiiiiii!. ANIMAL 185 SKIN / FUR / PLUMAGE RED STAINING (3) (HEAD) G: ANIMAL 186 SKIN / FUR / PLUMAGE ALOPECIA (3) (ABDOMEN) RED STAINING (3) (HEAD) g : iiiiiiiiiiiiiiiiiiiiiiiii.!.! G: ..................................... ...... ANIMAL 187 SKIN / FUR / PLUMAGE RED STAINING (3) (HEAD) RED STAINING (3) (EAR LEFT) RED STAINING (3) (EAR RIGHT) RED STAINING (3) (NECK) ANIMAL 189 SKIN / FUR / PLUMAGE ALOPECIA (3) (ABDOMEN) . . . ........... ......................................... G: ................1111...................................... ANIMAL 190 ::::::::::::::::::::::::::::: SKIN / FUR / PLUMAGE ALOPECIA (3) (ABDOMEN) I : : : : : : : : : : : : : : : I i i i I i :: i : : : : ............................ m i l l ..... m i l l . . . 111111111111 NO FURTHER CLINICAL SIOJS NOTED IN THIS GROUP G: Highest grades Time after treatment (H.Mi) A: 0.00 B: 4.00 1 51 000152 NOTOX Project 242933 CLINICAL SIGNS, DAILY FEMALES GROUP 6 (PFOS) SIGN (MAX.GRADE) (LOCATION) RECOVERY WEEKS: 1 ..... 2 ......3 ..... 4 ..... 5. ANIMAL 185 SKIN / FUR / PLUMAGE RED STAINING (3) (HEAD) G: ...11......... ANIMAL 186 SKIN / FUR / PLUMAGE RED STAINING (3) (HEAD) G: ...11111111111. ANIMAL 187 SKIN / FUR / PLUMAGE RED STAINING (3) (HEAD) RED STAINING (3) (EAR LEFT) RED STAINING (3) (EAR RIGHT) RED STAINING (3) (NECK) G: 1113211.... 11. G: ...111111111... G: ........ 111... G: ........ 11111. ANIMAL 190 SKIN / FUR / PLUMAGE ALOPECIA (3) (ABDOMEN) G: 11111....................... HO FURTHER CLINICAL SIGNS NOTED IN THIS GROUP SYM-IND - 27 2 5 - M A R - 99 G: Highest daily grades 152 000153 NOTOX Project 242933 BODY WEIGHTS (GRAM) MALES BW-IND - X 17-MAR-99 TREATMENT days WEEKS ANIMAL 1 1 5 1 8 12 15 2 2 .3 GROUP 1 (VEHICLE CONTROL) 1 232 219 2 202 253 3 228 252 4 196 214 5 209 235 6 221 249 7 222 245 8 197 221 9 207 236 10 184 206 11 207 232 12 .-- 13 208 238 14 190 217 15 211 233 16 GROUP 2 (TELOMER ALCOHOL) 17 224 245 18 230 261 19 219 241 20 209 235 21 189 217 22 228 254 23 216 241 24 228 248 25 205 230 26 190 209 27 197 223 28 -- 29 208 232 30 217 249 31 212 234 32 GROUP 3 (TELOMER ACRYLATE) 33 220 243 34 191 216 35 224 . 242 36 211 233 37 220 243 . 38 211 236 39 206 231 40 206 232 41 216 245 42 197 220 43 210 235 44 45 201 227 46 213 242 47 206 229 48 GROUP 4 49 222 239 50 201 228 51 217 246 52 211 244 53 209 236 235 257 274 297 274 ' "300 230 246 258 278 270 288 269 297 244 266 247 274 207 229 240 264 ...... 250 281 227 254 243 270 265 286 280 307 259 277 251 270 238 270 277 304 262 288 264 284 237 265 217 237 235 256 ... 240 270 257 290 245 267 261 234 250 250 263 261' 251 255 261 227 246 ------ 235 249 234 278 259 267 269 278 282 280 276 292 257 275 ...... 269 278 267 248 268 244 268 264 294 267 294 252 278 262 311 313 255 288 304 316 280 277 226 277 --- 285 262 275 299 329 288 285 287 321 302 300 265 245 260 277 297 273 296 273 277 281 290 298 287 290 294 262 288 ... 271 283 270 278 280 310 308 288 15 3 19 22 25 28 3 44 4 281 289 301 309 332 341 354 365 341 351 360 377 271 282 288 298 301 308 322 330 319 334 350 356 341 349 368 381 297 304 317 322 303 310 322 336 245 251 260 276 2. 9i5 310 316 ...... _-- 328 --. 311 323 345 356 286 299 309 322 309 319 328 342 319 329 342 359 354 '359 384 389 311 322 327 342 300 307 320 328 .310 322 338 348 343 348 363 386 322 328 336 343 307 321 333 346 289 292 308 319 269 277 287 294 283 288 303 311 .- ------ ---- 292 298 310 317 320 333 347 360 289 297 313 320 317 327 346 352 288 301 312 318 294 306 314 329 301 313 323 328 304 316 327 331 320 327 340 355 314 322 334 349 306 319 327 332 319 331 355 365 289 300 310 325 302 313 326 337 ------ ...... 304 310 326 341 304 311 325 336 298 313 324 338 294 303 308 324 301 303 316 333 336 345 . 360 378 335 338 347 360 315 324 346 354 000154 NOTOX Project 242933 BODY WEIGHTS (GRM) HALES BW-XND - 2 17-MAR-99 RECOVERY Eftys WEEKS ANIMAL 1 1 5 8 12 14 19 22 25 28 12223444 GROUP 1 (VEHICLE CONTROL) 1 2 3 4 --- --- 5-- 6-- 7 a -- -- ___ 9 318 348 10 253 279 - ... .-- ... --- ... -- -- ... 359 285 11 12 310 339 ... 351 ... 13 334 370 381 14 297 337 341 15 314 354 361 16 GROUP 2 (TELOMER a l c o h o l ) 17 ... 18 --- 19 20 --- 21 ... 22 -- 23 -- 24 ... 25 298 330 26 277 303 .-- --. --. .-- ... -- -- .-- 337 308 27 28 289 3X8 ... 330 ------ 29 289 315 317 30 336 385 388 31 296 334 345 32 GROUP 3 (TELOMER ACRYLATE) 33 -- 34 -- 35 . .-- 36 . . . ' 37 ... 38 -- 39 -- 40 -- 41 336 388 42 298 314 .-- ---- -- -- -- -- ... 39Q 325 43 44 45 46 47 . 48 312 347 350 ... ... 314 352 361 312 351 357 310 351 354 GROUP 4 ( 49 50 51 52 53 ... ... -- . ... ... .-- ---- ---- --. --... -- --. -- ... -- --- -- ... -- ... ... 364 373 299 303 362 366 ... ... 394 398 348 353 379 378 -- ... -- ------ ---- -- ----- -- .-- .-- ... ... 346 354 319 320 342 345 ... ... 334 328 402 401 357 358 ... ... ... -- ... ... -- ... -- --- -- -- ... -- 404 408 341 347 359 359 . . . ... 379 378 375 379 373 372 -- ... ---- -- ... ... -- 1 54 -- ... -- -- --- .-- -- -- ... ... -- -- ... -- -- -- -- -- ... -- -- -- -- .-- -- -- ... -- ... ... ... ... ---- -- --- --- -- --- ---- ---- ... ... ... ... 414 421 435 440 365 373 385 387 393 403 415 419 ... .-- -- ... --. -- .-- ... -- -- -- ... 342 413 371 ---- --- -- --- ----- ---- .-- -- ... . -... -- ---- ---- ---- ... ------ 349 353 416 430 381 389 -- -- -- -- -- -- -- -- -- .-- -- ... 355 429 388 -- ... -- -- ... -- -- .-- -- -- ... ... .-- ... ... .-- -- --- ... -- . -- --. ... -- - -- . ... ... ... ... -------- ------ -- -- .-- . . . -- ... ... ... ... 395 403 412 414 391 402 411 413 381 393 398 409 __ ___ -- -- -- -- - -- .-- -- -- ... .-- -- --- 000555 NOTOX Project 242933 BODY WEIGHTS (GRAM) MALES BW-IND - 3 1 7 - M A R - 99 TREATMENT DAYS HEEKS ANIMAL 1 1 GROUP 4 l 54 223 55 206 56 200 57 206 58 203 59 199 60 61 229 62 215 63 205 64 -- GROUP 5 (PFHS) 65 234 66 199 67 211 68 214 69 204 70 226 71 208 72 211 73 222 74 189 75 197 76 .... 77 206 78 184 79 200 80 -- GROUP 6 (PFOS) 81 198 82 203 83 200 84 213 85 222 86 213 87 227 88 211 89 222 90 212 91 204 92 --.O'. 93 187 94 220 95 211 96 -- 5 8 12 15 1 22 3 252 232 223 240 235' 228 ... 264 238 230 -- 270 246 232 252 ' 247 237 --278 253 240 -- 296 263 249 290 270 266 ------ 317 283 268 -- 300 268 252 298 281 276 ------ 327 288 274 -- 257 282 310 284 217 231 254 267 232 248 270 281 233 249 273 283 225 246 269 273 257 281 305 318 234 . 258 282 296 237 259 280 291 254 268 297 307 203 201 224 219 220 231 264 266. ------ ------ ... 233 240 267 272 210 211 233 236 226 238 255 255 -- --- --- -- 221 242 263 283 231 252 275 283 228 248 ' 269 281 240 260 281 295 254 277 314 328 237 252 275 279 256 281 310 327 236 252 279 292 253 270 304 . 317 240 254 284 289 234 242 276 282 ------ ------ ... -- -- 204 207 229 227 247 250 277 276 237 246 275 275 -- -- -- --- 19 22 34 321 330 290 293 267 266 336 348 309 321 299 304 ...... ... 359 369 316 321 291 300 ---- 351 364 282 285 300 304 301 310 296 295 343 355 315 317 310 314 338 343 241 245 296 307 ... ... 299 306 263 ` 271 276 285. ---- 300 310 298 302 300 307 311 314 360 371 294 295 350 361 312 320 343 352 321 335 318 333 ... ... 242 247 299 305 295 301 ---- 25 4 340 306 278 374 334 314 ... 380 345 316 -- 381 298 315 322 308 375 330 329 365 255 321 ... 318 287 291 -- 322 312 316 333 388 311 380 336 374 349 351 ... 261 320 312 -- 28 4 352 313 285 398 348 325 ... 397 359 329 -- 392 299 327 324 315 379 337 334 380 256 333 ... 327 290 301 --- 331 327 325 338 394 322 381 345 386 364 362 ... 265 325 321 -- 000156 NOTOX Project 242933 BODY WEIGHTS (GRAM) MALES BW-IND - 4 1 7 - M A R -9 9 RECOVERY DAYS WEEKS ANIMAL 1 1 5 1 GROUP 4 ( 54 -- 55 -- 56 57 365 58 321 59 301 CofO\ 61 362 62 326 63 302 64 _____ GROUP 5 (PFHS) 65 66 -- 67 -- 68 --69 -- 70 -71 -- -- 72 ... 73 352 74 234 75 307 76 ... 77 305 78 267 79 279 80 GROUP 6 (PFOS 81 82 83 84 85 86 87 88 89 90 __ -- --- -- ---- -- ... 354 340 91 339 92 --.-- 93 245 94 306 95 293 96 -- -- 414 363 338 406 370 342 -- -- -- -- -- -- -- -- 397 264 342 ------ 345 301 313 ... -- --- -- -- . ... ... 408 380 377 --.... 276 343 329 -- 8 12 14 19 22 25 28 2223444 ---- -- --- -- ---- -- - ---- 426 449 45S 367 383 383 -- -- - --- --- 344 357 356 -- -- -- -- 424 437 429 453 462 473 468 383 402 398 420 428 441 443 353 370 368 383 387 396 394 __-- -- -- -- -- -- . .-- ... -- .-- -- -- -- ... .-- ... -- -- --- -- -- - ... -- .-- ... ... --- -- - ... ---- -- -- -- .-- -- -- -- --- -- - -- -- -- -- -- --- .-- -- .-- -- ... -- -- ... -- -- ... ... -- ... 412 420 418 ___ -- ... 274 277 275 -- -- -- -- 350 365 361 .-- -- ... ------ -- ... ... ... ... ... 356 357 360 369 373 392 386 314 321 324 335 339 360 350 319 325 331 337 341 353 350 ... ... -- ... . . . ... ... ... . .-- -- - --- --- -- -- --- -- ... .-- -- -- -- -- --- ... -- -- -- -- ... .-- ... ... -- ... -- - . . . -- --. -- .-- -- . . . . . . . . . .-- ... -- ---- ... ... ... ... ... -- 412 428 429 ... __ 384 397 404 -- -- ... --- ---- 390 ... 405 ... 408 ... ... ... ... ... ... ... -- ... 284 296 298 306 315 331 326 349 362 362 381 387 396 401 338 356 355 366 375 385 384 . . . - -- . . . . . . . . . . . . .... 0001S7 1 56 NOTOX Project 242933 BODY WEIGHTS (GRM) FEMALES BW-IND - 5 1 7 - M A R - 99 TRETMEOT DAYS WEEKS ANIMAL 1 1 5 1 8 2 GROUP 1 (VEHICLE CONTROL) 97 168 172 98 164 170 99 165 171 100 179 178 101 182 190 102 194 200 103 163 164 104 179 193 105 158 169 106 196 210 107 108 172 1--8--0-- 109 163 162 110 169 180 111 184 192 112 GROUP 2 (TELOMER ALCOHOL) 113 170 176 114 182 191 115 182 184 116 180 188 117 157 167 118 168 174 119 163 168 120 166 182 121 163 170 122 163 171 123 124 175 1..8..3.. 125 162 165 126 164 168 127 166 182 128 GROUP 3 (TELOMER ACRYLATE) 129 170 179 130 154 161 131 171 171 132 175 180 133 153 164 134 172 181 135 181 192 136 166 170 137 157 164 138 167 177 139 140 _15--8 1--5--7 141 154 163 142 160 164 143 183 192 144 GROUP'4 ( ) 145 167 176 146 181 193 147 181 187 148 152 154 149 184 185 176 179 180 193 208 204 172 201 171 218 1..8..5.. 166 185 197 184 206 195 194 173 176 178 191 168 169 1--8--7 172 166 184 185 167 186 193 166 192 198 183 167 176 1--6--2 169 166 199 180 197 187 159 203 12 15 19 22 25 28 23 3 44 4 189 200 210 217 222 220 193 196 209 207 208 217 195 199 213 212 224 227 208 197 218 220 228 244 221 234 246 248 267 268 212 231 238 243 248 251 180 177 189 200 207 206 213 222 235 233 248 252 189 189 200 202 217 219 237 241 255 257 268 275 2--0--2-- 200 213 206 2..2...5. 2--3--2-- 179 181 188 195 199 204 204 200 219 215 238 247 211 216 230 235 243 243 191 205 213 222 233 227 220 230 249 255 266 271 203 208 222 219 234 238 207 218 229 233 242 242 184 191 204 200 214 224 190 200 212 216 227 221 193 202 211 213 220 233 198 211 218 214 238 241 178 178 189 195 208 208 184 180 193 206 212 209 2--0--0-- 204 2--1--6-- 221 236 2--3--8-- 184 186 204 203 209 216 181 183 197 199 20S 211 205 202 220 223 230 236 192 190 205 204 220 225 177 175 186 191 206 208 195 201 211 212 218 222 201 209 212 221 228 231 176 180 191 192 203 203 197 198 206 218 234 236 216 222 237 244 250 249 192 184 199 204 218 215 181 188 204 212 218 214 184 182 . 185 183 195 201 175 176 191 1..9...7. 2--02-- 1--9--9 186 186 200 197 203 206 182 178 191 192 205 204 215 215 230 229 249 248 193 195 204 201 217 220 210 218 233 229 248 250 205 219 231 237 242 243 175 183 194 196 207 205 215 216 230 238 240 248 00015S NOTOX Project 242933 BODY WEIGHTS (GRAM) FEMALES BW-IND - 6 17-MAR-99 RECOVERY DAYS WEEKS ANIMAL X 1 5 1 8 12 22 GROUP 1 (VEHICLE CONTROL) 97 98 99 100 101 102 103 104 105 106 ... ... ... ---... ---... 200 249 ... -- -- -- -- .-- ... 223 277 107 206 225 108 ... ... 109 185 210 110 217 245 111 222 251 112 -- GROUP 2 (TELQMER ALCOHOL) 113 114 115 116 117 118 119 120 121 122 ... -- ... -- -- ------ ... 191 193 -- ... -- -- ----- -... *-- ... 211 218 123 214 241 124 ... ... 125 198 225 126 194 226 127 211 237 128 ... ... GROUP 3 (TELCMER ACRYLATE) 129 130 .-- -- 131 -- 132 133 -- .. . . -- --- 134 -- ... 135 -- -- 136 -- ... 137 201 232 138 177 198 139 182 215 140 ... ... 141 190 211 142 184 211 143 221 249 144 ... ... GROUP 4 ( 145 146 147 148 149 ) ... -- -- -- -- -- -- -- ... ... -- -- --. ... 222 282 237 ... 214 257 254 -- --- ... -- -- -- ... -- ... 215 222 244 ... 222 227 246 ... -- --. ... .-- -- -- ... 227 288 243 ... 219 264 262 -- -- -- .-- -- -- -- ... 223 232 254 ... 232 235 252 ... .-- -- -- --.-- ... 235 199 215 ... 212 216 255 -- ... -- ... --- -- --. ... 247 212 229 ... 220 225 267 ... -- .-- ---- ---- ---- 1 58 14 2 -- 243 301 247 220 267 261 -- 217 223 255 236 232 258 ... ---- --- --- ... 244 211 224 ... 224 218 267 ... --. ... 19 22 25 28. 3 44 4 ---- ---- 222 226 230 237 272 275 281 290 267 274 278 278 -- -- -- 243 247 248 244 234 240 242 244 260 265 263 266 ... ... .-- --. -- .-- -- -- ... ... ... 232 228 276 1" -- -- -- -- -- - -- ... ... ... 239 229 277 ... --. .-- ... ... -- -- -- ... ... 235 233 278 ... .-- -- -- -- -- -- ____ ... 232 234 278 ... --- -- ... -- -- .-- -- .-- -- -- --. 000159 NOTOX Project 242933 BODY WEIGHTS (GRAM) FEMALES BW-IND - 7 17-MAR-99 TREATMENT DATS WEEKS ANIMAI. 1 1 GROUP 4 V ) 150 172 151 160 152 162 153 158 154 177 155 163 156 157 167 158 162 159 194 160 GROUP 5 (PFHS) 161 166 162 169 163 167 164 171 165 157 166 173 167 166 168 185 169 177 170 167 171 168 172 --- -- 173 175 174 175 175 153 176 GROUP 6 (PFOS) 177 177 178 154 179 173 180 169 181 185 182 169 183 172 184 164 185 161 186 161 187 157 188 ------ 189 160 190 157 191 166 192 -- 5 1 181 167 169 159 192 169 ---- . 173 169 207 """ *** 171 177 172 172 155 172 162 190 189 174 183 ----- 177 185 161 187 152 181 167 182 178 172 166 176 173 159 .-- o 162 163 172 -- 8 12 15 19 22 25 28 2233444 192 213 222 232 234 237 245 170 187 194 196 209 223 222 178 188 186 202 206 221 225 159 172 177 187 196 205 207 194 214 211 229 232 251 255 173 191 188 199 206 217 219 ------ ---- ------ -- ---- ------ -- 172 192 195 212 212 218 218 169 189 188 199 196 218 210 210 231 238 251 262 269 272 ----" 179 191 192 205 208 210 216 185 203 200 211 210 222 227 179 187 182 197 204 214 214 181 191 194 207 206 218 223 167 180 191 202 210 214 220 187 195 203 216 226 237 234 164 180 189 200 202 209 211 197 213 224 233 240 250 250 191 204 203 223 221 231 236 177 187 186 200 203 217 215 187 204 199 214 222 232 237 ------ -- ---- -- -- ... ___ -- 181 196 194 202 209 220 216 185 202 204 221 223 236 236 164 176 179 193 190 204 206 197 212 215 229 233 245 240 162 172 169 179 179 185 186 187 193 184 196 202 210 212 174 184 186 192 194 200 194 188 194 198 204 201 205 206 179 190 199 208 207 217 220 184 196 193 202 209 215 210 178 191 184 198 204 206 212 172 189 189 211 209 212 204 172 189 192 202 199 203 .206 168 180 178 187 194 201 203. -- ---- ------ -- ----~ -- -- . 165 179 178 187 188 193 197 167 180 179 195 200 208 215 169 181 180 186 183 192 193 -- -- ---- -- -- -- 000160 1 59 NOTOX Project 242933 BODY WEIGHTS (GRM) FEMALES BW-IND - 8 1 7 - M A R - 99 RECOVERY DAYS WEEKS ANIMAL 1 1 5 12 8 GROUP 4 150 151 152 ... ___ 153 189 154 230 155 201 156 ... 157 205 158 197 159 252 160 -- GROUP 5 (PFHS) 161 ... 162 -- 163 -- 164 -- 165 -- 166 -- 167 ... 168 ... 169 220 170 198 171 216 172 ... 173 200 174 216 175 188 176 GROUP 6 (PFOS) 177 ... 178 -- 179 --- 180 . . . 181 -- 182 -- 183 -- 184 -- 185 188 186 187 187 184 188 ... 189 178 190 196 191 177 192 ... ... ... 221 257 228 ... 225 220 267 -- ... ... -- -- ... ... ... ... 236 220 243 ... 226 249 211 -- -- -- ... `... ... ... 216 212 207 ... 197 216 194 -- -- __ 228 263 234 -- 233 214 268 -- ---- -- --.... ... ... ... 247 227 245 ... 225 251 217 ... -- -- -- -- -- ... 218 219 214 ... 204 222 201 12 14. 19 22 25 28 2 2344 4 -- -- ... ... ... ... ... -- -- - --- ... ... -- ... ... -- ... ... 238 236 ---- -- 273 271 -- -- --. 238 234 --- -- --- -- -- ... ------ ... ... ... 237 235 232 240 250 243 222 237 240 241 245 240 280 277 286 293 301 303 ------------ -- -- -- -- ... -- ... ... -- -- ..1 -- ... ... -- -- -- -- -- -- -- --- -- ... -- ... -- ... -- -... -- ... -- -- -. ... -- -- -- -- .-- -- ... ... ... ... ... ... ... 248 248 -- -- ... -- 236 232 -- -- -- -- 258 257 -- .-- -- ..l. ... ... ... ... ------ 233 226 238 239 250 249 256 254 258 263 273 269 227 229 234 237 239 244 -- ... ... ... -- -- -- ... ... ... -- -- -- ... .-- -- -- -- -- ... ... -- ... -- ... -- -- --- -- . -- - .-- ... -- ... -- -- ... -- .-- -- . -- .-- ... ... ... ... -- 226 222 ... ... ... -- 221 220 --. -- -- 223 223 .-- -- ... ... ... ... ... ... ... 209 215 219 218 219 221 227 228 239 235 238 244 209 213 220 218 220 222 1 60 000161 NOTOX Project 242933 BODY WEIGHT GAIN (%) NALES BWG-IND - 1 1 7 - M A R - 99 TREATMENT DAYS WEEKS ANIMAL 1. 1 5 1 GROUP 1 (VEHICLE CONTROL) 1 0 -6 2 0 25 3 0 11 4 09 5 0 12 6 0 13 7 0 10 8 0 12 9 0 14 10 0 12 11 12 0 12 ...-- 13 0 14 14 0 14 15 0 10 16 GROUP 2 (TELOMER ALCOHOL) 17 0 9 18 0 13 19 0 10 20 0 12 21 0 15 22 0 11 23 0 12 24 0 9 25 0 12 26 0 10 27 0 13 28 ...... 29 0 12 30 0 15 31 0 10 32 GROUP 3 (TELOMER ACRYLATE) 33 0 10 34 0 13 35 0 8 36 0 10 37 0 10 38 0 12 39 0 12 40 0 13 41 0 13 42 0 12 43 44 0 . 12 45 0 13 46 0 14 47 0 11 48 GROUP 4 49 50 . 51 52 53 08 0 13 0 13 0 16 0 13 8 12 15 19 22 25 28 2233444 1 11 13 21 25 30 33 36 47 54 64 69 75 81 20 32 37 50 54 58 65 17 26 30 38 44 47 52 23 33 38 44 47 54 58 22 30 38 44 51 58 61 21 34 42 54 57 66 72 24 35 42 51 54 61 63 19 32 34 46 50 56 62 13 24 23 33 36 41 50 16 28 34 43 50 53 58 ------ ...... -- -- 20 35 37 50 55 66 71 19 34 38 51 57 63 69 15 28 30 46 51 55 62 18 28 33 22 33 43 18 26 32 20 29 36 26 43 52 21 33 41 21 33 40 16 25 32 16 29 29 14 25 29 19 30 32 ...... ------ 15 30 33 18 34 37 16 26 29 42 47 54 56 42 47 44 47 64 70 50 53 49 52 35 41 41 42 42 46 44 46 ------ 40 43 47 53 36 40 53 60 67 69 49 56 53 57 79 84 59 69 56 59 46 52 50 56 51 55 54 58 -- ------ 49 52 60 66 48 51 19 26 35 44. 49 57 60 23 36 43 51 58 63 66 12 19 24 31 37 40 47 18 27 33 43 48 53 55 20 26 32 38 44 49 50 24 34 41 52 55 61 68 22 36 39 52 56 62 69 24 34 41 49 55 59 61 21 35 36 48 53 64 69 15 30 33 47 52 57 65 17 ...... 31 ----. 37 44 ------ ------ 49 ------ 55 60 ---- --- 17 34 35 51 54 62 70 17 31 33 43 46 53 58 14 30 31 45 52 57 64 12 21 25 32 36 39 46 21 33 39 50 51 57 66 22 35 43 55 59 66 74 27 39 46 59 60 64 71 21 33 38 51 55 66 69 000162 NOTOX Project 242933 BODY WEIGHT GAIN (%) MALES BWG-XND - 2 1 7 - M A R - 99 RECOVERY DAYS WEEKS ANIMAL 1 1 5 8 12 14 19 22 25 28 12223444 GROUP 1 (VEHICLE CONTROL) 1 2 3 4 5 ' -6 7 8 . 9 54 10 38 -- -- -- -- ---___ 68 52 11 50 64 12 13 61 78 14 56 77 15 49 68 16 -- GROUP 2 (TELOMER ALCOHOL) 17 18 -- 19 -- 20 21 -- 22 23 --- 24 ... 25 45 61 26 46 59 27 47 61 28 ... 29 39 51 30 55 77 31 40 58 32 -- - GROUP 3 (TELOMER ACRYLATE) 33 34 -- 35 -- 36 -- - 37 38 -- 39 -- 40 ... 41 56 80 42 51 59 43 49 65 44 45 56 75 46 46 65 47 50 70 48 --- GROUP 4 ( 49 50 -- 51 52 -- 53 -- . -- -- --- -- -- -- -*-- ... 73 55 70 ---- 83 79 71 ---- -- -- -- ... ... ... 64 62 68 ... 52 79 63 --- -- -- ... ... ... ... 81 65 67 ... 80 68 72 ... ---- -- -- - -- - ... -- -- .-- -- -- --- --- -- -- ------ --. --- -- --. -- -- -- - ... 76 80 -- 63 65 -- 75 77 -- ... ... ... 89 91 99 83 86 92 80 79 86 ... ... ... --- -- -- 4. -- - ... -- --- -- - -- ------ -- ---- ... --- ... ... ... 69 73 ... 68 68 -- 74 75 ... ... ... ... 61 58 64 85 85 * 90 68 69 75 ---- -- ---- --. --. -- -- -- ... -- ... -- -- ... -- -- .-- - -- -- ... ... 87 89 ... 73 76 -- 71 ... 71 ... ... ... 89 88 97 76 78 84 81 ... 81 . 85 --- * .-- -- -- -- . .-- -- -- - ... -- -- ... -- ... ... .-- -- -- -- ... -- -- -- -- 102 96 91 ... --- -- --- -- ... .-- -- -- -- ... ... 68 92 80 --- --- -- .-- -- -- __ ... -- ... ... 100 89 91 -- -- -- -- ... ... ... -- .-- -- . ... ... -- .-- -- --. -- -- - ... ... ... -- .-- ---- ... ... ... ... 109 112 103 104 97 99 ... -- .-- ------ --... ... ... -- ... ... 70 98 83 ... . --- ... .-- -- -- .-- ... -- -- .-- -- 71 98 83 ... ... .-- --- ------ ---- ... -- ... ___ ... -- ---- ___ -- __ ... 105 106 93 94 93 99 --. -- --- -- ---- --- -- --. -- 000163 NOTOX Project 242933 BODY WEIGHT GAIN (%) MALES BWG-IND - 3 1 7 - M A R - 99 TREATMENT DAYS WEEKS ANIMAL 1 5 8 12 15 19 22 25 28 112233444 GROUP 4 ( ) 54 0 55 0 56 0 57 0 58 0 59 60 0 ___ 61 0 62 0 63 0 64 GROUP 5 (PFHS) 65 0 66 0 67 0 68 0 69 0 70 0 71 0 72 0 73 0 74 0 75 0 76 77 0 78 0 79 0 80 GROUP 6 (PFOS) 81 0 82 0 83 0 84 0 85 0 86 0 87 0 88 0 89 0 90 0 91 0 92 -- -- -- 93 0 94 0 95 0 96 -- 13 . 13 12 17 16 15 ... 15 11 12 10 9 10 9 10 14 13 12 14 7 12 ------ 13 14 13 12 14 14 13 14 11 13 12 14 13 15 -- 9 12 12 -- 21 19 16 22 22 19 --- 21 ' 18 17 *""" 33 28 25 41 33 34 -- -- 33 32 31 21 32 16 28 18 28 16 28 21 32 24 35 24 36 23 33 21 34 6 19 17 34 ------ 17 30 15 27 19 28 35 30 26 45 38 39 43 34 34 21 34 33 32 34 41 42 38 38 16 35 ---- 32 28 28 22 33 43 24 35 39 24 35 41 22 32 38 25 41 48 18 29 31 24 37 44 19 32 38 22 37 43 20 34 36 19 35 38 ------ -- ---- 11 22 21 14 26 25 17 30 30 ---- - -- 44 43 52 41 42 49 34 33 39 63 69 82 52 58 65 50 53 58 ...... . 57 61 66 47 49 60 42 46 54 50 56 63 42 43 50 42 44 49 41 45 50 45 45 51 52 57 66 51 52 59 47 49 56 52 55 64 28 30 35 50 56 63 ------ -- 45 49 54 43 47 56 38 43 46 52 5 7 '. 63 47 49 54 50 54 58 46 47 56 62 67 75 38 38 46 54 59 67 48 52 59 55 59 68 51 58 65 56 63 72 ---- ... ------ 29 32 40 36 39 45 40 43 48 ---- -- 58 52 43 93 71 63 73 67 60 68 50 55 51 54 68 62 58 71 35 69 59 58 51 67 61 63 59 77 51 68 64 74 72 77 ------ 42 48 52 -- 000164 NOTOX Project 242933 BODY WEIGHT GAIN (%) HALES RECOVERY DAYS WEEKS ANIMAL 1 1 GROUP 4 I ) 54 -- 55 56 57 77 58 58 59 51 60 61 58 62 52 63 47 64 -- GROUP 5 (PFHS) 65 66 67 68 69 70 71 72 73 74 --- ---- --- -- ----------- --- --- 59 24 75 56 76 . . . 77 48 78 45 79 40 80 GROUP 6 (PFOS) 81 . . . 82 - -- 83 -- 84 -- 85 86 -- 87 -- 88 -- 89 59 90 60 91 66 92 . . . 93 31 94 39 95 39 96 . . . 58 12 -- 101 107 79 81 70 73 77 85 72 78 67 72 ---- -- -- --- -- -- -- ... 79 40 74 ... 67 64 57 -- -- -- -- --- -- ... 86 45 78 ... 73 71 60 ... --- ---- -- -- ... 84 79 85 ... 48 56 56 ... -- -- -- --- -- -- -- 86 81 91 ... 52 59 60 ... BWG-IND - 4 1 7 - M A X - 99 12 14 19 22 25 2 2 34 4 28 4 ::: 118 89 79 91 87 80 ----- -- -- .-- ... ... 89 47 85 ... 73 74 63 121 89 79 87 85 80 -- ... --. -- ... -- -- --- ... 88 46 83 ... 75 76 66 ---- -- -- 98 95 87 -- .-- .-- -- -- -- ... ... ... ... -- -- ... 79 82 69 -- ---- ---- 102 107 99 105 89 93 --- -- ... .-- --. -- -- ... ... -- .-- ... 81 84 71 -- -- -- -- -- -- -- -- ... 90 96 77 ---- --- -- -- 104 106 92 --- -- -- .-- ... ... ... .-- -- -- ... 87 90 75 --- -- -- .-- .-- --- .-- ... 93 87 99 ... 58 65 69 --- -- -- -- .-- -- -- -- ... 93 91 100 --. 59 65 68 ... -. . . ... -- -- -- -- ... ... ... -- ... ... 64 73 73 ... ____ -- -- ... -- -- -- ... ... -- ... ... 68 76 78 ... -- -- --- -- -- -- -- -- ... ... 77 80 82 ... -- -- -- -- ... --. -- ... -- -- -- -- 74 82 82 -- 000165 NOTOX Project 242933 BODY WEIGHT GAIN (%) FEMALES TREATMENT DAYS WEEKS ANIMAL 1. 1 5 1 8 12 22 GROUP 1 (VEHICLE CONTROL) 97 0 2 98 0 4 99 0 4 100 0 -1 101 0 4 102 0 3 103 0 1 104 0 8 105 0 7 106 0 7 107 0 5 108 109 0 -1 110 0 7 111 0 4 112 GROUP 2 (TELOMER ALCOHOL) 113 0 4 114 0 5 115 0 1 116 0 4 117 0 6 118 0 4 119 0 3 120 0 10 121 0 4 122 0 5 123 0 5 124 125 0 2 126 0 2 127 0 10 128 GROUP 3 (TELOMER ACRYLATE) 129 0 5 130 0 5 131 0 0 132 0 3 133 0 7 134 0 5 135 0 6 136 0 2 137 0 4 138 0 6 139 0 -1 140 141 0 6 142 0 3 143 0 5 144 GROUP 4 ( 145 146 147 148 149 ;. 0 0 0 0 0 5 7 3 1 1 5 9 9 8 14 5 6 12 8 11 8 2 9 7 8 13 7 8 10 5 9 15 3 4 7 6 1 11 9 8 9 10 8 12 9 10 6 5 3 10 4 9 8 9 3 5 10 13 18 18 16 21 9 10 19 20 21 17 10 21 15 12 21 12 15 17 13 18 19 9 13 14 14 10 23 13 15 14 15 15 15 19 16 15 10 11 21 14 17 16 16 13 15 17 1 65 BWG-IND - 5 17-MAR-9 9 15 19 22 25 28 3. 3 44 4 19 25 29 32 31 20 27 26 27 32 21 29 28 36 38 10 22 23 27 36 29 35 36 47 47 19 23 25 28 29 9 16 23 27 26 24 31 30 39 41 20 27 28 37 39 23 30 31 37 40 16 24 20 31 35 11 15 20 22 25 18 30 27 41 46 17 25 28 32 32 21 25 31 37 34 26 37 40 46 49 14 22 20 29 31 21 27 29 34 34 22 30 27 36 43 19 26 29 35 32 24 29 31 35 43 27 31 29 43 45 9 16 20 28 28 10 18 26 30 28 17 23 26 35 36 15 26 25 . 29 33 12 20 21 27 29 22 33 34 39 42 12 21 20 29 32 14 21 . 24 34 35 18 23 24 27 30 19 21 26 30 32 18 25 25 33 33 15 20 27 36 37 23 31 35 38 38 11 . 20 23 31 30 20 30 35 39 36 9 11 10 17 20 11 21 25 28 26 21 30 28 32 34 11 19 20 28 28 17 26 25 36 36 17 22 20 30 32 20 29 27 37 38 21 28 31 34 34 20 28 29 36 35 17 25 29 30 35 000166 NOTOX Project 242933 BODY WEIGHT GAIN (%) FEMALES BWG-IND - 6 17-MAR-9 9 RECOVERY DAYS WEEKS ANIMAL 1 1 5 8 12 14 19 22 25 28 12223444 GROUP 1 (VEHICLE CONTROL) 97 98 99 100 101 102 103 104 105 106 -- -- ... ... --- -... ... 27 27 -- -- -- --- --. --... 41 41 107 20 31 108 ... ... 109 13 29 110 28 45 111 21 36 112 --- -- GROUP 2 (TELOMER ALCOHOL) 113 114 -- 115 -- 116 . 117 118 119 120 121 17 29 122 18 34 123 22 38 124 125 22 39 126 18 38 127 27 43 128 -- -- GROUP 3 (TELOMER ACRYLATE) 129 130 131 132 133 134 135 136 137 138 ---------... ... -- --- -... ----- 28 6 -- -- -- ... .-- ... ... ... 43 19 139 140 141 142 143 144 GROUP 4 ( 15 ... 23 15 21 ... 36 ... 37 32 36 -- 145 146 147 148 149 ... -- -- -- -- --- -- --. ... ... -- -- -- -- ... 41 44 38 ... 31 52 38 ... -- 32 36 39 37 38 48 --- -- --- -- ... -- ... -- . . . 50 19 36 ... 38 35 39 -- -- -- ... .-- .-- .-- ... .-- --- .-- ... 44 47 41 ... 34 56 42 ... -- -- -- -- -- -- ---- 54 54 44 ... 35 58 42 --. -- -- 37 42 45 43 43 52 --- ... .-- -- -- -- ... ... 57 27 45 ... 43 41 46 -- 33 37 46 46 41 55 -- -- -- -- -- -- --- ---- 55 26 42 ... 45 36 46 ... ... -- -- ... -- -- -- 1 66 -- -- -- -- -- -- ... -- ... ... 36 61 45 ... -- -- -- -- 50 43 57 -- ... -- -- -- ... ... ... -- -- ... 51 43 51 -- -- -- .-- --- -- --. ... --. -- ... --. -- .-- ... 39 63 49 -- -- -- -- -- -- -- ... --. -- ... ... 41 66 51 .-- --... --- .-- -- ... ... -- ... ... 45 72 51 -- -- -- -- -- 52 46 60 -- ... ... --. --- ... -- ____ -- -- --. ... 55 43 51 -- ---- -- ---- ---- 53 51 48 49 58 60 ---- -- .-- ... .-- .-- --. .-- ... -- -- -- ... 53 46 52 -- -- ---- --. -- -- -- -- -- -- -- ... 51 46 52 ... ... -- .-- -- -- .-- -- -- -- -- -- 000167 NOTOX Project 242933 BODY WEIGHT GAIN (%) FEMALES BWG-IND - 7 17-MAR-99 TREATMENT DAYS . WEEKS ANIMAL 1 1 5 1 8 12 15 19 22 25 28 2 2 33 4 44 GROUP 4 ( 150 0 151 0 152 0 153 0 154 0 155 0 156 157 0 158 0 159 0 160 GROUP 5 (PFHS) 161 0 162 0 163 0 164 0 165 0 166 0 167 0 168 0 169 0 170 0 171 0 172 ---- 173 0 174 0 175 0 176 GROUP 6 (PFOS) 177 0 178 0 179 0 180 0 181 0 182 0 183 0 184 0 185 .0 186 0 187 0 188 ------ 189 0 190 0 191 0 192 -- 5 4 4 1 8 4 4 4 7- 12 6 10 1 10 6 ------ 3 4 8 38 59 37 16 -1 6 -1 8 -2 -1 36 78 46 9 ------ 1 6 5 11 3 6 7 6 -1 5 -1 -2 5 0 1 9 7 1 1 4 4 --- 11 5 8 3 2 6 7 9 7 7 7 ------ 3 6 2 -- 24 17 16 9 21 17 -- ... 15 17 19 ... 15 20 12 12 15 13 8 15 15 12 21 ---- 12 15 15 20 12 12 9 5 12 14 16 17 17 15 ------ 12 15 9 -- 29 35 21 23 15 25 12 18 19 29 15 22 17 27 16 23 23 29 .--m. ___ 16 . 23 18 25 9 18 13 21 22 29 17 25 14 20 21 26 15 26 11 20 18 27 11 15 17 26 17 26 21 29 10 16 6 13 10 14 7 10 18 23 12 17 12 21 17 31 19 25 13 19 11 17 14 24 8 12 36 38 42 31 39 39 27 36 39 24 30 31 31 42 44 26 33 34 27 31 31 21 35 30 35 39 40 --mm-- ______ 25 27 30 24 31 34 22 28 28 20 27 30 34 36 40 31 37 35 22 26 27 30 35 35 25 31 33 22 30 29 32 38 41 19 26 23 27 35 35 24 33 35 32 38 36 16 20 21 17 21 23 15 18 15 9 11 11 22 28 30 22 25 22 24 26 29 30 32 27 24 26 28 24 28 29 18 21 23 27 32 37 10 16 16 1 67 000168 NOTOX Project 242933 BODY WEIGHT GAIN (%) K k M AT BWG-IND - 8 17-MAR-99 RECOVERY DAYS WEEKS ANIMAL 1 1 51 8 2 12 2 14 2 19 34 22 4 25 4 28 GROOP 4 ( ) 150 151 152 153 20 154 30 155 23 156 157 23 158 22 159 30 160 GROUP 5 (PFHS) 161 162 163 164 165 166 167 168 169 24 170 19 . 171 29 172 173 14 174 23 175 23 176 GROUP 6 (PPOS) 177 178 179 180 181 182 183 184 185 17 186 16 187 17 188 189 11 190 25 191 7 192 -- ---- ---- - ... 40 44 45 49 40 44 ... ... 35 36 38 - 40 32 38 ---- ---- ---- -- 51 54 46 ------ 42 37 44 -- -- -- - --- -- --- -- - ---- -- -- - -- - --- --- -- --- -- --- --- -- ... -- 33 40 40 32 36 41 45 46 54 ---- -- 29 29 33 42 43 46 38 42 43 ---- -- ------ ------ ---- -- ------ ---- __ -- 34 35 40 32 36 37 32 36 42 ... -- 23 28 31 38 41 45 17 21 26 -- - ----- ---- ---- --- 49 -- 53 ... 44 -- ------ ... 41 39 46 48 43 47 -- ---- ---- --- -- ---- ---- -- ... ... 40 -- 39 -- 53 ... -- -- ... 29 36 45 47 50 53 ---- --- ----- -- ---- -- ... .-- ... ... ... ... 38 ... 37 -- 42 -- ... -- _ 34 37 45 52 28 33 -- ... ... ... -- ... -- ... ---- -- ---- ... ... 44 50 49 51 51 55 ---- -- . ... ---- -- . ... ... -- ... --. -- ... ... ... -- ---- ... ... ... ... 37 43 50 56 55 56 -- ... .-- ... -- ... -- .-- --- -- ... -- ... ... ... ... ___ ... ---- ... ... ... ... 36 37 50 52 31 33 ... ... .-- -- ___ -- -- -- ... 46 48 56 -- -- -- .-- .-- -- ... ___ -- .-- ... 42 54 59 -!- -- ... ... -- --... ... -- -- ___ ... 38 55 34 ... 1 68 000169 NOTOX Project 242933 FOOD CONSUMPTION (G/AN3MAL/DAY) MALES DAYS, WEEKS CAGE TREATMENT 1-8 1/2 8-15 2/3 GROUP 1 (VEHICLE CONTROL) 1 26 26 2 27 29 3 24 25 4 29 31 GROUP 2 (TELCMER ALCOHOL) 5 28 29 6 28 30 7 24 25 8 26 29 GROUP 3 (TELCMER ACRYLATE) 9 26 27 10 28 29 11 26 28 12 27 28 GROUP 4 ( ) 13 27 29 14 27 28 15 25 29 16 27 29 GROUP 5 (PEHS) 17 26 28 18 29 30 19 24 26 20 24 25 GROUP 6 (PFOS) 21 28 29 22 28 30 23 27 30 24 26 27 15-22 3/4 27 29 28 34 30 29 27 30 28 30 31 32 29 28 33 32 28 31 30 29 28 30 34 29 22-28 4 28 31 29 33 31 31 28 30 30 30 32 31 30 29 34 31 29 32 30 28 29 31 36 29 FC-IND - 1 0 1 - M A R - 99 RECOVERY 1-8 1/2 8-14 2 14-19 2/3 19-22 3/4 -- -- ... ------ 29 29 ... 32 31 30 -- -- -. 27 29 -- 27 29 -- ... -- 28 ... ' __ -- -. ... 29 30 32 32 30 __ ---. ... ------ 33 32 -31 30 30 ___ ... ... -- -- 30 30 -- 29 28 26 ... ... ... ---- 33 33 -28 27 27 -- ... -- 31 -- -- ... 29 ... ---- 32 ... -- -- 31 ... -- -- 27 -- ... -- 28 000170 1 69 NOTOX Project 242933 FOOD CONSOMPTION (G/AN3AL/DAY) MALES DAYS WEEKS CAGE RECOVERY 22-28 4 GROUP 1 (VEHICLE CONTROL) 1 2 3 4 31 GROUP 2 (TELCMER ALCOHOL) 5 6 7 8 28 GROUP 3 (TELCMER ACRYLATE) 9 10 11 12 30 GROUP 4 ( ) 13 14 15 16 29 GROUP 5 (PFHS) 17 --18 19 20 27 GROUP 6 (PFOS) 21 22 23 24 27 FC-IND - 2 01-MAR-99 1 70 000171 NOTOX Project 242933 FOOD CONSOMPTION (G/ANIMAL/DAY) FEMALES DAYS WEEKS CAGE TREATMENT 1-8 1/2 8-15 2/3 15-22 3/4 22-28 4 GROUP 1 {VEHICLE CONTROL) 25 18 20 21 22 26 20 21 22 23 27 20 21 23 25 28 19 21 24 25 GROUP 2 (TELOMER ALCOHOL) 29 19 21 22 24 30 19 21 21 23 31 17 .20 22 22 32 18 20 23 23 GROUP 3 (TELCMER ACRYLATE) 33 18 19 20 22 34 21 22 22 24 35 18 20 22 21 36 19 21 23 23 GROUP 4 37 19 20 21 23 38 19 21 22 23 39 20 22 23 24 40 19 22 23 23 GROUP 5 (PFHS) 41 19 19 21 22 42 22 23 24 24 43 19 21 23 23 44 19 22 23 23 GROUP 6 (PFOS) 45 22 20 20 20 46 '18 19 19 19 47 17 19 19 19 48 19 20 21 20 FC-IND - 3 01-MAR-99 RECOVERY 1-8 1/2 8-14 2 14-19 2/3 19-22 3/4 __ . . . ... . . . -- ---- --- .-- 25 24 -- ... 25 24 22 24 ... __ . . . ---- ... 23 22 -- -- 24 23 22 23 _ ___ __ ... ---- .... -- 23 22 -- -- 24 23 22 22 __ _ ... ___ ---- -- -- 25 24 . . . -- 23 22 20 21 .... __. ...... ... -- -- ... ... 25 24 --- .... 24 23 20 22 ___ __ . . . .-- -- -- -- ... 21 20 -- .-- 21 21 19 19 1 71 000172 NOTOX Project 242933 FOOD CONSOMPTION (G/ANMAL/DAY) FEMALES DAYS WEEKS CAGE RECOVERY 22-28 4 GROUP 1 (VEHICLE CONTROL) 25 26 27 28 24 GROUP 2 (TELOMER ALCOHOL) 29 30 31 32 22 GROUP 3 (TELOMER ACRYLATE) 33 34 35 36 22 GROUP 4 ( 37 38 39 40 22 GROUP 5 (PFHS) 41 42 43 44 21 GROUP 6 (PFOS) 45 46 47 48 19 FC-XND - 4 OX-MAR-99 1 72 000173 NOTOX Project 242933 RELATIVE FOOD CONSUMPTION (G/KG BODY WEIGHT/DAY) MALES GROUP 1 (VEHICLE CONTROL) DAYS WEEKS CAGE TREATMENT 1-8 1/2 1 110 2 115 3 107 4 126 8-15 2/3 94 102 99 116 15-22 3/4 89 93 99 114 22-28 4 86 90 96 101 DAYS WEEKS CASE RECOVERY 22-28 4 1 2 3 4 75 RFC-IND - 1 0 1 - M A R - 99 RECOVERY 1-8 1/2 8-14 2 14-19 . 19-22 2/3 3/4 -- -- ___ _--_ 89 84 -_ _.. 91 84 77 78 000174 1 73 NOTOX Project 242933 RELATIVE FOOD CONSUMPTION (G/KG BODY WEIGHT/DAY) MALES GROUP 2 (TELOMER ALCOHOL) DAYS WEEKS CAGE TREATMENT 1-8 1/2 5 115 6 116 7 109 8 109 8-15 2/3 101 106 98 104 15-22 3/4 93 91 97 101 22-28 4 90 91 93 92 DAYS WEEKS CAGE RECOVERY 22-28 4 5 6 7 8 72 REC-IND - 2 01-MAR-99 RECOVERY 1-8 1/2 ---- 84 85 8-14 2 ___ --- - 79 80 14-19 2/3 ---... 74 19-22 3/4 ... ... 76 1 74 000175 NOTOX Project 242933 RELATIVE FOOD CONSUMPTION (G/KG BODY WEIGHT/DAY) MALES GROUP 3 (TELOMER ACRYLATE) DAYS WEEKS CAGE TREATMENT 1-8 1/2 9 112 10 119 11 111 12 116 8-15 2/3 101 105 103 105 15-22 3/4 95 95 103 105 22-28 4 93 89 97 95 DAYS WEEKS CAGE RECOVERY 22-28 4 9 10 11 12 74 RFC-IND - 3 01-MAR-99 RECOVERY 1-8 1/2 mm--- -- 83 90 8-14 2 14-19 2/3 19-22 3/4 -- __ __ 80 __ __ 84 76 80 1 75 000176 NOTOX Project 242933 RELATIVE FOOD CONSOMPTION (G/KG BODY WEIGHT/DAY) MALES GROUP 4 ( } DAYS WEEKS CAGE TREAMEWT 1-8 1/2 13" 113 14 112 15 107 16 111 8-15 2/3 103 102 105 99 15-22 3/4 91 93 104 98 22-28 4 90 90 100 89 DAYS WEEKS CAGE RECOVERY 22-28 4 13 14 15 16 67 RFC-XND - 4 OX-MAR-99 RECOVERY 1-8 1/2 8-14 2 14-19 2/3 .19-22 3/4 -- ---- -- . . . 88 82 -- . . . 82 73 71 72 1 7 6 000177 NOTOX Project 242933 RELATIVE FOOD CONSOMPTION (G/KG BODY WEIGHT/DAY) MALES GROUP 5 (PFHS) DAYS WEEKS CAGE TREATMENT 1-8 1/2 17 110 18 122 19 106 20 108 8-15 2/3 101 105 99 100 15-22 .3/4 91 97 102 102 22-28 4 88 95 96 94 DAYS WEEKS CAGE RECOVERY 22-28 4 17 18 19 20 73 ' RFC-IND - 5 0 1 - M A R - 99 RECOVERY 1-8 1/2 8-14 2 14-19 2/3 19-22 3/4 ... ---- -- 91 83 92 - 83 -- -. 76 ____ 77 1 77 000178 NOTOX Project 242933 RELATIVE FOOD CONSUMPTION (G/KG BODY WEIGHT/DAY) MALES GROUP 6 (PFOS) DAYS WEEKS CAGE TREATMENT 1-8 1/2 21 120 22 114 23 111 24 113 8-15 2/3 106 102 105 103 15-22 3/4 22-28 4 94 . 91 104 103 92 87 100 99 DAYS WEEKS CAGE RECOVERY 22-28 4 21 22 23 24 72 RFC-IND - 6 0 1 - M A R - 99 RECOVERY 1-8 1/2 8-14 2 14-19 2/3 19-22 3/4 -- __ __ ___ 85 80 ___ ---- 88 81 76 78 1 78 000179 NOTOX Project 242933 RELATIVE FOOD CONSUMPTION (G/KG BODY WEIGHT/DAY) FEMALES GROUP 1 (VEHICLE CONTROL) DAYS WEEKS CAGE TREATMENT 1-8 1/2 25 106 26 105 27 107 28 107 8-15 2/3 104 102 103 107 15-22 3/4 98 97 104 112 22-28 4 101 94 104 109 DAYS WEEKS CAGE RECOVERY 22-28 4 25 26 27 28 91 RFC-IND - 7 0 1 - M A R - 99 RECOVERY 1-8 1/2 8-14 2 14-19 2/3 19-22 3/4 . -- mmm, 102 107 --- 95 95 -- -- 86 --- 92 000180 1 79 NOTOX Project 242933 RELATIVE FOOD CONSUMPTION (G/KG BODY WEIGHT/DAY) GROUP 2 (TELOMER ALCOHOL) DAYS WEEKS CAGE TREATMENT 1-8 1/2 29 104 30 110 31 96 32 105 8-15 2/3 102 108 105 106 15-22 3/4 98 100 110 111 22-28 4 97 102 ' 101 108 DAYS WEEKS CAGE RECOVERY 22-28 4 29 30 31 32 86 RFC-IND - 8 01-MAR-9 9 RECOVERY 1-8 1/2 ___ --- 102 106 8-14 2 14-19 2/3 19-22 3/4 ... -- __ 93 -- ...... 98 88 92 000181 1 80 NOTOX Project 242933 RELATIVE FOOD CONSUMPTION (G/KG BODY WEIGHT/DAY) FEMALES GROUP 3 (TELOMER ACRYLATE) ' TREATMENT DAYS WEEKS CAGE 1-8 1/2 8-15 2/3 33 105 100 34 117 110 35 108 110 36 110 109 15-22 3/4 22-28 4 100 101 107 107 112 . 105 112 107 DAYS WEEKS CASE RECOVERY 22-28 4 33 34 35 36 90 RFC-IND - 9 0 1 - M A R - 99 RECOVERY 1-8 1/2 -- 105 109 8-14 2 14-19 2/3 19-22 3/4 ___ -- - ... 96 -- __ 98 88 87 1 81 000182 NOTOX Project 242933 RELATIVE FOOD CONSUMPTION (G/KG BODY WEIGHT/DAY) FEMALES GROUP 4 ( ) DAYS WEEKS CAGE TREATMENT 1-8 1/2 37 104 38 110 39 115 40 104 8-15 2/3 104 102 113 107 15-22 3/4 98 102 112 106 22-28 4 100 100 106 100 DAYS WEEKS CAGE RECOVERY 22-28 4 37 38 39 40 81 RFC - I N D - 10 0 1 - M A R - 99 RECOVERY 1-8 1/2 ___ --106 98 8-14 2 14-19. 2/3 19-22 3/4 -- 97 91 -- .a ---- -- 81 ____ ----- 83 000183 1 82 NOTOX Project 242933 RELATIVE FOOD CONSUMPTION (G/KG BODY WEIGHT/DAY) FEMALES GROUP 5 (PFHS) DAYS WEEKS CAGE TREATMQIT 1-8 1/2 41 110 42 130 43 102 44 109 8-15 2/3 100 118 105 113 15-22 3/4 100 111 107 111 22-28 4 103 105 102 106 DAYS WEEKS CAGE RECOVERY 22-28 4 41 42 43 44 84 R F C - I N D - 11 0 1 - M A R - 99 RECOVERY 1-8 1/2 8-14 2 14-19 2/3 19-22 3/4 -- -- ... -- 107 97 -- -- 105 98 84 88 1 83 000184 NOTOX Project 242933 RELATIVE FOOD CONSUMPTION (G/KG BODY WEIGHT /DAY ) FEMALES GROUP 6 (PFOS) DAYS WEEKS CAGE TREATMENT 1-8 1/2 45 46 47 43 125 104 100 115 8-15 2/3 106 97 100 111 15-22 3/4 101 92 96 110 22-28 4 95 92 93 102 DAYS WEEKS CAGE RECOVERY 22-28 4 45 46 47 48 85 R F C - I N D - 12 0 1 - M A R - 99 RECOVERY 1-8 1/2 ---- 97 103 8-14 2 ___ -- 90 95 14-19 2/3 -- ... 85 19-22 3/4 ... -- 86 000185 1 84 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS KEY-IND - 1 22-MAR-99 KEY TO MISSING VALUES AND REMARKS HAEMATOLOGY / CLINICAL BIOCHEMISTRY AFTER 4 WEEKS A n i m a l 1, 2, 3, 4, 56 81, 84, 97, 98, 99, 114, 129, 145, 164, 177, 179, 180, ... = EDTA sample clotted A n i m a l 1, 33, 55, 59, 65, 72, 77, 78, 79, 89, 132, 145, 162, 168, - - - * Citrate sample clotted Animal 62, 174 Animal 129 A n i m a l 2, 17, 18, 19, 25, 36, 40, 49, 50, 66, 67, 71, 72, 74, 79, 87, 88, 89, 90 -- = PTT 1n plasma not reproducible - - - a d e v i a t i n g c u r v e noted f o r P T T 1n p l a s m a Serum sample showed haemolysis Animal 46 and 59 - - - a ALAT 1n serum not reproducible AFTER 2 WEEKS RECOVERY Animal 75, 169, 186 AFTER 4 WEEKS RECOVERY Animal 14, 29, 61, 78 Animal 127 --- a Citrate sample clotted --- a Citrate sample (partly) clotted --- a A L A T 1n s e r u m not r e p r o d u c i b l e 000186 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS MALES GROUP 1 (VEHICLE CONTROL) HEM-IND - 1 30-MAR-9 9 ANIMAL NUMBER HAEMATOLOGY PARAMETERS RBC HB HCT t /1 mraol/1 1/1 1 2-- 3 4 5 7.52 6 6.83 7 7.25 8 7.01 9 6.85 10 7.11 11 6.91 13 6.97 14 .7.29 15 6.80 9.7 9.2 9.6 9.4 8.9 9.0 9.0 8.6 9.2 8.7 -- 0.423 0.406 0.415 0.411 0.403 0.413 0.406 0.390 0.418 0.389 mcv fl -- 56.3 59.4 57.2 58.6 58.8 58.1 58.8 56.0 57.3 57.2 MCH fmol -- 1.290 1.347 1.324 1.341 1.299 1.266 1.302 1.234 1.262 1.279 MCHC itmol/1 -- -- -- -- 22.9 22.7 23.1 22.9 22.1 21.8 22.2 22.1 22.0 22.4 RDW % ---- -- --- 12.3 12.2 12.2 11.6 12.4 12.4 12.4 13.4 12.3 12.5 PLATELETS G /1 -- -- -- _____ 1329 1182 1340 1085 1237 988 1187 1074 1189 1204 ANIMAL NUMBER i 2 3 4 5 6 7 8 9 10 11 13 14 15 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/1 1 1 -- -- --10.9 17.6 14.1 16.2 8.8 6.6 9.9 10.9 9.3 9.0 ___ -- -- ---- 0.105 0.140 0.075 0.090 0.190 0.145 0.110 0.145 0.120 0.120 ___ -- -- ---- 0.010 0.010 0.000 0.005 0.015 0.005 0.010 0.000 0.010 0.005 BASO. 1 ___ -- --- -- 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 MONO. 1 -- -- -- 0.025 0.030 0.030 0.030 0.010 0.020 0.030 0.025 0.030 0.025 LYMPH. 1 FT SEC -- --- ---- 0.860 0.820 0.895 0.875 0.785 0.830 0.850 0.830 0.840 0.850 15.5 15.6 14.7 14.2 15.2 14.3 14.5 14.7 14.8 14.9 14.3 16.2 14.7 FTT SEC 15.5 16.2 17.2 16.7 16.3 ' 17.5 16.1 14.9 16.0 15.7 15.7 14.8 16.4 1 8 6 000187 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS MALES GROUP 2 (TELOMER ALCOHOL) HEM-IND - 2 3 0 - M A R - 99 ANIMAL NUMBER 17 18 19 20 21 22 23 24 25 26 27 29 30 31 HAEMATOLOGY PARAMETERS RBC HB HOT T/l rtmol/1 1/1 6.19 8.3 0.386 6.36 8.5 .0.371 6.21 8.4 0.368 6.49 8.2 0.377 6.70 9.0 0.403 6.76 8.9 0.391 7.09 9.2 0.405 6.93 9.2 0.407 6.83 8.9 0.399 6.93 9.1 0.411 7.02 8.9 0.404 7.21 9.5 0.425 6.51 8.7 0.389 6.80 8.6 0.391 mcv fl 62.4 58.3 59.3 58.1 60.1 57.8 57.1 58.7 58.4 59.3 57.5 58.9 59.8 57.5 MCH fmol 1.341 1.336 1.353 1.263 1.343 1.317 1.298 1.328 1.303 1.313 1.268 1.318 1.336 1.265 MCHC ittnol/1 21.5 22.9 22.8 21.8 22.3 22.8 22.7 22.6 22.3 22.1 22.0 22.4 22.4 22.0 ROW % 10.7 11.5 12.4 11.2 12.0 12.2 11.1 12.4 12.5 12.7 11.7 12.7 13.0 11.7 PLATELETS G/l 842 928 929 913 1111 1216 992 1047 1119 897 984 1051 1140 1184 ANIMAL NUMBER 17 18 19 20 21 22 23 24 25 26 27 29 . 30 31 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 10.1 7.2 6.4 7.3 10.4 12.3 8.6 10.9 10.9 11.7 10.5 8.6 12.5 11.9 0.085 0.085 0.190 0.155 0.105 0.115 0.120 0.080 0.130 0.105 0.100 0.225 0.130 0.130 0.000 0.025 0.005 0.015 0.000 0.015 0.005 0.010 0.015 0.040 0.000 0.010 0.015 0.005 BASO. 1 0.0QQ 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 MONO. 1 0.Q15 0.015 0.015 0.040 0.015 0.040 0.020 0.010 0.025 0.005 0.035 0.040 0.015 0.015 LYMPH. 1 0.900 0.875 0.790 0.790 0.880 0.830 0.855 0.900 0.830 0.850 0.865 0.725 0.840 0.850 PT SEC 15.8 14.8 15.6 14.5 14.4 14.5 15.0 15.4 13.9 15.3 14.8 15.7 15.3 14.5 PIT SEC 16.0 14.9 15.4 16.4 15.8 16.9 14.6 16.6 15.5 16.5 16.2 17.1 15.9 5.8 187 OOOISS NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS MALES GROUP 3 (TELOMER ACRYLATE) HSM-IND - 3 3 0 - M A R - 99 ANIMAL NUMBER 33 34 35 36 37 38 39. 40 41 42 43 45 46 47 HAEMATOLOGY PARAMETERS RBC HB HOT T/l nmol/l 1/1 6.12 6.50 6.36 6.43 6.76 6.83 6.55 7.16 6.49 6.34 6.83 6.73 6.56 6.82 8.2 8.5 8.0 8.2 9.0 9.2 8.5 9.4 8.7 8.3 9.0 8.9 8.9 9.0 0.367 0.382 0.372 0.380 0.397 0.402 0.372 0.409 0.387 0.374 0.409 0.386 0.390 0.403 mcv fl 60.0 58.8 58.5 59.1 58.7 58.9 56.8 57.1 59.6 59.0 59.9 57.4 59.5 59.1 MCH fnvol 1.340 1.308 1.258 1.275 1.331 1.347 1.298 1.313 1.341 1.309 1.318 1.322 1.357 1.320 MCHC mtnol/1 22.3 22.3 21.5 21.6 22.7 22.9 22.8 23.0 22.5 22.2 22.0 23.1 22.8 22.3 RDW % 12.2 11.5 11.5 11.5 12.7 12.3 12.5 11.6 13.1 12.4 11.8 12.1 12.1 13.4 PLATELETS q /\ 1244 957 1063 930 1388 1354 1191 1114 1099 1137 944 1268 904 1022 ANIMAL NUMBER 33 34 35 36 37 38 39 40 41 42 43 45 46 47 HAEMATOLOGY PARAMETERS WBC SBG. EO. G/l 1 1 11.8 9.9 9.1 11.2 13.4 9.4 9.6 9.3 11.2 11.8 8.9 13.8 6.7 6.8 0.170 0.155 0.080 0.140 0.100 0.065 0.090 0.080 0.095 0.090 0.120 0.145 0.155 0.150 0.005 0.010 0.000 0.015 0.005 0.005 0.020 0.005 0.005 0.000 0.005 0.005 0.005 0.010 BASO. 1 MONO. 1 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 ' 0.025 0.020 0.015 0.020 0.020 0.010 0.020 0.020 0.015 0.025 0.020 0.020 0.045 0.000 LYMPH. 1 0.800 0.815 0.905 0.825 0.875 0.920 0.870 0.895 0.885 0.885 0.855 0.830 0.795 0.840 PT SEC 15.6 15.0 15.3 13.9 14.3 14.7 15.6 15.1 13.9 15.5 15.5 14.4 14.8 PIT SEC 15.5 17.4 ' 23.8 17.1 16.5 18.7 15.5 16.2 15.9 16.7 15.3 16.1 17.8 18 8 000189 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS MALES GROUP 4 ( ) HEM-IND - 4 3 0 - M A R - 99 ANIMAL NUMBER 49 50 51 52 53 54 55 56 57 58 59 61 62 63 HAEMATOLOGY PARAMETERS RBC HB HCT ' T/l mnol/1 1/1 mcv fl 7.07 6.54 6.25 6.62 6.65 7.18 7.13 -- 6.42 6.48 7.21 6.82 6.94 6.90 8.7 8.2 7.6 8.5 8.7 9.6 9.4 8.7 8.7 9.2 8.9 9.4 8.8 0.406 0.371 0.358 0.387 0.384 0.429 0.418 57.4 56.7 57.3 58.5 57.7 59.7 58.6 0.386 60.1 0.389 60.0 0.418 58.0 0.402 58.9 0.418 60.2 0.395 57.2 MCH fmol 1.231 1.254 1.216 1.284 1.308 1.337 1.318 1.355 1.343 1.276 1.305 1.354 1.275 MCHC irrool/1 21.4 22.1 21.2 22.0 22.7 22.4 22.5 22.5 22.4 22.0 22.1 22.5 22.3 RDW % 11.7 11.5 11.7 11.7 11.9 11.7 12.1 12.2 11.9 12.5 12.4 12.1 12.1 PLATELETS g /1 1063 1149 1030 1072 1462 874 876 1084 1084 860 . .1049 932 1121 ANIMAL NUMBER 49 50 51 52 53 54 55 56 57 58 59 61 62 63 HAEMATOLOGY PARAMETERS WBC SEE. EQ. G/1 1 1 12.4 15.2 14.3 14.5 10.6 8.2 10.8 -- 14.1 10.4 12.2 9.6 11.7 7.6 . 0.100 0.105 0.070 0.085 0.065 0.055 0.110 -- 0.095 0.100 0.075 0.055 0.140 0.070 0.010 0.005 0.000 0.010 0.010 0.005 0.010 -- 0.000 0.010 0.010 0.005 0.005 0.015 BASO. 1 MONO. 1 0.000 0.000 0.000 0.000 0.000 0.000 0.000 --- 0.000 0.000 0.000 0.000 0.000 0.000 0.025 0.020 0.020 0.010 0.015 . 0.020 ' 0.040 -- 0.035 0.015 0.030 0.020 0.035 0.015 LYMPH. 1 0.865 0.870 0.910 0.895 0.910 0.920 0.840 -0.870 0.875 0.885 0.920 0.820 0.900 FT SEC 14.9 14.9 13.7 15.4 15.2 14.1 -- 13.8 13.8 13.8 14.8 14.1 14.5 PIT SEC 15.7 15.2 16.0 19.0 17.4 19.5 26.8 16.7 1_6_.7 19.5 ___ . 18.1 000190 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS MALES GROUP 5 (PFHS) HEM-IND - 5 3 0-MAR-99 ANIMAL NUMBER HAEMATOLOGY PARAMETERS RBC HB Her T/l mmol/1 l/i 65 66 67 68 69 70 71 72 73 74 75 77 78 79 6.14 5.71 5.55 6.50 7.04 7.06 7.47 6.40 6.64 6.72 6.65 '6.35 6.95 6.80 8.0 7.5 7.6 8.1 9.1 9.0 9.7 8.4 8.5 8.7 8.5 8.5 8.6 9.0 0.357 0.347 0.347 0.365 0.395 0.409 0.442 0.371 0.388 0.388 0.380 0.378 0.395 0.404 mcv fl 58.1 60.8 62.5 56.2 56.1 57.9 59.2 58.0 58.4 57.7 57.1 59.5 56.8 59.4 ICH fmol 1.303 1.313 1.369 1.246 1.293 1.275 1.299 1.312 1.280 1.295 1.278 1.339 1.237 1.324 MCHC mmol/l 22.4 21.6 21.9 22.2 23.0 22.0 21.9 22.6 21.9 22.4 22.4 22.5 21.8 22.3 FEW % 11.8 11.1 13.1 11.0 11.1 11.6 12.2 11.8 12.6 12.3 12.0 12.8 12.2 12.8 PLATELETS G/l 1017 929 946 969 1074 977 1011 873 997 943 1092 1031 221 105 ANIMAL NUMBER 65 66 67 68 69 70 71 72 73 74 75 77 78 79 HAEMATOLOGY PARAMETERS WBC SBG. EO. G/l 1 1 7.3 8.1 11.1 9.2 7.1 13.6 14.2 12.1 13.9 8.7 6.4 11.0 6,0 6.5 0.175 0.255 0.185 0.125 0.085 0.170 0.140 0.115 0.220 0.100 0.130 0.105 0.160 0.105 0.005 0.020 0.010 0.000 0.000 0.010 0.000 0.010 0.005 0.020 0.000 0.015 0.005 0.015 BASO. 1 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 MONO. 1 0.030 0.020 0.015 0.035 0.020 0.025 0.040 0.025 0.050 0.025 0.025 0.040 0.005 0.005 LYMPH. 1 0.790 0.705 0.790 0.840 0.895 0.795 0.820 0.850 0.725 0.855 0.845 0.840 0.830 0.875 FT SEC 13.9 14.4 14.1 14.1 13.5 14.7 -- 14.7 13.7 1--3- -.7 ... -- PIT SEC 15.9 15.8 15.8 17.1 17.4 18.1 ______ 17.3 17.4. . 16.7 -- -- -- 19 0 000191 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS MALES GROUP 6 (PFOS) HEM-IND - 6 3 0-MAR-9 9 ANIMAL NUMBER 81 82 83 84 85 86 87 88 89 90 91 93 94 95 HAEMATOLOGY PARAMETERS RBC HB HCT T/l nmol/1 1/1 _____ 6.44 -6-.20 6.36 7.37 6.95 6.15 6.44 6.48 6.55 7.13 7.02 6.82 8.7 8.2 -- 8.9 9.4 9.6 8.3 9.0 8.7 8.9 8.9 9.1 9.1 0.377 0-.-361 0.395 0.429 0.414 0.367 0.395 0.382 0.390 0.389 0.409 0.398 KICV fl ... 58.5 5--8.2 62.1 58.2 59.6 59.7 61.3 59.0 59.5 54.6 58.3 58.4 MCH fmol Mac 'nraol/1 RDW % PLATELETS G/l 1.351 1-.-323 1.399 1.275 1.381 1.350 1.398 1.343 1.359 1.248 1.296 1.334 23.1 2__2_.7 22.5 21.9 23.2 22.6 22.8 22.8 22.8 22.9 22.2 22.9 11.3 1_1_.5 11.2 12.7 11.3 13.7 11.5 12.3 12.2 12.7 11.8 11.5 1120 1150 1031 935 1109 1239 1019 1114 1111 1127 ' 1071 1082 ANIMAL NUMBER 81 82 83 84 85 86 87 88 89 90 91 93 94 95 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 -- 7.5 10.2 -- 11.3 10.8 12.3 8.4 13.2 14.2 10.4 7.4 10.2 12.9 ___ - 0.110 0.095 -- 0.075 0.165 0.075 0.190 0.080 0.145 0.075 0.095 0.115 0.145 0.000 0.010 0.015 0.005 0.005 0.005 0.005 0.005 0.000 0.005 0.000 0.000 BASO. 1 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 MONO. 1 0.025 0.020 0.035 0.010 0.015 0.025 0.015 0.035 0.010 0.030 0.025 0.035 LYMPH. 1 -- 0.865 0.875 -- 0.875 0.820 0.905 0.780 0.900 0.815 0.915 0.870 0.860 0.820 PT SEC 14.1 14.8 15.6 15.4 14.7 14.4 14.5' 14.1 -- 15.6 14.7 14.6 14.5 13.8 PTT SEC 20.8 15.2 20.0 15.0 16.9 16.1 19.2 15.9 -- ' 17.1 16.4 18.0 17.7 15.7 1 91 000192 N O TOX Project 242933. HAEMATOLOGY AFTER 4 WEEKS FEMALES GROUP 1 (VEHICLE CONTROL) HEM-IND - 7 3 0 - M A R - 99 ANIMAL NUMBER 97 98 99 100 101 102 103 104 105 106 107 109 110 111 HAEMATOLOGY PARAMETERS RBC HB HCT T/l ranol/1 1/1 __ -- 6.50 6.66 6.80 6.82 7.02 6.78 6.79 6.68 6.54 6.63 6.73 --- 8.9 9.5 9.0 9.2 9.6 8.9 9.2 8.7 8.7 9.0 9.1 -- 0.376 0.392 0.369 0.379 0.389 0.363 0.389 0.369 0.356 0.392 0.380 mcv fl --- -- 57.8 58.9 54.3 55.6 55.4 53.5 57.3 55.2 54.4 59.1 56.5 MCH fmol ___ -- --- 1.369 1.426 1.324 1.349 1.368 1.313 1.355 1.302 1.330 1.357 1.352 MOHC mnol/l RDW % -- ... 23.7 24.2 24.4 24.3 24.7 24.5 23.7 23.6 24.4 23.0 23.9 -- .... 10.9 11.2 11.5 11.1 11.6 11.5 10.9 11.9 11.4 11.6 10.5 PLATELETS G/l ._._. 1271 1114 1324 1050 1302 1335 1078 1214 1019 996 1121 ANIMAL NUMBER. HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 97 -- -- -- 98 --- -- -- 99 -- -- -- 100 7.0 0.080 0.015 101 11.1 0.060 0.000 102 7.0 0.070 0.010 103 9.8 0.045 0.005 104 9.5 0.070 0.015 105 9.0 0.060 0.010 106 6.3 0.090 0.005 107 4.9 0.130 0.025 109 5.2 0.075 0.010 110 5.9 0.095 0.010 111 5.5 0.125 0.000 BASO. 1 -- -- -- 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 MONO. 1 LYMPH. 1 -- -- -- 0.020 0.040 0.045 0.010 0.020 0.015 0.020 0.040 0.025 0.025 0.020 -- -- -- , 0.885 0.900 0.875 0.940 0.895' 0.915 0.885 0.805 0.890 0.870 0.855 FT SEC 14.2 13.9 13.9 14.3 16.5 17.3 15.6 15.5 16.0 15.3 15.9 16.0 15.1 15.4 FTT SEC 14.2 17.7 16.1 18.2 17.0 14.1 17.5 16.3 17.0 16.1 14.1 15.5 14.6 14.7 000193 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS FEMALES GROUP 2 (TELOMER ALCOHOL) HEM-IND - 8 3 0 - M A R - 99 ANIMAL NUMBER 113 114 115 116 117 118 119 120 121 122 123 125 126 127 HAEMATOLOGY PARAMETERS RBC HB HCT T/l ranol/1 1/1 5.44 -- 5.59 6.52 6.28 6.76 6.51 6.21 6.00 6.61 6.29 6.50 6.55 6.29 7.2 -- 7.7 8.7 8.9 9.2 9.0 8.6 8.3 8.6 8.2 8.7 8.8 8.7 0.312 0.331 0.376 0.362 0.372 0.365 0.353 0.340 0.356 0.348 0.363 0.369 0.367 mcv fl 57.4 59.2 57.7 57.6 55.0 56.1 56.8 56.7 53.9 55.3 55.8 56.3 58.3 MCH fmol 1.324 1.377 1.334 1.417 1.361 1.382 1.385 1.383 1.301 1.304 1.338 1.344 1.383 MCHC . irmol/i 23.1 - 23.3 23.1 24.6 24.7 24.7 24.4 24.4 24.2 23.6 24.0 23.8 23.7 RDW % 10.8 ---- 10.8 11.2 11.2 11.2 10.7 11.2 11.0 11.8 11.6 12.1 11.9 10.7 PLATELETS g /1 1041 _____ 1114 970 1134 1463 1275 1262 1283 1097 1016 1165 1095 920 ANIMAL NUMBER 113 114 115 116 117 118 119 120 121 122 123 125 126 127 HAEMATOLOGY PARAMETERS WBC .G/1 SEG. 1 ED. 1 BASO. 11 8.9 0.135 0.000 0.000 -- ___ - 6.9 0.110 0.020 0.000 8.8 0.040 0.000 0.000 5.6 0.175 0.005 0.000 8.5 0.060 0.005 0.000 6.8 0.105 0.005 0.000 8.3 0.160 0.005 0.000 9.8 0.075 0.005 0.000 4.2 0.115 0.000 0.000 8.6 0.140 0.000 0.000 7.8 0.065 0.000 0.000 5.4 0.085 0.005 0.000 8.2 0.070 0.000 0.000 MONO. 1 0.000 0.035 0.010 0.025 0.040 0.010 0.025 0.025 0.015 0.020 0.025 0.025 0.010 LYMPH. 0.865 -- 0.835 0.950 0.795 0.895 0.880 0.810 0.895 0.870 0.840 0.910 0.885 0.920 PT SET 13.8 14.6 14.4 14.1 15.3 15.6 15.8 15.3 15.1 15.2 14.7 15.8 15.3 15.6 PTT ftf;<- 16.2 16.4 14.5 15.2 15.5 16.4 15.0 15.1 13.5 15.0 14.9 13.8 14.6 14.2 1 93 000194 SIOTOX P r o j e c t 242933 HAEMATOLOGY AFTER 4 WEEKS FEMALES GROUP 3 (TELOMER ACRYLATE) HEM-IND - 9 30-MAR-99 ANIMAL NUMBER 129 130 131 132 133 134 135 136 137 138 139 141 142 143 HAEMATOLOGY PARAMETERS RBC HB HCT T/l nnol/1 1/1 -- 7.23 5.98 6.30 6.69 6.36 6.82 6.48 6.54 6.70 6.90 6.83 6.86 6.22 -- 9.4 7.5 8.1 8.9 8.9 9.6 8.7 9.0 8.8 8.8 8.9 9.0 8.6 0.408 0.327 0.360 0.372 0.370 0.388 0.359 0.379 0.362 0.373 0:366 0.378 0.363 mcv fl 56.4 54.7 57.1 55.6 58.2 56.9 55.4 58.0 54.0 54.1 53.6 55.1 58.4 MCH feci MCHC itinol/1 RDW % 1.300 1.254 1.286 1.330 1.399 1.408 1.343 1.376 1.313 1.275 1.303 1.312 1.383 23.0 22.9 22.5 23.9 24.1 24.7 24.2 23.7 24.3 23.6 24.3 23.8 23.7 11.3 12.0 11.0 11.5 10.9 10.7 10.8 10.5 12.2 12.6 11.5 11.6 11.1 PLATELETS g /1 1136 1004 1089 1082 1383 1304 1180 1062 1247 1068 1317 1040 1029 ANIMAL NUMBER 129 130 131 132 133 134 135 136 137 138 139 141 142 143 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/1 1 1 -- 5.3 6.4 6.8 5.7 8.2 6.6 5.4 8.2 6.4 4.2 13.2 7.9 4.7 -- 0.130 0.195 0.070 0.085 0.110 0.110 0.075 0.095 0.090 0.095 0.120 0.070 0.175 0.005 0.005 0.000 0.000 0.000 0.015 0.005 0.030 0.020 0.015 0.005 0.015 0.005 BASO. 1 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 MONO. 1 0.025 0.015 0.020 0.015 0.005 0.015 0.010 0.030 0.025 0.000 0.030 0.015 0.015 LYMPH. 1 -- 0.840 0.785 0.910 0.900 0.885 0.860 0.910 0.845 0.865 0.890 0.845 0.900 0.805 FT SEC 14.7 13.8 13.7 -- 14.4 15.6 15.9 15.9 16.0 14.9 15.4 15.3 15.5 14.1 PIT SEC -- 16.0 16.3 -- 17.1 15.5 16.4 16.0 16.3 14.7 14.7 14.7 14.6 15.6 194 000195 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS FEMALES GROUP 4 ( ) HEM-IND - 10 3 0 - M A R - 99 animal NUMBER 145 146 147 148 149 150 151 152 153 154 155 157 158 159 HAEMATOLOGY PARAMETERS RBC HB HOT T/l irmol/1 1/1 6.23 6.64 6.45 6.66 6.07 6.86 6.64 6.79 6.99 6.22 7.33 6.86 6.33 8.9 9.0 8.7 9.6 8.4 9.4 9.2 8.7 9.4 8.6 9.4 8.9 9.0 ____ 0.380 0.388 0.363 0.392 0.347 0.385 0.383 0.378 0.382 0.363 0.402 0.375 0.368 mcv MCH 1 fmol --w 61.0 58.4 56.3 58.9 57.2 56.1 57.7 55.7 54.6 58.4 54.8 54.7 58.1 . 1.429 1.355 1.349 1.441 1.384 1.370 1.386 1.281 1.345 1.383 1.282 1.297 1.422 MCHC nnol/1 RDW % 23.4 23.2 24.0 24.5 24.2 24.4 24.0 23.0 24.6 23.7 23.4 23.7 24.5 11.5 11.5 11.5 11.3 .11.3 11.4 10.5 11.9 11.4 11.0 11.4 11.3 11.0 PLATELETS G/l 1194 1032 1102 1172 1276 1134 1136 1137 1177 1169 1176 1332 1165 ANIMAL NUMBER 145 146 147 148 149 ISO 151 152 153 154 155 157 158 159 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 10.1 7.1 9.1 8.3 4.9 9.8 6.5 5.8 7.8 4.7 8.9 9.0 6.9 _______ 0.075 0.080 0.075 0.090 0.065 0.075 0.080 0.145 0.105 0.125 0.070 0.070 0.080 0.005 0.005 0.005 0.010 0.020 0.005 0.010 0.015 0.015 0.015 0.020 0.005 0.015 BASO. 1 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 MONO. 1 0.020 0.015 0.030 0.010 0.025 0.035 0.025 0.025 0.030 0.040 0.025 0.020 0.015 LYMPH. 1 PT SEC 0.900 0.900 0.890 0.890 0.890 0.885 0.885 0.815 0.850 0.820 0.885 0.905 0.890 14.3 14.8 13.5 14.5 14.4 14.7 14.9 14.6 14.4 13.8 15.5 14.4 14.6 PTT SEC 16.8 16.6 16.4 17.5 17.5 18.2 17.6 16.2 15.5 15.7 16.6 17.4 18.7 1 95 000196 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS FEMALES GROUP 5 (PFHS) HEM-IND - 11 30-MAR-99 ANIMAL NUMBER 161 162 163 164 165 166 167 168 169 170 171 173 174 175 HAEMATOLOGY PARAMETERS RBC HB HOT T/l mnol/1 1/1 5.92 6.55 6.70 --- 6.23 6.58 6..65 6.36 6.07 6.42 6.50 6.63 5.94 6.02 8.4 9.0 8.7 -- 8.6 9.0 8.8 9.1 8.5 8.4 9.1 8.5 8.7 7.8 0.356 0.375 0.366 -- 0.353 0.374 0.360 0.374 0.333 0.342 0.381 0.350 0.359 0.325 mcv 1 60.1 57.3 -54-.6 56.7 56.8 54.1 58.8 54.9 53.3 58.6 52.8 60.4 54.0 MCH fraol ' 1.419 1.374 1.299 -- 1.380 1.368 1.323 1.431 1.400 1.308 1.400 1.282 1.343 1.296 MCHC nmol/1 REW % 23.6 24.0 2-3-.8 24.4 24.1 24.4 24.3 25.5 24.6 23.9 24.3 24.8 24.0 10.9 10.9 11.8 .... 11.7 11.0 11.9 10.6 11.3 10.9 10.7 11.6 10.6 12.7 PLATELETS G/l 1112 314 _9_75 1192 1178 1044 1120 1053 1066 1157 1019 938 1281 ANIMAL NUMBER 161 162 163 164 165 166 167 168 169 170 171 173 174 175 HAEMATOLOGY PARAMETERS WBC SE3. EO. G/l 1 1 6.3 4.8 5.2 --- 7.2 10.8 5.8 9.1 4.6 6.7 5.5 4.5 4.1 7.2 0.065 0.050 0--.065 0.040 0.040 0.090 0.065 0.115 0.110 0.045 0.095 0.155 0.100 0.005 0.005 0.015 -- - 0.010 0.010 0.020 0.005 0.005 0.010 0.005 0.020 0.005 0.005 BASO. 1 0.000 0.000 0.000 -- 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 MONO. 1 0.020 0.010 0. ...005 0.045 0.035 0.035 0.015 0.035 0.015 0.020 0.025 0.035 0.020 LYMPH. 1 0.910 0.935 0.915 __ 0.905 0.915 0.855 0.915 0.845 0.865 0.930 0.860 0.805 0.875 PT SEC 13.7 ... 14.0 14.3 14.1 13.9 1_5_.8 15.9 14.4 14.2 14.4 15.1 14.0 PIT SEC 15.8 15.7 15.1 16.4 17.9 22.1 ... 16.0 15.5 18.1 15.9 -- 16.8 196 000197 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS FEMALES GROUP 6 (PFOS) H E M - I N D - 12 3 0 - M A R - 99 ANIMAL NUMBER 177 178 179 180 181 182 183 184 185 186 187 189 190 191 HAEMATOLOGY PARAMETERS RBC HB HOT T/l itmol/l 1/1 _____ 6.69 -- ------ 6.54 6.30 7.23 6.51 6.38 5.98 6.66 6.07 5.95 6.21 _____ 8.6 -- -- 8.9 8.6 9.6 9.0 8.5 8.0 8.9 8.1 8.6 8.2 ___ 0.360 ---- -- 0.369 0.356 0.399 0.369 0.354 0.334 0.371 0.338 0.3610.333 mcv fl ___ 53.8 --- 56.4 56.5 55.2 56.7 55.5 55.9 55.7 55.7 60.7 53.6 MCH fmol ___ 1.286 -- ------ 1.361 1.365 1.328 1.382 1.332 1.338 1.336 1.334 1.445 1.320 MCHC mmol/1 ROW % 23.9 -- 24.1 24.2 24.1 24.4 24.0 24.0 24.0 24.0 23.8 24.6 11.7 ------ ... 10.7 10.9 11.2 10.4 12.0 12.0 11.3 11.1 10.7 11.3 PLATELETS G/l 988 -- ... 1068 1220 1027 1208 1229 1187 1069 1423 1033 1024 ANIMAL NUMBER 177 178 179 180 181 182 183 184 185 186 187 189 190 191 HAEMATOLOGY PARAMETERS me SEG. EO. G/l 1 1 -- 4.5 -- -- 7.4 11.8 11.1 8.3 7.2 6.6 6.7 7.9 8.3 12.1 -- 0.055 -- -- 0.075 0.080 0.040 0.085 0.090 0.120 0.080 0.070 0.080 0.075 0.000 0.005 0.005 0.005 0.005 0.000 0.010 0.010 0.000 0.010 0.005 BASO. 1 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 MONO. 1 0.010 0.015 0.020 0.025 0.025 0.010 0.030 0.025 0.020 0.025 0.015 LYMPH. 1 -- 0.935 -- -- 0.905 0.895 0.930 0.885 0.900 0.840 0.885 0.910 0.885 0.905 PT SEC 13.3 13.9 14.8 14.7 14.2 14.7 14.3 14.3 14.8 14.4 14.7 14.1 14.7 14.5 PTT SBC 13.6 12.9 16.7 14.6 16.8 17.7 20.0 20.5 15.0 16.2 15.8 16.4 16.0 18.1 1 97 000198 NOTOX Project 242933 HAEMATOLOGY AFTER 2 WEEKS RECOVERY MALES GROUP 1 (VEHICLE CONTROL) HEM-IND - 13 30-MAR-99 ANIMAL NUMBER 9 10 11 HAEMATOLOGY PARAMETERS RBC HB HCT T/l nrool/1 1/1 7.05 7.41 7.23 8.7 9.2 9.4 0.406 0.428 0.417 rocv fi 57.6 57.8 57.7 ICH fmol 1.234 1.242 1.300 MCHC romol/l 21.4 21.5 22.5 ROW % 14.1 14.5 13.6 PLATELETS G/l 1293 1086 1152 ANIMAL NUMBER 9 10 11 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 8.1 6.9 10.5 0.150 0.120 0.065 0.010 0.015 0.015 BASO. 1 0.000 0.000 0.000 MONO. 1 0.030 0.025 0.025 LYMPH. 1 0.810 0.840 0.895 PT SEC 14.6 14.3 15.0 PTT SEC 17.4 15.3 15.9 198 000199 NOTOX Project 242933 HAEMATOLOGY AFTER 2 WEEKS RECOVERY MALES GROUP 2 (TELOMER ALCOHOL) HEM-IND - 14 3 0 - M A R - 99 ANIMAL NUMBER 25 26 27 HAEMATOLOGY PARAMETERS RBC HB HOT T/l mmol/1 1/1 6.79 7.06 7.28 8.8 8.9 8.9 0.395 0.407 0.409 mcv fl 58.2 57.6 56.2 MCH fmol 1.296 1.261 1.223 MCHC imtol/1 22.3 21.9 21.8 RW % 14.2 13.9 13.0 PLATELETS G/l 1198 1015 1030 ANIMAL NUMBER 25 26 27 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 14.9 8.6 12.5 0.075 0.210 0.095 0.005 0.000 0.010 BASO. 1 0.000 0.000 0.000 MONO. 1 LYMPH. 1 0.015 0.905 0.030 0.760 0.020 0.875 PT SEC 15.3 15.6 14.7 PTT SEC 15.0 16.1 14.8 000200 NOTOX Project 242933 HAEMATOLOGY AFTER 2 WEEKS RECOVERY MALES GROUP 3 (TELQMER ACRYLATE) HEM-IND - 15 3 0 - M A R - 99 ANIMAL NUMBER 41 42 43 HAEMATOLOGY PARAMETERS RBC HB HOT T/l mmol/1 1/1 6.83 6.80 7.28 8.7 8.3 9.2 0.396 0.386 0.421 mcv fl 58.0 56.8 57.8 MCH fmol 1.274 1.221 1.264 MCHC mmol/1 22.0 21.5 21.9 RTW % 13.8 13.8 12.5 . PLATELETS G/l 1239 1323 995 ANIMAL NUMBER 41 42 43 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 12.1 13.9 10.2 0.090 0.040 0.135 0.010 0.000 0.005 BASO. 1 0.000 0.000 0.000 MONO. 1 0.025 0.020 0.030 LYMPH. 1 0.875 0.940 0.830 PT SEC 15.3 14.1 15.2 PIT SEC 17.1 15.8 15.2 000201 200 NOTOX Project 242933 HAEMATOLOGY AFTER 2 WEEKS RECOVERY MALES GROUP 4 ( ) H E M - I N D - 16 3 0 - M A R - 99 ANIMAL NUMBER 57 58 59 HAEMATOLOGY PARAMETERS RBC KB HCT T/l nrool/1 1/1 6.76 6.94 7.29 8.7 8.8 8.9 0.389 0.400 0.416 rrvcv 1 57.5 57.6 57.1 MCH finol 1.287 1.268 1.221 MCHC innol/1 22.4 22.0 21.4 ROW % 12.9 12.3 14.8 PLATELETS G/l 1099 1116 1024 ANIMAL NUMBER 57 58 59 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 14.0 12.2 10.5 0.080 0.050 0.045 0.000 0.005 0.005 BASO. 1 0.000 0.000 0.000 MONO. 1 0.030 0.020 0.020 LYMPH. 1 0.890 0.925 0.930 PT SEC 15.0 14.8 13.9 FIT SEC 16.2 15.3 13.6 000202 201 NOTOX Project 242933 HAEMATOLOGY AFTER 2 WEEKS RECOVERY MALES GROUP 5 (PFHS) H E M - I N D - 17 3 0 - M A R - 99 ANIMAL NUMBER 73 74 75 HAEMATOLOGY PARAMETERS RBC HB HOT T/l rcirol/1 1/1 6.86 6.84 7.21 8.5 8.5 8.7 0.388 0.395 0.394 mcv 1 56.6 57.7 54.6 MCH fmol 1.239 1.243 1.207 MCHC mcnol/1 21.9 21.5 22.1 RIM % 14.0 15.0 14.2 PLATELETS G/l 1028 1071 1059 ANIMAL NUMBER 73 74 75 HAEMATOLOGY PARAMETERS WBC SEG. BO. G/l 1 1 11.1 6.4 7.9 0.200 0.075 0.125 0.015 0.010 0.010 BASO. 1 0.000 0.000 0.000 MONO. 1 0.025 0.010 0.020 LYMPH. 1 0.760 0.905 0.845 PT PIT SEC SEC 15.5 ' 14.9 15.3 15.0 -- 000203 202 NOTOX Project 242933 HAEMATOLOGY AFTER 2 WEEKS RECOVERY MALES GROUP 6 (PFOS) H EM-IND - 18 30-MAR-99 ANIMAL NUMBER 89 90 91 . HAEMATOLOGY PARAMETERS RBC HB HCT T/l innol/1 1/1 6.76 7.15 7.13 8.9 8.9 8.9 0.401 0.412 0.411 mcv fl 59.3 57.6 57.6 MCK nol 1.317 1.245 1.248 MCHC imol/1 22.2 21.6 21.7 REW % 14.0 12.9 12.5 PLATELETS G/l 1068 1026 1140 ANIMAL NUMBER 89 90 91 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 12.7 12.8 9.4 0.125 0.155 0.130 0.000 0.005 0.000 BASO. 1 0.000 0.000 0.000 MONO. 1 0.020 0.020 0.015 LYMPH. 1 0.855 0.820 0.855 FT SEC 15.6 15.9 14.9 PIT SEC 16.3 14.6 13.2 2 0 3 000204 NOTOX Project 242933 HAEMATOLOGY AFTER 2 WEEKS RECOVERY FEMALES GROUP 1 (VEHICLE CONTROL) H E M - I N D - 19 3 0 - M A R - 99 ANIMAL NUMBER 105 106 107 HAEMATOLOGY PARAMETERS RBC HB HOT T/l mnol/1 1/1 7.02 7.11 6.93 8.8 9.2 8.9 0.399 0.414 0.398 mcv fl 56.8 58.2 57.4 MCH fmol 1.254 1.294 1.284 MCHC imol/1 22.1 22.2 22.4 ROW % 15.8 12.9 14.7 PLATELETS G/l 1410 1083 1204 ANIMAL NUMBER 105 106 107 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 9.2 0.055 0.000 7.1 0.115 0.010 5.7 0.055 0.005 BASO. 1 0.000 0.000 0.000 MONO. 1 0.025 0.015 0.010 LYMPH. 1 0.920 0.860 0.930 PT SEC 16.2 15.5 16.3 PTT SEC 17.7 14.7 14.0 000205 NOTOX Project 242933 HAEMATOLOGY AFTER 2 WEEKS RECOVERY FEMALES GROUP 2 (TELOMER ALCOHOL) HEM - I N D - 20 30-MAR-99 ANIMAL NUMBER 121 122 123 HAEMATOLOGY PARAMETERS RBC HB HOT T/l rtmol/1 1/1 6.26 6.63 6.52 8.6 8.4 8.3 0.378 0.382 0.373 mcv fl 60.4 57.6 57.2 MCH fmol 1.374 1.267 1.273 MCHC mmol/1 22.8 22.0 22.3 ROT % 14.8 16.4 14.4 PLATELETS G/l 1283 1024 1045 ANIMAL NUMBER 121 122 123 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 10.9 5.6 9.6 0.095 0.080 0.055 0.000 0.005 0.015 BASO. 1 0.000 0.000 0.000 MONO. 1 0.035 0.025 0.015 LYMPH. 1 0.870 0.890 0.915 PT SEC 14.6 14.9 15.3 PIT SEC 14.6 14.1 14.6 000206 205 NOTOX Project 242933 HAEMATOLOGY AFTER 2 WEEKS RECOVERY FEMALES GROUP 3 (TELOMER ACRYLATE) H E M - I N D - 21 3 0 - M A R - 99 ANIMAL NUMBER 137 138 139 HAEMATOLOGY PARAMETERS RBC KB HOT T/l nmol/1 1/1 6.49 6.88 6.49 8.9 8.7 8.4 0.402 0.387 0.379 mcv fl 61.9 56.3 58.4 MCH fmol . 1.371 1.265 1.294 MCHC moiol/1 22.1 22.5 22.2 REW % 15.9 13.9 16.3 PLATELETS G/l 1053 1205 939 ANIMAL NUMBER 137 138 139 HAEMATOLOGY PARAMETERS WBC SEG. SO. G/l 1 1 11.0 6.0 4.8 0.060 0.050 0.085 0.005 0.005 0.000 baso; 1 0.000 0.000 0.000 MONO. 1 0.030 0.005 0.015 LYMPH. 1 PT SEC 0.905 0.940 0.900 ' 16.1 15.8 15.0 PIT SEC 16.3 14.8 14.2 206 000207 NOTOX Project 242933 HAEMATOLOGY AFTER 2 WEEKS RECOVERY FEMALES GROUP 4 ( ) H E M - I N D - 22 3 0 - M A R - 99 ANIMAL NUMBER 153 154 155 HAEMATOLOGY PARAMETERS RBC HB HCT T/l mmol A 1/1 6.59 7.27 6.27 8.8 9.4 8.7 . 0.397 0.408 0.384 mcv fl 60.2 56.1 61.2 MCH fmol 1.335 1.293 1.388 MCHC Mtvol/1 22.2 23.0 22.7. REW % 17.2 14.0 14.7 PLATELETS G/l 1060 1171 1102 ANIMAL HUMBER 153 154 155 HAEMATOLOGY PARAMETERS WBC G/l SEG. 1 EO. 1 7.9 0.075 0.005 6.9 0.050 0.015 5.3 0.115 0.010 BASO. 1 0.000 0.000 0.000 MONO. 1 0.045 0.035 0.020 LYMPH. 1 0.875 0.900 0.855 PT PTT SEC SEC 14.8 ' 15.1 14.5 15.7 14.0 14.6 000208 207 NOTOX Project 242933 HAEMATOLOGY AFTER 2 WEEKS RECOVERY FEMALES GROUP 5 (PFHS) H E M - I N D - 23 3 0 - M A R - 99 ANIMAL NUMBER 169 170 171 haematology parameters RBC HB HOT T/l mmol/1 1/1 6.22 6.70 6.91 8.2 8.4 9.2 0.357 0.376 0.416 mcv fl 57.4 56.1 60.2 MCH fmol 1.318 1.254 1.331 M3HC irowl/1 23.0 22.3 22.1 REW % 14.0 15.8 13.9 PLATELETS G/l 1010 828 723 ANIMAL NUMBER 169 170 171 HAEMATOLOGY PARAMETERS . NBC SB3. EO. G/l 1 1 5.9 0.085 0.005 7.7 0.035 0.020 6.1 0.030 0.000 BASO. 1 0.000 0.000 0.000 MONO. 1 0.015 0.000 0.015 LYMPH. 1 0.895 0.945 0.955 PT SEC 14.7 14.9 PTT SEC 16.6 14.8 000209 208 NOTOX Project 242933 HAEMATOLOGY AFTER 2 WEEKS RECOVERY FEMALES GROUP 6 (PFOS) H E M - I N D - 24 3 0 - M A R - 99 ANIMAL NUMBER 185 186 187 HAEMATOLOGY PARAMETERS RBC HB HCT T/l mmol/1 1/1 6.48 6.23 6.88 8.5 8.2 8.9 0.382 0.374 0.405 racv fl 59.0 60.0 58.9 MCH fmol 1.312 1.316 1.294 MCHC ltmol/1 22.3 21.9 22.0 RDW % 15.8 15.8 15.6 PLATELETS G/l 1206 769 1127 ANIMAL NUMBER 185 186 187 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 5.3 0.115 0.000 9.6 0.100 0.000 5.4 0.085 0.005 BASO. 1 0.000 0.000 0.000 MONO. 1 0.025 0.020 0.035 LYMPH. 1 0.860 0.880 0.875 FT PTT SEC SEC 15.4 ___ - 15.5 ' 13.7 _____ 13.7 209 000210 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS RECOVERY MALES GROUP 1 (VEHICLE CONTROL) HEM - I N D - 25 3 0 - M A R - 99 ANIMAL NUMBER 13 14 15 HAEMATOLOGY PARAMETERS RBC HB HOT T/l mmol/1 1/1 7.52 7.75 6.79 8.9 9.8 8.7 0.391 0.424 0.373 mcv fl 52.0 54.7 54.9 MCH final 1.184 1.265 1.281 MCHC ranol/1 22.8 23.1 23.3 RDW % 14.4 14.1 14.9 PLATELETS G/l 1062 981 1204 ANIMAL NUMBER 13 14 15 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 13.0 12.5 11.2 0.055 0.160 0.095 0.010 0.010 0.000 BASO. 1 0.000 0.000 0.000 MONO. 1 0.075 0.055 0.025 LYMPH. 1 0.860 0.775 0.880 PT SBC 12.7 ... 13.5 PTT SEC 1. 6. ..1 15.9 21 0 000211 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS RECOVERY MALES GROUP 2 (TELOMER ALCOHOL) H E M - I N D - 26 3 0 - M A R - 99 ANIMAL NUMBER 29 30 31 HAEMATOLOGY PARAMETERS RBC HB HOT T/l mnol/l 1/1 7.16 6.88 6.98 9.1 9.2 8.9 0.396 0.390 0.386 nxrv fl 55.3 56.7 55.3 MCH fmol 1.271 1.337 1.275 MCHC mnol/l 23.0 23.6 23.1 REW % 12.7 12.6 13.5 PLATELETS G/l 917 1097 1062 ANIMAL NUMBER 29 30 31 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 10.7 10.5 15.8 0.120 0.065 0.100 0.010 0.000 0.000 BASO. 1 0.000 0.000 0.000 MONO. 1 0.075 0.040 0.050 LYMPH. 1 PT SEC PIT SEC 0.795 0.895 0.850 ' 13.3 12.7 14.6 15.7 000212 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS RECOVERY MALES GROUP 3 (TELOMER ACRYLATE) HEM-IND - 27 30-MAR-9 9 ANIMAL NUMBER ' HAEMATOLOGY PARAMETERS RBC HB HOT T/l nnvol/1 1/1 45 6.84 8.9 46 6.70 8.9 47 7.01 9.4 0.372 0.386 0.395 mcv fl 54.4 57.6 56.3 MCH fool 1.301 1.328 1.341 MCHC ismol/1 23.9 23.1 23.8 RTW % 13.9 13.8 13.3 PLATELETS G/l 1244 960 1024 ANIMAL NUMBER 45 46 47 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 BASO. 1 15.6 8.6 8.2 0.085 0.125 0.060 0.005 0.000 0.015 ' 0.000 0.010 0.000 MONO. 1 0.025 0.085 0.030 LYMPH. 1 0.885 0.775 0.900 PT SEC 13.3 13.6 13.2 PTT SEC 16.7 16.6 17.0 21 2 000213 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS RECOVERY MALES GROUP 4 { ) HEM - I N D - 28 3 0 - M A R - 99 ANIMAL NUMBER 61 62 63 HAEMATOLOGY PARAMETERS RBC h b HOT T/l itmol/1 1/1 6.84 7.18 7.01 9.2 9.5 9.0 0.379 0.408 0.388 mcv 1 55.4 56.8 55.3 MCH fmol 1.345 1.323 1.284 MCHC Kinol/1 24.3 23.3 23.2 JUS! % .13.4 12.6 12.7 PLATELETS G/l 1232 1206 1100 ANIMAL NUMBER HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 61 62 63 10.7 9.2 8.2 0.055 0.055 0.070 0.005 0.010 0.000 BASO. 1 0.000 0.000 0.000 MCNO. 1 0.030 0.015 0.015 LYMPH. 1 0.910 0.920 0.915 FT SEC 13.0 14.6 PTT SEC 15.9 17.0 21 3 000214 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS RECOVERY MALES GROUP 5 (PFHS) H E M - I N D - 29 30-MAR-99 ANIMAL NUMBER. 77 78 79 HAEMATOLOGY PARAMETERS RBC HB HOT T/l irmol/1 1/1 6.82 6.87 6.97 8.9 8.7 9.4 0.384 0.381 0.406 mcv fl 56.3 55.5 58.2 MCH fnsi 1.305 1.266 1.349 MCHC mmol/1 23.2 22.8 23.2 RDW % 13.2 13.8 13.8 PLATELETS G/l 1000 884 1013 ANIMAL NUMBER 77 78 79 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 9.5 0.060 0.005 7.1 0.065 0.010 6.5 0.065 0.005 BASO. ' MONO. 11 0.000 0.000 0.000 0.020 0.035 0.020 LYMPH. 1 0.915 0.890 0.910 PT SBC 1--4.5 13.8 PTT SEC 14.9 15.5 000215 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS RECOVERY MALES GROUP 6 (PFOS) HEM-IND - 30 30-MAR-9 9 ANIMAL NUMBER 93 94 95 HAEMATOLOGY PARAMETERS RBC KB HOT T/l mnol/1 1/1 7.14 7.20 6. S3 8.9 9.2 8.8 0.383 0.406 0.378 ircv fl 53.6 56.4 57.0 MCH mol 1.246 1.278 1.327 MCHC irimol/1 23.2 22.7 23.3 REW % 14.7 13.2 13.2 PLATELETS G/l 1083 1047 1101 ANIMAL NUMBER. HAEMATOLOGY PARAMETERS WBC G/l SBG. 1 EO. 1 93 7.5 0.040 0.005 94 12.7 0.065 0.010 95 13.5 0.130 0.005 BASO. 1 0.000 0.000 0.000 MONO. 1 0.030 0.005 0.045 LYMPH. 1 0.925 0.920 0.820 PT . SEC 14.2 13.9 13.8 PTT SEC 13.2 16.9 13.7 21 5 000216 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS RECOVERY FEMALES GROUP 1 (VEHICLE CONTROL) HEM-IND - 31 3 0 - M A R - 99 ANIMAL NUMBER 109 110 111 HAEMATOLOGY PARAMETERS SBC HB HCT T/l mmol/1 1/1 6.76 7.09 6.76 9.2 9.4 9.2 0.380 0.423 0.389 0CV fl 56.2 59.7 57.5 MCH fmol 1.361 1.326 1.361 mchc nmol/l 24.2 22.2 23.7 RDW % 12.2 13.7 12.5 PLATELETS G/l 911 992 1013 ANIMAL NUMBER 109 110 111 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 5.9 0.020 0.000 6.7 0.080 0.005 5.5 0.060 0.020 BASO. 1 0.000 0.000 0.000 MONO. 1 0.020 0.015 0.010 LYMPH. 1 0.960 0.900 0.910 PT PTT SEC SEC 13.0 12.0 11.8 14.6 16.9 15.6 21 6 000217 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS RECOVERY FEMALES GROUP 2 (TELQMER ALCOHOL) HEM-IND - 32 3 0 - M A R - 99 ANIMAL NUMBER 125 126 127 HAEMATOLOGY PARAMETERS RBC HB HOT T/l mnol/1 1/1 6.95 6.85 6.77 9.4 9.5 9.2 0.400 0.403 0.404 racv fl 57.6 58.8 59.7 MCH fmol 1.353 1.387 1.359 MCHC nnol/1 23.5 23.6 22.8 ROW % 13.1 14.0 13.4 PLATELETS G/l 1088 882 969 ANIMAL NUMBER 125 126 127 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 8.7 0.055 0.005 9.9 0.075 0.005 7.8 0.080 0.000 BASO. 1 0.000 0.000 0.000 MONO. 1 0.035 0.025 0.020 LYMPH. 1 0.905 0.895 0.900 PT SEC 11.9 12.2 12.5 PIT SEC 14.1 14.7 15.0 000218 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS RECOVERY FEMALES GROUP 3 (TELOMER ACRYLATE) H E M - I N D - 33 3 0 - M A R - 99 ANIMAL NUMBER 141 142 143 HAEMATOLOGY PARAMETERS RBC HB HCT T/l itmol/1 1/1 6.87 7.01 6.48 8.9 9.2 8.8 0.381 0.398 0.388 mcv fl 55.5 56.8 59.9 MCH fmol 1.295 1.312 1.358 MCHC imol/1 23.4 23.1 22.7 REW % 13.3 13.1 13.4 PLATELETS G/l 1093 841 961 ANIMAL NUMBER 141 142 143 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 10.7 8.9 3.5 0.025 0.055 0.035 0.010 0.010 0.010 BASO. 1 0.000 0.000 0.000 MONO. 1 0.035 0.010 0.010 LYMPH. 1 0.930 0.925 0.945 PT SEC 12.2 11.9 11.5 PTT SEC 14.6 ' 16.7 15.9 218 000219 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS RECOVERY FEMALES GROUP 4 ( ) HEM-IND - 34 3 0 - M A R - 99 ANIMAL NUMBER 157 158 159 HAEMATOLOGY PARAMETERS KBC KB HCT T/l smol/1 1/1 7.25 .88 6.85 9.2 8.9 9.1 0.402 0.386 0.391 mcv fl 55.4 56.1 57.1 MEH fmol - 1.269 1.294 . 1.328 MCHC imol/1 22.9 23.1 23.3 RDW % 12.9 12.5 12.3 PLATELETS G/l 1028 1045 969 ANIMAL NUMBER 157 158 159 HAEMATOLOGY PARAMETERS VJBC SEG. BO. G/l 1 1 6.3 0.025 0.020 6.5 0.095 0.020 5.B 0.110 0.020 BASO. 1 0.000 0.000 0.000 MONO. 1 0.030 0.030 0.030 LYMPH. 1 FT SEC 0.925 0.855 0.840 . 12.5 11.5 12.6 PTT SBC 14.6 14.6 15.7 000220 21 9 V NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS RECOVERY k 'rtM A T i'R S GROUP 5 (PFHS) HE M - I N D - 35 3 0 - M A R - 99 ANIMAL NUMBER 173 174 175 HAEMATOLOGY PARAMETERS RBC KB HCT T/l mnol/1 1/1 7.08 6.73 6.59 9.0 9.2 8.6 0.388 0.411 0.368 mcv fl 54.8 61.1 55.8 MCH fmol 1.271 1.367 1.305 MCHC mtnol/1 23.2 22.4 23.4 RTW % 13.7 12.1 14.1 platelets G/l 939 874 1120 ANIMAL NUMBER 173 174 175 HAEMATOLOGY PARAMETERS WBC SBG. EO. G/l 1 1 6.9 0.095 0.010 4.5 0.065 0.005 9.1 0.065 0.005 BASO. 1 0.000 0.000 0.000 MONO. 1 0.040 0.050 0.015 LYMPH. 1 0.855 0.880 0.915 PT PIT SEC SEC 11.8 12.0 11.4 15.2 15.5 15.1 000221 220 NOTOX Project 242933 HAEMATOLOGY AFTER 4 WEEKS RECOVERY FEMALES GROUP 6 (PFOS) H E M - I N D - 36 30-MAR-99 ANIMAL NUMBER 189 190 191 HAEMATOLOGY PARAMETERS RBC HB HCT T/l imel/l 1/1 6.49 6.73 6.45 8.7 9.2 8.1 0.370 0.413 0.355 mcv fl 57.0 61.4 55.0 MCH fmol 1.341 1.367 1.256 MCHC mnol/1 23.5 22.3 22.8 REW % 11.9 13.3 13.5 PLATELETS G/l 1062 906 1013 ANIMAL NUMBER 189 190 191 HAEMATOLOGY PARAMETERS WBC SEG. EO. G/l 1 1 11.3 7.4 7.4 0.085 0.065 0.035 0.000 0.015 0.000 BASO. 1 0.000 0.000 0.000 MONO. .1 0.015 0.025 0.010 LYMPH. 1 0.900 0.895 0.955 FT SEC 12.0 12.7 12.0 PTT SEC 13.6 15.5 15.5 000222 221 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS MALES GROUP 1 (VEHICLE CONTROL) CHE-IND - 1 3O-MAR-9 9 ANIMAL NUMBER 1 2 3 45 6 7 8 9 10 11 13 14 15 ALAT(GPT) ASAT(GOT) b u j t . CHOLEST.T. TRIGL. ukat/1 ukat/1 umol/1 smol/1 itmol/l 0.88 0.69 0.79 0.60 0.66 0.51 0.67 0.50 0.58 0.70 0.56 0.54 0.53 0.80 3.21 2.55 2.34 3.28 3.30 2.77 2.76 2.16 2.42 2.33 3.13 2.92 2.86 3.10 . 3 1 2 1 3 3 3 2 3 3 2 2 2 3 1.58 1.94 2.63 2.36 1.47 2.14 2.07 1.70 2.47 2.53 1.53 2.04 1.85 1.64 , 0.75 0.80 0.63 1.27 0.54 0.83 1.12 0.59 0.53 0.88 0.61 1.05 0.52 1.07 CREATININE GLUCOSE umol/1 irmol/1 UREA itmol/l 35 6.63 6.5 29 5.67 5.9 37 6.01 8.8 31 5.65 5.8 32 7.14 6.5 29 7.50 5.9 29 6.31 5.5 28 5.56 6.5 38 6.70 8.1 38 6.04 8.6 33 6.93 7.7 38 6.14 7.5 30 4.94 5.9 39 7.31 6.9 ANIMAL NUMBER 1 2 3 4 5 6 7 8 $ 10 11 13 14 15 PROTEIN T. ALBUMIN g/i g/1 GLOBULIN A/G RATIO ALP g/i ukat/1 54.4 56.6 57.5 57.8 59.9 59.1 62.5 57.5 55.2 50.8 53.5 55.9 57.6 56.6 29.0 29.6 30.4 30.4 30.4 28.9 30.2 28.5 28.5 27.7 30.0 29.2 28.6 29.2 25.4 27.0 27.1 27.4 29.5 30.2 32.3 29.0 26.7 23.1 23.5 26.7 29.0 27.4 1.1 1.1 1.1 1.1 1.0 1.0 0.9 1.0 1.1 1.2 1.3 1.1 1.0 1.1 12.54 7.29 6.03 7.45 8.56 6.65 6.99 8.54 6.11 10.02 7.26 7.58 7.29 6.26 XNORG PHOS SQDXUM nxnol/1 mol/1 2.76 3.22 2.79 2.63 2.86 2.71 2.85 3.04 2.73 2.70 2.78 2.80 3.00 2.78 143.5 143.8 143.1 143.1 144.8 142.3 143.3 142.8 141.6 143.1 143.3 141.3 139.8 140.6 POTASSIUM itmol/l 4.70 5.32 4.50 4.72 4.50 4.72 4.70 4.69 5.10 4.70 5.07 4.67 5.56 4.96 ANIMAL NUMBER 1 2 3 4 5 6 7 8 9 10 11 13 14 15 CALCIUM nrnol/1 CHLORIDE itmol/l 2.46 2.68 2.53 2.55 2.63 2.58 2.64 2.48 2.47 2.43 2.47 2.49 2.58 2.49 104 101 101 102 98 97 99 100 100 100 99 102 95 97 000223 222 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS MALES GROUP 2 (TELOMER ALCOHOL) CHE-IND - 2 30-MAR-9 9 ANIMAL NUMBER 17 18 19 20 21 22 23 24 25 26 27 29 30 31 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 CHOLEST.T. TRIGL. nmol/l nmol/l 0.56 0.47 0.71 0.83 0.52 0.62 0.70 0.65 0.56 0.48 0.64 0.51 0.60 0.66 1.85 2.26 2.48 3.02 2.20 2.63 2.63 2.38 2.46 2.64 2.96 2.68 3.14 3.41 - 2 2 2 2 2 2 2 2 2 3 3 3 2 2 1.37 1.67 1.34 0.99 1.01 1.11 0.86 1.02 2.58 1.14 1.31 1.48 1.13 0.92 0.87 1.23 1.20 0.30 0.37 0.80 0.47 0.39 0.54 0.43 0.56 0.56 0.60 0.49 CREATININE GLUCOSE umol/1 nmol/l urea' nmol/l 29 6.37 6.2 31 6.47 6.5 31 7.16 7.4 34 5.68 8.1 26 8.71 6.7 29 7.19 6.1 31 6.58 6.1 30 6.85 8.3 32 6.17 6.7 30 4.50 8.3 34 6.68 8.3 29 6.33 5.5 29 5.58 5.9 24 6.49 7.2 ANIMAL NUMBER 17 18 19 20 21 22 23 24 25 26 27 29 30 31 PROTEIN T. ALBUMIN g/i g/x GLOBULIN A/G RATIO ALP g/i ukat/1 53.0 53.8 54.3 54.9 54.2 53.0 52.6 52.6 53.1 53.1 50.5 58.0 51.9 49.1 28.0 29.3 31.5 30.8 27.3 28.8 27.6 29.5 27.8 28.2 27.7 29.3 29.2 27.4 25.0 24.5 22.8 24.1 26.9 24.2 25.0 23.1 25.3 24.9 22.8 28.7 22.7 21.7 1.1 1.2 1.4 1.3 1.0 1.2 1.1 1.3 1.1 1.1 1.2 1.0 1.3 1.3 6.46 8.92 7.59 6.81 8.12 7.04 6.03 6.84 8.21 11.53 7.94 9.19 12.49 6.01 INORG PHDS SODIUM nmol/l mnol/1 2.60 3.04 2.93 2.69 2.64 2.90 2.69 2.76 2.65 2.71 2.72 2.80 2.61 2.76 143.9 143.3 143.1 143.3 143.4 142.6 142.1 141.4 142.3 143.5 141.8 144.8 142.5 141.9 POTASSIUM nmol/l 4.25 4.65 4.40 4.55 5.07 4.64 4.49 5.14 4.60 4.34 4.78 4.69 4.24 4.51 ANIMAL NUMBER 17 18 19 20 21 22 23 24 25 26 27 29 30 31 CALCIUM mnol/1 CHLORIDE nmol/l 2.58 2.48 2.55 2.50 2.49 2.47 2.43 2.44 2.42 2.42 2.37 2.59 2.43 2.44 101 100 102 103 94 99 101 99 101 102 101 100 101 100 000224 223 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS MALES ROUP 3 (TELOMER ACRYLATE) CHE-IND - 3 30-MAR-99 ANIMAL NUMBER 33 34 35 36 37 38 39 40 41 42 43 45 46 47 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/l umol/1 CHOLEST.T. TRIGL. mnol/1 mnol/1 0.58 0.85 0.64 0.62 0.52 0.45 0.81 0.44 0.48 0.50 0.73 0.72 -- - 0.57 3.74 2.81 2.72 2.46 2.00 2.31 2.85 1.87 2.46 2.27 2.62 2.98 2.48 2.52 . 2 2 1 2 2 2 3 5 2 2 2 3 2 2 1.28 2.72 1.19 0.89 1.13 1.91 1.13 1.10 1.64 1.40 1.51 1.72 1.02 1.33 1.72 0.71 0.62 0.44 0.66 1.34 0.46 0.68 1.13 0.56 0.43 0.51 0.43 0.57 CREATININE GLUCOSE umol/1 mnol/1 UREA mnol/1 31 6.30 5.7 29 5.63 6.0 34 6.80 7.2 33 5.77 7.2 28 6.56 5.7 29 6.66 7.5 30 6.95 6.2 32 7.48 8.5 31 7.21 5.7 31 6.26 8.1 30 5.24 6.2 34 5.48 7.7 31 5.86 6.5 27 5.22 4.9 ANIMAL NUMBER PROTEIN T. ALBUMIN g/i g/i GLOBULIN A/G RATIO ALP g/i ukat/l 33 57.8 33.4 24.4 1.4 34 58.1 30.0 28.1 1.1 35 51.9 29.6 22.3 1.3 36 52.6 29.5 23.1 1.3 37 51.9 30.2 21.7 1.4 38 56.0 29.9 26.1 1.1 39 54.2 28.4 25.8 1.1 40 55.2 29.0 26.2 1.1 41 55.4 29.2 26.2 1.1 42 50.9 26.9 24.0 1.1 43 54.0 29.5 24.5 1.2 45 52.7 29.2 23.5 1.2 46 47.6 25.8 21.8 1.2 47 56.3 29.4 26.9 1.1 8.10 7.91 8.31 8.85 7.99 6.99 5.23 8.66 7.93 6.91 6.98 6.06 9.35 8.53 INORG PHOS SODIUM mnol/1 mnol/1 2.88 2.95 2.80 3.10 3.04 2.69 2.90 3.22 2.92 2.79 2.55 2.90 3.01 2.61 .143.7 143.5 143.2 144.5 143.1 144.0 142.6 143.7 143.6 143.0 142.4 141.7 143.0 142.6 POTASSIUM mnol/1 4.81 3.92 4.81 4.32 4.95 4.85 4.66 5.14 5.30 4.69 4.58 4.81 5.13 4.09 ANIMAL NUMBER 33 34 35 36 37 38 39 40 41 42 43 45 46 47 CALCIUM nrnol/l CHLORIDE ranol/1 2.57 2.53 2.38 2.62 2.48 2.55 2.48 2.57 2.54 2.44 2.47 2.50 2.44 2.46 101 100 103 102 102 100 100 102 104 104 102 101 103 101 000225 224 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS HALES GROUP 4 ( ) CHE-IND - 4 3 O-MAR-99 ANIMAL NUMBER 49 50 51 52 53 54 55 56 57 58 59 61 62 63 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 CHOLEST.T. TRIGL. mmol/l nmol/1 0.68 0.47 0.63 0.52 0.69 0.53 0.73 0.62 0.67 0.49 -- 0.45 0.38 0.52 2.49 2.41 2.09 2.30 2.85 2.16 2.43 2.19 2.48 2.58 2.52 2.28 1.67 . 1.85 . 2 2 2 3 2 2 2 3 3 2 3 2 2 2 1.62 1.73 1.75 1.76 1.65 1.39 1.33 2.56 2.37 2.23 1.54 1.15 1.98 1.51 ' 0.56 0.58 1.22 0.85 0.51 0.50 0.73 0.84 0.66 0.75 0.60 0.45 0.50 0.40 CREATININE GLUCOSE umol/1 mmol/l UREA mmol/l 35 34 29 31 29 37 34 32 42 32 35 38 40 . 31 7.70 6.58 8.07 7.05 5.86 7.41 7.04 7.39 7.38 5.75 6.29 6.57 4.62 4.58 7.8 6.7 6.4 6.8 5.7 5.6 7.1 6.9 8.6 6.8 6.2 6.6 9.0 6.2 ANIMAL NUMBER 49 50 51 52 53 54 55 56 57 58 59 61 62 63 PROTEIN T. ALBUMIN g/1 g/1 GLOBULIN A/G RATIO ALP g/1 ukat/1 57.3 51.9 57.0 56.7 54.2 52.8 53.5 53.2 51.0 56.4 53.2 53.3 51.8 50.7 . 31.0 30.2 31.0 32.5 28.8 28.9 30.4 28.6 29.3 31.1 28.6 30.5 28.3 28.2 26.3 21.7 26.0 24.2 25.4 23.9 23.1 24.6 21.7 25.3 . 24.6 22.8 23.5 22.5 1.2 1.4 1.2 1.3 1.1 1.2 1.3 1.2 1.4 1.2 1.2 1.3 1.2 1.3 8.01 7.08 8.24 10.97 7.10 9.03 8.06 8.42 8.47 7.39 6.63 6.76 7.03 8.81 INGRG PHDS SODIUM mmol/l mmol/l 2.56 2.84 2.67 2.59 2.83 2.72 2.54 2.72 3.19 2.40 2.58 2.76 3.15 2.45 143.8 143.1 141.3 142.6 143.2 143.4 142.4 143.0 142.5 142.7 143.3 143.0 143.8 144.3 POTASSIUM mmol/l 4.67 4.81 4.46 4.51 4.70 4.60 4.31 4.65 4.50 4.21 4.15 4.33 4.85 4.29 ANIMAL NUMBER 49 50 51 52 53 54 55 56 57 58 59 61 62 63 CALCIUM mmol/l CHLORIDE mnol/1 2.45 2.43 2.52 2.55 2.48 2.41 2.45 2.36 2.54 2.57 2.37 2.47 2.56 2.45 101 104 100 98 102 102 102 101 103 101 99 95 104 102 000226 225 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS MALES GROUP 5 (PFHS) CHE-IND - 5 30-MAR-99 ANIMAL NUMBER 65 66 67 68 69 70 71 72 73 74 75 77 78 79 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 CHQLEST.T. TRIGL. mnol/1 mnol/1 0.56 0.68 0.59 0.63 0.50 0.57 0.60 0.66 0.61 0.65 0.59 0.56 1.53 0.64 1.95 2.21 2.08 2.30 2.69 2.44 2.73 2.57 2.42 2.43 2.01 2.27 2.74 2.60 . 2 1 2 1 2 2 2 2 2 3 2 2 2 2 1.22 1.20 1.12 0.91 0.87 0.83 0.83 1.15 0.78 1.19 1.23 . 0.92 0.70 0.68 0.83 0.46 0.59 0.37 0.29 0.30 0.42 0.51 0.33 0.51 0.40 0.36 0.23 0.37 CREATININE GLUCOSE umol/1 iraiol/l UREA mnol/1 32 9.60 7.7 31 7.63 7.0 30 6.33 7.9 32 7.08 7.5 37 7.01 8.4 32 8.35 6.2 36 6.43 5.9 34 7.18 9.0 34 5.22 6.9 36 6.65 8.2 35 7.43 7.3 42 4.36 8.3 50 4.03 11.8 32 6.75 6.0 ANIMAL NUMBER 65 66 67 68 69 70 71 72 73 74 75 77 78 79 PROTEIN T. ALBUMIN g/i g/1 GLOBULIN A/G-RATIO ALP g/i ukat/1 56.0 55.2 51.6 50.1 54.0 52.3 58.3 59.1 51.0 53.0 55.3 54.0 50.4 51.1 28.2 31.1 31.2 29.9 30.1 29.4 32.9 32.5 30.4 29.7 31.5 28.6 29.8 29.7 27.8 24.1 20.4 20.2 23.9 22.9 25.4 26.6 20.6 23.3 23.8 25.4 20.6 21.4 1.0 1.3 1.5 1.5 1.3 1.3 1.3 1.2 1.5 1.3 1.3 1.1 1.4 1.4 7.03 10.00 8.63 8.60 9.07 10.97 10.10 7.64 8.94 9.14 11.09 9.33 7.62 12.50 INORG PHDS SODIUM mnol/1 mnol/1 3.16 2.75 3.05 2.65 3.00 3.05 3.74 2.85 3.15 3.23 2.88 2.49 3.11 3.12 143.1 143.1 143.9 143.1 144.3 142.9 144.6 142.2 144.5 143.0 143.4 142.4 142.1 143.7 POTASSIUM mnol/1 4.44 4.04 4.56 4.23 4.48 4.62 5.64 4.35 4.17 5.41 4.39 4.24 4.30 4.78 ANIMAL NUMBER 65 66 67 68 69 70 71 72 73 74 75 77 78 79 CALCIUM mnol/1 CHLORIDE mnol/1 2.66 2.45 2.56 2.40 2.54 2.51 2.64 2.53 2.54 2.56 2.44 2.40 2.49 2.48 100 101 103 101 105 102 105 104 104 102 98 103 103 106 000227 226 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS MALES GROUP 6 (PFOS) CHE-IND - 6 30-MAR-9 9 ANIMAL NUMBER 81 82 83 84 85 86 87 88 89 . 90 91 93 94 95 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 CHOLEST.T. TRIGL. itmol/1 imol/1 0.60 0.58 0.49 0.67 0.49 0.62 0.60 0.54 0.62 0.66 0.56 0.62 0.65 0.61 1.88 2.80 1.70 2.05 1.67 2.88 2.06 2.61 2.78 2.28 3.05 2.40 2.34 2.68 ' . 3 1 2 2 3 3 2 3 3 3 3 2 2 2 1.99 1.09 0.81 1.11 1.77 0.88 1.13 0.96 1.16 1.49 1.19 0.40 0.88 0.91 0.47 0.91 0.34 0.37 0.45 0.52 0.48 0.48 0.43 0.41 0.79 0.27 0.39 0.42 CREATININE GLUCOSE umol/1 rratol/1 UREA innol/1 30 5.84 6.5 28 7.19 6.5 38 8.85 8.8 30 5.70 7.1 29 4.92 7.0 30 8.51 6.1 37 6.72 10.7 30 4.50 8.1 33 6.45 7.9 29 6.00 7.4 37 5.13 9.0 30 6.20 7.7 28 6.92 6.9 32 6.35 6.9 ANIMAL NUMBER 81 82 83 84 85 86 87 88 89 90 91 93 94 95 PROTEIN T. ALBUMIN g /l g/l GLOBULIN A/G RATIO ALP g/l ukat/1 53.0 54.9 54.9 55.9 53.1 54.7 57.5 51.6 53.0 53.7 56.4 49.7 53.6 55.0 31.2 30.3 31.4 29.5 30.1 29.2 29.4 28.2 28.5 28.4 27.7 28.0 28.1 29.7 21.8 24.6 23.5 26.4 23.0 25.5 28.1 23.4 24.5 25.3 28.7 21.7 25.5 25.3 1.4 1.2 1.3 1.1 1.3 1.1 1.0 1.2 1.2 1.1 1.0 1.3 1.1 1.2 5.41 8.58 9.87 4.56 5.55 8.46 7.00 7.24 7.98 6.12 8.68 8.14 7.23 6.78 INORG PHOS SODIUM mmol/1 mnoel/1 POTASSIUM itmol/1 2.60 2.95 3.11 2.95 2.91 2.80 3.07 2.83 3.01 3.37 3.16 2.67 2.94 3.03 143.4 143.9 143.1 142.7 144.6 143.3 143.3 143.2 143.2 142.0 141.8 141.9 142.5 141.6 . 4.39 4.99 5.27 5.00 3.98 4.55 4.39 4.67 4.46 4.75 4.59 4.72 5.15 4.34 ANIMAL NUMBER 81 82 83 84 85 86 87 88 89 90 91 93 94 95 CALCIUM rrmol/1 CHLORIDE mmol/1 2.59 2.47 2.58 2.52 2.58 2.66 2.57 2.44 2.50 2.57 2.52 2.35 2.53 2.45 101 100 102 106 105 101 106 102 104 106 100 103 106 99 000228 227 NOTOX Project 242933 CLINICAL BIOCHEMISTRY' AFTER 4 WEEKS FEMALES GROUP 1 (VEHICLE CONTROL) CHE-IND - 7 3 0 - M A R - 99 ANIMAL NUMBER 97 98 99 100 101 102 103 104 105 106 107 109 110 111 ALAT(GPT) ASAT(GOT) BILI T. ukat/l ukat/l umal/1 CHOLEST.T. TRIGL. rrmol/1 irmol/1 0.69 0.39 0.44 0.69 0.61 0.53 0.47 0.52 0.65 0.40 0.46 0.33 0.64 0.46 2.74 1.94 2.47 3.09 2.94 2.97 2.75 2.70 2.39 2.35 2.86 2.26 2.93 2.22 . 4 3 2 2 4 3 3 2 2 3 2 3 2 3 2.74 1.68 2.44 1.81 1.97 1.87 1.75 2.44 1.68 2.86 1.92 2.45 2.47 2.81 0.81 0.33 0.71 0.40 0.80 0.51 0.44 0.62 0.48 0.88 0.37 0.68 0.69 0.74 CREATININE GLUCOSE umol/1 irnol/1 UREA rrmol/1 39 37 35 40 42 41 38 46 38 39 44 ' 42 40 40 5.58 5.92 5.98 6.07 5.96 5.69 5.65 6.20 5.66 7.58 6.41 5.67 6.42 5.95 10.1 6.1 6.2 6.4 11.0 11.6 7.1 8.6 9.4 8.8 8.3 7.9 6.7 8.6 ANIMAL NUMBER 97 98 99 100 101 102 103 104 105 106 107 109 110 111 PROTEIN T. ALBUMIN 3/1 3/1 63.1 67.9 61.3 67.4 67.1 61.5 70.1 70.9 67.3 65.5 64.8 60.8 69.8 64.7 32.0 35.1 32.2 34.1 34.4 33.4 36.4 34.9 34.0 34.6 32.6 32.1 36.1 34.2 GLOBULIN A/G RATIO ALP 3/1 ukat/l 31.1 32.8 29.1 33.3 32.7 28.1 33.7 36.0 33.3 30.9 32.2 28.7 33.7 30.5 1.0 1.1 1.1 1.0 1.1 1.2 1.1 1.0 1.0 1.1 1.0 1.1 1.1 1.1 3.33 4.34 5.17 5.53 4.09 4.41 3.91 5.50 4.21 3.87 4.50 4.79 4.35 4.39 INORG PHOS SODIUM itmol/1 mnol/1 POTASSIUM iranol/1 2.87 2.50 2.67. 2.61 2.68 2.93 2.27 2.52 2.87 2.68 2.50 2.12 2.37 2.49 142.4 144.1 146.1 139.8 143.7 142.1 141.6 141.7 141.0 141.4 142.0 141.4 142.7 141.1 4.85 3.41 3.96 4.59 4.03 4.78 4.08 4.18 4.13 4.09 3.77 3.91 3.87 4.21 ANIMAL NUMBER 97 98 99 100 101 102 103 104 105 106 107 109 110 111 CALCIUM irmol/1 CHLORIDE nmol/1 2.72 2.60 2.59 2.47 2.66 2.52 2.59 2.58 2.59 2.66 2.45 2.37 2.52 2.58 103 101 100 98 93 98 98 96 93 94 96 97 96 96 000229 228 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS FEMALES GROUP 2 (TELOMER ALCOHOL) CHE-INd - 8 30-MAR-99 ANIMAL NUMBER 113 114 115 116 117 118 119 120 121 122 123 125 126 127 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 utnol/1 CHOLEST.T. TRIGL. mmol/1 mmol/1 0.60 0.48 0.56 0.43 0.39 0.47 0.66 0.35 0.51 0.38 0.39 0.37 0.45 0.47 1.59 2.06 2.28 2.22 1.98 3.45 3.15 2.12 2.34 2.91 2.15 2.76 2.40 1.75 - 3 3 3 3 2 3 3 2 2 2 2 2 2 2 2.41 2.66 2.22 2.56 1.70 2.14 2.86 2.14 2.24 2.15 1.46 2.57 1.85 2.69 0.47 0.52 1.07 0.48 0.47 0.60 0.69 0.46 0.52 0.60 0.42 0.63 0.31 0.69 CREATININE GLUCOSE umol/1 nmol/l UREA mmol/1 33 5.30 7.4 34 5.86 7.1 36 5.63 6.9 44 6.82 10.1 35 6.08 7.2 42 6.00 11.7 40 5.66 9.1 36 5.90 8.6 41 7.40 9.5 39 5.79 7.4 36 5.70 6.3 37 5.76 8.5 39 5.38 8.6 44 5.29 8.7 ANIMAL NUMBER 113 114 115 116 117 118 119 120 121 122 123 125 126 127 PROTEIN T. ALBUMIN gA gA GLOBULIN A/G RATIO ALP g/i ukat/1 66.6 66.1 68.2 65.6 61.3 67.0 67.9 63.6 59.6 68.8 64.6 63.3 63.2 61.3 34.2 30.8 34.1 34.0 32.5 35.0 33.7 33.6 32.5 37.0 34.6 34.2 33.9 32.9 32.4 35.3 34.1 31.6 28.8 32.0 34.2 30.0 27.1 31.8 30.0 29.1 29.3 28.4 1.1 0.9 1.0 1.1 1.1 1.1 1.0 1.1 1.2 1.2 1.2 1.2 1.2 1.2 2.57 4.21 3.54 3.67 4.13 3.19 5.23 4.08 5.43 5.30 3.19 2.78 4.25 5.05 INORG PHOS SODIUM nmol/l nmol/l 2.57 2.69 2.43 2.63 2.28 2.70 2.69 2.71 2.60 2.39 2.48 2.57 2.41 2.20 141.5 142.5 143.3 143.1 143.0 142.2 140.9 142.5 143.2 143.5 142.0 142.4 142.7 143.7 POTASSIUM mmol/1 4.20 4.43 4.08 3.91 3.79 4.79 4.55 4.14 4.44 4.19 3.79 4.04 4.10 3.49 ANIMAL NUMBER CALCIUM mmol/I CHLORIDE ztmol/1 113 2.66 102 114 2.60 99 115 2.67 102 116 2.63 99 117 2.50 100 118 2.57 101 119 2.63 97 120 2.60 96 121 2.57 96 122 2.65 98 123 2.57 96 125 2.65 98 126 2.54 97 127 2.51 99 000230 229 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS FEMALES GROUP 3 (TELOMER ACRYLATE) CHE-IND - 9 3 0 - M A R - 99 ANIMAL NUMBER 129 130 131 132 133 134 135 136 137 138 139 141 142 143 ALAT(GFT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 CHOLEST.T. TRIGL. mnol/1 mnol/1 0.30 0.57 0.47 0.49 0.84 0.76 0.66 0.60 0.43 0.44 0.47 0.55 0.58 0.51 1.66 2.18 2.08 1.97 2.32 2.15 2.60 2.45 1.99 2.82 1.73 2.47 2.12 2.82 2 3 2 2 3 3 3 3 2 2 3 3 3 3 1.74 1.83 1.76 2.50 2.88 2.53 2.17 1.68 1.41 2.03 1.99 2.14 2.18 2.39 0.51 0.49 0.67 0.56 0.74 0.81 0.80 0.62 0.41 0.60 0.53 0.38 0.40 0.59 CREATININE GLUCOSE umol/1 mnol/1 UREA mnol/1 32 5.27 5.5 37 5.23 8.4 34 6.67 7.0 37 5.78 9.4 37 6.32 10.4 38 5.83 9.7 44 5.62 9.5 38 6.25 8.5 45 5.83 11.4 40 6.89 8.4 40 6.20 7.3 41 6.08 11.3 38 5.98 7.0 43 7.96 9.6 ANIMAL NUMBER 129 130 131 132 ' 133 134 135 136 137 138 139 141 142 143 PROTEIN T. ALBUMIN g/i g/i GLOBULIN A/G RATIO ALP g/i ukat/1 64.4 66.2 68.0 62.0 69.5 62.8 65.6 66.7 60.2 65.8 64.2 66.9 66.4 66.8 32.3 34.0 35.3 33.5 34.8 32.0 33.5 34.5 31.2 35.0 36.2 33.8 35.5 36.4 32.1 32.2 32.7 28.5 34.7 30.8 32.1 32.2 29.0 30.8 28.0 33.1 30.9 30.4 1.0 1.1 1.1 1.2 1.0 1.0 1.0 1.1 1.1 1.1 1.3 1.0 1.1 1.2 3.01 4.48 3.02 5.49 3.20 5.05 5.59 3.32 5.91 5.72 3.94 6.27 3.43 4.90 INORG PHOS SODIUM mnol/1 mnol/1 POTASSIUM mnol/1 2.43 2.58 2.40 2.73 2.41 2.72 2.69 2.38 2.29 2.45 2.14 2.64 2.55 2.10 143.8 143.2 143.1 142.7 142.8 140.9 140.9 143.4 142.6 144.3 143.0 142.0 143.1 140.8 3.81 4.28 3.64 3.97 3.89 4.31 4.41 4.04 4.44 3.63 4.01 4.59 4.02 4.56 ANIMAL NUMBER 129 130 131 132 133 134 135 136 137 138 139 141 142 143 CALCIUM mnol/1 CHLORIDE mnol/1 2.60 2.60 2.54 2.57 2.72 2.55 2.64 2.61 2.52 2.60 2.65 2.63 2.64 2.54 99 99 100 99 98 96 96 96 100 98 96 102 95 100 Q0 0 2 3 1 230 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS FEMALES GROUP 4 ( ) C H E - I N D - 10 3 0 - M A R -9 9 ANIMAL NUMBER 145 146 147 148 149 150 151 152 153 154 155 157 158 159 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 CHOLEST.T. TRIGL. rtmol/1 mtiol/l 0.41 0.26 0.49 0.57 0.44 0.61 0.56 0.55 0.49 0.47 0.54 0.49 0.68 0.74 2.21 2.15 2.27 1.80 1.74 2.67 2.34 2.21 2.67 2.18 2.64 2.99 1.97 2.31 - 2 3 3 2 3 5 4 4 2 2 2 3 3 3 1.73 2.25 2.61 2.38 2.20 2.70 2.80 2.08 ' 2.04 2.55 2.14 2.83 2.05 2.09 0.65 0.53 0.46 0.56 0.73 0.47 0.87 0.44 0.56 0.56 0.42 0.45 0.48 0.62 CREATININE GLUCOSE urool/1 mmol/l UREA nmol/1 37 5.98 6.7 42 6.02 8.2 41 5.37 8.5 34 5.79 7.1 36 6.92 9.8 42 5.40 10.6 43 6.00 9.9 45 5.98 10.6 43 5.78 8.9 37 6.69 5.5 43 6.21 10.9 44 5.68 9.2 40 5^39 8.4 46 6.74 11.3 ANIMAL NUMBER 145 146 147 148 149 150 151 152 153 154 155 157 158 159 PROTEIN T. ALBUMIN g/i s/i GLOBULIN A/G RATIO ALP g/1 ukat/1 67.8 67.5 64.8 61.7 67.7 67.2 65.3 70.3 70.7 60.9 65.0 67.6 67.0 63.3 35.0 33.0 30.1 32.0 34.5 34.1 34.7 37.6 38.3 32.9 32.4 32.7 33.6 32.8 32.8 34.5 34.7 29.7 33.2 33.1 30.6 32.7 32.4 28.0 32.6 34.9 33.4 30.5 1.1 1.0 0.9 1.1 1.0 1.0 1.1 1.1 1.2 1.2 1.0 0.9 1.0 1.1 3.53 5.95 4.82 4.31 3.45 3.68 3.07 3.66 3.72 5.74 4.54 4.17 5.22 4.36 HJOBG FHOS SODIUM nmol/1 mmol/l 2.18 2.34 2.30 2.46 2.60 2.61 2.90 2.29 2.25 2.33 2.47 2.28 2.50 2.30 143.7 143.0 141.9 140.4 142.7 142.0 141.6 143.4 141.9 141.9 143.2 140.6 141.5 140.8 POTASSIUM nmol/1 3.82 4.06 4.45 3.91 4.47 4.31 4.28 3.82 4.30 4.24 4.46 4.37 3.93 4.30 ANIMAL NUMBER 145 146 147 148 149 150 151 152 153 154 155 157 158 159 CALCIUM nmol/1 CHLORIDE nmol/1 2.57 2.63 2.52 2.58 2.64 2.63 2.66 2.64 2.60 2.57 2.55 2.58 2.68 2.50 100 103 99 98 95 98 98 97 101 99 102 100 100 99 000232 231 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS FEMALES GROUP 5 (PFHS) C H E - I N D - 11 3 0 - M A R - 99 ANIMAL NUMBER 161 162 163 164 165 166 167 168 169 170 171 173 174 175 ALAT(GPT) ASAT(GOT) .BILX T. ukat/1 ukat/1 uxnol/1 CHOLEST.T. TRIGL. mnol/1 mnol/1 0.52 0.50 0.78 0.53 0.57 0.49 0.57 0.62 0.65 0.59 0.60 0.40 0.62 0.53 1.77 3.54 2.18 1.61 2.01 3.77 2.27 2.86 2.49 1.75 1.61 2.79 2.88 2.73 3 3 2 3 3 2 3 2 2 2 2 2 2 3 1.93 2.16 1.64 1.80 2.23 1.76 1.46 1.94 1.59 2.06 2.16 1.32 1.66 1.68 1.00 0.52 0.48 0.32 0.55 0.45 0.49 0.55 0.59 0.44 0.44 0.38 0.33 0.53 CREATININE GLUCOSE umol/1 mnol/1 UREA itmol/1 38 6.34 7.7 40 . 5.01 7.2 38 4.93 9.6 35 6.21 7.9 35 5.64 7.8 37 5.33 7.6 39 6.02 9.6 45 5.96 9.1 44 5.77 8.5 40 5.92 8.2 42 7.44 7.8 44 6.18 8.6 44 6.23 9.2 42 7.30 9.9 ANIMAL NUMBER 161 162 163 164 165 166 167 168 169 170 171 173 174 175 PROTEIN T. ALBUMIN g/1 g/i GLOBULIN A/G RATIO ALP g/i ukat/1 74.6 66.1 71.1 66.5 63.9 60.5 63.1 66.2 63.2 62.4 70.0 64.5 60.1 63.5 35.6 32.4 35.0 34.7 33.3 31.3 33.8 33.9 32.2 33.2 35.8 33.8 31.3 35.4 39.0 33.7 36.1 31.8 30.6 29.2 29.3 32.3 31.0 29.2 34.2 30.7 28.8 28.1 0.9 1.0 1.0 1.1 1.1 1.1 1.2 1.0 1.0 1.1 1.0 1.1 1.1 1.3 3.89 6.82 4.63 3.95 3.02 4.31 3.49 4.11 5.07 3.03 3.41 2.49 5.06 3.54 INORG PHOS SODIUM mnol/1 mnol/1 2.16 2.28 2.42 2.32 2.81 2.79 2.64 2.56 2.39 2.21 2.35 2.47 2.36 2.22 141.3 141.8 141.5 142.2 141.9 143.1 141.9 142.3 140.8 142.7 142.8 141.0 141.1 141.0 POTASSIUM mmol/1 3.90 3.86 3.90 4.06 4.19 4.49 3.89 4.34 4.14 3.70 3,91 4.53 4.47 3.79 ANIMAL NUMBER 161 162 163 164 165 166 167 168 169 170 171 173 174 175 CALCIUM mnol/1 CHLORIDE mnol/1 2.70 2.57 2.62 2.53 2.61 2.54 2.53 2.55 2.55 2.52 2.64 2.52 2.50 2.51 104 101 98 102 99 99 103 101 104 105 98 104 102 103 000233 232 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS FEMALES GROUP 6 (PFOS) C H E - I N D - 12 30-MAR-99 ANIMAL NUMBER 177 178 179 180 181 182 183 184 185 186 187 189 190 191 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 vrnol/1 CHOLEST.T. TRIGL. ItWOlA nmol A 0.56 0.42 0.72 0.42 0.38 0.63 0.78 0.48 0.51 0.67 0.45 0.57 0.61 1.67 2.04 2.09 2.36 2.48 2.45 1.85 2.32 1.52 2.59 2.95 2.59 2.39 2.77 2.01 . 2 2 3 4 3 3 4 3 3 3 2 2 2 3 2.56 1.46 2.29 2.14 1.71 2.48 2.19 1.97 1.96 2.00 1.46 . 2.47 2.06 1.83 0.60 0.30 0.38 0.52 0.58 0.82 0.63 0.63 0.58 0.38 0.33 0.65 0.77 0.39 CREATININE GLUCOSE vnol/1 mnol/l UREA nmolA 41 5.31 11.3 35 5.90 8.6 38 4.83 7.9 47 5.02 . 12.6 36 5.85 9.1 41 6.81 11.1 43 4.80 9.8 49 5.38 11.6 44 5.12 9.3 39 5.93 9.8 41 6.39 8.2 42 7.96 10.3 37 7.71 8.2 45 6.64 14.4 ANIMAL NUMBER 177 178 179 180 181 182 183 184 185 186 187 189 190 191 PROTEIN T. ALBUMIN g/1 g/1 65.0 66.6 71.5 65.3 67.5 67.5 70.6 68.8 68.8 63.9 63.1 61.2 64.5 70.3 35.1 35.7 33.3 32.6 35.9 34.7 37.6 35.8 35.3 34.0 33.8 32.2 35.0 38.1 GLOBULIN A/G RATIO ALP g/i ukat/1 29.9 30.9 38.2 32.7 31.6 32.8 33.0 33.0 33.5 29.9 29.3 29.0 29.5 32.2 1.2 1.2 0.9 1.0 1.1 1.1 1.1 1.1 1.1 1.1 1.2 1.1 1.2 1.2 2.84 3.47 3.85 3.07 3.12 4.80 5.14 4.60 4.12 3.71 7.14 4.32 5.50 4.50 INORG EHOS SODIUM mmol/1 nmol/1 2.55 2.15 2.47 2.69 2.92 2.62 2.64 3.01 2.77 2.74 2.37 2.57 2.36 2.37 143.7 143.4 143.3 142.2 142.9 142.2 142.0 143.4 141.8 144.3 141.9 142.5 141.7 140.0 POTASSIUM nnvol/1 4.03 3.80 3.77 4.14 4.09 4.03 3.82 3.77 4.87 4.05 3.84 4.41 4.27 3.95 ANIMAL NUMBER CALCIUM nmol/1 CHLORIDE mcnol/1 177 2.58 178 2.54 179 2.59 180 2.56 181 2.59 182 2.73 183 2.72 184 2.62 185 . 2.63 186 2.49 187 2.57 189 2.59 190 2.53 191 2.63 101 102 99 99 102 103 99 104 99 103 104 102 102 99 2 3 3 000234 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 2 WEEKS RECOVERY MALES GROUP 1 (VEHICLE CONTROL) C H E - I N D - 13 30-MAR-99 ANIMAL NUMBER 9 10 11 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 0.82 1.07 0.70 2.50 2.46 3.43 3 3 3 CHDLEST.T. TRIGL. mnol/1 mnol/1 2.35 2.11 1.39 0.49 0.46 0.63 CREATININE GLUCOSE umol/1 mnol/1 UREA nrool/1 43 5.79 7.2 35 5.21 7.9 28 5.95 5.3 ANIMAL NUMBER 9 10 11 PROTEIN T. ALBUMIN s/i g/i 57.6 54.9 55.1 28.4 28.4 30.1 GLOBULIN A/G RATIO ALP 3/1 ukat/1 29.2 26.5 25.0 1.0 1.1 1.2 4.77 8.85 6.16 INORG FHOS SODIUM mnol/1 mnol/1 POTASSIUM mnol/1 2.87 2.76 2.80 144.9 144.9 143.0 4.53 4.01 4.85 ANIMAL NUMBER 9 10 11 CALCIUM nmol/1 CHLORIDE mnol/1 2.52 2.44 2.48 103 102 103 000235 234 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 2 WEEKS RECOVERY MALES GROUP 2 (TELOMER ALCOHOL) CHE-IND - 14 30-MAR-9 9 ANIMAL NUMBER 25 26 27 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 . ukat/1 vapol/1 0.71 0.58 0.56 2.42 3.16 2.52 3 3 2 CHDLEST.T. TRIGL. irmol/1 Itmol/l 2.42 1.07 1.53 0.67 0.39 0.77 CREATININE GLUCOSE umol/1 nrool/1 UREA nrool/1 36 7.39 6.8 33 4.33 7.4 32 6.96 7.7 ANIMAL NUMBER 25 26 27 PROTEIN T. ALBUMIN g/i g/i GLOBULIN A/G RATIO ALP g/i ukat/1 52.0 50.3 52.2 28.6 27.7 28.0 23.4 22.6 24.2 1.2 1.2 1.2 7.04 7.89 5.86 INQRG PHDS SODIUM mnol/1 itmol/l 2.94 2.76 2.63 142.1 145.9 142.3 POTASSIUM nrool/1 4.59 4.26 4.69 ANIMAL NUMBER 25 26 27 CALCIUM nrool/1 CHLORIDE nrool/1 2.50 2.39 2.44 100 105 102 000236 235 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 2 WEEKS RECOVERY MALES GROUP 3 (TELOMER ACRYLATE) CHE-IND - 15 30-MAR-9 9 ANIMAL NUMBER 41 42 43 ALAT(GPT) ASAT (GOT) BILI T. ukat/1 ukat/1 umol/1 CHQLEST.T. TRIGL. mmol/1 mmol/1 0.61 0.55 0.78 2.89 2.95 2.89 3 3 2 1.61 1.57 1.54 1.23 0.89 0.54 CREATININE GLUCOSE umol/1 mnol/1 UREA mnol/1 31 7.79 6.2 34 6.81 7.5 33 5.94 7.1 ANIMAL NUMBER 41 42 43 PROTEjN T. ALBUMIN g/i g/1 57.5 56.8 58.6 29.7 29.2 29.6 GLOBULIN A/G RATIO ALP g/i ukat/1 27.8 27.6 29.0 1.1 1.1 1.0 7.13 4.72 5.60 INCRG PHOS SODIUM mmol/1 mnol/1 POTASSIUM mnol/1 2.98 2.73 2.52 142.6 142.2 141.1 4.97 5.07 4.82 ANIMAL NUMBER 41 42 43 CALCIUM mnol/1 CHLORIDE mmol/1 2.51 2.46 2.47 99 102 99 000237 236 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 2 WEEKS RECOVERY MALES CROUP 4 ( ) C H E - I N D - 16 3 0-MAR-99 ANIMAL NUMBER 57 53 59 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 uraol/1 0.87 0.66 1.01 2.49 3.54 2.56 3 3 2 CHOLEST.T. t r i g l . mmol/1 mmol/1 2.30 2.03 1.45 0.S2 0.62 0.67 CREATININE GLUCOSE umol/1 mmol/1 UREA ninol/1 40 8.32 6.7 37 8.45 7.4 40 8.23 6.4 ANIMAL NUMBER 57 58 59 PROTEIN T. ALBUMIN g/i g/x GLOBULIN A/G RATIO ALP g/1 ukat/1 52.3 57.3 51.3 27.9 29.1 26.5 24.4 28.2 24.8 1.1 1.0. . 1.1 6.34 6.70 4.78 INORG PHOS SODIUM mrool/1 nrool/1 POTASSIUM mmol/1 2.73 2.68 2.52 140.3 141.2 141.7 4.35 4.64 4.25 ANIMAL NUMBER 57 58 59 CALCIUM nxnol/1 CHLORIDE uciol/1 2.57 2.56 2.37 99 101 101 237 000238 NOTOX Project 242933 CLINICAL BIOCHEMXSTR.Y AFTER 2 WEEKS RECOVERY HALES GROUP 5 (PFHS) CHE-IND - 17 30-MAR-99 ANIMAL NUMBER 73 74 75 ALAT(GFT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 CHOLEST.T. TRIGL. inmol/I mmol/1 0.71 0.96 0.75 2.82 2.49 1.99 2 2 2 1.29 1.63 1.21 0.58 0.62 0.75 CREATININE GLUCOSE umol/1 nmol/1 OREA mmol/1 39 7.25 6.6 42 6.96 7.6 35 7.21 6.0 ANIMAL NUMBER 73 74 75 PROTEIN T. ALBUMIN g/i g/i 53.9 55.1 55.1 28.4 28.2 30.0 GLOBULIN A/G RATIO ALP s/i ukat/1 25.5 26.9 25.1 1.1 1.0 1.2 5.85 6.89 7.43 DJORG PHOS SQDIUM mmol/1 rmnol/1 2.67 2.43 2.42 142.1 143.4 141.7 POTASSIUM mmol/1 4.71 4.57 4.41 ANIMAL NUMBER 73 74 75 CALCIUM mmol/1 CHLQRIDE itmol/1 2.44 2.49 2.42 101 104 100 2 3 8 000239 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 2 WEEKS RECOVERY MALES GROUP 6 (PFOS) C HE-IND - 18 3 0 - M A R - 99 ANIMAL NUMBER 89 90 91 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 CHOLEST.T. TRIGL. mnol/1 nmol/1 0.83 0.61 0.49 2.48 1.63 1.66 2 3 3 1.22 1.48 1.12 0.51 0.40 0.60 CREATININE GLUCOSE umol/1 nmol/1 UREA nmol/1 34 7.21 7.3 34 6.29 6.7 49 5.17 8.1 ANIMAL NUMBER 89 90 91 PROTEIN T. ALBUMIN S / l g/i 56.3 55.9 57.3 30.0 29.0 30.1 GLOBULIN A/G RATIO ALP S / l ukat/1 26.3 26.9 27.2 1.1 1.1 1.1 6.36 4.22 6.26 INORG PHOS SODIUM mnol/1 mnol/1 POTASSIUM nmol/1 2.52 2.67 2.75 142.8 142.7 142.8 . 4.52 4.82 4.35 ANIMAL NUMBER 89 90 91 CALCIUM nmol/1 CHLORIDE nmol/1 2.53 2.65 2.53 101 102 0.05 000240 239 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 2 WEEKS RECOVERY FEMALES GROUP 1 (VEHICLE CONTROL) CHE-IND - 19 3 0 - M A R - 99 ANIMAL NUMBER 105 106 107 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 CHQLEST.T. TRIGL. mmol/1 nrool/1 0.52 0.43 0.46 2.50 1.96 3.12 3 3 2 1.95 2.59 1.93 0.56 0.97 0.55 CREATININE GLUCOSE umol/1 umol/1 UREA nrool/1 37 6.72 6.7 38 9.25 6.2 41 6.06 7.6 ANIMAL NUMBER 105 106 107 PROTEIN T. ALBUMIN g/i s/i GLOBULIN A/G RATIO 'ALP g/i ukat/1 65.2 65.3 60.4 32.4 34.7 29.4 32.8 30.6 31.0 1.0 1.1 0.9 3.43 3.21 3.26 INORG PHOS SODIUM umol/1 nmol/1 POTASSIUM umol/1 2.45 2.39 2.56 143.3 142.5 141.4 . 3.98 4.14 4.12 ANIMAL NUMBER 105 106 107 CALCIUM mmol/1 CHLORIDE nmol/1 2.60 2.79 2.51 98 99 99 000241 240 NOTOX Project 242933 CLINICAL BIOCHEMISTRY . AFTER 2 WEEKS RECOVERY FEMALES GROUP 2 (TELOMER ALCOHOL) CHE-IND - 20 3O-MAR-9 9 ANIMAL NUMBER 121 122 123 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 CHDLEST.T. TRIGL. mmol/1 nmol/1 0.52 1.02 0.3S 2.44 3.36 2.02 2 3 2 2.14 2.20 1.42 0.43 0.40 0.46 CREATININE GLUCOSE umol/1 nmol/1 UREA mmol/1 40 7.26 6.3 41 6.31 8.9 38 5.98 6.7 ANIMAL NUMBER 121 122 123 PROTEIN T. ALBUMIN g/i g/i 58.1 61.3 65.6 29.6 34.9 33.6 GLOBULIN A/G RATIO ALP g/i ukat/1 28.5 26.4 32.0 1.0 1.3 1.1 4.38 4.07 2.34 INORG PHDS SODIUM nmol/1 mnol/1 2.64 2.89 2.18 142.4' 144.2 141.7 POTASSIUM nmol/1 3.95 4.16 3.77 ANIMAL NUMBER 121 122 123 CALCIUM nmol/1 CHLORIDE nmol/1 2.54 2.65 2.59 98 100 99 241 000242 NOTOX Project 242933 CLINICAL BIOCHEMISTRY . AFTER 2 WEEKS RECOVERY FEMALES GROUP 3 (TELOMER ACRYLATE) C H E - X N D - 21 3 0 - M A R - 99 ANIMAL NUMBER 137 138 139 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 0.58 0.51 0.37 2.27 2.35 1.69 2 2 2 CHDLEST.T. TRIGL. umol/1 umol/1 1.27 1.97 1.97 0.39 0.87 0.57 CREATININE GLUCOSE umol/1 mmol/1 UREA ramol/1 37 6.71 7.1 40 7.44 9.3 47 7.77 8.1 ANIMAL NUMBER 137 138 139 PROTEIN T. ALBUMIN s/i S/l 60.7 62.9 59.7 29.5 32.5 32.9 GLOBULIN A/G RATIO ALP g/l ukat/1 31.2 30.4 26.8 0.9 1.1 1.2 5.56 4.02 3.49 INORG PHDS SODIUM umol/1 mnol/1 2.27 2.38 2.30 143.1 141.4 141.5 POTASSIUM nmol/1 3.76 4.54 3.86 ANIMAL NUMBER 137 138 139 CALCIUM umol/1 CHLORIDE umol/1 2.46 2,61 2.63 98 103 96 000243 242 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 2 WEEKS RECOVERY FEMALES GROUP 4 ( ) C H E - I N D - 22 3 0 - M A R - 99 ANIMAL NUMBER 153 154 155 ALAT(GPT) ASAT(GOT) BILI T . ' CHQLEST.T. TRIGL. ukat/1 ukat/1 umol/1 mnol/1 mnol/1 0.48 0.63 0.60 2.35 2.32 2.93 3 2 3 2.17 2.72 2.34 1.03 0.53 0.63 CHEATININE GLUCOSE UREA. umol/1 mmol/1 nmol/1 43 7.47 39 8.41 53 6.34 ANIMAL NUMBER 153 154 155 PROTEIN T. ALBUMIN g/i g/i GLOBULIN A/G RATIO ALP g/i ukat/1 67.8 61.8 66.1 35.7 32.4 33.4 32.1 29.4 32.7 1.1 1.1 1.0 3.09 4.81 3.65 INQRG PHDS SODIUM nnmol/1 mnol/1 POTASSIUM mnol/1 2.70 2.23 2.71 142.7 139.7 141.4 > 3.90 4.61 4.50 ANIMAL NUMBER 153 154 155 CALCIUM nmol/1 CHLORIDE nmol/1 2.69 2.64 2.70 100 98 97 2 43 000244 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 2 WEEKS RECOVERY FEMALES GROUP 5 (PFHS) C H E - I N D - 23 30-MAR-99 ANIMAL NUMBER 169 170 171 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 CHOLEST.T. raca. mmol/1 ntmol/l 0.48 0.43 0.65 1.83 1.56 1.58 3 3 3 1.66 2.42 2.24 0.50 0.35 0.34 CREATININE GLUCOSE umol/1 nmol/1 UREA nmol/1 46 7.25 7.7 39 6.01 7.2 47 9.38 7.9 ANIMAL NUMBER 169 170 171 PROTEIN T. ALBUMIN 9/1 3/1 65.5 62.8 71.0 30.7 30.9 32.5 GLOBULIN A/G RATIO ALP g/1 ukat/1 34.8 31.9 38.5 0.9 1.0 0.8 4.62 2.30 2.90 INORG PHDS SODIUM nmol/1 nmol/1 2.37 2.19 2.70 141.1 141.1 142.5 POTASSIUM nmol/1 3.98 3.65 4.08 ANIMAL NUMBER 169 170 171 CALCIUM nmol/1 CHLORIDE nmol/1 2.58 2.62 2.84 100 99 95 2 4 4 000245 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 2 WEEKS RECOVERY FEMALES GROUP 6 (PFOS) CHE-IND - 24 3 0 - M A R - 99 ANIMAL NUMBER 185 186 187 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 0.37 0.51 0.48 2.22 2.15 1.89 2 3 2 CHOLEST.T. TRIGL. intiol/1 nnvol/1 2.04 2.37 1.64 0.40 0.25 0.29 CREATININE GLUCOSE umol/1 amol/1 UREA itmol/l .43 8.03 8.2 41 7.67 9.0 42 7.37 6.7 ANIMAL NUMBER 185 186 187 PROTEIN T. ALBUMIN 8/1 g/i 66.6 57.4 57.9 33.9 31.6 32.0 GLOBULIN A/G RATIO ALP g/i ukat/1 32.7 25.8 25.9 1.0 1.2 1.2 3.66 3.25 6.04 INORG PHDS SODIUM nrnol/1 nrnol/1 2.40 2.21 2.27 141.9 143.4 142.2 POTASSIUM umol/1 3.97 4.27 4.08 ANIMAL NUMBER 185 186 187 CALCIUM nrnol/1 CHLORIDE nmol/1 2.65 2.56 2.69 99 103 99 2 4 5 000246 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS RECOVERY MALES GROUP 1 (VEHICLE CONTROL) C H E - I N D - 25 3 0 - M A R - 99 ANIMAL NUMBER 13 14 15 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 0.78 0.54 0.44 2.88 2.39 2.69 4 3 3 CHOLEST.T. TRIGL. mmol/1 nmol/l 2.07 2.01 1.73 1.17 0.39 0.71 CREATININE GLUCOSE umol/1 nmol/1 UREA mmol/1 37 8.42 6.1 35 7.63 6.1 37 7.97 6.7 ANIMAL NUMBER 13 14 15 PROTEIN T. ALBUMIN g/i 3/1 GLOBULIN A/G RATIO ALP ff/1 ukat/1 62.1 62.2 62.2 29.3 28.2 28.4 32.8 34.0 33.8 0.9 0.8 0.8 4.61 4.79 3.58 INORG PROS SODIUM nmol/1 mmol/l 2.91 3.17 2.99 140.8 142.5 141.6 POTASSIUM nmol/1 5.15 5.56 5.28 ANIMAL NUMBER 13 14 15 CALCIUM nmol/1 CHLORIDE nmol/1 2.56 2.60 . 2.58 104 101 102 000247 246 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS RECOVERY MALES GROUP 2 (TELOMER ALCOHOL) C H E - I N D - 26 3 0 - M A R - 99 ANIMAL NUMBER 29 30 31 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 unol/1 0.70 0.61 0.74 2.66 2.49 2.17 2 2 3 CHDLEST.T. TRIGL. mmol/1 mnol/1 1.39 1.22 1.14 0.57 0.55 0.61 CREATININE GLUCOSE umol/1 ranol/1 UREA mnol/1 29 5.87 6.5 33 8.32 6.3 36 8.16 6.2 ANIMAL NUMBER 29 30 31 PROTEIN T. ALBUMIN g/i S/l GLOBULIN A/G RATIO ALP g/i ukat/1 57.8 54.2 55.6 26.7 27.5 27.7 31.1 26.7 27.9 0.9 1.0 1.0 6.15 8.13 4.31 INORO PHOS SODIUM mmol/1 mnol/1 2.44 2.51 2.96 143.4 141.4 143.9 POTASSIUM mmol/1 4.53 4.50 4.75 ANIMAL NUMBER 29 30 31 CALCIUM mnol/1 CHLORIDE mnol/1 2.44 2.46 2.55 106 103 101 2 4 7 000248 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS RECOVERY MALES GROUP 3 (TELQMER ACRYLATE) C H E - X N D - 27 3 0 - M A R - 99 ANIMAL NUMBER 45 46 47 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 CHOLEST.T. TKIGL. mmol/1 nrtol/1 0.62 0.57 0.60 2.00 2.33 1.86 3 2 3 1.93 1.16 1.51 0.42 0.53 0.64 CREATININE GLUCOSE umol/1 . nrool/1 UREA nmol/1 32 7.91 7.4 39 7.38 6.7 31 5.88 5.6 ANIMAL NUMBER 45 46 47 PROTEIN T. ALBUMIN g/i g/x 58.4 51.6 56.2 27.7 25.4 27.9 GLOBULIN A/G RATIO ALP ' g/i ukat/1 30.7 26.2 28.3 0.9 1.0 1.0 3.83 6.75 5.27 INORG PHDS SODIUM umol/1 mmol/1 POTASSIUM itmol/l 2.67 2.86 2.38 141.4 143.8 142.3 ' 4.86 4.81 4.26 ANIMAL NUMBER 45 46 47 CALCIUM mmol/1 2.53 2.47 2.44 CHLORIDE itmol/1 102 105 104 24 8 000249 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS RECOVERY MALES GROUP 4 ( ) CHE-IND - 28 3 0 - M A R - 99 ANIMAL NUMBER si 62 63 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 untol/1 0.67 0.38 0.69 2.96 2.16 2.05 3 2 3 CHOLEST.T. TRIGL. mnol/l mmol/1 1.37 2.05 1.56 0.55 0.59 0.55 CREATININE GLUCOSE umol/1 mmol/1 UREA mnol/l 39 5.58 6.9 37 6.68 8.2 39 6.11 7.3 ANIMAL NUMBER 61 62 63 PROTEIN T. ALBUMIN g/i g/i GLOBULIN A/G RATIO ALP g/1 ukat/1 59.5 54.9 56.6 29.0 27.7 26.5 30.5 27.2 30.1 1.0 1.0 0.9 4.68 4.66 6.94 INORG PHDS SODIUM POTASSIUM mnol/l mmol/1 . mnol/l 2.46 2.64 2.28 141.5 141.8 142.7 4.61 4.62 4.41 ANIMAL NUMBE>R 61 62 63 CALCIUM nrool/1 CHLORIDE mnol/l 2.49 2.45 2.44 103 104 105 000250 NOTOX Project 242933 CLINICAL BIOCHEMISTRY . AFTER 4 WEEKS RECOVERY HALES GROUP 5 (PFHS) CHE-IND - 29 30 - M A R -99 ANIMAL NUMBER 77 78 79 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 uinol/1 0.60 0.94 0.71 2.61 2.21 2.38 3 2 2 CHOLEST.T. TRIGL. mnol/1 ranol/1 1.22 1.34 1.16 0.57 0.26 0.24 CREATININE GLUCOSE umol/X mnol/1 UREA mnol/1 47 5.95 8.1 47 4.77 10.4 36 6.00 6.5 ANIMAL NUMBER 77 78 79 PROTEIN T. ALBUMIN g/1 g/1 GLOBULIN A/G RATIO ALP g/1 ukat/1 57.9 58.1 56.0 27.0 28.0 27.0 30.9 30.1 29.0 0.9 0.9 0.9 5.79 4.17 8.04 INORG PHDS SODIUM ranol/1 mnol/1 2.55 2.55 2.86 143.5 142.9 144.9 POTASSIUM mnol/1 4.40 4.26 5.04 ANIMAL NUMBER 77 78 79 CALCIUM mnol/1 CHLORIDE mnol/1 2.43 2.49 2.51 104 103 103 2 5 0 000251 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS RECOVERY MALES GROUP 6 (PFOS) C H E - I N D - 30 3 0 - M A R - 99 ANIMAL NUMBER 93 94 95 ALAT(GPT) ASAT(GOT) BiLi t . ukat/1 ukat/1 umol/1 CHDLEST.T. TRIGL. mmol/1 nmol/1 CREATININE GLUCOSE unvol/1 nmol/1 UREA mmol/l 0.56 0.77 0.58 1.99 1.73 1.89 2 2 2 0.92 1.47 1.62 0.35 0.58 . 0.43 29 31 36 6.01 7.23 6.85 5.8 5.6 6.5' ANIMAL NUMBER 93 94 95 PROTEIN T. ALBUMIN g/1 g/1 51.7 55.0 56.7 27.0 27.3 28.3 GLOBULIN A/G RATIO ALP g/1 ukat/1 24.7 27.7 28.4 1.1 1.0 1.0 4.89 4.78 4.52 DJORG PHDS SODIUM ltmol/1 nmol/1 2.58 2.40 2.79 142.8 142.7 142.5 POTASSIUM nmol/1 4.60 4.78 4.58 ANIMAL NUMBER CALCIUM nmol/1 CHLORIDE nmol/1 . 93 . 2.43 94 2.52 95 2.49 105 107 109 251 000252 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS RECOVERY FEMALES GROUP 1 (VEHICLE CONTROL) C H E - I N D - 31 3 0 - M A R - 99 ANIMAL NUMBER 109 110 111 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 CHOLEST.T. TRIGL. mraol/l mmol/1 0.41 0.45 0.28 2.28 2.54 1.92 3 2 2 2.25 2.31 2.94 0.60 0.78 0.52 CREATININE GLUCOSE UREA umol/1 . imiol/1 mmol/1 45 6.19 7.7 40 8.58 5.9 39 6.70 9.0 ANIMAL NUMBER 109 110 111 PROTEIN T. ALBUMIN g/1 g/1 61.4 69.4 63.8 30.1 33.2 30.5 GLOBULIN A/G RATIO ALP g/1 ukat/1 31.3 36.2 33.3 1.0 0.9 0.9 3.41 2.49 2.96 INORG PHDS SODIUM mmol/1 . nmol/1 2.46 2.14 2.39 144.0 142.5 140.5 POTASSIUM romol/l 3.84 4.01 4.50 ANIMAL CALCIUM NUMBER nmol/1 CHLORIDE mmol/1 109 2.47 103 110 2.55 101 111 2.55 96 000253 252 NOTOX Project 242933 CLINICAL BIOCHEMISTRY . AFTER 4 WEEKS RECOVERY FEMALES GROUP 2 (TELOMER ALCOHOL) CHE-IND - 32 30-MAR-99 ANIMAL NUMBER 125 126 127 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 0.39 0.34 -- 2.66 2.26 2.01 2 2 3 CHOLEST.T. TRIGL. rtmol/1 ranol/1 2.68 2.01 2.55 1.00 0.47 0.76 CREATININE GLUCOSE umol/1 mmol/1 UREA mmol/1 39 6.83 6.7 40 6.54 6.8 48 5.91 9.0 ANIMAL NUMBER 125 126 127 PROTEIN T. ALBUMIN g/i 9/1 67.0 62.2 63.6 32.2 30.3 32.4 GLOBULIN A/G RATIO ALP g/i ukat/1 34.8 31.9 31.2 0.9 0.9 1.0 1.73 3.18 4.19 INORG PHDS SODIUM itmol/1 ntnol/1 2.26 2.35 2.11 141.4 142.2 141.3 POTASSIUM mmol/1 4.25 4.36 3.82 ANIMAL NUMBER 125 126 127 CALCIUM rmnol/1 CHLORIDE mmol/1 2.64 2.49 2.46 104 98 102 2 5 3 000254 NOTOX Project 242933 CLINICAL BIOCHEMISTRY . AFTER 4 WEEKS RECOVERY FEMALES GROUP 3 (TELOMER ACRYLATE) C H E - I N D - 33 30-MAS-9 9 ANIMAL NUMBER X4X X42 X43 ALAT{GFT) ASAT(GOT) BILX T. ukat/1 ukat/1 , umol/1 0.43 0.36 0.59 X.74 X.54 2.40 2 3 3 CHOLEST.T . TRIGL. nnl/l mraol/1 2.X8 2.39 2.32 0.43 0.50 0.49 CREATININE GLUCOSE wnol/1 iraioX/X UREA mnol/1 40 6.64 8.3 41 6.73 6.9 45 7.32 8.8 ANIMAL NUMBER X4X X42 X43 PROTEIN T. ALBUMIN g/X g/X GLOBULIN A/G RATIO ALP g/X ukat/1 65.5 67.8 69.9 29.5 34.7 35.9 36.0 33.X 34.0 0.8 X.O 1.1 3.86 2.08 3.40 INORG PHOS SODIUM mraoX/X nrooX/X 2.19 1.95 1.79 138.7 141.6 141.7 POTASSIUM irmol/1 5.43 3.66 4.34 ANIMAL NUMBER 141 142 143 CALCIUM mrol/1 CHLORIDE irtnol/1 2.47 2.60 2.59 96 103 102 000255 254 NOTOX Project 242933 CLINICAL BIOCHEMISTRY . AFTER 4 WEEKS RECOVERY K h !MAT tRfl GROUP 4 ( ) CHE-IMD - 34 3 0 - M A R - 99 ANIMAL NUMBER 157 158 159 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 0.43 0.98 0.47 2.75 2.30 2.31 2 2 2 CHOLEST.T. TRIGL. irmol/1 ntnol/1 2.99 2.52 2.02 0.41 0.40 0.72 CREATININE GLUCOSE umol/1 iml/l UREA umol/1 43 5.89 8.2 40 8.08 6.9 48 5.05 9.9 ANIMAL NUMBER 157 158 159 PROTEIN T. ALBUMIN g/i g/i GLOBULIN A/G RATIO ALP g/l ukat/1 64.8 68.9 62.2 30.3 32.0 29.4 34.5 36.9 32.8 0.9 0.9 0.9 2.48 3.91 2.40 INORG PHDS SODIUM irenol/1 mnol/1 2.20 1.93 2.52 141.0 142.1 140.9 POTASSIUM nmol/l 4.51 3.67 4.59 ANIMAL NUMBER 157 158 159 CALCIUM mnol/1 CHLORIDE inmol/1 2..60 2..57 2..53 100 96 101 255 000256 NOTOX Project 242933 CLINICAL BIOCHEMISTRY . AFTER 4 WEEKS RECOVERY FEMALES GROUP 5 (PFHS) CHE-IND - 35 3O-MAR-99 ANIMAL NUMBER 173 174 175 ALAT(GPT) ASAT(GOT) BILI T. ukat/1 ukat/1 umol/1 0.33 0.64 0.45 2.27 3.09 2.21 2 2 2 CHOLEST.T. TRIGL. ianol/1 nmol/1 ' CREATININE GLUCOSE umol/1 nrool/1 1.68 2.12 2.37 0.40 0.34 0.46 38 39 39 6.77 6.50 7.31 UREA. nmol/1 6.8 6.9 7.3 ANIMAL NUMBER 173 174 175 PROTEIN T. ALBUMIN g/1 g/i 68.5 69.4 70.2 34.9 33.5 34.2 GLOBULIN A/G RATIO ALP g/i ukat/1 33.6 35.9 36.0 1.0 0.9 1.0 1.78 3.46 2.85 INORG PROS SODIUM mnol/1 nmol/1 2.15 2.08 2.24 139.9 140.5 142.6 POTASSIUM nmol/1 4.17 4.25 3.65 ANIMAL NUMBER 173 174 175 CALCIUM nmol/1 CHLORIDE nmol/1 2.59 2.59 2.61 104 99 102 25 6 000257 NOTOX Project 242933 CLINICAL BIOCHEMISTRY AFTER 4 WEEKS RECOVERY FEMALES GROUP 6 (PFOS) CHE-IND - 3 6 30-MAR-9 9 ANIMAL NUMBER 189 190 191 ALAT(GPT) ABAT (GOT) BILI T. ukat/1 ukat/1 unaol/1 0.52 0.49 0.50 1.96 1.94 1.86 2 2 3 CHOLEST.T. TRIGL. ntnol/1 ntnol/1 2.38 1.99 2.01 0.39 0.74 0.37 CREATININE GLUCOSE vunol/1 nmol/1 UREA nmol/1 39 6.77 9.4 38 8.87 7.9 39 7.31 14.9 ANIMAL NUMBER 189 190 191 PROTEIN T. ALBUMIN g/i g/i 59.5 66.2 70.1 30.6 33.2 34.6 GLOBULIN A/G RATIO ALP g/i ukat/1 28.9 33.0 35.5 1.1 1.0 1.0 3.56 3.19 3.40 USORG PHDS SODIUM ntnol/1 ntnol/1 2.56 2.18 2.07 142.7 141.0 139.5 POTASSIUM ntnol/1 4.13 4.36 4.00 ANIMAL NUMBER 189 190 191 CALCIUM ntnol/1 CHLORIDE mmol/1 2.63 2.61 2.67 100 108 100 000258 2 57 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS MACROSCOPIC FINDINGS M ALES GROUP 1 (VEHICLE CONTROL) ANIMAL 1 NO FINDINGS NOTED ANIMAL 2 NO FINDINGS NOTED ANIMAL 3 NO FINDINGS NOTED ANIMAL 4 NO FINDINGS NOTEO ANIMAL 5 NO FINDINGS NOTED ANIMAL 6 NO FINDINGS NOTED ANIMAL 7 NO FINDINGS NOTED ANIMAL 8 NO FINDINGS NOTED ANIMAL 9 SKIN.............. . CHEST REGION: ALOPECIA. ANIMAL 10 NO FINDINGS NOTED ANIMAL 11 NO FINDINGS NOTED MAC-IND - 1 25-FEB-99 (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 04-N0V-98) (SCHEDULED NECROPSY, 04-N0V-98) (SCHEDULED NECROPSY, 04-N0V-98) (SCHEDULED NECROPSY, 04-N0V-98) (SCHEDULED NECROPSY, 18-N0V-98) (SCHEDULED NECROPSY, 18-N0V-98) (SCHEDULED NECROPSY, 18-N0V-98) 258 000259 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS MACROSCOPIC FINDINGS M ALES GROUP 1 (VEHICLE CONTROL) ANIMAL 13 NO FINDINGS NOTED ANIMAL 14 NO FINDINGS NOTED ANIMAL 15 NO FINDINGS NOTED MAC-IND - 2 2 5 - F E B -99 (SCHEDULED NECROPSY, 02-DEC-98) (SCHEDULED NECROPSY, 02-DEC-98) (SCHEDULED NECROPSY, 02-DEC-98) 000260 259 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ ,/PFHS/PFOS MACROSCOPIC FINDINGS M ALES GROUP 2 (TELOM ER ALCOHOL) ANIMAL 17 NO FINDINGS NOTED ANIMAL 18 NO FINDINGS NOTED ANIMAL 19 NO FINDINGS NOTED ANIMAL 20 NO FINDINGS NOTED ANIMAL 21 NO FINDINGS NOTED ANIMAL 22 NO FINDINGS NOTED ANIMAL 23 NO FINDINGS NOTED ANIMAL 24 NO FINDINGS NOTED ANIMAL 25 NO FINDINGS NOTED . ANIMAL 26 NO FINDINGS NOTED ANIMAL 27 TESTES............. REDUCED IN SIZE, FLACCID. MAC-IND - 3. 25-FEB-99 (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 03-NOV-98) (SCHEDULED NECROPSY, 03-N0V-9B) (SCHEDULED NECROPSY, 04-N0V-9B) (SCHEDULED NECROPSY, 04-N0V-9B) (SCHEDULED NECROPSY, 04-N0V-9B) (SCHEDULED NECROPSY, 04-N0V-9B) (SCHEDULED NECROPSY, 18-N0V-98) (SCHEDULED NECROPSY, 18-N0V-98) (SCHEDULED NECROPSY, 18-N0V-98) 260 0 0 0 2 6 1 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ -/PFHS/PFOS M ACROSCOPIC FINDINGS M ALES GROUP 2 (TELOM ER ALCOHOL) ANIMAL 29 NO FINDINGS NOTED ANIMAL 30 NO FINDINGS NOTED ANIMAL 31 NO FINDINGS NOTED MAC-IND - 4 2 5 - F E B -99 (SCHEDULED NECROPSY, 02-DEC-98) (SCHEDULED NECROPSY, 02-DEC-98) (SCHEDULED NECROPSY, 02-DEC-98) 261 000262 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS M ACROSCOPIC FINDINGS M ALES GROUP 3 (TELOM ER ACRYLATE) ANIMAL 33 NO FINDINGS NOTED ANIMAL 34 NO FINDINGS NOTED ANIMAL 35 NO FINDINGS NOTED ANIMAL 36 NO FINDINGS NOTED ANIMAL 37 NO FINDINGS NOTED ANIMAL 38 NO FINDINGS NOTED ANIMAL 39 NO FINDINGS NOTED ANIMAL 40 NO FINDINGS NOTED ANIMAL 41 NO FINDINGS NOTED ANIMAL 42 NO FINDINGS NOTED ANIMAL 43 NO FINDINGS NOTED MAC-IND - 5 25-FEB-99 (SCHEDULED NECROPSY, 03-NOV-98) (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 03-NOV-98) (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 04-NOV-98) (SCHEDULED NECROPSY, 04-NOV-98) (SCHEDULED NECROPSY, 04-N0V-98) (SCHEDULED NECROPSY, 04-N0V-98) (SCHEDULED NECROPSY, 1B-N0V-98) (SCHEDULED NECROPSY, 1S-N0V-98) (SCHEDULED NECROPSY, 18-N0V-98) 000263 262 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ -/PFHS/PFOS M ACROSCOPIC FINDINGS M ALES GROUP 3 (TELOMER ACRYLATE) ANIMAL 45 NO FINOINGS NOTED ANIMAL 46 NO FINDINGS NOTED ANIMAL 47 NO FINDINGS NOTED MAC-IND - 6 25-FEB-99 (SCHEDULED NECROPSY, 02-DEC-98) (SCHEDULED NECROPSY, 02-DEC-98) (SCHEDULED NECROPSY, 02-DEC-98) 000264 263 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE. M ACROSCOPIC FINDINGS M ALES GROUP 4 ( ) ANIMAL 49 NO FINDINGS NOTED ANIMAL 50 NO FINDINGS NOTED ANIMAL 51 NO FINDINGS NOTED ANIMAL 52 NO FINDINGS NOTED ANIMAL 53 NO FINDINGS NOTED ANIMAL 54 NO FINDINGS NOTED ANIMAL 55 NO FINDINGS NOTED ANIMAL 56 NO FINDINGS NOTED ANIMAL 57 NO FINDINGS NOTED ANIMAL 58 NO FINOINGS NOTED ANIMAL 59 NO FINDINGS NOTED /PFHS/PFOS * MAC-IND - 7 2 5 - F E B -99 (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 03-NOV-98) (SCHEDULED NECROPSY, 04-N0V-98) (SCHEDULED NECROPSY, 04-NOV-98) (SCHEDULED NECROPSY, 04-NOV-98) (SCHEDULED NECROPSY, 04-N0V-98) (SCHEDULED NECROPSY, 18-N0V-98) (SCHEDULED NECROPSY, 18-N0V-98) (SCHEDULED NECROPSY, 18-N0V-98) 2 6 4 000265 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS M ACROSCOPIC FINDINGS M ALES GROUP4( ) ANIMAL 61 E Y E S ............... RIGHT SIDE, LENS: REDUCED IN SIZE. ANIMAL 62 NO FINOINGS NOTED ANIMAL 63 NO FINDINGS NOTED MAC-IND - 8 2 5 - F E B -99 (SCHEDULED NECROPSY, 02-DEC-98) (SCHEDULED NECROPSY, 02-DEC-98) (SCHEDULED NECROPSY, 02-0EC-98) 000266 265 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS M ACROSCOPIC FINDINGS M ALES GROUP 5 (PFHS) ANIMAL 65 NO FINDINGS NOTED ANIMAL 66 LUNGS.............. STOMACH............ TESTES............. EPIDIDYMIDES....... HEMORRHAGE. GLANDULAR MUCOSA: HEMORRHAGE. REDUCED IN SIZE. REDUCED IN SIZE. ANIMAL 67 NO FINDINGS NOTED ANIMAL 68 NO FINOINGS NOTED ANIMAL 69 NO FINDINGS NOTED ANIMAL 70 NO FINDINGS NOTED ANIMAL 71 NO FINDINGS NOTED ANIMAL 72 LIVER.............. ENLARGED. ANIMAL 73 NO FINDINGS NOTED ANIMAL 74 TESTES............. REDUCED IN SIZE. 266 MAC-IND - 9 2 5 - F E B -99 (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY. 04-N0V-9B) (SCHEDULED NECROPSY, 04-N0V-98) (SCHEDULED NECROPSY. 04-N0V-98) (SCHEDULED NECROPSY, 04-N0V-98) (SCHEDULED NECROPSY, 18-N0V-98) (SCHEDULED NECROPSY. 18-N0V-98) 000267 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS MACROSCOPIC FINDINGS M ALES GROUP 5 (PFHS) ANIMAL 75 NO FINDINGS NOTED ANIMAL 77 NO FINDINGS NOTED ANIMAL 78 NO FINOINGS NOTED ANIMAL 79 NO FINDINGS NOTED MAC-IND -10 2 5 - F E B -99 (SCHEDULED NECROPSY, 18-N0V-98) (SCHEDULED NECROPSY, 02-DEC-98) (SCHEDULED NECROPSY. 02-DEC-98) (SCHEDULED NECROPSY, 02-DEC-98) 000268 267 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ -/PFHS/PFOS M ACROSCOPIC FINDINGS M ALES GROUP 6 (PFOS) ANIMAL 81 NO FINDINGS NOTED ANIMAL 82 NO FINDINGS NOTED ANIMAL 83 NO FINDINGS NOTED ANIMAL 84 NO FINDINGS NOTED ANIMAL 85 NO FINDINGS NOTED ANIMAL 86 NO FINDINGS NOTED ANIMAL 87 NO FINDINGS NOTED ANIMAL 88 NO FINDINGS NOTED ANIMAL 89 NO FINDINGS NOTED ANIMAL 90 LIVER.............. ACCENTUATED LOBULAR PATTERN. ANIMAL 91 NO FINDINGS NOTED MAC-IND -11 25-FEB-99 (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY, 03-N0V-98) (SCHEDULED NECROPSY. 03-N0V-98) (SCHEDULED NECROPSY, 03-NOV-98) (SCHEDULED NECROPSY, 04-NOV-98) (SCHEDULED NECROPSY, 04-N0V-98) (SCHEDULED NECROPSY, 04-N0V-98) (SCHEDULED NECROPSY, 04-N0V-98) (SCHEDULED NECROPSY, 18-N0V-98) (SCHEDULED NECROPSY, 18-N0V-98) (SCHEDULED NECROPSY, 18-N0V-98) 000269 268 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS M ACROSCOPIC FINDINGS M ALES GROUP 6 (PFOS) ANIMAL 93 NO FINDINGS NOTED ANIMAL 94 NO FINDINGS NOTED ANIMAL 95 NO FINDINGS NOTED MAC-IND -12 2 5 - F E B -99 (SCHEDULED NECROPSY, 02-0EC-98) (SCHEDULED NECROPSY, 02-DEC-98) (SCHEDULED NECROPSY, 02-DEC-98) 2 6 9 000270 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS MACROSCOPIC FINDINGS FEM ALES GROUP 1 (VEHICLE CONTROL) ANIMAL 97 NO FINDINGS NOTED ANIMAL 98 OVARIES............ LEFT SIDE: WATERY CYST. ANIMAL 99 NO FINDINGS NOTED ANIMAL 100 NO FINDINGS NOTEO ANIMAL 101 NO FINDINGS NOTED ANIMAL 102 NO FINDINGS NOTED ANIMAL 103 NO FINDINGS NOTED ANIMAL 104 NO FINDINGS NOTED ANIMAL 105 SKIN................ ABDOMINAL REGION: SCAB FORMATION. ANIMAL 106 NO FINDINGS NOTED ANIMAL 107 NO FINDINGS NOTED MAC-IND -13 25-FEB-99 (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 06-N0V-98) (SCHEDULED NECROPSY. 06-N0V-98) (SCHEDULED NECROPSY, 06-N0V-98) (SCHEDULED NECROPSY, 06-N0V-98) (SCHEDULED NECROPSY, 20-N0V-98) (SCHEDULED NECROPSY, 20-N0V-98) (SCHEDULED NECROPSY, 20-NOV-98) 2 7 0 000271 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ ./PFHS/PFOS MACROSCOPIC FINDINGS FEM ALES GROUP 1 (VEHICLE CONTROL) ANIMAL 109 NO FINDINGS NOTED ANIMAL 110 NO FINDINGS NOTED ANIMAL 111 NO FINDINGS NOTED MAC-IND -14 2 5 -FEB-99 {SCHEDULED NECROPSY, 04-DEC-98) (SCHEDULED NECROPSY, 04-DEC-98) (SCHEDULED NECROPSY, 04-DEC-98) 27 1 000272 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS M ACROSCOPIC FINDINGS FEM ALES GROUP 2 fTELOM ER ALCOHOL) ANIMAL 113 NO FINDINGS NOTED ANIMAL 114 NO FINOINGS NOTED ANIMAL 115 NO FINDINGS NOTED ANIMAL 116 NO FINDINGS NOTED ANIMAL 117 KIDNEYS............ RIGHT SIDE: PELVIC DILATION. ANIMAL 118 NO FINDINGS NOTED ANIMAL 119 NO FINDINGS NOTED ANIMAL 120 NO FINDINGS NOTED ANIMAL 121 NO FINDINGS NOTED ANIMAL 122 SKIN................ ALOPECIA. ANIMAL 123 NO FINDINGS NOTED MAC-IND -15 25-FEB-99 (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED lCROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 06-N0V-9B) (SCHEDULED NECROPSY,' 06-N0V-98) (SCHEDULED NECROPSY, 06-N0V-98) (SCHEDULED NECROPSY, 06-N0y-98) (SCHEDULED NECROPSY, 20-N0V-98) (SCHEDULED NECROPSY, 20-NOV-98) (SCHEDULED NECROPSY, 20-NOV-98) 000273 272 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS M ACROSCOPIC FINDINGS FEM ALES GROUP 2 (TELOM ER ALCOHOL) ANIMAL 125 NO FINDINGS NOTED ANIMAL 126 NO FINDINGS NOTED ANIMAL 127 NO FINDINGS NOTED MAC-IND -16 2 5 - F E B -99 (SCHEDULED NECROPSY, 04-DEC-98) (SCHEDULED NECROPSY, 04-DEC-98) (SCHEDULED NECROPSY, 04-DEC-98) 000274 273 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ 7PFHS/PFOS M ACROSCOPIC FINDINGS FEM ALES GROUP 3 fTELOM ER ACRYLATE) ANIMAL 129 NO FINDINGS NOTED ANIMAL 130 NO FINOINGS NOTED ANIMAL 131 NO FILINGS NOTED ANIMAL 132 NO FINDINGS NOTED ANIMAL 133 NO FINDINGS NOTED ANIMAL 134 NO FINDINGS NOTED ANIMAL 135 NO FINDINGS NOTED ANIMAL 136 NO FINDINGS NOTED ANIMAL 137 NO FINDINGS NOTED ANIMAL 138 NO FINDINGS NOTED ANIMAL 139 NO FINOINGS NOTED - MAC-IND -17 2 5 - F E B -99 (OTHER. 05-N0V-98) (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 06-N0V-98) (SCHEDULED NECROPSY, 06-NOV-98) (SCHEDULED NECROPSY. 06-N0V-98) (SCHEDULED NECROPSY, 06-N0V-98) (SCHEDULED NECROPSY, 20-N0V-98) (SCHEDULED NECROPSY, 20-N0V-98) (SCHEDULED NECROPSY, 20-NOV-98) 2 7 4 000275 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS MACROSCOPIC FINDINGS FEM ALES GROUP 3 (TELOM ER ACRYLATE) ANIMAL 141 NO FINDINGS NOTED ANIMAL 142 NO FINDINGS NOTED ANIMAL 143 NO FINDINGS NOTED MAC-IND -18 25-FEB-99 (SCHEDULED NECROPSY, 04-DEC-98) (SCHEDULED NECROPSY, 04-DEC-98) (SCHEDULED NECROPSY, 04-DEC-98) 000276 275 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS MACROSCOPIC FINDINGS FEM ALES GROUP 4( ) ANIMAL 145 NO FINDINGS NOTED ANIMAL 146 NO FINDINGS NOTED ANIMAL 147 NO FINDINGS NOTED ANIMAL 148 NO FINDINGS NOTED ANIMAL 149 NO FINDINGS NOTED ANIMAL 150 NO FINDINGS NOTED ANIMAL 151 UTERUS............. LEFT SIDE: CYST(S). ANIMAL 152 NO FINDINGS NOTED ANIMAL 153 NO FINDINGS NOTED ANIMAL 154 NO FINDINGS NOTED ANIMAL 155 NO FINDINGS NOTED MAC-IND-19 25-FEB-99 (SCHEDULED NECROPSY, 05-NOV-98) (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 05-NOV-98) (SCHEDULED NECROPSY, 05-NOV-98) (SCHEDULED NECROPSY, 06-NOV-98) . (SCHEDULED NECROPSY, 06-NOV-98) (SCHEDULED NECROPSY, 06-NOV-98) (SCHEDULED NECROPSY, 06-NOV-98) (SCHEDULED NECROPSY, 20-N0V-98) (SCHEDULED NECROPSY, 20-N0V-98) (SCHEDULED NECROPSY, 20-N0V-98) 000277 276 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS M ACROSCOPIC FINDINGS FEM ALES GROUP 4( ) ANIMAL 157 NO FINDINGS NOTED ANIMAL 158 NO FINDINGS NOTED ANIMAL 159 NO FINDINGS NOTED MAC-IND -20 2 5 - F E B -99 (SCHEDULED NECROPSY, 04-DEC-98) (SCHEDULED NECROPSY, 04-DEC-98) (SCHEDULED NECROPSY, 04-DEC-98) 2 7 7 000278 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS MACROSCOPIC FINDINGS FEM ALES GROUP 5 (PFHS) ANIMAL 161 NO FINDINGS NOTED ANIMAL 162 NO FINDINGS NOTED ANIMAL 163 NO FINDINGS NOTED ANIMAL 164 NO FINDINGS NOTED ANIMAL 165 NO FINDINGS NOTED ANIMAL 166 NO FINDINGS NOTED ANIMAL 167 NO FINDINGS NOTED ANIMAL 168 NO FINDINGS NOTED ANIMAL 169 NO FINDINGS NOTED ANIMAL 170 NO FINDINGS NOTED ANIMAL 171 NO FINDINGS NOTED - MAC-IND -21 25-FEB-99 (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY. 05-N0V-98) (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 06-NOV-98) (SCHEDULED NECROPSY, 06-NOV-98) (SCHEDULED NECROPSY, 06-NOV-98) (SCHEDULED NECROPSY, 06-NOV-98) (SCHEDULED NECROPSY, 20-N0V-98) (SCHEDULED NECROPSY, 20-N0V-98) (SCHEDULED NECROPSY. 20-NOV-98) 000279 278 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ -/PFHS/PFOS MACROSCOPIC FINDINGS FEM ALES GROUP 5 (PFHS) ANIMAL 173 NO FINDINGS NOTED ANIMAL 174 NO FINDINGS NOTED ANIMAL 175 NO FINDINGS NOTED MAC-IND -22 2 5 - F E B -99 (SCHEDULED NECROPSY, 04-DEC-98) (SCHEDULED NECROPSY, 04-DEC-98) (SCHEDULED NECROPSY, 04-DEC-98) 000280 279 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS M ACROSCOPIC FINDINGS FEM ALES GROUP 6 (PFOS) ANIMAL 177 NO FINDINGS NOTED ANIMAL 178 NO FINDINGS NOTED ANIMAL 179 NO FINDINGS NOTED ANIMAL 180 NO FINDINGS NOTED ANIMAL 181 NO FINDINGS NOTED ANIMAL 182 NO FINDINGS NOTED ANIMAL 183 NO FINDINGS NOTED ANIMAL 184 NO FINDINGS NOTED ANIMAL 185 NO FINDINGS NOTED ANIMAL 186 NO FINDINGS NOTED ANIMAL 187 NO FINDINGS NOTED MAC-IND -23 25-FEB-99 (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY. 05-N0V-98) (SCHEDULED NECROPSY, 05-N0V-98) (SCHEDULED NECROPSY, 06-N0V-98) (SCHEDULED NECROPSY, 06-N0V-98) (SCHEDULED NECROPSY, 06-N0V-98) (SCHEDULED NECROPSY, 06-N0V-98) (SCHEDULED NECROPSY, 20-NOV-98) (SCHEDULED NECROPSY, 20-N0V-98) (SCHEDULED NECROPSY, 20-N0V-98) 2 8 0 000281 NOTOX Project 242933 TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS MACROSCOPIC FINDINGS FEM ALES GROUP 6 (PFOS) ANIMAL 189 NO FINDINGS NOTED ANIMAL 190 NO FINDINGS NOTED ANIMAL 191 NO FINDINGS NOTED MAC-IND -24 25-FEB-99 (SCHEDULED NECROPSY, 04-DEC-98) (SCHEDULED NECROPSY, 04-DEC-98) (SCHEDULED NECROPSY, 04-DEC-98) 281 000282 NOTOX Project 242933 ORGAN WEIGHTS (GRAM) AFTER 4 WEEKS MALES GROUP 1 (VEHICLE CONTROL) ANIMAL NUMBER BODY W. BRAIN HEART i 284 2 332 3 348 4 270 5 303 6 327 7 351 8 301 1.95 2.04 2.03 2.00 1.92 2.01 2.14 1.99 1.081 1.390 1.108 1.070 1.141 1.088 1.123 1.059 LIVER 8.04 10.76 10.40 8.54 10.49 10.38 11.92 9.84 OW-IND - 1 3 0 - M A R - 99 KIDNEYS ADRENALS SPLEEN TESTES 1.84 2.59 2.41 1.75 2.54 2.06 2.63 2.59 0.038 0.050 0.037 0.040 0.053 0.044 0.051 0.047 0.434 0.565 0.563 0.482 0.488 0.733 0.766 0.605 2.71 2.79 3.32 2.53 2.91 2.82 3.03 2.82 GROUP 2 (TELOMER ALCOHOL) ANIMAL NUMBER BODY W. BRAIN HEART 17 322 18 295 19 312 20 299 21 315 22 348 23 313 24 312 1.99 2.01 2.00 1.96 1.84 2.05 1.87 1.95 1.149 1.300 0.935 1.033 1.129 1.309 0.972 1.241 LIVER 10.16 11.71 9.71 9.50 10.48 10.71 10.15 10.42 KIDNEYS ADRENALS SPLEEN TESTES 2.35 2.57 2.35 2.24 2.40 2.57 2.12 2.09 0.049 0.050 0.053 0.055 0.050 0.049 0.072 0.049 0.465 0.551 0.541 0.540 0.565 0.712 0.560 0.590 3.05 3.27 3.19 3.21 2.63 3.18 2.87 2.96 GROUP 3 (TELOMER ACRYLATE) ANIMAL NUMBER BODY W. BRAIN HEART 33 313 1.97 34 288 1.93 35 293 1.95 36 293 1.94 37 303 2.02 38 324 1.98 39 319 > 1.99 40 304 1.82 1.127 0.943 1.131 0.972 1.321 1.079 1.077 1.122 LIVER 9.89 8.88 8.71 8.90 9.66 10.40 9.48 8.95 KIDNEYS ADRENALS SPLEEN TESTES 2.08 2.16 2.08 2.14 2.50 2.37 2.19 2.12 0.053 0.046 0.038 0.059 0.058 0.056 0.046 0.056 0.637 0.498 0.476 0.530 0.603 0.592 0.656 0.547 2.52 2.77 2.77 2.74 2.84 2.97 2.69 2.94 GROUP 4 ( ) ANIMAL NUMBER BODY W. BRAIN 49 290 50 296 51 342 52 324 53 320 54 330 55 284 56 263 1.96 2.07 2.11 1.97 1.98 1.99 1.97 1.93 HEART 1.055 1.193 1.156 1.224 1.331 1.207 1.025 1.043 LIVER 8.23 9.16 10.83 9.52 9.39 9.53 8.50 7.18 KIDNEYS ADRENALS SPLEEN TESTES 1.99 2.08 2.54 2.26 2.36 2.25 2.07 1.73 0.046 0.033 0.046 0.053 0.042 0.041 0.045 0.058 0.488 0.627 0.719 0.559 0.629 0.547 0.537 0.519 3.18 3.00 2.77 2.96 2.58 2.70 2.95 2.75 282 000283 NOTOX Project 242933 ORGAN WE IGHTS (GRAM) AFTER 4 WEEKS MALES GROUP 5 (PFHS) ANIMAL NUMBER BODY W. BRAIN HEART 65 352 66 270 67 297 68 297 69 287 70 347 71 311 72 306 2.02 1.89 2.03 1.94 1.86 2.07 1.83 2.04 1.267 0.992 1.131 1.148 1.096 1.153 1.030 1.040 GROUP 6 (PFOS) ANIMAL NUMBER BODY W. BRAIN 81 303 82 295 83 308 84 318 85 362 86 293 87 351 88 317 1.99 1.98 2.06 2.00 1.96 1.93 1.97 2.07 HEART 1.102 1.165 0.961 1.171 1.223 1.259 1.163 1.004 LIVER 16.85 11.52 13.86 13.10 12.96 14.49 11.84 15.62 LIVER 11.04 11.17 10.67 11.52 13.46 12.90 12.33 11.19 OW-IND - 2 3 0 - M A R - 99 KIDNEYS ADRENALS SPLEEN TESTES 2.77 2.14 2.49 2.31 2.11 2.47 2.19 2.28 0.037 0.038 0.059 0.046 0.058 0.057 0.051 0.056 0.595 0.504 0.549 0.541 0.570 0.745 0.516 0.539 3.22 0.85 3.18 3.07 2.82 3.18 3.05 3.04 KIDNEYS ADRENALS SPLEEN TESTES 2.15 2.21 1.91 2.42 2.34 2.28 2.26 1.96 0.039 0.055 0.039 0.032 0.060 0.039 0.067 0.040 0.501 0.433 0.560 0.510 0.692 0.664 0.634 0.469 2.80 2.86 2.82 2.79 2.88 2.58 3.22 2.84 000284 283 NOTOX Project 242933 ORGAN/BODY WEIGHT RATIOS (%) AFTER 4 WEEKS HALES GROUP 1 (VEHICLE CONTROL) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART LIVER KIDNEYS ADRENALS SPLEEN 1 284 2 332 3 348 4 270 5 303 6 327 '7 351 8 301 0.69 0.61 0.58 0.74 0.63 0.62 0.61 0.66 0.381 0.419 0.318 0.396 0.377 0.333 0.320 0.352 2.83 3.24 2.99 3.16 3.46 3.18 3.40 3.27 0.65 0.78 0.69 0.65 0.84 0.63 0.75 0.86 0.013 0.015 0.011 0.015 0.017 0.013 0.015 0.016 0.153 0.170 0.162 0.179 0.161 0.224 0.218 0.201 OW-IND - 3 3 0 - M A R -9 9 TESTES 0.95 0.84 0.95 0.94 0.96 0.86 0.86 0.94 GROUP 2 (TELOMER ALCOHOL) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART 17 322 18 295 19 312 20 299 21 315 22 348 23 313 24 312 0.62 0.68 0.64 0.65 0.58 0.59 0.60 0.62 0.357 0.441 0.300 0.345 0.358 0.376 0.311 0.398 LIVER 3.15 3.97 3.11 3.18 3.33 3.08 3.24 3.34 KIDNEYS ADRENALS SPLEEN TESTES 0.73 0.87 0.75 0.75 0.76 0.74 0.68 0.67 0.015 0.017 0.017 0.018 0.016 0.014 0.023 0.016 0.144 0.187 0.173 0.181 0.179 0.205 0.179 0.189 0.95 1.11 1.02 1.07 0.83 0.91 0.92 0.95 GROUP 3 (TELOMER ACRYLATE) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART 33 313 34 288 35 293 36 293 37 303 38 324 39 319 40 304 0.63 0.67 0.66 0.66 0.67 0.61 0.62 0.60 0.360 0.327 0.386 0.332 0.436 0.333 0.338 0.369 LIVER 3.16 3.08 2.97 3.04 3.19 3.21 2.97 2.94 KIDNEYS ADRENALS SPLEEN TESTES 0.66 0.75 0.71 0.73 0.83 0.73 0.68 0.70 0.017 0.016 0.013 0.020 0.019 0.017 0.014 0.018 0.204 0.173 0.162 0.181 0.199 0.183 0.206 0.180 0.80 0.96 0.95 0.94 0.94 0.92 0.84 0.97 GROUP 4 ( ) ANIMAL NUMBER BODY W. (GRAM) BRAIN 49 290 50 296 51 342 52 324 53 320 54 330 55 284 56 263 0.67 0.70 0.62 0.61 0.62 0.60 0.69 0.73 HEART 0.364 0.403 0.338 0.378 0.416 0.366 0.361 0.397 LIVER 2.84 3.09 3.17 2.94 2.93 2.89 2.99 2.73 KIDNEYS ADRENALS SPLEEN TESTES 0.69 0.70 0.74 0.70 0.74 0.68 0.73 0.66 0.016 0.011 0.013 0.016 0.013 0.012 0.016 0.022 0.168 0.212 0.210 0.173 0.197 0.166 0.189 0.197 1.10 1.01 0.81 0.91 0.81 0.82 1.04 1.05 000285 284 NOTOX Project 242933 ORGAN/BODY WEIGHT RATIOS (%) AFTER 4 WEEKS MALES GROUP 5 (PFHS) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART LIVER 65 352 66 270 67 297 68 297 69 287 70 347 71 311 72 306 0.57 0.70 0.68 0.65 0.65 0.60 0.59 0.67 0.360 0.367 0.381 0.387 0.382 0.332 0.331 0.340 4.79 4.27 4.67 4.41 4.52 4.18 3.81 5.10 GROUP 6 (PFOS) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART 81 303 82 295 83 308 84 318 85 362 86 293 87 351 88 317 0.66 0.67 0.67 0.63 0.54 0.66 0.56 0.65 0.364 0.395 0.312 0.368 0.338 0.430 . 0.331 0.317 LIVER 3.64 3.79 3.46 3.62 3.72 4.40 3.51 3.53 OW-IND - 4 30-MAR-99 KIDNEYS ADRENALS SPLEEN TESTES 0.79 0.79 0.84 0.78 0.73 0.71 0.70 0.74 0.011 0.014 0.020 0 ..015 0.020 0.016 0.016 0.018 0.169 0.187 0.185 0.182 0.199 0.215 0.166 0.176 0.91 0.31 1.07 1.03 0.98 0.92 0.98 0.99 KIDNEYS ADRENALS SPLEEN TESTES 0.71 0.75 0.62 0.76 0.65 0.78 0.64 0.62 0.013 0.019 0.013 0.010 0.017 0.013 0.019 0.013 0.165 0.147 0.182 0.160 0.191 0.227 0.181 0.148 0.92 0.97 0.91 0.88 0.80 0.88 0.92 0.90 000286 NOTOX Project 242933 ORGAN WEIGHTS (GRM) AFTER 4 WEEKS FEMALES GROUP 1 (VEHICLE CONTROL) ANIMAL NUMBER BODY W. BRAIN heart 97 201 98 194 99 204 100 217 101 241 102 229 103 183 104 242 1.93 1.92 1.89 1.96 1.91 1.89 1.70 1.85 0.861 0.799 0.750 0.869 0.917 0.901 0.855 0.867 LIVER 6.95 6.34 6.13 6.82 7.19 6.61 5.79 7.13 OW-IND - 5 3 0 - M A R - 99 KIDNEYS ADRENALS SPLEEN OVARIES 1.44 1.39 1.35 1.56 1.71 1.49 1.36 1.71 0.060 0.075 0.052 0.057 0.046 0.065 0.062 0.061 0.424 0.345 0.398 0.433 0.458 0.366 0.426 0.481 0.089 0.142 0.128 0.119 0.130 0.163 0.100 0.122 GROUP 2 (TELOMER ALCOHOL) ANIMAL NUMBER BODY W. BRAIN HEART 113 204 114 246 115 215 116 218 117 194 118 200 119 201 120 213 1.91 2.03 1.92 2.08 1.82 1.89 1.93 1.88 0.890 0.883 0.785 0.827 0.749 0.829 0.751 0.786 LIVER 6.96 8.13 7.39 7.59 6.97 6.78 6.35 7.29 KIDNEYS ADRENALS SPLEEN OVARIES 1.47 1.85 1.75 1.44 1.68 1.59 1.48 1.75 0.055 0.056 0.078 0.062 0.073 0.054 0.067 0.069 0.470 0.479 0.501 0.378 0.433 0.435 0.446 0.457 0.129 0.130 0.123 0.121 0.172 0.144 0.104 0.142 GROUP 3 (TELOMER ACRYLATE) ANIMAL NUMBER BODY W. BRAIN HEART 129 204 _____ 130 182 1.84 131 196 1.86 132 205 ' 1.88 133 181 1.77 134 215 1.92 135 227 1.85 136 193 1.79 _____ 0.744 0.736 0.847 0.770 0.799 0.917 0.714 LIVER -- 5.70 6.48 6.23 6.19 6.84 7.07 6.09 KIDNEYS ADRENALS SPLEEN OVARIES -- 1.42 1.61 1.59 1.36 1.57 1.62 1.41 -- 0.052 0.053 0.060 0.054 0.063 0.077 0.060 -- 0.298 0.300 0.479 0.454 0.494 0.4870.409 -- 0.127 0.162 0.138 0.125 0.127 0.146 0.118 GROUP 4 ( ) ANIMAL NUMBER BODY W. BRAIN 145 193 146 222 147 223 148 186 149 220 150 219 151 200 152 201 1.80 1.89 2.01 1.84 1.96 2.00 1.84 1.85 HEART 0.794 0.961 0.794 0.767 0.855 0.773 0.778 0.719 LIVER 6.44 6.76 6.05 5.72 8.10 6.71 6.22 6.28 KIDNEYS ADRENALS SPLEEN OVARIES 1.53 1.46 1.64 1.50 1.89 1.48 1.41 1.33 0.066 0.160 0.057 0.043 0.055 0.068 0.049 0.061 1.527 0.529 0.511 0.506 0.420 0.478 0.463 0.429 0.131 0.055 0.138 0.116 0.156 0.130 0.136 0.129 286 000287 NOTOX Project 242933 ORGAN WEIGHTS (GRAM) AFTER 4 WEEKS FEMALES GROUP 5 (PFHS) ANIMAL NUMBER BODY W. BRAIN HEART 161 193 162 201 163 191 164 202 165 198 166 208 167 183 168 228 1.94 1.93 1.78 1.78 1.81 1.98 1.86 1.99 0.769 0.703 0.816 0.800 0.910 0.881 0.688 0.880 GROUP 6 (PFOS) ANIMAL NUMBER BODY W. BRAIN 177 215 178 163 179 185 180 173 181 185 182 199 183 191 184 188 1.86 1.79 1.91 1.86 1.88 1.96 1.91 1.88 HEART 0.788 0.660 0.663 0.673 0.818 0.845 0.777 0.757 LIVER 7.96 6.70 5.97 6.57 7.08 6.67 5.68 7.08 LIVER 9.28 6.47 7.23 7.16 7.62 8.41 7.85 8.36 OW-IND - 6 30 -MAR-99 KIDNEYS ADRENALS SPLEEN OVARIES 1.61 1.42 1.32 1.68 1.46 1.48 1.47 1.62 0.068 0.056 0.060 0.047 0.071 0.062 0.049 0.052 0.436 0.419 0.397 0.443 0.361 0.431 0.357 0.415 0.150 0.102 0.121 0.138 0.138 0.152 0.115 0.141 KIDNEYS ADRENALS SPLEEN OVARIES 1.69 1.29 1.48 1.41 1.39 1.47 1.43 1.52 0.053 0.044 0.047 0.061 0.055 0.059 0.059 0.057 0.474 0.327 0.386 0.394 0.404 0.420 0.442 0.450 0.111 0.135 0.108 0.115 0.146 0.110 0.154 0.148 2 8 7 000288 NOTOX Project 242933 ORGAN/BODY WEIGHT RATIOS (%) AFTER 4 WEEKS FEMALES GROUP 1 (VEHICLE CONTROL) NIHli NUMBER BODY W. (GRAM) BRAIN HEART 'LIVER 97 201 98 194 99 204 100 217 101 241 102 229 103 183 104 242 0.96 0.99 0.93 0.90 0.79 0.83 0.93 0.76 0.428 0.412 0.368 0.400 0.380 0.393 0.467 0.358 3.46 3.27 3.01 3.14 2.98 2.89 3.16 2.95 OW-IND - 7 3 0- MAR-99 KIDNEYS ADRENALS SPLEEN OVARIES 0.71 0.71 0.66 0.72 0.71 0.65 0.74 0.71 0.030 0.039 0.025 0.026 0.019 0.028 0.034 0.025 0.211 0.178 0.195 0.223 0.190 0.160 0.233 0.199 0.044 0.073 0.063 0.055 0.054 0.071 0.055 0.050 GROUP 2 (TELOMER ALCOHOL) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART 113 204 114 246 115 215 116 218 in 194 118 200 119 201 120 213 0.94 0.83 0.89 0.95 0.94 0.95 0.96 0.88 0.436 0.359 0.365 0.379 . 0.386 0.415 0.374 0.369 LIVER 3.41 3.31 3.44 3.48 3.59 3.39 3.16 3.42 KIDNEYS ADRENALS SPLEEN OVARIES 0.72 0.75 0.81 0.66 0.87 0.80 0.73 0.82 0.027 0.023 0.036 0.028 0.038 0.027 0.033 0.032 0.230 0.195 0.233 0.173 0.223 0.218 0.222 0.215 0.063 0.053 0.057 0.056 0.089 0.072 0.052 0.067 GROUP 3 (TELOMER ACRYLATE) ANIMAL NUMBER 129 130 131 132 133 134 135 136 BODY W. (GRAM) 204 182 196 205 181 215 227 193 BRAIN -- 1.01 0.95 0.92 0.98 0.89 0.81 0.93 HEART 0.409 0.376 0.413 0.425 0.372 0.404 0.370 LIVER 3.13 3.31 3.04 3.42 3.18 3.11 3.16 KIDNEYS ADRENALS SPLEEN OVARIES 0.78 0.82 0.78 0.75 0.73 0.71 0.73 0.029 0.027 0.029 0.030 0.029 0.034 0.031 0.164 0.153 0.234 0.251 0.230 0.215 0.212 0.070 0.083 0.067 0.069 0.059 0.064 0.061 GROUP 4 ( ) ANIMAL NUMBER BODY W. (GRAM) BRAIN 145 193 146 222 147 223 143 186 149 220 150 219 151 200 152 201 0.93 0.85 0.90 0.99 0.89 0.91 0.92 0.92 HEART 0.411 0.433 0.356 0.412 0.389 0.353 0.389 0.358 LIVER 3.34 3.04 2.71 3.07 3.68 3.06 3.11 3.12 KIDNEYS ADRENALS SPLEEN OVARIES 0.79 0.66 0.73 0.80 0.86 0.68 0.70 0.66 0.034 0.072 0.026 0.023 0.025 0.031 0.025 0.030 0.791 0.238 0.229 0.272 0.191 0.218 0.232 0.213 0.068 0.025 0.062 0.062 0.071 0.059 0.068 0.064 000289 NOTOX Project 242933 ORGAN/BODY WEIGHT RATIOS (%) AFTER 4 WEEKS FEMALES GROUP 5 (PFHS) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART LIVER 161 193 162 201 163 191 164 202 165 198 166 208 167 183 168 228 1.01 0.96 0.93 0.88 0.92 0.95 1.01 0.87 0.398 0.350 0.427 0.396 0.460 0.424 0,376 0.386 4.13 3.33 3.13 3.25 3.57 3.21 3.10 3.10 GROUP 6 (PFOS) ANIMAL NUMBER BODY W. (GRAM) BRAIN 177 178 179 180 . 181 182 183 184 215 163 185 173 185 199 191 188 0.86 1.10 1.03 1.07 1.02 0.99 1.00 1.00 HEART 0.367 0.405 0.358 0.389 0.442 0.425 0.407 0.403 LIVER 4.32 3.97 3.91 4.14 4.12 4.23 4.11 4.45 OW-IND - 8 3 0 - M A R - 99 KIDNEYS ADRENALS SPLEEN OVARIES 0.83 0.70 0.69 0.83 0.74 0.71 0.80 0.71 0.035 0.028 0.031 0.023 0.036 0.030 0.027 0.023 0.226 0.208 0.208 0.219 0.182 0.207 0.195 0.182 0.078 0.051 0.063 0.068 0.070 0.073 0.063 0.062 KIDNEYS ADRENALS SPLEEN OVARIES 0.79 0.79 0.80 0.82 0.75 0.74 0.75 0.81 0.025 0.027 0.025 0.035 0.030 0.030 0.031 0.030 0.220 0.201 0.209 0.228 0.218 0.211 0.231 0.239 0.052 0.083 0.058 0.066 0.079 0.055 0.081 0.079 000290 289 NOTOX Project 242933 ORGAN WEIGHTS (GRAM) AFTER 2 WEEKS RECOVERY MALES GROUP 1 (VEHICLE CONTROL) ANIMAL NUMBER BODY W. BRAIN HEART 9 344 10 277 11 338 2.03 1.81 2.01 1.185 0.960 1.128 LIVER 8.98 7.42 8.32 OW-IND - 9 3 0 - M A H - 99 KIDNEYS ADRENALS SPLEEN TESTES 2.02 1.74 2.35 0.039 0.037 0.050 0.440 0.358 0.526 2.88 2.55 3.01 GROUP 2 (TELOMER ALCOHOL) ANIMAL NUMBER BODY W. BRAIN HEART 25 328 26 295 27 320 1.93 1.96 2.05 1.007 1.068 1.112 LIVER 8.62 7.54 8.65 KIDNEYS ADRENALS SPLEEN TESTES 2.04 2.11 2.09 0.041 0.046 0.031 0.578 0.571 0.555 2.67 2.62 1.10 GROUP 3 (TELOMER ACRYLATE) ANIMAL NUMBER BODY W. BRAIN HEART 41 379 42 319 43 334 2.01 2.04 1.80 1.113 1.284 1.119 LIVER 12.10 8.88 8.71 KIDNEYS ADRENALS SPLEEN TESTES 2.75 2.15 2.33 0.047 0.036 0.047 0.504 0.578 0.547 3.16 3.19 2.91 GROUP 4 ( ANIMAL NUMBER BODY W. BRAIN 57 415 ' 58 354 59 329 2.13 2.02 1.91 HEART 1.125 1.179 1.155 LIVER 11.41 10.45 9.05 KIDNEYS ADRENALS SPLEEN TESTES 2.56 2.50 2.11 0.041 0.063 0.062 0.739 0.582 0.548 3.53 3.35 3.18 GROUP 5 (PFHS) ANIMAL NUMBER BODY W. BRAIN 73 386 74 249 75 336 2.00 1.73 2.06 HEART 1.309 1.027 1.112 LIVER 12.15 6.89 9.62 KIDNEYS ADRENALS SPLEEN TESTES 2.54 1.60 2.41 0.045 0.035 0.043 0.630 0.476 0.517 3.27 1.34 3.21 000291 290 NOTOX Project 242933 ORGAN WEIGHTS (GRAM) AFTER 2 WEEKS RECOVERY MALES GROUP 6 (PFOS) ANIMAL NUMBER BODY W. BRAIN HEART 89 394 90 370 91 377 2.03 2.07 2.00 1.333 1.237 1.328 LIVER 14.20 14.62 13.39 O W - I N D - 10 3 0 -M A R -9 9 KIDNEYS ADRENALS SPLEEN TESTES 2.66 2.58 2.70 0.041 0.048 0.054 0.758 0.631 0.517 3.31 2.80 2.97 000292 291 NOTOX Project 242933 ORGAN/BODY WEIGHT RATIOS (%) AFTER 2 WEEKS RECOVERY MALES GROUP 1 (VEHICLE CONTROL) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART LIVER 9 344 10 277 11 338 0.59 0.65 0.60 0.344 0.347 0.334 2.61 2.68 2.46. O W - I N D - 11 3 0 - M A R - 99 KIDNEYS ADRENALS SPLEEN TESTES 0.59 0.63 0.70 0.011 0.013 0.015 0.128 0.129 0.156 0.84 0.92 0.89 GROUP 2 (TELOMER ALCOHOL) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART 25 328 26 295 27 320 0.59 0.67 0.64 0.307 0.362 0.348 LIVER 2.63 2.56 2.70 KIDNEYS ADRENALS SPLEEN TESTES 0.62 0.72 0.65 0.013 0.016 0.010 0.176 0.194 0.173 0.81 0.89 0.34 GROUP 3 (TELOMER ACRYLATE) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART 41 379 42 319 43 334 0.53 0.64 0.54 0.294 0.403 0.335 LIVER 3.19 2.78 2.61 KIDNEYS ADRENALS SPLEEN TESTES 0.73 0.67 0.70 0.012 0.011 0.014 0.133 0.181 0.164 0.83 1.00 0.87 GROUP 4 ( ) ANIMAL NUMBER BODY W. (GRAM) BRAIN 57 415 58 354 59 329 0.51 0.57 0.58 HEART 0.271 0.333 0.351 LIVER 2.75 2.95 2.75 KIDNEYS '1 ADRENALS SPLEEN TESTES 0.62 0.71 0.64 0.010 0.018 0.019 0.178 0.164 0.167 0.85 0.95 0.97 GROUP 5 (PFHS) ANIMAL NUMBER BODY W. (GRAM) BRAIN 73 386 74 249 75 336 0.52 0.69 0.61 HEART 0.339 0.412 0.331 LIVER 3.15 2.77 2.86 KIDNEYS ADRENALS SPLEEN TESTES 0.66 0.64 0.72 0.012 0.014 0.013 0.163 0.191 0.154 0.85 0.54 0.95 2 9 2 000293 NOTOX Project 242933 ORGAN/BODY WEIGHT RATIOS (%) AFTER 2 WEEKS RECOVERY HALES GROUP 6 (PFOS) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART LIVER 89 394 90 370 91 377 0.52 0.56 0.53 0.338 0.334 0.352 3.60 3.95 3.55 O W - I N D - 12 3 0 - M A R - 99 KIDNEYS ADRENALS SPLEEN TESTES 0.68 0.70 0.72 0.010 0.013 0.014 0.192 0.171 0.137 0.84 0.76 0.79 29 J 000294 NOTOX Project 242933 ORGAN WEIGHTS (GRAM) AFTER 2 WEEKS RECOVERY FEMALES GROUP 1 (VEHICLE CONTROL) ANIMAL NUMBER BODY W. BRAIN HEART 105 217 106 272 107 227 1.98 2.05 1.85 0.867 0.960 0.868 LIVER 6.95 9.23 6.90 O W - I N D - 13 3 0 -MAR-99 KIDNEYS ADRENALS SPLEEN OVARIES 1.51 1.71 1.39 0.052 0.056 0.057 0.449 0.439 0.372 0.150 0.574 0.132 GROUP 2 (TELOMER ALCOHOL) ANIMAL NUMBER BODY W. BRAIN HEART 121 200 122 203 123 231 1.85 1.85 1.98 0.812 0.915 0.848 LIVER 6.72 6.01 7.72 KIDNEYS ADRENALS SPLEEN OVARIES 1.60 1.31 1.62 0.074 0.057 0.057 0.367 0.370 0.536 0.125 0.135 0.131 GROUP 3 (TELOMER ACRYLATE) ANIMAL NUMBER BODY W. BRAIN HEART 137 217 138 189 139 200 1.88 1.91 1.94 0.873 0.767 0.853 LIVER 7.40 5.66 6.06 KIDNEYS ADRENALS SPLEEN OVARIES 1.70 1.41 1.44 0.080 0.047 0.067 0.523 0.382 0.344 0.120 0.120 0.138 GROUP 4 ( ) ANIMAL NUMBER BODY W. BRAIN 153 214' 154 246 155 191 1.89 1.95 1.90 HEART 0.980 0.950 0.878 LIVER KIDNEYS ADRENALS SPLEEN OVARIES 7.05 7.00 7.18 ' 1.61 1.72 1.48 0.075 0.065 0.068 0.404 0.432 0.405 0.149 0.162 0.123 GROUP 5 (PFHS) ANIMAL NUMBER BODY W. BRAIN 169 228 170 211 171 232 1.90 1.92 L.95 HEART 0.844 0.784 0.892 LIVER 6.77 6.84 7.96 KIDNEYS ADRENALS SPLEEN OVARIES 1.54 1.55 1.45 0.061 0.055 0.059 0.362 0.508 0.476 0.135 0.118 0.147 000295 294 NOTOX Project 242933 ORGAN WEIGHTS (GRAM) AFTER 2 WEEKS RECOVERY FEMALES GROUP 6 (PFOS) ANIMAL NUMBER BODY W. BRAIN HEART 185 197 186 199 187 203 2.02 1.93 2.04 0.702 0.735 0.732 LIVER 8.18 7.10 7.37 O W-IND - 14 3 0 - M A R - 99 KIDNEYS ADRENALS SPLEEN OVARIES 1.48 1.41 1.26 0.057 0.056 0.055 0.397 0.415 0.365 0.138 0.132 0.127 000296 295 NOTOX Project 242933 ORGAN/BODY WEIGHT RATIOS (%) AFTER 2 WEEKS RECOVERY FEMALES GROUP 1 (VEHICLE CONTROL) ANIMAL NUMBER BODY- W. BRAIN (GRAM) ' HEART LIVER 105 217 106 272 107 227 0.91 0.75 0.81 0.400 0.353 0.382 3.20 3.39 3.04 O W - I N D - 15 3 0 - M A R - 99 KIDNEYS ADRENALS SPLEEN OVARIES 0.69 0.63 0.61 0.024 0.021 0.025 0.207 0.161 0.164 0.069 0.211 0.058 GROUP 2 (TELOMER ALCOHOL) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART 121 200 122 203 123 231 0.93 0.91 0.86 ' 0.406 0.451 0.367 LIVER KIDNEYS ADRENALS SPLEEN OVARIES 3.36 2.96 3.34 0.80 0.65 . 0.70 0.037 0.028 0.025 0.184 0.182 0.232 0.063 0.067 0.057 GROUP 3 (TELOMER ACRYLATE) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART 137 217 138 189 139 200 0.87 1.01 0.97 0.402 0.406 0.427 LIVER 3.41 3.00 3.03 KIDNEYS ADRENALS SPLEEN OVARIES 0.79 0.75 0.72 0.037 0.025 0.034 0.241 0.202 0.172 0.055 0.063 0.069 GROUP 4 ( ) ANIMAL NUMBER BODY W. (GRAM) BRAIN 153 214154 246 155 191 0.88 0.79 0.99 HEART LIVER 0.458 0.386 . 0.460 3.29 2.85 3.76 KIDNEYS ADRENALS SPLEEN OVARIES 0.75 0.70 0.77 0.035 0.026 0.036 0.189 0.176 0.212 0.070 0.066 0.064 GROUP 5 (PFHS) ANIMAL NUMBER BODY W. (GRAM) BRAIN 169 228 170 211 171 232 0.83 0.91 0.84 HEART 0.370 0.372 0.384 LIVER 2.97 3.24 3.43 KIDNEYS ADRENALS SPLEEN OVARIES 0.68 0.74 0.62 0.027 0.026 0.025 0.159 0.241 0.205 0.059 0.056 0.063 2 9 6 000297 NOTOX Project 242933 ORGAN/BODY WEIGHT RATIOS (%) AFTER 2 WEEKS RECOVERY FEMALES GROUP 6 (PFOS) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART LIVER 185 197 186 199 187 203 1.02 0.97 1.00 0.356 0.369 0.361 4.15 3.57 3.63 O W - I N D - 16 30-MAR-99 KIDNEYS ADRENALS SPLEEN OVARIES 0.75 0.71 0.62 0.029 0.028 0.027 0.202 0.209 0.180 0.070 0.066 0.063 0002S8 2S7 NOTOX Project 242933 ORGAN WEIGHTS (GRAM) AFTER 4 WEEKS RECOVERY MALES GROUP 1 (VEHICLE CONTROL) ANIMAL NUMBER BODY W. BRAIN HEART 13 415 14 360 15 392 1.97 1.83 2.12 1.284 1.206 1.099- LIVER 12.26 9.57 10.47 OW-IND - 17 30-MAR-9 9 KIDNEYS ADRENALS SPLEEN TESTES 2.69 2.38 2.24 0.038 0.041 0.058 0.576 0.611 0.656 2.86 2.73 3.01 GROUP 2 (TELOMER ALCOHOL) ANIMAL NUMBER BODY W. BRAIN HEART 29 330 30 396 31 362 32 2.01 2.08 2.08 1.195 1.199 1.228 LIVER 9.41 10.27 9.66 KIDNEYS ADRENALS SPLEEN TESTES 2.35 2.48 2.44 0.048 0.059 0.042 0.456 0.544 0.620 2.97 2.92 3.68 GROUP 3 (TELOMER ACRYLATE) ANIMAL NUMBER BODY W. BRAIN HEART 45 380 46 380 47 375 2.07 2.07 2.12 1.282 1.237 1.132 LIVER 11.08 9.77 10.05 KIDNEYS ADRENALS SPLEEN TESTES 2.55 2.48 2.50 0.050 0.056 0.057 0.656 0.534 0.582 3.06 3.11 3.17 GROUP 4 ( ) ANIMAL NUMBER BODY W. BRAIN 61 434 62 406 63 363 2.33 1.99 2.00 HEART 1.378 1.389 1.129 LIVER 9.91 10.46 9.81 KIDNEYS ADRENALS SPLEEN TESTES 2.79 2.32 2.67 0.070 0.046 0.051 0.692 0.705 0.762 3.36 2.97 2.98 GROUP 5 (PFHS) ANIMAL NUMBER BODY W. BRAIN 77 358 78 321 79 326 2.11 1.95 1.99 HEART 1.105 0.875 1.164 LIVER 9.57 8.43 8.54 KIDNEYS ADRENALS SPLEEN TESTES 2.13 1.89 2.69 0.050 0.045 0.047 0.625 0.529 0.502 3.22 3.03 3.01 000299 298 NOTOX Project 242933 ORGAN WEIGHTS (GRAM) AFTER 4 WEEKS RECOVERY MALES GROUP 6 (PFOS) ANIMAL NUMBER BODY W. BRAIN HEART 93 301 94 374 95 356 1.96 2.08 1.98 0.953 1.429 1.311 LIVER 8.98 12.66 11.87 O W - I N D - 18 30-MAR-9 9 KIDNEYS ADRENALS SPLEEN TESTES 2.26 2.66 2.53 0.055 0.037 0.047 0.505 0.774 0.607 3.10 3.62 3.09 000.700 299 NOTOX Project 242933 ORGAN/BODY WEIGHT RATIOS (%) AFTER 4 WEEKS RECOVERY MALES GROUP 1 (VEHICLE CONTROL) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART LIVER 13 415 14 360 15 392 0.47 0.51 0.54 0.309 0.335 0.280 2.96 2.66 2.67 O W - I N D - 19 3 0 - M A R - 99 KIDNEYS ADRENALS SPLEEN TESTES 0.65 0.66 0.57 0.009 0.011 0.015 0.139 0.170 0.167 0.69 0.76 0.77 GROUP 2 (TELOMER ALCOHOL) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART 29 330 30 396 31 362 32 0.61 0.52 0.57 ' 0.362 0.303 0.339 LIVER 2.85 2.59 2.67 KIDNEYS ADRENALS SPLEEN TESTES 0,71 0.63 0.67 0.015 0.015 0.012 0.138 0.137 0.171 0.90 0.74 1.02 GROUP 3 (TELOMER ACRYLATE) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART 45 380 46 380 47 375 0.54 0.55 0.57 0.337 0.326 0.302 LIVER KIDNEYS ADRENALS SPLEEN 2.92 2.57 ' 2.68 0.67 0.65 0.67 0.013 0.015 0.015 0.173 0.141 0.155 TESTES 0.80 0.82 0.85 GROUP 4 ( ) ANIMAL NUMBER BODY W. (GRAM) BRAIN 61 434 62 406 63 363 0.54 0.49 0.55 HEART 0.318 0.342 0.311 LXVER 2.28 2.58 2.70 KIDNEYS ADRENALS SPLEEN TESTES 0.64 0.57 0.74 0.016 0.011 0.014 0.159 0.174 0.210 0.77 0.73 0.82 GROUP 5 (PFHS) ANIMAL NUMBER BODY W. (GRAM) BRAIN 77 358 78 321 79 326 0.59 0.61 0.61 HEART 0.309 0.273 0.357 LXVER 2.67 2.62 2.62 KUNEYS ADRENALS SPLEEN TESTES 0.59 0.59 ' 0.83 0.014 0.014 0.014 0.175 0.165 0.154 0.90 0.94 0.92 000301 300 NOTOX Project 242933 ORGAN/BODY W EIGHT RATIOS (%) AFTER 4 WEEKS RECOVERY MALES GROUP 6 (PFOS) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART LIVER 93 301 94 374 95 356 0.65 0.56 0.5S 0.317 0.382 0.368 2.98 3.39 3.34 O W - I N D - 20 3 0 - M A R - 99 KIDNEYS ADRENALS SPLEEN TESTES 0.75 0.71 0.71 0.018 0.010 0.013 0.168 0.207 0.171 1.03 0.97 0.87 000302 301 NOTOX Project 242933 ORGAN WEIGHTS (GRAM) AFTER 4 WEEKS RECOVERY FEMALES GROUP 1 (VEHICLE CONTROL) ANIMAL NUMBER BODY W. BRAIN HEART 109 212 110 261 111 255 1.86 1.87 2.01 0.847 1.052 0.850 LIVER 5.83 8.12 7.09 O W - I N D - 21 3 0-MAR-9 9 KIDNEYS ADRENALS SPLEEN OVARIES 1.34 1.84 1.60 0.062 0.426 0.078 0.508 0.055 - 0.402 0.137 0.144 0.118 GROUP 2 (TELOMER ALCOHOL) ANIMAL NUMBER BODY W. BRAIN HEART 125 223 126 220 127 241 128 2.00 1.89 2.00 0.826 0.757 0.971 LIVER 7.21 6.22 7.20 KIDNEYS ADRENALS SPLEEN OVARIES 1.62 1.72 1.53 0.079 0.053 0.061 0.430 0.309 0.589 0.122 0.138 0.179 GROUP 3 (TELOMER ACRYLATE) ANIMAL NUMBER BODY W. BRAIN HEART 141 212 142 211 143 254 1.83 1.86 1.94 0.854 0.834 0.922 LIVER 6.69 6.09 7.79 KIDNEYS ADRENALS SPLEEN OVARIES 1.64 1.38 1.61 0.068 0.053 0.066 0.429 0.489 0.360 0.160 0.138 0.136 GROUP 4 ( ) ANIMAL NUMBER BODY W. BRAIN 157 219 158 211 159 275 2.02 1.94 1.94 HEART 0.900 0.836 1.018 LIVER 6.04 6.82 9.04 KIDNEYS ADRENALS SPLEEN OVARIES 1.46 1.62 1.95 0.061 0.061 0.062 0.595 0.391 0.525 0.125 0.167 0.204 GROUP 5 (PFHS) ANIMAL NUMBER BODY W. BRAIN 173 219 174 241 175 219 1.85 1.97 1.81 HEART 0.866 0.922 0.793 LIVER 6.99 6.88 6.60 KIDNEYS ADRENALS SPLEEN OVARIES 1.75 1.58 1.52 0.064 0.068 0.063 0.377 0.329 0.358 0.123 0.128 0.207 000303 302 NOTOX Project 242933 ORGAN WEIGHTS (GRAM) AFTER 4 WEEKS RECOVERY FEMALES GROUP 6 (PFOS) ANIMAI. NUMBER BODY W. BRAIN HEART 189 201 190 220 191 202 1.78 1.92 1.93 0.854 0.799 0.823 LIVER 7.72 7.61 7.15 O W - I N D - 22 3O-MAR-99 KIDNEYS ADRENALS SPLEEN OVARIES 1.55 1.80 1.68 0.069 0.049 0.055 0.485 0.431 0.366 0.139 0.144 0.141 000304 303 NOTOX Project 242933 ORGAN/BODY WEIGHT RATIOS (%) AFTER 4 WEEKS RECOVERY FEMALES GROUP 1 (VEHICLE CONTROL) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART LIVER 109 212 110 261 111 255 0.88 0.71 0.79 0.400 0.403 0.333 2.75 3.11 2.78 O W - I N D - 23 3 0 - M A R - 99 KIDNEYS ' ADRENALS SPLEEN OVARIES 0.63 0.70 0.63 0.029 0.030 0.022 0.201 0.195 0.158 0.065 0.055 0.046 GROUP 2 (TELOMER ALCOHOL) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART 125 223 126 220 127 241 128 0.90 0.86 0.83 - 0.370 0.344 0.403 LIVER 3.23 2.83 2.99 KIDNEYS ADRENALS SPLEEN OVARIES 0.73 0.78 0.64 0.035 0.024 0.025 0.193 0.140 0.244 0.055 0.063 0.074 GROUP 3 (TELOMER ACRYLATE) ANIMAL NUMBER BODY W. (GRAM) BRAIN HEART 141 212 142 211 143 254 0.87 0.88 0.76 0.403 0.395 0.363 LIVER 3.15 2.89 3.07 KIDNEYS ADRENALS SPLEEN OVARIES 0.77 0.66 0.63 0.032 0.025 0.026 0.202 0.232 0.142 0.075 0.065 0.054 GROUP 4 ( ) ANIMAL NUMBER BODY W. (GRAM) BRAIN 157 219 158 211 159 275 0.92 0.92 0.70 HEART 0.411 0.396 0.370 LIVER 2.76 3.23 3.29 KIDNEYS ADRENALS SPLEEN OVARIES 0.67 0.77 0.71 0.028 0.029 0.023 0.272 0.185 0.191 0.057 0.079 0.074 GROUP 5 (PFHS) ANIMAL NUMBER BODY W. (GRAM) BRAIN 173 219 174- 241 175 219 0.85 0.82 0.83 HEART 0.395 0.383 0.362 LIVER 3.19 2.86 3.02 KIDNEYS ADRENALS SPLEEN OVARIES 0.80 0.65 0.69 0.029 0.028 0.029 0.172 0.137 0.163 0.056 0.053 0.095 000305 304 NOTOX Project 242933 ORGAN/BODY WEIGHT RATIOS (%} AFTER 4 WEEKS RECOVERY FEMALES GROUP 6 {PFOS) ANIMAL BODY W. HUMBER . (GRAM) BRAIN HEART LIVER 189 201 190 .220 191 202 0.88 0.87 0.96 0.425 0.363 0.407 3.84 3.46 3.54 OW-IND - 24 3 0 - M A R -9 9 KIDNEYS ADRENALS SPLEEN OVARIES 0.77 0.82 0.83 0.034 0.022 0.027 0.241 0.196 0.181 0.069 0.065 0.070 000306 305 / i ProPath GmbH APPENDIX 1 K NOTOX Safety & Environmental Research B.V. Pathology R eport Exploratory 28-Day Oral Toxicity Study with Teiomer Alcohol, Teiomer Acrylate, , P FH S and P F O S (positive control) by Daily Gavage in the Rat followed by a 14/28-Day Recovery Period N O TO X Project 242933 N O T O X Substances83484, 83493, 83502, 84456 and 84141 3M Test no. T-7023, T-7024, T-7022, T-7032, T-6295 This report contains 146 pages Dr. J.Th. Wilson Oberemattstr.52a Pratteln4133 Switzerland tel: +41 61 823 0 4 10 to c +41 61 623 0411 000307 PATHOLOGY REPORT Page 2/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /eras/pros Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: ' 99010 Date : 21.Apr.1999 Table of Contents Table of contents.................. 2 Authentication.............................................. 3 S u m mary........................................................................... 4 Materials and methods ........................................................... 4 R e s u l t s............................................ 4 Conclusions ...................................................................... 4 Incidence table - macroscopicfindings .......................................... 4 Incidence table - selected microscopic findings with grades ................... 4 Incidence table - microscopicfindings............ 4 Individual animal microscopicfindings ...... 4 Animal data l i s t ..................................................... 4 Individual animal data records .................................................. 4 000308 PATHOLOGY REPORT Page 3/146 Test Article: t e l o m e r l c o h o l /t e l o m e r a c r y l a t e / V p f h s /pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Authentication The undersigned hereby declares, that the histopathology data in this report were compiled by him, and that they reflect accurately the primary data records. This report, consisting of 146 pages, was created by the computer system of Propath GmbH. Jeffrey Th. Wilson, Dr.med.vet, BVSc, MSc, MRCVS Toxicologic Pathologist Propath QnbH CH-4133 Pratteln, Switzerland 000309 PATHOLOGY REPORT Page 4/146 Teat Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Summary P'athomorphologic examination was performed on.168 Sprague Dawley rats (84 males, 84 females) which had been subjected to an exploratory 28-day oral (gavage) toxicity study with the test articles Telomer alcohol/ Telomer acrylate/ '{ PFHS/ PFOS. The rats were assigned to' six dose groups each containing fourteen males and fourteen females. Test articles were administered once daily by gavage at doses of 30 (telomer alcohol, telomer acrylate and ), 10 (PFHS) and 3 mg/kg (PFOS) (dose groups 2, 3, 4, 5 and 6 respectively) for 28 days. The rats of the control group 1 received the vehicle, 1% aqueous carboxymethyl cellulose, alone. At the end of the treatment period eight animals of each sex from all groups were killed and subjected to corrplete necropsies (main study) . Three males and three females from each dose group were subjected to necropsy following 14-day or 28-day treatment-free periods (recovery allocation 1 and 2). All rats were necropsied. Histopathologic examination was performed on adrenal glands, kidneys, liver, lymph nodes - mandibular and mesenteric, ovaries, pancreas, spleen, testes, thymus and all organs or tissues with macroscopic findings. All animals survived their allocated treatment periods. Hepatocellular hypertrophy was present in group 2 (30 mg/kg/day telomer alcohol), group 5 (10 mg/kg/day PFHS) males and in both sexes of group 6 (3 mg/kg/day PFOS) at the end of the main study. In the pancreas a slight increase in the incidence of exocrine apoptosis/single cell necrosis was recorded in group 2 males. Following the recovery periods, the hepatocellular hypertrophy had undergone partial or complete resolution in group 2 and 5 males and in group 6 females. The incidence of pancreas apoptosis/single cell necrosis in group 2 males had also returned to the level of the vehicle control group. 000310 PATHOLOGY REPORT Page 5/146 Teat Article: t e l q m e r a l c o h o l /t e l o m e r a c r y l a t e /, .,/p f h s /p f o s Teat System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Materials and Methods Study Design Dose Dose group mg/kg i Vehicle control Telomer alcohol Telomer acrylate 4 5 PFHS 6 PFOS 30 30 30 10 3 Number of rats males females mai.n re^c.l mai,n re^c.l 9 3/3 8 3/3 8 3/3 8 3/3 8 3/3 8 3/3 8 3/3 8 3/3 8 3/3 8 3/3 8 3/3 8 3/3 main 1-8 Animal numbers siales rec.l ree.2 females stain rec.l ree. 2 9-11 13-15 97-104 105-107 109-111 17-24 25-27 29-31 113-120 121-123 125-127 33-40 . 41-43 49-56 65-72 81-88 57-59 73-75 89-91 45-47 129-136 137-139 141-143 61-63 77-79 93-95 145-152 161-168 177-184 153-155 169-171 185-187 157-159 73-17S 189-191 Administration of the Test Article The test article was administered daily by gavage for 28 days. The recovery group rats were allowed a 14-day (recovery 1) or 28-day (recovery 2) treatment free period. Rats of the control group 1 received the vehicle, 1% aqueous carboxymethyl cellulose, alone. Necropsy and Histopathology At the end of the assigned study periods, the rats were killed by exsanguination following anesthesia by ether vapour. Complete necropsies were performed on all rats. Representative tissue samples of the following organs were preserved in 4% phosphate buffered neutral formaldehyde solution (10% formalin). Adrenal glands, aorta, bone - sternum and femur including joint; bone marrow sternal, brain, clitoral glands, epididymides, esophagus, eyes with optic nerve and Harderian glands; heart, kidneys, lacrimal glands - exorbital, large intestine - cecum, colon and rectum; larynx, liver, lungs, lymph nodes mandibular and mesenteric; female mammary gland area, nasopharynx, ovaries, pancreas, pituitary gland, preputial glands, prostate gland, salivary glands mandibular and sublingual; sciatic nerve, seminal vesicles, skeletal muscle, skin, small intestine - duodenum, jejunum and ileum with Peyer's patches; spinal cord - cervical, midthoracic and lumbar; spleen, stomach, testes, thymus, thyroid glands with parathyroid glands, tongue, trachea, urinary bladder, uterus with uterine cervix, vagina and all organs or tissues with macroscopic abnormalities. 000311 PATHOLOG REPORT Page 6/14S Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Materials and Methods Following fixation, the following organs from all animals, were trimmed, processed and embedded in paraffin wax. Sections were cut at a thickness of 2-4 micrometers and stained with hematoxylin and eosin. Numbers of sections made are given in parentheses. Adrenal glands (2), kidneys (2), liver (2), lymph nodes - mandibular (2) and mesenteric (1), ovaries (2), pancreas (1), spleen (1), testes (2), thymus (1) and all organs or tissues with macroscopic findings. Initially sections of the above organs from all main study rats were examined by light microscopy. Following this examination, sections of lives from groups 1 (vehicle control), 2 (telomer alcohol), 5 (PFHS) and 6 (PFOS) males and groups 1 and 6 females recovery allocations 1 and 2 were examined. Sections of pancreas from group 1 and 2 males of recovery allocations 1 and 2 were also examined. The sections were in February/March, 1999. Data Compilation The animal data and macroscopic findings were electronically transferred from the necropsy raw data files of NOTOX into the computer system of Propath GmbH where the microscopic findings were recorded by the undersigned pathologist using on line input Macroscopic findings are presented in summary in the table "Incidence of Macroscopic Findings" and in full descriptive terms in the "Individual Animal Data Records". Wherever possible, macroscopic findings were correlated with a microscopic finding. Microscopic findings are listed for each animal along with severity grades in the table "Individual Microscopic Findings" and summarized in the tables "Incidence of All Microscopic Findings" and "Incidence Table - Selected Microscopic Findings with Grades". They are further given in full descriptive terms in the "Individual Animal Data Records". Histologic changes were described according to their distribution, severity, and morphologic character. 0 0 3 12 PATHOLOGY REPORT Page 7/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / ,/p f h s /p fos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no Date 242933 99010 21.Apr.1999 Results Mortality A female group 3 rat, no. 129, died at blood sampling on the day of scheduled sacrifice. All other rats survived their assigned study periods. Macroscopic Findings The few macroscopic findings recorded at all sacrifices were unremarkable nri did not distinguish treated rats from-the vehicle control group. Microscopic Findings Treatment related microscopic findings were noted in the liver and pancreas. At the end of the main study, midzonal/centrilobular hypertrophy was seen at a minimal or slight degree in six group 2 (telomer alcohol) males, minimal to moderate degrees in all group 5 (PFHS) males and all group 6 (PFOS) rats of both sexes. By the end of the 28-day recovery period (recovery 2)this finding had partially or completely resolved in group 2 and 5 males and in group 6 females, however remained in evidence in group 6 males. In the pancreas a slight increase in the incidence of minimal or slight degrees of exocrine apoptosis/single cell necrosis was recorded in group 2 males at the end of the main study. The incidence of this finding returned to the level of the vehicle control group following the recovery periods. The remainder of the microscopic findings recorded at both necropsies, were within the range of background pathology encountered in Sprague Dawley rats of this age and strain and occurred at similar incidences and severity in both control and treated rats. 000313 PATHOLOGY REPORT Page 8/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.A p r . 1999 Conclusions Morphologic alterations following the administration of Telomer alcohol/Telomer acrylate/ /PFHS/PFOS by once daily gavage to Sprague Dawley rats for twenty eight days, were present in the liver of telomer alcohol, PFHS and PFOS treated rats and in the pancreas of telomer alcohol treated rats. Hepatocellular hypertrophy was present in group 2 (30 mg/kg/day telomer alcohol), group 5 (10 mg/kg/day PFHS) males and in both sexes of group 6 (3 mg/kg/day PFOS) at the end of the main study. In the pancreas a slight increase in the incidence of exocrine apoptosis/single cell necrosis was recorded in group 2 males. Following the recovery periods, the hepatocellular hypertrophy had undergone partial or complete resolution in group 2 and 5 males and in group 6 females. The incidence of pancreas apoptosis/single cell necrosis in group 2 males had also returned to the level of the vehicle control group. 000314 PATHOLOGY REPORT Page 9/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e /' ,/p f h s /p fos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Incidence Table - Macroscopic Findings Mais Study SEX: DOSE GROUP: number of animals Lungs Hemorrhage Stomach Hemorrhage Liver Enlarged Kidnevs Pelvic dilation Testes Reduced in size Epididymides Reduced in size Ovaries Watery cyst Uterus Cyst(s) to u s 1 2 '3 4 5 6 888888 0 0 0 010 0 0 0 010 000010 0 0 0 000 000010 0 0 00 10 WSMAT.TB 12 3 4 5 6 888 88 8 000 00 0 000 00 0 00000 0 01000 0 10000 0 00010 0 000315 PATHOLOGY REPORT Page 10/146 Test Article: t e l o m e r a l c o h o l /t'e l o m e r a c r y l a t e / /p f h s /pf o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Incidence Table - Macroscopic Findings Recovery Allocation 1 SEX: DOSE GROUP: number of animals Liver Accentuated lobular pattern Testes Reduced In size Skin Alopecia general chest region Scab formation abdominal region MALE 12 33 345 333 6 3 0 00001 0 10 0 10 0 0 0000 100000 TEMALE 12 3 3 6 3 010000 000000 000316 PATHOLOGY REPORT Page 11/146 Test Article: t e l o m e r AICOHOl /t e l o m e r a c r y l a t e / /p f h s /p fos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Incidence Table - Macroscopic Findings R e c o v e r y Allocation 2 SEX: DOSE GROUP: number of animals Eves Reduced in size lens MALE 1 2 3 45 6 3 3 3 33 3 0 0 0 100 FEMALE 1 2 3 4 56 3 3 4 3 33 0 0 0 0 00 000317 PATHOLOGY REPORT Page 12/146 Test Article: telomer alcohol/telqmer acrylate/ ,/pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 TnH Table - Selected Microscopic Findings with Grades Main Study SEX: DOSE GROUP: number of animals Liver number examined Mldzonal/ cent rilobular hypertrophy, diffuse (minimal) (slight) (moderate) Total Pancreas number examined Apoptosis/single cell necrosis, exocrine (minimal) (slight) Total mis 12345 6 8 aa888 8 a 8888 FEMALE 12345 6 888 88 8 888 88 8 0 5 0000 0 l0022 000066 0 60088 888888 1 42021 120101 2 62122 000 0 0 1 000 00 4 000 00 3 000 00 8 888 8 8 8 200 01 0 000 00 0 20001 0 000318 PATHOLOGY REPORT Page 13/146 Test Article: TELOMSR ALCOHOL/TELOMER ACRYLATE/ ,/PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no. : 99010 Date : 21.Apr.1999 Incidence Table - Selected Microscopic Findings with Grades Recovery Allocation 1 SEX: DOSE GROUP: number of animals Liver number examined Midzonal/ cent rilobular hypertrophy, diffuse (minimal) (slight) (moderate) Total HALS 1 2 '3 333 45 3. 3 6 3 33 33 FEMALE 12345 6 333 33 3 33 01 00 00 01 10 11 02 23 0 0 0 0 1 0 0 1 Recovery Allocation 2 SEX: DOSE GROUP: number of animals Liver number examined Midzonal/ centrilobular hypertrophy, diffuse (minimal) (slight) (moderate) Total Pancreas number examined Apoptosis/single cell necrosis, exocrine (minimal) HALS 1 2 3 45 6 333333 33 33 FEMALE 12345 6 333 33 3 33 01 00 00 01 33 10 01 01 01 03 0 0 0 0 1 0 0 1 000319 PATHOLOGY REPORT Page 14/146 Test Article: t e l o m e r a l c o h o l / e l o m e r a c r y l a t e /, ./p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Incidence Table -- Microscopic Findings Main Study SEX: DOSE GROUP: number of animals Lunas number examined Intra-alveolar blood, necropsy artefact Vascular mineralisation, focal Stomach 'number examined Liver number examined Inflammatory cell foci Single cell necrosis Midzonal/ centrilobular hypertrophy, diffuse Hepatocellular vacuolation Hematopoietic cell foci Coagulative necrosis, focal Pancreas number examined Apoptosis/single cell necrosis, exocrine Exocrine atrophy, focal MALS 123 45 6 a 8 88 88 1 1 1 1 8 8 8888 8 888 88 6 663 66 0 60088 100034 3 00001 0 000 10 8 88888 2 62 122 011000 52MSX5 12345 6 88888 8 8 8 8 .8 8 8 888 88 8 7 65 35 4 00000 8 10101 0 000 10 0 00000 0 88888 8 2000 1 0 00100 0 000320 PATHOLOGY REPORT Page 15/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Incidence Table -- Microscopic Findings SEX: DOSE GROUP: number of animals MALE 123 45 6 888888 Pancreas Inflammation, mixed granulocytic/ lymphocytic 000010 Kidneys number examined 8 8. 8 8 8 8 Tubular atrophy, cortical Interstitial inflammation, lymphocytic 355346 312132 Hyaline cast(s) 110202 Tubular mine rali zat ion 010000 Pelvic inflammation, lymphoid 001000 Pelvic dilation 000000 Cystic tubules 0 0 00 11 Pelvic mineralization 0 100 00 Tubular epithelial hypertrophy, focal 0 0 00 00 Testes number examined 8 8 88 88 Spermatidic giant cell(s) 1 0 00 01 Seminiferous tubular atrophy 1 0 00 10 WTXM&TJg 12 345 6 88888 8 00000 0 88888 8 41210 5 00210 3 00000 0 10000 0 00000 0 01000 0 00011 0 1000 0 0 00001 0 000321 PATHOLOGY REPORT Page 16/146 Test Article: telomer alcohol/telomer acrylate/ ./efhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Incidence Table -- Microscopic Findings SEX: DOSE GROUP: number of animals MUS 12 88 3 8 Epididymides number examined 1 Atrophy 1 Aspermia 1 Ovaries number examined Uterus number examined Cyst(s) Adrenal Glands number examined 8 8 8 888 Extracapsular nodule 0 0 0 110 Vacuo1ation, multifocal in z. fasiculata Atrophy, cortical diffuse 0 0 0 0 02 0 0 0 001 Spleen number examined 8 8 8 88a Hemopoiesis, primarily erythropoiesis 8 8 8 888 Hemosiderin pigment 675 744 Thymus number examined 8 8 8 888 Lymphoid atrophy involution 0 0 1 102 IEMALE 12345 6 8 88 88 8 888 88 8 r l 888 88 8 01101 1 000 00 0 000 00 0 88888 8 7 88 5 8 5 88888 8 888 88 8 11311 1 000322 PATHOLOGY REPORT Page 17/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Incidence Table - Microscopic Findings SEX: DOSE GROUP: number of animals MAZE 12345 6 a 88888 Thymus Lymphocytolysis, increased 00 11 0 0 Mesenteric Lymph Node number examined 888888 Congestion/ erythrophagocytosis 010100 Mandibular Lvmoh Node number examined 888888 Plasmacytosis 5 632 42 Lymphoid hyperplasia 200100 Congestion/ e rythrophagocyto sis 00112 0 ffSMALS i2345 6 88888 8 01111 0 88888 8 00000 0 88888 8 03211 2 1123 1 0 000 00 0 000323 PATHOLOGY REPORT Page 18/146 Test Articles t e l o m e r a l c o h o l /Te l o m e r a c r y l a t e / ,/p f h s /pfos NOTOX no. : 242933 Test System : Exploratory 28-Day Gavage Study in Rats ' Propath no.: 99010 Sponsor : 3M Toxicology Services Date : 21.Apr.1999 Incidence Table - Microscopic Findings Recovery Allocation 1 SEX: DOSE GROUP: number of animals Liver number examined Inflammatory cell foci Single cell necrosis Midzonal/ centrilobular hypertrophy, diffuse Hepatocellular vacuolation Hematopoietic cell foci Pancreas number examined Exocrine atrophy, focal Testes number examined Seminiferous tubular atrophy Skin number examined Inflammation, exudative MUS 123 45 6 333333 33 33 23 01 33 33 32 23 10 01 03 00 33 01 11 11 EISMAUS 12 33 3 3 2 0 1 0 10 56 33 3 3 1 1 000324 PATHOLOGY REPORT Page 19/146 Test Article: TELOMER ALCOHOL/TELOMER ACRYLATE/'. j/PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Incidence Table - Microscopic Findings Recovery Allocation 2 SEX: DOSE GROUP: number of animals Liver number examined Inflammatory cell foci Single cell necrosis Midzonal/ centrilobular hypertrophy, diffuse Hepatocellular vacuolation Coagulative necrosis, focal Pancreas number examined Apoptosis/single cell necrosis, exocrine Eyes number examined Periorbital inflammation due to blood sampling MALE 1 2 3 456 3 3 33 33 33 33 22 01 33 33 22 03 10 01 11 00 33 10 1 1 IEMALE 12345 6 333333 33 33 12 01 00 0. C 000325 PATHOLOGX REPORT Page 20/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / V p f h s /pfos NOTOX no. : 242933 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: ' 99010 Sponsor : 3M Toxicology Services Date : 21.Apr.1999 Individual Animal Microscopic Findings Codes and symbols in table heading: m Males f Females Codes and symbols in animal lines: p Planned sacrifice (main study) r Recovery 1 (plannedsacrifice) s Recovery 2 (plannedsacrifice) o Other Grading system used in finding lines: 0 finding not present 1 minimal 2 slight 3 moderate 4 severe 5 very severe x present Only organs/groups with findings are listed in the table 000326 PATHOLOGY REPORT Page 21/145 Test Article: t e l o m e r a l c o h o l /t'e l o m e r a c r y l a t e / /p f h s /p fos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: ' 99010 Date : 21.Apr.1999 Individual Animal Microscopie Findings Males, Dose group 1 12345 678 m .m m m m m m m necropsy status Liver PPPPP PPP Inflammatory cell foci 22221122 Single cell necrosis 01111 12 0 Hepatocellular vacuolation 00000010 Hematopoietic cell foci 10100010 Pancreas Apoptosis/single cell necrosis, 0 0 1 0 2 0 0 0 exocrine Kidneys Tubular atrophy, cortical 00010 101 Interstitial inflammation, lymphocytic 00001101 Hyaline cast{s) 00000010 Testes Spermatidic giant cell(s) 0 .1 0 0 0 0 0 0 Seminiferous tubular atrophy 0 10 0 0 00 0 Spleen Hemopoiesis, primarily erythropoiesis 2 2211 12 1 Hemosiderin pigment 01112210 Mandibular Lymph Node Plasmacytosis 2 22 2 0 3 0 0 Lymphoid hyperplasia 02200000 000327 PATHOLOGY REPORT Page 22/146 Test Article: TELOMER ALCOHOL/TELOMER ACRYLATE/ ,/PEHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no. : 99010 Date : 21.Apr.1999 Individual Animal Microscopic Findings Hales, Dose group 1 necropsy status 9 10 11 13 14 IS m .m m m m m rrr3s3 Liver Inflammatory cell foci Single cell necrosis Hepatocellular vacuolation 232222 02 1110 001100 Pancreas Apoptosis/single cell necrosis, 0 0 0 0 0 1 exocrine 000328 PATHOLOGY REPORT Page 23/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s / pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Microscopic Findings Males, Dose group 2 17 18 19 20 21 22 23 24 m .m m m m m m m necropsy status Liver PPP PPPPP Inflammatory cell foci Single cell necrosis 12122222 10011111 Midzonal/centrilobular hypertrophy, diffuse 01111201 Pancreas Apoptosis/single cell necrosis, 2 1 0 1 0 2 1 1 exocrine Exocrine atrophy, focal 00000001 Kidneys Tubular atrophy, cortical 2 1011100 Interstitial inflammation, lymphocytic 0 00 01 0 0 0 Hyaline cast(s) 00001000 Tubular mineralization 010 00000 Pelvic mineralization 01000000 Spleen Hemopoiesis, primarily erythropoiesis 111112 12 Hemosiderin pigment 01121111 Mesenteric Lymph Node Congestion/erythrophagocytosis 0 0 1 0 0 0 0 0 Mandibular Lymph Node Plasmacytosis 2 32 02 022 000329 PATHOLOGY DEPORT Page 24/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / ,/p fhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Individual Animal Microscopio Findings Males, Dose group 2 25 26 27 29 30 31 m .m m m m m necropsy status rrrs3s Liver Inflammatory cell foci 2 3 32 2 2 Single cell necrosis 1 11011 Midzonal/centrilobular hypertrophy, diffuse 0 10100 Hematopoietic cell foci 100000 Coagulative necrosis, focal 0 0 00 1 0 Pancreas Exocrine atrophy, focal 001000 Testes Seminiferous tubular atrophy 4 000330 PATHOLOGY REPORT Page 25/146 Test Article: telomer alcohol/telomer acrylate/ ./pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Microscopic Findings Males, Dose group 3 33 34 35 36 37 38 39 40 m mmmmmmm necropsy status P PPPPPPP Liver Inflammatory cell foci 2 1123222 Single cell necrosis 1 10 11110 Pancreas Apoptosis/single cell necrosis, 1 exocrine 0 0 00 0 10 Exocrine atrophy, focal 0 0000010 Kidneys Tubular atrophy, cortical 1 0 0 1 1 0 1 1 Interstitial inflammation, lymphocytic 0 1010000 Pelvic inflammation, lymphoid 0 0000010 Spleen Hemopoiesis, primarily erythropoiesis 2 1112221 Hemosiderin pigment 1 0001111 Thymus Lymphoid atrophy - involution 0 0 0 0 0 1 0 0 Lymphocytolysis, increased 0 0000002 Mandibular Lymph Node Plasmacytosis 0 20 02200 Congestion/erythrophagocytosis 0 0000003 000331 PATHOLOGY REPORT Page 26/146 Test Article: telomer alcohol/telomer acrylate/ ,/pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Microscopic Findings iblea, Dose group 4 49 50 51 52 53 54 55 56 m . m m m m m mi m necropsy status Liver PppPPPPP Inflammatory cell foci Single cell necrosis 2 111222 1 1X 00 0 1 0 0 Pancreas Apoptosis/single cell necrosis, 0 0 0 0 0 0 2 0 exocrine Kidneys Tlobular atrophy, cortical 10001001 Interstitial inflammation, lymphocytic 0 0 00 1 0 0 0 Hyaline cast(s) 00000101 Adrenal Glands Extracapsular nodule 0000000X Spleen Hemopoiesis, primarily erythropoiesis X 121212 1 Hemosiderin pigment 0 1 11 1 1 1 1 Thymus Lymphoid atrophy - involution 0 0 00 0 0 0 1 Lymphocytolysis, increased 0 0 0 0 0 0 0. 2 Mesenteric Lymph Mode Congestion/erythrophagocytosis 0 0 0 1 0 0 0 0 Mandibular Lymph Node Plasmacytosis Lymphoid hyperplasia 0 0 0 2 .0 0 2 0 00020000 Congestion/erythrophagocytosis 0 0 0 2 0 0 0 0 000332 PATHOLOGX REPORT Page 27/146 Test Article: telomer alcohol/telomer acrylate/ ,/pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Microscopic Findings Halas, Dose group 4 57 58 59 61 62 63 m .m m m m m necropsy status rrr3 3 3 Eyes Periorbital inflammation due to blood sampling 3 000333 PATHOLOGY REPORT Page 28/146 Teat Article: telomer alcohol/telomer acrylate/' /pfhs/peos NOTOX no. : 242933 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 99010 Sponsor : 3M Toxicology Services Date : 21.Apr.1999 Individual Animal Microscopic Findings Males, Dose group S 65 66 67 68 69 70 71 72 m .m m m m m m m necropsy status Lungs P PP PPP PP Intra-alveolar blood, necropsy artefact X Vascular mineralisation, focal 1 Liver Inflammatory cell foci 2 1222222 Single cell necrosis 1 0101 11 1 Midzonal/centrilobular hypertrophy, diffuse 33333223 Hepatocellular vacuolation 20100001 Coagulative necrosis, focal 00100000 Pancreas Apoptosis/single cell necrosis, 0 1 0 1 0 0 0 0 exocrine Inflammation, mixed granulocytic/1ymphocytic 00000100 Kidneys Tubular atrophy, cortical 11110000 Interstitial inflammation, lymphocytic 0 00 11 1 0 0 Cystic tubules 0 000002 0 Testes Seminiferous tubular atrophy 0 4000000 Epididymides Atrophy 3 Aspermia X 000334 PATHOLOGY REPORT Page 29/145 Test Article: TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Individual Animal Mi.exoscopie Findings Males, Cose group 5 65 66 67 68 69 70 71 72 mmmmmmmm necropsy status Adrenal Glands P PPP P P P P Extracapsular nodule 0000X 0 00 Spleen Hemopoiesis, primarily erythropoiesis Hemosiderin pigment 2121 12 12 0102 00 12 Mandibular Lymph Node Plasmacytosis 032 0002 2 Congestion/erythrophagocytosis 0 1 0 0 0 0 0 2 000335 PATHOLOGY REPORT Page 30/146 Test Article: telomer alcohol/telomer acrylate/ /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Microscopic Findings Males, Dose group 5 73 74 75 77 78 79 m .m m m m m necropsy status rrr3 3 3 Liver Inflammatory cell foci 322222 Single cell necrosis 2 11110 Midzonal/centrilobular hypertrophy, diffuse 201000 Hepatocellular vacuolation 000001 Testes Seminiferous tubular atrophy 3 000336 PATHOLOGY REPORT Page 31/146 Test Article: telomer alcohol/telomer acrylate/ /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Microscopic Findings Males, Dose group 6 81 82 83 84 85 86 87 88 m .m m m m m m m necropsy status Liver Inflammatory cell foci P PPPPPPP 2 22212 22 Single cell necrosis 1 0 11 011 1 Midzonal/centrilobular hypertrophy, diffuse 2 3333233 Hepatocellular vacuolation 01 100120 Hematopoietic cell foci 1 0 00000 0 Pancreas Apoptosis/single cell necrosis, 0 2 0 0 0 0 0 1 exocrine Kidneys Tubular atrophy, cortical 1 1 0 1 11 10 Interstitial inflammation, lymphocytic 0 02 1000 0 Hyaline cast(s) 00000110 Cystic tubules 00200000 Testes Spermatidic giant cell(s) 00100000 Adrenal Glands Vacuolation, multifocal in z. fasiculata 0 0 0 00 10 1 Atrophy, cortical diffuse 0 0 02000 0 000337 PATHOLOGY REPORT Page 32/146 Test Article: telomer alcohol/telomer acrylate/ /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Microscopic Findings Males, Dose group 6 81 82 83 84 85 86 87 m .m m m m m m necropsy status P PP PPP P Spleen Hemopoiesis, primarily erythropoiesis 1 111121 Hemosiderin pigment 1110000 Thymus Lymphoid atrophy - involution 00000201 Mandibular Lymph Node Plasmacytosis 30020000 88 m P 1 1 000338 PATHOLOGY REPORT Page 33/146 Test Article: telomer alcohol/tslomer acrylate/ ,'pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Microscopic Findings Halas, Dosa group 6 89 90 91 93 94 95 m m m SL m m necropsy status r rrs5 3 Liver Inflammatory cell foci Single cell necrosis 2 2212 2 1 1010 1 Midzonal/eentrilobular hypertrophy, diffuse 2 33132 Hepatocellular vacuolation 1 2201 0 000339 PATHOLOGY REPORT Page 34/146 Test Article: telomer alcohol/telomer acrylate/ /pfhs/ptos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date :' 21.Apr.1999 Individual Animal Microscopic Findings females, Dose group Z 97 98 99 fff necropsy status PPP Liver Inflammatory cell foci Single cell necrosis 2 12 101 Hepatocellular vacuolation 000 Pancreas Apoptosis/single cell necrosis, 0 1 1 exocrine Kidneys Tubular atrophy, cortical 100 Tubular mineralization 0 0 0 Pelvic mineralization 010 Spleen Hemopoiesis, primarily erythropoiesis 111 Hemosiderin pigment 322 Thymus Lymphoid atrophy - involution 000 Mandibular Lymph Node Lymphoid hyperplasia 000 100 101 102 103 104 fffff ppPPP 12 221 11111 00001 00000 10101 01000 00000 10111 23322 00010 0 2 0' 0 0 000340 PATHOLOGY REPORT Page 35/146 Test Article: telomer alcohol/telomer acrylate/ /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 I n d i v i d u a l A n i m a l Microscopic F i n d ings Females, Dose group 2 105 106 107 109 110 111 ffffff necropsy status rrrsss Liver Inflammatory cell foci 2 22 22 1 Single cell necrosis Hepatocellular vacuolation 1 10 10 0 020000 Skin Inflammation, exudative 2 000341 PATHOLOGY DEPORT Page 36/146 Test Article: telqmer alcohol/telomer acrylate/ .'pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Microscopic Findings Females, Cose group 2 113 114 115 116 117 118 119 120 f f f f f f f f necropsy status Liver P PPPPPPP Inflammatory cell foci Single cell necrosis 2 2111112 1 1010111 Kidneys Tubular atrophy, cortical Pelvic dilation 0 0000010 0 0 00X 000 Adrenal Glands Extracapsular nodule 0 000X 00 0 Spleen Hemopoiesis, primarily erythropoiesis 1 1111111 Hemosiderin pigment 2 2 222 23 2 Thymus Lymphoid atrophy - involution 0 0000 100 Lymphocytolysis, increased 0 00000 10 Mandibular Lymph Node Plasmacytosis 2 2 00030 0 Lymphoid hyperplasia 2 0 0000 00 000342 PATHOLOGY REPORT Page 37/146 Test Article: telomer alcohol/telomer acrylate/ ../pfhs/efos NOTOX no. : 242933 Test System : Exploratory 28-Day Gavage Study in Rats ' Propath no.: 99010 Sponsor : 3M Toxicology Services Date : 21.Apr.1999 Individual Animal Microscopic Findings Females/ Dose group 3 129 130 131 132 133 134 135 136 ffffffff necropsy status Liver oP P P PP P P Inflammatory cell foci Single cell necrosis 22 112 1 12 11102001 Hepatocellular vacuolation 01000000 Pancreas Exocrine atrophy, focal 0 0 0 1 0 0 0 0 Kidneys Tubular atrophy, cortical 0 1 0 0 0 1 0 0 Interstitial inflammation, lymphocytic 0 00 001 0 1 Adrenal Glands Extracapsular nodule 0 0 0000 0X Spleen Hemopoiesis, primarily erythropoiesis 2 1 112 1 1 1 Hemosiderin pigment 1 22 122 2 3 Thymus Lymphoid atrophy - involution 0 10 010 0 1 Lymphocytolysis, increased 00000100 Mandibular Lymph Node Plasmacytosis 00000022 Lymphoid hyperplasia 0 00 00 02 2 000343 PATHOLOGY REPORT Page 38/146 Test Article: telomer alcohol/telomer acrylate/ /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propth no.: 99010 Date : 21.Apr.1999 Individual Animal Microscopic Findings Tamales, Dosa group 4 145 146 147 148 149 150 151 152 f f f f f f f f necropsy status Liver Inflammatory cell foci P PPPPP PP 1 2 1 2 2 2 2 1 Single cell necrosis 0 1100001 Hematopoietic cell foci 0 0000100 Kidneys Tubular atrophy, cortical 0 0000001 Interstitial inflammation, lymphocytic 0 0010 000 Cystic tubules 0 0200000 Uterus Cyst(s) X Spleen Hemopoiesis, primarily erythropoiesis 1 101100 1 Hemosiderin pigment 22222322 Thymus Lymphoid atrophy - involution 0 00000 01 Lymphocytolysis, increased 0 0010 00 0 Mandibular Lymph Node Plasmacytosis 0 000020 0 Lymphoid hyperplasia 2 02002 00 000344 PATHOLOGY REPORT Page 39/146 Test Article: telomer alcohol/telomer acrylate/ /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Microscopic Findings Females, Dosa group 5 161 162 163 164 165 166 167 168 f .f f f f f f f necropsy status Liver PPPPP PP P Inflammatory cell foci 2 2321111 Single cell necrosis 0 1 101 0 1 1 Hepatocellular vacuolation 000000 01 Pancreas Apoptosis/single cell necrosis, 0 0 0 0 1 0 0 0 exocrine Kidneys Cystic tubules 0 0 000 0 0 1 Tubular epithelial hypertrophy, 1 0 0 0 0 0 0 0 focal Adrenal Glands Extracapsular nodule 00000X 00 Spleen Hemopoiesis, primarily erythropoiesis 11211111 Hemosiderin pigment 22222223 Thymus Lymphoid atrophy - involution 0 0 0200 00 Lymphocytolysis, increased 001 00000 Mandibular Lymph Node Plasmacytosis 00200000 Lymphoid hyperplasia 000002 00 000345 PATHOLOGY REPORT Page 40/146 Test Article: telomer alcohol/telomer acrylate/ ./pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Microscopic Findings Females, V o s a gzcnxp 6 177 178 179 180 181 182 183 184 f ffffff f necropsy status Liver P PPPPPPP Inflammatory cell foci 2 122111 1 Single cell necrosis 10101010 Midzonal/centrilobular hypertrophy, diffuse 2 23123 3 2 Kidneys Tubular atrophy, cortical 1 100110 1 Interstitial inflammation, lymphocytic 0 1010010 Adrenal Glands Extracapsular nodule X 000000 0 Spleen Hemopoiesis, primarily erythropoiesis i 0 011 1 0 1 Hemosiderin pigment 2 1323222 Thymus Lymphoid atrophy - involution 10000000 Mandibular Lymph Node ' Plasmacytosis 0 000022 0 000346 PATHOLOGY REPORT Page 41/146 Test Article; telcmer alcohol/telomer acrylate/ /pfhs/pfos NOTOX no. : 242933 Test System : Exploratory 28-Day Gavage Study in Rats Propath, no.: 99010' Sponsor : 3M Toxicology Services Date : 21.Apr.1999 Individual Animal Microscopic Findings .Females, D o s e g r o u p 6 185 186 187 189 190 191 f .f f f f f necropsy status rrr3ss Liver Inflammatory cell foci Single cell necrosis 1 12211 0 01110 Midzonal/centrilobular hypertrophy, diffuse 0 10001 000347 PATHOLOGY REPORT Page 42/146 Test Article: telomer alcohol/telomer acrylate/ /pfhs/pfos NOTOX no. : 242933 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 99010 Sponsor : 3M Toxicology Services Date : 21.Apr.1999 Animal Data List Malea ANIMAL SEX FINAL TEST FIRST NUMBER M/F STATE DAYS DAY DOSE GROUP 1 1m P 2m P 3m P 4m P Sm P 6m P 7m P 8m P 9m r 10 m r 11 m r 13 m s 14 m 3 15 m 3 DOSE GROUP 2 17 m P 18 m P 19 m P 20 m P 21 m P 22 m P 23 m P 24 m P 25 m r 26 m r 27 m r 29 m 3 30 m s 31 m 3 DOSE GROUP 3 33 m P 34 m P 35 m P 36 in P 37 m P 38 m P 39 m P 40 in P 41 m r 42 m r 43 m r 45 m 3 46 m 3 47 m 3 28 06/10/98 28 06/10/98 28 06/10/98 28 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 28 06/10/98 28 06/10/98 28 06/10/98 28 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 28 06/10/98 28 06/10/98 28 06/10/98 28 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 29 06/10/98 LAST DAY 02/11/98 02/11/98 02/11/98 02/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 02/11/98 02/11/98 02/11/98 02/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 02/11/98 02/11/98 02/11/98 02/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 03/11/98 DATE NECROPSY 03/11/98 03/11/98 03/11/98 03/11/98 04/11/98 04/11/98 04/11/98 04/11/98 18/11/98 18/11/98 18/11/98 02/12/98 02/12/98 02/12/98 03/11/98 03/11/98 03/11/98 03/11/98 04/11/98 04/11/98 04/11/98 04/11/98 18/11/98 18/11/98 18/11/98 02/12/98 02/12/98 02/12/98 03/11/98 03/11/98 03/11/98 03/11/98 04/11/98 04/11/98 04/11/98 04/11/98 18/11/98 18/11/98 18/11/98 02/12/98 02/12/98 02/12/98 000348 PATHOLOGY REPORT Page 43/146 Test Article: teller alcohol/telomer acrylate/ ./pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Animal Data list Kales ANIMAL SEX FINAL TEST FIRST NUMBER M/F STATE DAYS DAY LAST DAY DATE NECROPSY DOSE GROUP 4 49 m p 50 m p 51 m p 52 m p 53 m p 54 m p 55 m p 56 m p 57 m r 58 m r 59 m r 61 m 3 62 m S 63 m s DOSE GROUP 5 65 m p 66 m p 67 m p 68 m p 69 m p 70 m p 71 m p 72 m p 73 m r 74 m r 75 m r 77 m s 78 m s 79 m s DOSE GROUP 6 81 m P 82 m P 83 m P 84 m P 85 m P 86 m P 87 m P 88 m P 89 m r 90 m r 91 m r 93 m s 94 m s 95 m s 28 06/10/98 02/11/98 03/11/98 28 06/10/98 02/11/98 03/11/98 28 06/10/98 02/11/98 03/11/98 28 06/10/98 02/11/98 03/11/98 29 06/10/98 03/11/98 04/11/98 29 06/10/98 03/11/98 04/11/98 29 06/10/98 03/11/98 04/11/98 29 06/10/98 03/11/98 04/11/98 29 06/10/98 03/11/98 18/11/98 29 06/10/98 03/11/98 18/11/98 29 06/10/98 03/11/98 18/11/98 29 06/10/98 03/11/98 02/12/98 29 06/10/98 03/11/98 02/12/98 29 06/10/98 03/11/98 02/12/98 28 06/10/98 02/11/98 03/11/98 28 06/10/98 02/11/98 03/11/98 28 06/10/98 02/11/98 03/11/98 28 06/10/98 02/11/98 03/11/98 29 06/10/98 03/11/98 04/11/98 29 06/10/98 03/11/98 04/11/98 29 06/10/98 03/11/98 04/11/98 29 06/10/98 03/11/98 04/11/98 29 06/10/98 03/11/98 18/11/98 29 06/10/98 03/11/98 18/11/98 29 06/10/98 03/11/98 18/11/98 29 06/10/98 03/11/98 02/12/98 29 06/10/98 03/11/98 02/12/98 29 06/10/98 03/11/98 02/12/98 28 06/10/98 02/11/98 03/11/98 28 06/10/98. 02/11/98 03/11/98 28 06/10/98 02/11/98 03/11/98 28 06/10/98 02/11/98 03/11/98 29 06/10/98 03/11/98 04/11/98 29 06/10/98 03/11/98 04/11/98 29 06/10/98 03/11/98 04/11/98 29 06/10/98 03/11/98 04/11/98 29 06/10/98 03/11/98 18/11/98 29 06/10/98 03/11/98 18/11/98 29 06/10/98 03/11/98 18/11/98 29 06/10/98 03/11/98 02/12/98 29 06/10/98 03/11/98 02/12/98 29 06/10/98 03/11/98 02/12/98 000349 PATHOLOGY REPORT Page 44/145 Test Article: telomer alcohol/telomer acrylate/ /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Animal Data List Pernales ANIMAL SEX PINAL TEST FIRST NUMBER M/P STATE DAYS DAY DOSE GROUP 1 97 f 98 f 99 f 100 f 101 f 102 f 103 f 104 f 105 f 106 107 109 110 f 111 f DOSE GROUP 2 113 114 f 115 f 116 f 117 f 118 119 f 120 f 121 f 122 f 123 f 125 f 126 f 127 f DOSE GROUP 3 129 f 130 131 f 132 f 133 f 134 f 135 f 136 f 137 138 f 139 f 141 f 142 f 143 f P P P P p p p p r r r s s s P P P P P P P P r r r 3 s a 6 P P P P P P P r r r 3 3 3 28 08/10/98 28 08/10/98 28 08/10/98 28 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 28 08/10/98 28 08/10/98 28 08/10/98 28 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 28 08/10/98 28 08/10/98 28 08/10/98 28 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 LAST DAY 04/11/98 04/11/98 04/11/98 04/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 04/11/98 04/11/98 04/11/98 04/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 04/11/98 04/11/98 04/11/98 04/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 DATE NECROPSY 05/11/98 05/11/98 05/11/98 05/11/98 06/11/98 06/11/98 06/11/98 06/11/98 20/11/98 20/11/98 20/11/98 04/12/98 04/12/98 04/12/98 05/11/98 05/11/98 05/11/98 05/11/98 06/11/98 06/11/98 06/11/98 06/11/98 20/11/98 20/11/98 20/11/98 04/12/98 04/12/98 04/12/98 05/11/98 05/11/98 05/11/98 05/11/98 06/11/98 06/11/98 06/11/98 06/11/98 20/11/98 20/11/98 20/11/98 04/12/98 04/12/98 04/12/98 000350 PATHOLOGY REPORT Page 45/146 Test Article: telomer alcohol/telomer acrylate/ /efhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Animal Data List females ANIMAL SEX FINAL TEST FIRST NUMBER M/F STATE DAYS DAY DOSE GROUP 4 145 p 14? P 147 f p 148 f p 149 f P 150 f p 151 f p 152 p 153 f r 154 r 155 f r 157 f s 158 f s 159 f 3 DOSE GROUP 5 161 P 162 f p 163 f P 164 f P 165 f P 166 f p 167 f p 168 f P 169 f r 170 f r 171 f r 173 f s 174 s 175 s DOSE GROUP 6 177 f p 178 P 179 f P 180 f P 181 f P 182 f P 183 f P 184 f P 185 f r 186 f r 187 f r 189 f s 190 f s 191 f s 28 08/10/98 28 08/10/98 28 08/10/98 28 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 28 08/10/98 28 08/10/98 28 08/10/98 28 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 28 08/10/98 28 08/10/98 28 08/10/98 28 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 29 08/10/98 LAST DAY 04/11/98 04/11/98 04/11/98 04/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 04/11/98 04/11/98 04/11/98 04/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 04/11/98 04/11/98 04/11/98 04/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 05/11/98 DATE NECROPSY 05/11/98 05/11/98 05/11/98 05/11/98 06/11/98 06/11/98 06/11/98 06/11/98 20/11/98 20/11/98 20/11/98 04/12/98 04/12/98 04/12/98 05/11/98 05/11/98 05/11/98 05/11/98 06/11/98 06/11/98 06/11/98 06/11/98 20/11/98 20/11/98 20/11/98 04/12/98 04/12/98 04/12/98 05/11/98 05/11/98 05/11/98 05/11/98 06/11/98 06/11/98 06/11/98 06/11/98 20/11/98 20/11/98 20/11/98 04/12/98 04/12/98 04/12/98 000351 PATHOLOGY REPORT Page 46/146 Test Article: telomer alcohol/telomer acrylate/ /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 1 Hale Vehicle Control MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Mandibular Lymph Node/ 1 Mandibular Lymph Node/ 2 Animal No: 2 MACROSCOPIC FINDINGS days of treatment :28 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy :03/11/98 No findings noted Inflammatory cell foci (slight) Hematopoietic cell foci (minimal) Hemopoiesis, primarily erythropoiesis (slight) Plasmacytosis (slight) Plasmacytosis (slight) N o abnormalities found in: Pancreas, Kidney/1, Kidney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node. days of treatment :28 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy :03/11/98 No findings noted 000352 PATHOLOGY REPORT Page 47/146 Test Article: telomer alcohol/telomer acrylate/ 'pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 2 Male Vehicle Control MICROSCOPIC FINDINGS Liver Testes/1 Testes/2 Spleen Mandibular Lymph Node/ 1 Animal No: 3 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Pancreas Spleen Mandibular Lymph Node/ 1 Inflammatory cell foci (slight) Single cell necrosis (minimal) Seminiferous tubular atrophy (minimal) Spermatidic giant cell(s) (minimal) Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (minimal) Plasmacytosis (slight) Lymphoid hyperplasia (slight) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy : 03/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hematopoietic cell foci (mdniioal) Apoptosis/single cell necrosis, exocrine (minimal) Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (minimal) Plasmacytosis (slight) Lymphoid hyperplasia (slight) 000353 PATHOLOGY REPORT Page 48/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / 'p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 3 Male Vehicle Control MICROSCOPIC FINDINGS (continued) Mandibular Lymph Node/ 2 Animal No: 4 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Mandibular Lymph Node/ 1 Plasmacytosis (slight) No abnormalities found in: Kidney/1, Kidney/2, Testes/1, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node. days of treatment :28 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy :03/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) Plasmacytosis (slight) No abnormalities found in: Pancreas, Kidney/2, Testes/1, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. 000354 PATHOLOGY REPORT Page 49/146 Test Article: telomer alcohol/telomer acrylate/ ./pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.f 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal Ho: SEX: DOSE GROUP: 5 Male Vehicle Control MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Pancreas Kidney/1 Spleen Animal No: 6 MACROSCOPIC FINDINGS days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :04/11/98 No findings noted Inflammatory cell foci (minimal) Single cell necrosis (minimal) Apoptosis/single cell necrosis, exocrine (slight) Interstitial inflammation, lymphocytic (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Kldney/2, Testes/1, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 No findings noted 000355 PATHOLOGY REPORT Page 50/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: ' 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 6 Male Vehicle Control MICROSCOPIC FINDINGS Liver Kidney/1 Kidney/2 Spleen Mandibular Lymph Node/ 1 Mandibular Lymph Node/ 2 Animal No: 7 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Inflammatory cell foci (minimal) Single cell necrosis (minimal) Tubular atrophy, cortical (minimal) Interstitial inflammation, lymphocytic (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Plasmacytosis (moderate) Plasmacytosis (moderate) No abnormalities found in: Pancreas, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node. days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :04/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (slight) Hepatocellular vacuolation (minimal) Hematopoietic cell foci (minimal) Hyaline cast(s) (minimal) 000356 PATHOLOGY REPORT Page 51/146 Test Article: TEL0MER ALCOHOL/TELOMER ACRYLATE/ 'PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no. : 9901 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 7 Male Vehicle Control MICROSCOPIC FINDINGS (continued) Spleen Animal No: 8 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Kidney/2 Spleen Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (minimal) No abnormalities found in: Pancreas, Kidney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :04/11/98 No findings noted Inflammatory cell foci (slight) Tubular atrophy, cortical (minimal) Interstitial inflammation, lymphocytic (minimal) Hemopoiesis, primarily erythropoiesis (minimal) No abnormalities found in: Pancreas, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000357 PATHOLOGY REPORT Page 52/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 9 Hale Vehicle Control MACROSCOPIC FINDINGS Skin MICROSCOPIC FINDINGS Liver Animal No: 10 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver days of treatment : 29 sacrifice group : recovery group necropsy status :planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 18/11/98 chest region: Alopecia No abnormalities were found in any of the other tissues examined Inflammatory cell foci (slight) No abnormalities found in: Pancreas. days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :18/11/98 No findings noted Inflammatory cell foci (moderate) Single cell necrosis (slight) No abnormalities found in: Pancreas. 000358 PATHOLOGY REPORT Page 53/146 Test Article: t e l o m e r a l c o h o l /t'e l o m e r a c r y l a t e / /p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Eropath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP 11 Male Vehicle Control MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Animal No: 13 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :18/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hepatocellular vacuolation (minimal) No abnormalities found in: Pancreas. days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 02/12/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hepatocellular vacuolation (minimal) No abnormalities found in: Pancreas. 000359 PATHOLOGY REPORT Page 54/146 Test Article: t e l o m e r a l c o h o l /t e l c m e r a c r y l a t e / /p f h s /pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP 14 Male Vehicle Control MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Animal No: 15 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Pancreas days of treatment :29 sacrifice group :recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :02/12/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) No abnormalities found in: Pancreas. days of treatment :29 sacrifice group :recovery grot?) 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :02/12/98 No findings noted Inflammatory cell foci (slight) Apoptosis/single cell necrosis, exocrine (minimal) 000360 PATHOLOGY REPORT Page 55/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / ,/p f h s /p fos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 97 Female Vehicle Control MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver KLdney/1 Spleen Animal No: 98 MACROSCOPIC FINDINGS Ovaries days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (moderate) No abnormalities found in: Pancreas, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment :28 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy :05/11/98 left side Watery cyst No abnormalities were found in any of the other tissues examined 000361 PATHOLOGY REPORT Page 56/146 Test Article: telomer alcohol/telomer acrylate/ /pfhs/pfos NOTOX no. : 242933 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 99010 Sponsor : 3M Toxicology Services Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 98 Female Vehicle Control MICROSCOPIC FINDINGS Liver Pancreas Kidney/1 Ovary/1 Spleen Animal No: 99 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Pancreas Spleen Inflammatory cell foci (minimal) Apoptosis/single cell necrosis, exocrine (minimal) Pelvic mineralization (minimal) No micro correlate Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Kidney/2, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 28 sacrifice group : terminal sacrifice necropsy status ; planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Apoptosis/single cell necrosis, exocrine (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000362 PATHOLOGY REPORT Page 57/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / ./p f h s /p fos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 100 Female Vehicle Control MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Animal No: 101 MACROSCOPIC FINDINGS days of treatment : 28 sacrifice group : terminal sacrifice necropsy status : planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (minimal) Single cell necrosis (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Pancreas, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :06/11/98 No findings noted 000363 PATHOLOGY REPORT Page 58/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / / p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal Ho: SEX: DOSE GROUP: 101 Female Vehicle Control MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Mandibular Lymph Node/ 1 Animal No: 102 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Inflammatory cell foci (slight) Single cell necrosis (minimal) Tubular mineralization (minimal) Hemosiderin pigment (moderate) Lymphoid hyperplasia (slight) No abnormalities found in: Pancreas, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :06/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (moderate) No abnormalities found in: Pancreas, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000364 PATHOLOGY REPORT Page 59/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 103 Female Vehicle Control MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Thymus Animal No: 104 MACROSCOPIC FINDINGS days of treatment :29 sacrifice group :terminal sacrifice necropsy status :piaimed terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :06/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Lymphoid atrophy - involution (minimal) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 06/11/98 No findings noted 000365 PATHOLOGY REPORT Page 60/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services N O T O X no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal Ho: SEX: DOSE GROUP: 104 Female Vehicle Control MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Animal No: 105 MACROSCOPIC FINDINGS Skin MICROSCOPIC FINDINGS Liver Skin Inflammatory cell foci (minimal) Single cell necrosis (minimal) Hepatocellular vacuolation (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Pancreas, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :20/11/98 abdominal region: Scab formation No abnormalities were found in any of the other tissues examined Inflammatory cell foci (slight) Single cell necrosis (minimal) Inflammation, exudative (slight) (correlates to GROSS finding) 000366 PATHOLOGY REPORT Page 61/146 Test Article: telomer alcohol/telomer acrylate/ /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal Ho: SEX: DOSE GROUP 106 Female Vehicle Control MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Animal No: 107 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Animal No: 109 MACROSCOPIC FINDINGS days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :20/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hepatocellular vacuolation (slight) days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :20/11/98 No findings noted Inflammatory cell foci (slight) days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 000367 PATHOLOGY REPORT Page 62/146 Test Article: telomer alcohol/telomer acrylate/ ,/pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 109 Female Vehicle Control MACROSCOPIC FINDINGS (continued) MICROSCOPIC FINDINGS Liver Animal No: 110 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Animal No: 111 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) days of treatment : 29 sacrifice group : recovery group 2 necropsy status : planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted Inflammatory cell foci (slight) days of treatment : 29 sacrifice group : recovery group 2 necropsy status : planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted Inflammatory cell foci (minimal) 000368 PATHOLOGY REPORT Page 63/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 17 Male Telomer Alcohol MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Pancreas Kidney/1 Kidney/2 Spleen Mandibular Lymph Node/ 1 Animal No: 18 MACROSCOPIC FINDINGS days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy : 03/11/98 No findings noted Inflammatory cell foci (minimal) Single cell necrosis (minimal) Apoptosis/single cell necrosis, exocrine (slight) Tubular atrophy, cortical (slight) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Plasmacytosis (slight) No abnormalities found in: Testes/1, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy : 03/11/98 No findings noted 000369 PATHOLOGY REPORT Page 64/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / .,'p fhs/pfos ' Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : Propath no.: Date : 242933 99010 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 18 Male Telamer Alcohol MICROSCOPIC FINDINGS Liver Pancreas Kidney/1 Kidney/2 Spleen Mandibular Lymph Node/ 1 Animal No: 19 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Inflammatory cell foci (slight) Midzonal/centrilobular hypertrophy, diffuse (minimal) Apoptosis/single cell necrosis, exocrine (minimal) Tubular atrophy, cortical (minimal) Pelvic mineralization (minimal) Tubular mineralization (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) Plasmacytosis (moderate) No abnormalities found in: Testes/1, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment : 28 . sacrifice group : terminal sacrifice necropsy status : planned terminal date of start of treatment: 06/10/98 date of end of treatment': 02/11/98 date of necropsy : 03/11/98 No findings noted Inflammatory cell foci (minimal) Midzonal/centrilobular hypertrophy, diffuse (minimal ) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) 00370 PATHOLOGY REPORT Page 65/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p fhs/peos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal NO: SEX: DOSE GROUP: 19 Male Telomer Alcohol MICROSCOPIC FINDINGS (continued) Mesenteric Lymph Node Mandibular Lymph Node/ 1 Animal No: 20 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Pancreas Kidney/1 Spleen Congestion/erythrophagocytosis (minimal) Plasmacytosis (slight) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mandibular Lymph Node/2. days of treatment :28 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy :03/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (minimal) Apoptosis/single cell necrosis, exocrine (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Kidney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. r 000371 PATHOLOGY REPORT Page 66/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /p f o s NOTOX no. : 242933 Test System : Exploratory 28-Day Gavage Study in Rats' Propath no.: 99010 Sponsor : 3M Toxicology Services Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 21 Male Telomer Alcohol MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Kidney/2 Spleen Mandibular Lymph Node/ 1 Animal No: 22 MACROSCOPIC FINDINGS days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (minimal) Interstitial inflammation, lymphocytic (minimal) Hyaline cast(s) (minimal) Tubular atrophy, cortical (minimal) Interstitial inflammation, lymphocytic (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) Plasmacytosis (slight) No abnormalities found in: Pancreas, Testes/1, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status : planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 000372 PATHOLOGY REPORT Page 67/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p e w pros NOTOX no. : 242933 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 99010 Sponsor : 3M Toxicology Services Date : 21.Apr.1999 Individual Animal Data Records Animal Ho: SEX: DOSE GROUP: 22 Male Telomer Alcohol MACROSCOPIC FINDINGS (continued) MICROSCOPIC FINDINGS Liver Pancreas Kidney/1 Kidney/2 Spleen Animal No: 23 MACROSCOPIC FINDINGS No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (slight) Apoptosis/single cell necrosis, exocrine (slight) Tubular atrophy, cortical (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (minimal) No abnormalities found in: Testes/1, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 No findings noted 000373 PATHOLOGY REPORT Page 68/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / ,/p fhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.:' 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 23 Male Telomer Alcohol MICROSCOPIC FINDINGS Liver Pancreas Spleen Mandibular Lymph Node/ 1 Animal No: 24 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Pancreas Spleen Inflammatory cell foci (slight) Single cell necrosis (minimal) Apoptosis/single cell necrosis, exocrine (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) Plasmacytosis (slight) No abnormalities found in: Kidney/1, Kidney/2, Testes/1, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (minimal) Apoptosis/single cell necrosis, exocrine (minimal) Exocrine atrophy, focal (minimal) Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment' (minimal) 000374 PATHOLOGY REPORT Page 69/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.A p r . 1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 24 Male Telomer Alcohol MICROSCOPIC FINDINGS (continued) Mandibular Lymph Node/ 1 Animal No: 25 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Animal No: 26 MACROSCOPIC FINDINGS Plasmacytosis (slight) No abnormalities found in: Kidney/1, Kidney/2, TesteS/l, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment :29 sacrifice group :recovery group necropsy status :piaimed recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :18/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hematopoietic cell foci (minimal) No abnormalities found in: Pancreas. days of treatment : 29 sacrifice group : recovery group necropsy status : planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 18/1/98 No findings noted 000375 PATHOLOGY REPORT Page 70/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /p fos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010' Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 26 Hale Telomer Alcohol MICROSCOPIC FINDINGS liver Animal No: 27 MACROSCOPIC FINDINGS Testes MICROSCOPIC FINDINGS Liver Pancreas Testes/l Testes/2 Inflammatory cell foci (moderate) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (minimal) No abnormalities found in: Pancreas. days of treatment : 29 sacrifice group : recovery group necropsy status : planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 18/11/98 Reduced in size FLACCID No abnormalities were found in any of the other tissues examined Inflammatory cell foci (moderate) Single cell necrosis (minimal) Exocrine atrophy, focal (minimal) Seminiferous tubular atrophy (severe) (correlates to GROSS finding) Seminiferous tubular atrophy (severe) (correlates to GROSS finding) 000376 PATHOLOGY REPORT Page 71/146 Teat Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p fhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 29 Male Telomer Alcohol MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS liver Animal No: 30 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver days of treatment :29 sacrifice group :recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :02/12/98 No findings noted Inflammatory cell foci (slight) Midzonal/centrilobular hypertrophy, diffuse (minimal) No abnormalities found in: Pancreas. days of treatment :29 sacrifice group :recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :02/12/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Coagulative necrosis, focal (minimal) No abnormalities found in: Pancreas. 000377 PATHOLOGY REPORT Page 72/146 Test Article: t e l o m e r a l c o h o l /t e l q m e r a c r y l a t e / /eras/pros Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 31 Male Telomer Alcohol MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS liver Animal No: SEX: 113 Female MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS liver Spleen Mandibular lymph Node/ 1 days of treatment : 29 sacrifice group : recovery group 2 necropsy status : planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 02/12/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) No abnormalities found in: Pancreas. days of treatment : 28 sacrifice group : terminal sacrifice necropsy status : planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Plasmacytosis (slight) lymphoid hyperplasia (slight) 000378 PATHOLOGY REPORT Page 73/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 113 Female Telomer Alcohol MICROSCOPIC FINDINGS (continued) Animal No: 114 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Mandibular Lymph Node/ 1 No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment :28 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy :05/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Plasmacytosis (slight) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. 000379 PATHOLOGY REPORT Page 74/146 Test Article: telomer alcohol/telomer acrylate/ ./pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 115 Female Telomer Alcohol MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Animal No: 116 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/l, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (minimal) Single cell necrosis (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) 000380 PATHOLOGY REPORT Page 75/146 Test Article: TELOMER ALCOHOL/TELOMER ACRYLATE/ ,/PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 116 Female Telomer Alcohol MICROSCOPIC FINDINGS (continued) Animal No: 117 MACROSCOPIC FINDINGS Kidneys MICROSCOPIC FINDINGS Liver Kidney/2 Adrenal Gland/1 Spleen No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status : planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 06/11/98 right side Pelvic dilation No abnormalities were found in any of the other tissues examined Inflammatory cell foci (minimal) Pelvic dilation present (correlatesto GROSS finding) Extracapsular nodule present Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Pancreas, Kidney/1, Ovary/1, Ovary/2, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2.. . 000381 PATHOLOGY REPORT Page 76/146 Test Article: telomer alcohol/telomer acrylate/ ./pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 118 Female Telomer Alcohol MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Thymus Mandibular Lymph Node/ 1 Animal No: 119 MACROSCOPIC FINDINGS days of treatment : 29 sacrifice group :terminal sacrifice necropsy status : planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :06/11/98 No findings noted Inflammatory cell foci (minimal) Single cell necrosis (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Lymphoid atrophy - involution (minimal) Plasmacytosis (moderate) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :06/11/98 No findings noted 000382 PATHOLOGY REPORT Page 77/146 Test Article: telomer alcohol/Telomer acrylate/ /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 119 Female Telomer Alcohol MICROSCOPIC FINDINGS Liver Kidney/2 Spleen Thymus Animal No: 120 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Inflammatory cell foci (minimal) Single cell necrosis (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (moderate) Lymphocytolysis, increased (minimal) No abnormalities found in: Pancreas, Kidney/1, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :06/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000383 PATHOLOGY REPORT Page 78/146 Test Article: telomer alcohol/telomer acrylate/ /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. ! 242933 Propath no. : 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal Ho: SEX: DOSE GROUP 121 Female Telomer Alcohol MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 122 MACROSCOPIC FINDINGS Skin MICROSCOPIC FINDINGS Skin Animal No: 123 MACROSCOPIC FINDINGS days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :20/11/98 No findings noted No tissues examined days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :20/11/98 Alopecia No abnormalities were found in any of the other tissues examined No micro correlate days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :20/11/98 000384 PATHOLOGY REPORT Page 79/146 Test Article: telomer alcohol/telomer acrylate/ ./pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Eropath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 123 Female Telomer Alcohol MACROSCOPIC FINDINGS (continued) MICROSCOPIC FINDINGS Animal No: 125 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 126 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS No Findings noted No tissues examined days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted No tissues examined days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted No tissues examined 000385 PATHOLOGY REPORT T e s t A r t i c l e : TELOMER ALCOHOL/tELOMER ACRYLATE/ /PFHS/PF0S Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services Page 80/146 NOTOX no. : Propath no. Date : 242933 99010 21.A p r . 1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 127 Female Telomer Alcohol MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: SEX: DOSE GROUP: 33 Male Telomer Acrylat MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Pancreas Kidney/1 Kidney/2 Spleen days of treatment : 29 sacrifice group : recovery group 2 necropsy status : piaimed recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted No tissues examined days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy : 03/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Apoptosis/single cell necrosis, exocrine (minimal) Tubular atrophy, cortical (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (minimal) 000386 PATHOLOGY REPORT Page 81/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / / p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Eropath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 33 Male Telomer Acrylat MICROSCOPIC FINDINGS (continued) Animal No: 34 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Mandibular Lymph Node/ 1 Mandibular Lymph Node/ 2 Number of Sections less than protocol for Mandibular Lymph Node/1 (0). No abnormalities found in: Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy : 03/11/98 No findings noted Inflammatory cell foci (minimal) Single cell necrosis (minimal) Interstitial inflammation, lymphocytic (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Plasmacytosis (slight) Plasmacytosis (slight) No abnormalities found in: Pancreas, Kidney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node. 000387 PATHOLOGY REPORT Page 82/146 Test Article: t e l c m e r a l c o h o l / t e l o m e r a c r y l a t e / /p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 35 Hale Telomer Acrylat MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Animal No: 36 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy : 03/11/98 No findings noted Inflammatory cell foci (minimal) Hemopoiesis, primarily erythropoiesis (minimal) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Testes/1, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy : 03/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Tubular atrophy, cortical (minimal) Interstitial inflammation, lymphocytic (minimal) Hemopoiesis, primarily erythropoiesis (minimal) 000388 PATHOLOGY REPORT Page 83/146 T e s t A x t i c l e : TELOMER ALCOHOL/TELOMER ACRYLATE/ ./PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services N O TOX no. : Propath no. : Date : 242933 99010 21.A p r . 1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 36 Male Telomer Acrylat MICROSCOPIC FINDINGS (continued) Animal No: 37 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Mandibular Lymph Node/ 1 Number of Sections less than protocol for Mandibular Lym p h Node/1 (0). No abnormalities found in: Pancreas, KLdney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Nod e / 2. days of treatment : 29 sacrifice group : terminal sacrifice, necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 No findings noted Inflammatory cell foci (moderate) Single cell necrosis (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (minimal) Plasmacytosis (slight) No abnormalities found in: Pancreas, Kidney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node, Mandibular L y m p h Node/2. 000389 PATHOLOGY REPORT Page 84/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / /p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 38 Hale Telomer Acrylat MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Mandibular Lymph Node/ 1 Mandibular Lymph Node/ 2 Animal No: 39 MACROSCOPIC FINDINGS days of treatment : 29 sacrifice group : terminal sacrifice necropsy status : planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (minimal) Plasmacytosis (slight) Plasmacytosis (slight) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node. days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :04/11/98 No findings noted 000390 PATHOLOGY REPORT Page 85/146 Test Article: t e l o m e r a l c o h o l / T e l o m e r a c r y l a t e / /p f h s / pf os Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 39 Hale Telomer Acrylat MICROSCOPIC FINDINGS Liver Pancreas Kidney/1 Spleen Animal No: 40 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Thymus Mandibular Lymph Node/ 1 Inflammatory cell foci (slight) Single cell necrosis (minimal) Apoptosis/single cell necrosis, exocrine (minimal) Exocrine atrophy, focal (minimal) Tubular atrophy, cortical (minimal) Pelvic inflammation, lymphoid (minimal) Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (minimal) No abnormalities found in: Kidney/2, Testes/1, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status : pi sinned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 No findings noted Inflammatory cell foci (slight) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) Lyraphocytolysis, increased (slight) Congestion/erythrophagocytosis (moderate) 000391 PATHOLOGY REPORT Page 86/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / ./p f h s / p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propth no. Date 242933 99010 21.A p r . 1999 Individual Animal Data Records An i m a l No: SEX: DOSE GROUP: 40 Naie Telomer Acrylat MICROSCOPIC FINDINGS (continued) Animal No: 41 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 42 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS No abnormalities found in: Pancreas, Kidney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : recovery group necropsy status : planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 18/11/98 No findings noted No tissues examined days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :18/11/98 No findings noted No tissues examined 000392 PATHOLOGY REPORT Page 87/146 Test Article: TELOMER ALCOHOL/TELOMER ACRYLATE/ ./PFHS/EFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.A p r . 1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 43 Hale Telomer Acrylat MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 45 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 46 MACROSCOPIC FINDINGS days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :18/11/98 No findings noted No tissues examined days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 02/12/98 No findings noted No tissues examined days of treatment :29 sacrifice group :recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :02/12/98 No findings noted 000393 PATHOLOGY REPORT Test Article: t e l q m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M T o x i c o l o g y Services Page 88/146 NOTOX no. : 2J J 933 Propath no.: Date . 21.Apr.1999 Individual Animal Data Recoxds Animal No: SEX: DOSE GROUP 46 Male Telomer Acrylat MICROSCOPIC FINDINGS Animal No: 47 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: SEX: 129 Female MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen .No tissues examined days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 02/12/98 No findings noted No tissues examined days of treatment : 28 sacrifice group : terminal sacrifice necropsy status : other date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (minimal) 000394 PATHOLOGY REPORT Page 89/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / /p f h s /pf os Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 129 Female Telomer Acrylat MICROSCOPIC FINDINGS (continued) Animal No: 130 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Kidney/2 Spleen Thymus No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandib u la r Lymph Node/1, Mandibular Lymph Nod e / 2. days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hepatocellular vacuolation (minimal) Tubular atrophy, cortical (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Lymphoid atrophy - involution (minimal) No abnormalities found in: Pancreas, Ovary/1, Ovary/ 2, Adrenal Gland/1, Adrenal Gland/2, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000395 PATHOLOGY REPORT Page 90/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / -/p f h s / p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 131 Female Telomer Acrylat MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Animal No: 132 MACROSCOPIC FINDINGS days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (minimal) Single cell necrosis (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted 000396 PATHOLOGY REPORT Page 91/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / ./p f h s / p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 132 Female Telomer Aorylat MICROSCOPIC FINDINGS Liver Pancreas Spleen Animal No: 133 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS' Liver Spleen Thymus Inflammatory cell foci (min imal) Exocrine atrophy, focal (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) No abnormalities found in: Kidney/1, KLdney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status : planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 06/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (slight) Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (slight) Lymphoid atrophy - involution (minimal) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000397 PATHOLOGY REPORT Page 92/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / /p f h s /pf os Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 134 Female Telomer Acrylat MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/2 Spleen Thymus Animal No: 135 MACROSCOPIC FINDINGS days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 06/11/98 No findings noted Inflammatory cell foci (minimal) Tubular atrophy, cortical (minimal) Interstitial inflammation, lymphocytic (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Lymphocytolysis, increased (minimal) No abnormalities found in: Pancreas, Kidney/1, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 06/11/98 No findings noted 000398 PATHOLOGY REPORT Page 93/146 Test Article: t e l o m e r a l c o h o l /t e l c m e r a c r y l a t e / /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 135 Female Telomer Acrylat MICROSCOPIC FINDINGS Liver Spleen Mandibular Lymph Node/ 1 Animal No: 136 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/2 Adrenal Gland/1 Spleen Thymus Mandibular Lymph Node/ 1 Inflammatory cell foci (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Plasroacytosis (slight) Lymphoid hyperplasia (slight) No abnormalities found in: Pancreas, Kidney/l, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :06/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Interstitial inflammation, lymphocytic (minimal) Extracapsular nodule present Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (moderate) Lymphoid atrophy - involution (minimal) Plasmacytosis (slight) 000399 PATHOLOGY PEPORT Page 94/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / / p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP 136 Female Telomer Acrylat MICROSCOPIC FINDINGS (continued) Mandibular Lymph Node/ 2 Animal No: 137 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 138 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Lymphoid hyperplasia (slight) No abnormalities found in: Pancreas, Kidney/1, Ovary/1, Ovary/2, Adrenal Gland/2, Mesenteric Lymph Node. days of treatment : 29 sacrifice group : recovery group necropsy status : planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 20/11/98 No findings noted No tissues examined days of treatment : 29 sacrifice group : recovery group necropsy status : planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 20/11/98 No findings noted No-tissues examined 000400 PATHOLOGY REPORT Page 95/146 Test Article: t e l o m e r a l c o h o l /t e l c m e r a c r y l a t e / /p f h s /pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no Date 242933 99010 21.A p r . 1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 139 Female Telomer Acrylat MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 141 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 142 MACROSCOPIC FINDINGS days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :20/11/98 No findings noted No tissues examined days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted No tissues examined days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted 000401 PATHOLOGY REPORT Page 96/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / ,/p f h s / p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : Propath no.: Date : 242933 99010 21.A p r . 1999 Individual Animal Data Records Animal Ho: SEX: DOSE GROUP: 142 Female Telomer Acrylat MICROSCOPIC FINDINGS Animal No: 143 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: SEX: DOSE GROUP: 49 Male MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen No tissues examined days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted No tissues examined days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy : 03/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) 000402 PATHOLOGY REPORT Page 98/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / ,/p f h s / p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 51 Male MACROSCOPIC FINDINGS (continued) MICROSCOPIC FINDINGS Liver Spleen Animal No: 52 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Mesenteric Lymph Node Mandibular Lymph Node/ 1 Mandibular Lymph Node/ 2 No findings noted Inflammatory cell foci (minimal) .. Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (minimal) N o abnormalities found in: Pancreas, Kidney/1, Kidney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment :28 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy :03/11/98 No findings noted Inflammatory cell foci (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal ) Congestion/erythrophagocytosis (minimal) Plasmacytosis (slight) Lymphoid hyperplasia (slight) Congestion/erythrophagocytosis (slight) Congestion/erythrophagocytosis (slight) 000403 PATHOLOGY REPORT T e s t A r t i c l e : TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services Page 99/146 NOTOX no. : Propath no. : Date : 242933 99010 21.A p r . 1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 52 Hale MICROSCOPIC FINDINGS (continued) Animal No: 53 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Animal No: 54 MACROSCOPIC FINDINGS No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Testes/l, Testes/2; Adrenal Gland/1, Adrenal Gland/2, Thymus. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 No findings noted Inflammatory cell foci (slight) Tubular atrophy, cortical (minimal) Interstitial inflanimation, lymphocytic (minimal) Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (minimal) No abnormalities found in: Pancreas, Kidney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node, M andibular L y m p h Node/1, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 000404 PATHOLOGY REPORT Page 100/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /pf os Test System : Exploratory 28-Day Gavag Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21 .Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 54 Male MACROSCOPIC FINDINGS (continued) MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Animal No: 55 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Pancreas Spleen Mandibular Lymph Node/ 1 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hyaline cast(s) (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) No abnormalities found in: Pancreas, Kidney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node, M andibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 No findings noted Inflammatory cell foci (slight) Apoptosis/single cell necrosis, exocrine (slight) Hemopoiesis, primarilyerythropoiesis (slight) Hemosiderin pigment (minimal) Plasmacytosis (slight) 000405 PATHOLOGY REPORT Page 101/146 Teat Article: t e l q m e r a l c o h o l / t e l o m e r a c r y l a t e / /p f h s /p f o s Teat System : Exploratory 23-Day Gavage Study in Rata Sponaor : 3M Toxicology Servicea NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 55 Male MICROSCOPIC FINDINGS (continued) Mandibular Lymph Node/ 2 Animal No: 56 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Kidney/2 Adrenal Gland/1 Spleen Thymus Plaamacytoaia (alight) No abnormalities found in: KLdney/1, Kidney/2, Teatea/l, Testea/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node. days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :04/11/98 No findings noted Inflammatory cell foci (minimal) Tubular atrophy, cortical (minimal) Tubular atrophy, cortical (minimal) Hyaline cast(s) (minimal) Extracapsular nodule present Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) Lymphoid atrophy - involution (minimal) Lymphocytolysis, increased (slight) No abnormalities found in: Pancreas, Testes/1, Testes/2, Adrenal Gland/2, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000406 PATHOLOGY REPORT Page 102/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 57 Male MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 58 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 59 MACROSCOPIC FINDINGS days of treatment : 29 sacrifice group : recovery group necropsy status : planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 18/11/98 No findings noted No tissues examined days of treatment : 29 sacrifice group : recovery group necropsy status : planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 18/11/98 No findings noted No tissues examined days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :18/11/98 No findings noted 000407 PATHOLOG REPORT Page 103/146 Test Article: t e l o m e r a i c o h o l /t e l o m e r a c r y l a t e / /p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal Mo: SEX: DOSE GROUP: 59 Male MICROSCOPIC FINDINGS Animal No: 61 MACROSCOPIC FINDINGS Eyes MICROSCOPIC FINDINGS Eyes Animal No: 62 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS No tissues examined days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 02/12/98 lens: right side Reduced in size No abnormalities were found in any of the other tissues examined Periorbital inflammation due to blood sampling (moderate) (correlates to GROSS finding) days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 02/12/98 No findings noted No tissues examined 000408 PATHOLOGY REPORT Page 104/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / /pf hs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 63 Male MACROSCOEIC FINDINGS MICROSCOPIC FINDINGS Animal No: SEX: 145 Female MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Mandibular Lymph Node/ 1 days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 02/12/98 No findings noted No tissues examined days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Lymphoid hyperplasia (slight) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. 000409 PATHOLOGY REPORT Page 105/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / ./p f h s / p f o s NOTOX no. : 242933 Test System : Exploratory 28-Day Gavage Study in Rats Propath no.: 99010 Sponsor : 3M Toxicology Services Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 146 Female MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Animal No: 147 MACROSCOPIC FINDINGS days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/l, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment :28 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy :05/11/98 No findings noted 000410 PATHOLOGY REPORT Page 106/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / /p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 9910 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 147 Female MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Mandibular Lymph Node/ 1 Animal No: 148 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS liver Kidney/1 Spleen ' Thymus Inflammatory cell foci (minimal) Single cell necrosis (minimal) Cystic tubules (slight) Hemosiderin pigment (slight) Lymphoid hyperplasia (slight) No abnormalities found in: Pancreas, Kidney/2, Ovary/l, Ovary/2, Adrenal Gland/1, Adrenal Gland / 2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment :28 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy :05/11/98 No findings noted Inflammatory cell foci (slight) Interstitial inflammation, lymphocytic (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Lymphocytolysis, increased (minimal) N o abnormalities found in: Pancreas, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000411 PATHOLOGY REPORT Page 107/146 Test Article: TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 149 Female MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Animal No: 150 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Mandibular Lymph Node/ 1 days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 06/11/98 No findings noted 1inflammatory cell foci (slight) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) N o abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 06/11/98 No findings noted Inflammatory cell foci (slight) Hematopoietic cell foci (minimal) Hemosiderin pigment (moderate) Plasmacytosis (slight) Lymphoid hyperplasia (slight) 000412 PATHOLOGY REPORT Page 108/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / /p f h s / p f o s Test System ; Exploratory 28-Day Gavage Study in Rats' Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 150 Female MICROSCOPIC FINDINGS (continued) Animal No: 151 MACROSCOPIC FINDINGS Uterus MICROSCOPIC FINDINGS Liver Uterus Spleen N o abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 06/11/98 left side Cyst(s) No abnormalities were found in any of the other tissues examined Inflammatory cell foci (slight) Cyst(s) present simple serosal) (correlates to GROSS finding) Hemosiderin pigment (slight) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000413 PATHOLOGY REPORT Page 109/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / /p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 152 Female MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver KLdney/1 Spleen Thymus Animal No: 153 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS days of treatment : 29 sacrifice group : terminal sacrifice necropsy status . : planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 06/11/98 No findings noted Inflammatory cell foci (minimal) Single cell necrosis (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Lymphoid atrophy - involution (minimal) No abnormalities found in: Pancreas, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :20/11/98 No findings noted No tissues examined 000414 PATHOLOGY REPORT Page 110/146 T e s t A r t i c l e : t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /pf os Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. P r o p a t h no'. Date 242933 99010 21.A p r . 1999 Individual Animal Data Records Animal Wo: SEX: DOSE GROUP: 154 Female MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 155 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 157 MACROSCOPIC FINDINGS days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :20/11/98 No findings noted No tissues examined days of treatment : 29 sacrifice group : recovery group necropsy status :planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 20/11/98 No findings noted No tissues examined days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted 000415 PATHOLOGY REPORT Page 111/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f k s /pf os Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. ! 242933 Propath no. s 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 157 Female MICROSCOPIC FINDINGS Animal No: 158 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 159 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS No tissues examined days of treatment :29 sacrifice group :recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :04/12/98 No findings noted No tissues examined days of treatment :29 sacrifice group :recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :04/12/98 No findings noted No tissues examined 000416 PATHOLOGY REPORT Page 112/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 9900 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 65 Male PFHS MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Animal No: 66 MACROSCOPIC FINDINGS Lungs Stomach Testes days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy : 03/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (moderate) Hepatocellular vacuolation (slight) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (slight) N o abnormalities found in: Pancreas, Kidney/2, Teste s/ 1, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy : 03/11/98 Hemorrhage glandular mucosa Hemorrhage Reduced in size 000417 PATHOLOGY REPORT Page 113/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / /p f h s /p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 66 Hale PFHS MACROSCOPIC FINDINGS (continued) Epididymides MICROSCOPIC FINDINGS Lungs Stomach Liver Pancreas Kidney/1 Testes/1 Testes/2 Epididymides Spleen Mandibular Lymph Node/ 1 Mandibular Lymph Node/ 2 Reduced in size No abnormalities were found in any of the other tissues examined Intra-alveolar blood, necropsy artefact present (correlates to GROSS finding) Vascular mineralisation, focal (minimal) No micro correlate Inflammatory cell foci (minimal) Midzonal/centrilobular hypertrophy, diffuse (moderate) Apoptosis/single cell necrosis, exocrine (minimal) Tubular atrophy, cortical (minimal) Seminiferous tubular atrophy (severe) (correlates to GROSS finding) Seminiferous tubular atrophy (severe) (correlates to GROSS finding) Atrophy (moderate) (correlates to GROSS finding) Aspermia present Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) Plasmacytosis (moderate) Congestion/erythrophagocytosis (minimal) No abnormalities found in: Kidney/2, Adrenal Gland/ 1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node. 000418 PATHOLOGY REPORT Page 114/146 Teat Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /pf o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no.. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 67 Male PFHS MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Mandibular Lymph Node/ 1 Animal No: 68 MACROSCOPIC FINDINGS days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy : 03/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (moderate) Hepatocellular vacuolation (minimal) Coagulative necrosis, focal (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (slight) Plasmacytosis (slight) No abnormalities found in: Pancreas, Kidney/2, Testes/1, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy : 03/11/98 No findings noted 000419 PATHOLOGY REPORT Page 116/146 Teat Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / ,'p f h s / p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal Ho: SEX: DOSE GROUP: 69 Male PFHS MICROSCOPIC FINDINGS (continued) Animal No: 70 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Pancreas Kidney/1 Spleen No abnormalities found in: Pancreas, Kidney/2, Testes/1, Testes/2, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status : planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (slight) Inflammation, mixed granulocytic/lymphocytic (minimal) Interstitial inflammation, lymphocytic (minimal) Hemopoiesis, primarily erythropoiesis (slight) No abnormalities found in: Kidney/2, Testes/1, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000420 PATHOLOGY REPORT Page 117/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / ,p f h s / p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 71 Male PFHS MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver KLdney/1 Spleen Mandibular Lymph Node/ 1 Mandibular Lymph Node/ 2 Animal No: 72 MACROSCOPIC FINDINGS Liver days of treatment : 29 sacrifice group : terminal sacrifice necropsy status : planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (slight) Cystic tubules (slight) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) Plasmacytosis (slight) Plasmacytosis (slight) No abnormalities found in: Pancreas, Kidney/2, Testes/1, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node. days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminati date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :04/11/98 Enlarged 000421 PATHOLOGY REPORT Page 119/146 Test Article: TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 '99010 21.A p r . 1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 74 Male PFHS MACROSCOPIC FINDINGS Testes MICROSCOPIC FINDINGS Liver Testes/l Testes/2 Animal No: 75 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :18/11/98 Reduced in size No abnormalities were found in any of the other tissues examined Inflammatory cell foci (slight) Single cell necrosis (minimal) Seminiferous tubular atrophy (moderate) (correlates to GROSS finding) Seminiferous tubular atrophy (moderate) (correlates to GROSS finding) days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :18/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (minimal) 000422 PATHOLOGY REPORT Page 120/146 Test Article: TELOMER ALCOHOL/TELOMER ACRYLATE/ . /PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Eropath no. : 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 77 Male PFHS MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS liver Animal No: 78 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Animal No: 79 MACROSCOPIC FINDINGS days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 02/12/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 02/12/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 02/12/98 000423 PATHOLOGX REPORT Page 121/146 Test Article: TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 79 Male PFHS MACROSCOPIC FINDINGS (continued) MICROSCOPIC FINDINGS liver Animal No: SEX: 161 Female MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS liver Kidney/1 Spleen No findings noted Inflammatory cell foci (slight) Hepatocellular vacuolation (minimal) days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (slight) Tubular epithelial hypertrophy, focal (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Pancreas, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000424 PATHOLOGY REPORT Page 122/146 Test Article: TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor 3M Toxicology Services NOTOX no. : 242933 Propath no. : 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 162 Female PFHS MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Animal No: 163 MACROSCOPIC FINDINGS days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted . 000425 PATHOLOGY REPORT Page 123/146 Test Article: t e l o m e r a l c o h o l / T E L O m e r a c r y l a t e / /p f h s /pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 163 Female PFHS MICROSCOPIC FINDINGS Liver Spleen Thymus Mandibular Lymph Node/ 1 Animal No: 164 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Thymus Inflammatory cell foci (moderate) Single cell necrosis (minimal) Hemopoiesis, primarily erythropoiesis (slight) Hemosiderin pigment (slight) Lymphocytolysis, increased (minimal) Plasmacytosis (slight) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment :28 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy :05/11/98 No findings noted Inflammatory cell foci (slight) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Lymphoid atrophy - involution (slight) No abnormalities found in: Pancreas, Kidney/1, KLdney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lyxnph Node/2. 000426 PATHOLOGY REPORT Page 124/146 Test Article: telqmer alcohol/telomr acrlate/ ,/pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.A p r . 1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 165 Female PFHS MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Pancreas Spleen Animal No: 166 MACROSCOPIC FINDINGS days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :06/11/98 No findings noted Inflammatory cell foci (minimal) Single cell necrosis (minimal) Apoptosis/single cell necrosis, exocrine (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :06/11/98 No findings noted 000427 PATHOLOGY REPORT Page 125/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / 'p f h s / p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 166 Female PFHS MICROSCOPIC FINDINGS Liver Adrenal Gland/1 Spleen Mandibular Lymph Node/ 1 Animal No: 167 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Spleen Inflammatory cell foci (minimal) Extracapsular nodule present Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Lymphoid hyperplasia (slight) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status : planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 06/11/98 No findings noted Inflammatory cell foci (minimal) Single cell necrosis (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Pancreas, Kidney/1, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000428 PATHOLOGY REPORT Page 126/146 Teat Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 168 Female PFHS MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Animal No: 169 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 06/11/98 No findings noted Inflammatory cell foci (minimal) Single cell necrosis (minimal) Hepatocellular vacuolation (minimal) Cystic tubules (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (moderate) No abnormalities found in: Pancreas, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : recovery group necropsy status : planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 20/11/98 No findings noted No tissues examined 000429 PATHOLOGY REPORT Page 127/146 Test Article: telomer alcohol/telomer acrylate/ /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.A p r . 1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: X70 Female PFHS MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 171 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal. No: 173 MACROSCOPIC FINDINGS days of treatment : 29 sacrifice group : recovery group necropsy status : planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 20/11/98 No findings noted No tissues examined days of treatment : 29 sacrifice group : recovery group necropsy status : planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 20/11/98 No findings noted No tissues examined days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted 000430 PATHOLOGY REPORT Page 128/146 Test Article: TELOMER ALCOHOL/TELOMER ACRYLATE/ ,/PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21 .Apr.1999 Individual Animal Data Records Animal No: 173 SEX: Female DOSE GROUP: PFHS MICROSCOPIC FINDINGS Animal No: 174 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Animal No: 175 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS No tissues examined days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted No tissues examined days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted No tissues examined 000431 PATHOLOGX RESORT Page 129/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /peos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 81 Male PFOS. MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Mandibular Lymph Node/ 1 Animal No: 82 MACROSCOPIC FINDINGS days of treatment : 28 sacrifice group : terminal sacrifice necropsy status : planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy : 03/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (slight) Hematopoietic cell foci (minimal) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) Plasmacytosis (moderate) No abnormalities found in: Pancreas, Kidney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment :28 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy :03/11/98 No findings noted 000432 PATHOLOGY REPORT Page 130/146 Teat Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / /pfhs/pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individuad. Animal Data Records Animal No: SEX: DOSE GROUP: 82 Male PFOS MICROSCOPIC FINDINGS Liver Pancreas Kidney/1 Spleen Animal No: 83 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Kidney/2 Inflammatory cell foci (slight) Midzonal/centrilobular hypertrophy, diffuse (moderate) Hepatocellular vacuolatian (minimal) Apoptosis/single cell necrosis, exocrine (slight) Tubular atrophy, cortical {minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) No abnormalities found in: KLdney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lyrph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 02/11/98 date of necropsy : 03/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (moderate) Hepatocellular vacuolation (minimal) Interstitial inflammation, lymphocytic (slight) Cystic tubules (slight) Interstitial inflammation, lymphocytic (minimal) 000433 PATHOLOGY REPORT Page 132/146 Test Article: TEL0MER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 2 1 .Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 84 Hale PFOS MICROSCOPIC FINDINGS (continued) Animal No: 85 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver KLdney/1 Spleen Animal No: 86 MACROSCOPIC FINDINGS No abnormalities found in: Pancreas, Kidney/2, Testes/l, Testes/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 No findings noted Inflammatory cell foci (minimal) Midzonal/centrilobular hypertrophy, diffuse (moderate) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) No abnormalities found in: Pancreas, Kidney/2, Testes/l, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 000434 PATHOLOGY REPORT Page 133/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /pfos Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no Date 242933 99010 2 1 .Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 86 Hale PFOS MACROSCOPIC FINDINGS (continued) MICROSCOPIC FINDINGS Liver Kidney/1 Kidney/2 Adrenal Gland/1 Adrenal Gland/2 Spleen Thymus Animal No: 87 MACROSCOPIC FINDINGS No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (slight) Hepatocellular vacuolation (minimal) Tubular atrophy, cortical (minimal) Hyaline cast(s) (minimal) Tubular atrophy, cortical (minimal) Vacuolation, multifocal in z. fasiculata (minimal) Vacuolation, multifocal in z. fasiculata (minimal) Hemopoiesis, primarily erythropoiesis (slight) Lymphoid atrophy - involution (slight) No abnormalities found in: Pancreas, Testes/1, Testes/2, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :04/11/98 No findings noted 000435 PATHOLOGY REPORT Page 134/146 Test Article: TELOMER ALCOHOL/TELOMER ACRYLATE/ /PFHS/PFOS Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 87 Male PFOS MICROSCOPIC FINDINGS Liver Kidney/l Spleen Animal No: 88 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Pancreas Adrenal Gland/1 Adrenal Gland/2 Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (moderate) Hepatocellular vacuolation (slight) Tubular atrophy, cortical (minimal) Hyaline cast(s) (minimal) Hemopoiesis, primarily erythropoiesis (minimal) No abnormalities found in: Pancreas, KLdney/2, Testes/1, Testes/2, Adrenal Gland/1, Adrenal Gland/ 2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 04/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (moderate) Apoptosis/single cell necrosis, exocrine (minimal) Vacuolation, multifocal in z. fasiculata (minimal) Vacuolation, multifocal in z. fasiculata (minimal) 000436 PATHOLOGY REPORT Page 135/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /p f o s NOTOX no. : Test System : Exploratory 28-Day Gavage Study in Rats 'Propath no.: Sponsor : 3M Toxicology Services Date : 242933 99010 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 88 Male PFOS MICROSCOPIC FINDINGS (continued) Spleen Thymus Animal No: 89 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Animal No: 90 MACROSCOPIC FINDINGS Liver Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (minimal) Lymphoid atrophy - involution (minimal) No abnormalities found in: Kidney/1, Kidney/2, Testes/1, Testes/2, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :18/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (slight) Hepatocellular vacuolation (minimal) days of treatment : 29 sacrifice group : recovery group necropsy status : planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 18/11/98 Accentuated lobular pattern 000437 PATHOLOGY REPORT Page 136/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /pf os Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 90 Hale PFOS MACROSCOPIC FINDINGS (continued) MICROSCOPIC FINDINGS Liver Animal No: 91 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Animal No: 93 MACROSCOPIC FINDINGS No abnormalities were found in any of the other tissues examined Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (moderate) (correlates to GROSS finding) Hepatocellular vacuolation (slight) (correlates to GROSS finding) days of treatment :29 sacrifice group :recovery group necropsy status :planned recovery date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy :18/11/98 No findings noted Inflammatory cell foci (slight) Midzonal/centrilobular hypertrophy, diffuse (moderate) Hepatocellular vacuolation (slight) days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 02/12/98 000438 PATHOLOGY REPORT Page 137/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / /p f h s /pf os Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : Propath no.': Date : 242933 99010 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 93 Male PROS MACROSCOPIC FINDINGS (continued) MICROSCOPIC FINDINGS Liver Animal No: 94 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Animal No: 95 MACROSCOPIC FINDINGS No findings noted Inflammatory cell foci (minimal) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (minimal) days of treatment : 29 sacrifice group : recovery group 2 necropsy status : planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 02/12/98 No findings noted Inflammatory cell foci (slight) Midzonal/centrilobular hypertrophy, diffuse (moderate) Hepatocellular vacuolation (minimal) days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 06/10/98 date of end of treatment: 03/11/98 date of necropsy : 02/12/98 No findings noted 000439 PATHOLOGX REPORT Page 138/146 Test Article: TELOMER ALCOHOL/TELOMER ACRYLATE/ .'PFHS/PF0S Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 95 Male PFOS MICROSCOPIC FINDINGS Liver Animal No: SEX: 177 Female MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/2 Adrenal Gland/1 Spleen Thymus Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (slight) days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (slight) Tubular atrophy, cortical (minimal) Extracapsular nodule present Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) Lymphoid atrophy - involution (minimal) No abnormalities found in: Pancreas, Kidney/1, Ovary/1, Ovary/2, Adrenal Gland/2, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000440 PATHOLOGY REPORT Page 139/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / ,/p f h s / p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 9901 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 178 Female PFOS MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/2 Adrenal Gland/1 Spleen Animal No: 179 MACROSCOPIC FINDINGS days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (minimal) Midzonal/centrilobular hypertrophy, diffuse (slight) Tubular atrophy, cortical (minimal) Interstitial inflammation, lymphocytic (minimal) Small glands, normal morphology. Hemosiderin pigment (minimal) No abnormalities found in: Pancreas, Kidney/1, Ovary/1, Ovary/2, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. days of treatment :28 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy :05/11/98 No findings noted 000441 PATHOLOGT REPORT Page 140/146 Test Article: t e l c m e r a l c o h o l /t e l o m e r a c r y l a t e / ,/p f h s / p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 179 Female PFOS MICROSCOPIC FINDINGS Liver Spleen Animal No: 180 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver KLdney/1 Spleen Inflammatory cell foci (alight) Single cell necroaia (minimal) Midzonal/centrilobular hypertrophy, diffuae (moderate) Hemoaiderin pigment (moderate) No abnormalitiea found in: Pancreaa, Kidney/1, KLdney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymua, Mesenteric Lymph Node, Mandibular Lyuph Node/1, Mandibular Lymph Node/2. days of treatment : 28 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 04/11/98 date of necropsy : 05/11/98 No findings noted Inflammatory cell foci (slight) Midzonal/centrilobular hypertrophy, diffuse (minimal) Interstitial inflammation, lymphocytic (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Pancreas, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000442 PATHOLOGY REPORT Page 142/146 Test Article: t e l q m e r a l c o h o l / t e l o m e r a c r y l a t e / ,/p f h s / p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 182 Female PFOS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Mandibular Lymph Node/ 1 Animal No: 183 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen Mandibular Lymph Node/ 1 Inflammatory cell foci (minimal) Midzonal/centrilobular hypertrophy, diffuse (moderate) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythxopoiesis (minimal) Hemosiderin pigment (slight) Plasmacytosis (slight) No abnormalities found in: Pancreas, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment :29 sacrifice group :terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy :06/11/98 No findings noted Inflammatory cell foci (minimal) Single cell necrosis (minimal) Midzonal/centrilobular hypertrophy, diffuse (moderate) Interstitial inflammation, lymphocytic (minimal) Hemosiderin pigment (slight) Plasmacytosis (slight) 000443 PATHOLOGY REPORT Page 143/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / ,/p f h s / p f o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal Mo: SEX: DOSE GROUP: 183 Female PFOS MICROSCOPIC FINDINGS (continued) Animal No: 184 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Kidney/1 Spleen No abnormalities found in: Pancreas, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/2. days of treatment : 29 sacrifice group : terminal sacrifice necropsy status :planned terminal date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 06/11/98 No findings noted Inflammatory cell foci (minimal) Midzonal/centrilobular hypertrophy, diffuse (slight) Tubular atrophy, cortical (minimal) Hemopoiesis, primarily erythropoiesis (minimal) Hemosiderin pigment (slight) No abnormalities found in: Pancreas, Kidney/2, Ovary/1, Ovary/2, Adrenal Gland/1, Adrenal Gland/2, Thymus, Mesenteric Lymph Node, Mandibular Lymph Node/1, Mandibular Lymph Node/2. 000444 PATHOLOGY REPORT Page 144/146 Test Article: t e l o m e r a l c o h o l /t e l o m e r a c r y l a t e / /p f h s /pfos Test System : Exploratory 28-Day Gvage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. Propath no. Date 242933 99010 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 185 Female PFOS MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Animal No: 186 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Animal No: 187 MACROSCOPIC FINDINGS days of treatment : 29 sacrifice group : recovery group necropsy status : planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 20/11/98 No findings noted Inflammatory cell foci (minimal) days of treatment : 29 sacrifice group : recovery group necropsy status : planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 20/11/98 No findings noted Inflammatory cell foci (minimal) Midzonal/centrilobular hypertrophy, diffuse (minimal) days of treatment : 29 sacrifice group : recovery group necropsy status : planned recovery date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 20/11/98 000445 PATHOLOGY REPORT Page 145/146 Test Article: t e l o k e r a l c o h o l /t e l o m e r a c r y l a t e / ./p f h s / p e o s Test System : Exploratory 28-Day Gavage Study in Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 187 Female PFOS MACROSCOPIC FINDINGS (continued) MICROSCOPIC FINDINGS Liver Animal No: 189 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver Animal No: 190 MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted Inflammatory cell foci (slight) Single cell necrosis (minimal) days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted Inflammatory cell foci (minimal) Single cell necrosis (minimal) 000446 PATHOLOGY REPORT Page 146/146 Test Article: t e l o m e r a l c o h o l / t e l o m e r a c r y l a t e / ./p f h s / p f o s Test System : Exploratory 28-Day Gavage Study iii Rats Sponsor : 3M Toxicology Services NOTOX no. : 242933 Propath no.: 99010 Date : 21.Apr.1999 Individual Animal Data Records Animal No: SEX: DOSE GROUP: 191 Female PFOS MACROSCOPIC FINDINGS MICROSCOPIC FINDINGS Liver days of treatment : 29 sacrifice group : recovery group 2 necropsy status :planned recovery 2 date of start of treatment: 08/10/98 date of end of treatment: 05/11/98 date of necropsy : 04/12/98 No findings noted Inflammatory cell foci (miniami) Midzonal/centrilobular hypertrophy, diffuse (minimal) 000447
Contact UsLoginSign Up
CUNY - The Graduate CenterColumbia University Mailman School of Public Health - Sociomedical Sciences